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Summary
Developmental Dyslexia (DD) is a complex, cognitive disorder which is 
characterised by an impairment in reading despite adequate educational, motivational 
and intellectual opportunities. Family and twin studies have shown that this common 
neurodevelopmental disorder has a highly heritable component.
The aim of this thesis was to identify novel susceptibility variants for DD using 
several approaches.
A candidate gene study was conducted, testing variants within the genes CDC42, 
PRTG, KIAA0319L, DCDC2b and RIOK3 for association with DD in the Cardiff case- 
control sample. None of the variants within these genes showed a significant association 
with DD.
A genome-wide association study (GWAS) was conducted in collaboration with 
other groups as part of the NeuroDys consortium, using DD cases from Europe and 
population controls. 27 of the most significant SNPs identified were selected and 
genotyped in a larger replication sample. 8 of these showed a significant association 
with DD, with the most interesting SNPs within the gene SNX29.
An additional GWAS was conducted by the NeuroDys consortium in the form of a 
pooling study using a larger array. 38 of the most significant SNPs identified were 
selected for individual genotyping after which 14 remained significant, with the most 
interesting within the genes TMC1 and WDR78.
Another GWAS was conducted in the form of a pooling study using the Cardiff 
cases and screened controls only. 57 of the most significant SNPs identified were 
selected for individual genotyping of which 54 remained significant. This study 
highlighted a number of interesting genes and demonstrated the effect of using a 
homogeneous case-control sample when conducting pooling studies.
Analysis of copy number variants (CNVs) was also conducted using data from the 
initial NeuroDys GWAS. This study highlighted the technical issues that can affect the 
outcome of such studies. As such, the CNVs in this study need to be validated before 
these results can be relied upon.
To conclude, some interesting variants have been identified in this thesis but further 
work is required to confirm these findings.
Chapter 1: Introduction
1.1 Developmental Dyslexia
1.1.1 Definition
The World Health Organisation (WHO 2003) define dyslexia as:
“...an unexpected specific and persistent failure to acquire efficient reading skills 
despite conventional instruction, adequate intelligence and sociocultural opportunity.” 
Dyslexia is also referred to as specific reading disability (SRD) or developmental 
dyslexia (DD). Throughout this thesis I use the term DD as this refers to individuals 
who fail to develop competent reading skills, rather than those that have lost their ability 
to read competently as a result of brain damage (i.e. ‘acquired dyslexia’).
1.1.2 Epidemiology
Epidemiological data has suggested that reading ability occurs along a continuum, 
where individuals with DD form the lower tail end of the normal distribution and no 
‘cut point’ can be used to distinguish individuals with DD from typically normal readers 
(Shaywitz et al. 1992). It is the most common of the learning disabilities, affecting 
between 5 and 10% of children of a school age (Shaywitz et al. 1990). Typically, these 
epidemiological studies of DD have been conducted using Western populations, many 
of which had English as their first language. English is considered to be a non­
transparent language and the prevalence rates of DD may vary when studying more 
transparent languages such as German, Italian and Spanish. DD has also been found in 
non-Westem populations at varying prevalence. A study of Chinese children from Hong 
Kong estimated prevalence rates of DD to be between 9.7% -12.6% (Chan et al. 2007) 
and a large study of Egyptian children with DD estimated the prevalence to be 1.3% 
(Farrag et al. 1988).
Epidemiological studies have observed that DD is often found in males at a greater 
rate than in females, with a ratio of -2:1 (Flannery et al. 2000). Some studies have 
suggested that this increase in prevalence in boys reflects an ascertainment bias rather 
than a gender difference, due to teachers rating boys as being significantly more
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inattentive and having more behaviour, language and academic problems than girls, 
resulting in more boys being referred for help (Shaywitz et al. 1990; Wadsworth et al. 
1992; Katusic et al. 2001). However, large studies conducted on unselected samples 
have made this argument difficult to justify, with twice as many more boys affected by 
DD than girls in a large US sample of 32,223 children (Flannery et al. 2000), and a 
study of reading ability in nearly 200,000 children finding that girls outperformed boys 
on reading tests in every one of the 43 countries examined (Chiu & McBride-Chang 
2006). Geschwind and Behan (1982) have hypothesised that gender differences could 
be explained by an excess of, or sensitivity to, androgens such as testosterone. This may 
delay left-hemisphere maturation which could result in abnormalities of neuronal 
migration and/or connections during gestation and ultimately DD.
1.1.3 Theories of DD
The exact processes involved in learning to read are unknown. Learning to read an 
alphabetic system requires learning the grapheme-phoneme correspondence. A 
grapheme is a written representation of a sound. For example, in Table 1.1, the word 
‘book’ is spelt using the graphemes, ‘b’, ‘oo’ and ‘k \  Phonemes represent the smallest 
discernible segments of speech. For example, in Table 1.1, the word ‘scarf is spoken 
using the phonemes /s/, /k/, /ahr/ and /f/.
Item Examples
Word Book Scarf
Grapheme B OO K S C AR F
Phoneme lb/ /oo/ /k/ Is/ /k/ /ahr/ IV
Table 1.1: Terminology used to describe units of written and spoken language. Adapted from Paracchini 
et al. (2007).
Skills involved in processing phonemes include phonological coding/decoding, and 
phonological or phonemic awareness. Phonological coding is the ability to identify, 
discriminate and manipulate the phonological structure of a written word (Snowling
1995). Phonological awareness is the ability to be aware of and manipulate the sound 
structure of spoken words (Olson et al. 1994).
Orthographic processes are also important when learning to read, as these involve 
exploiting whole-word information, in particular, the visual appearance or shape 
(orthography) of a written word (Olson et al. 1994). Orthographic coding is the ability
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to recognise spelling patterns to establish the proper meaning of words. These skills are 
of particular importance when reading the English language for example, as the English 
language has many instances where identical sounding words differ in their meaning 
depending on how they are spelt (e.g. ‘there’ versus ‘their’). In addition, the English 
language contains words whose sound do not represent their spelling (e.g. ‘yacht’).
There have been a number of theories put forward to explain the deficits observed in 
DD individuals but none of these theories are able to account for all cases of DD on 
their own.
1.1.3.1 The Phonological Core Deficit Theory
The phonological core deficit theory suggests that DD may be caused by a problem 
in representing, storing or retrieving phonemes from long-term memory, impairing an 
individual’s ability to segment a word into its phonological units, resulting in poor or 
ineffectual reading (Snowling 1981). The phonological deficit is believed to be 
independent of non-phonologic abilities and so higher-order cognitive and linguistic 
functions (such as IQ and vocabulary) remain intact.
At the neurological level, it is usually assumed that the origin of the disorder is a 
congenital dysfunction of left-hemisphere perisylvian brain areas underlying 
phonological representations, or connecting between phonological and orthographic 
representations (Ramus et al. 2003b). Anatomical work (Galaburda et al. 1985) and 
functional brain images have supported this theory (Paulesu et al. 1996; Paulesu et al. 
2001; Shaywitz et al. 1998; Brunswick et al. 1999; McCrory et al. 2000; Pugh et al. 
2000; Temple et al. 2001; Shaywitz et al. 2002).
The phonological core deficit theory is the most widely accepted theory of DD. 
Castles and Coltheart (2004) have criticised this theory as no study has been able to 
show unequivocal evidence that there is a causal link for ability in phonological 
awareness and success in reading and spelling acquisition. It also suffers from its 
inability to explain the sensory and motor disorders that occur in a significant 
proportion of individuals with DD (Ramus et al. 2003b). However, supporters of the 
theory tend to dismiss these disorders as not being part of the core features of dyslexia, 
considering them to be potential markers of DD rather than playing a causal role 
(Snowling 2000).
3
1.1.3.2 The Double Deficit Hypothesis
The double-deficit hypothesis proposes that DD arises from deficits in both 
phonological processes and the rapid naming of simple stimuli (Wolf & Bowers 1999). 
Studies have shown that naming-speed deficits can cause variance in reading, 
independent of the variance contributed by phonological awareness measures 
(Blachman 1984; Bowers & Swanson 1991; Olson et al. 1994).
Wolf and Bowers (1999) have suggested that deficits in the processes underlying 
naming-speed hinder lower level perceptual requirements that result in non-fluent word 
identification and hinder comprehension. They also suggest that deficits in naming- 
speed represent a broader system of rate or efficiency-based difficulties that affect 
orthographic and phonological routes and representations.
1.1.3.3 The Rapid Auditory Processing Theory
This theory suggests that DD develops from an auditory deficit that inhibits the 
perception of short or rapidly varying sounds (Tallal 1980; Tallal et al. 1993). Dyslexics 
show poor performance on a number of auditory tasks, including frequency 
discrimination (McAnally & Stein 1996; Ahissar et al. 2000) and temporal order 
judgement (Tallal 1980; Nagarajan et al. 1999).
A failure to correctly identify short sounds and fast transitions can cause difficulties 
when such acoustic events are the cues to phonemic contrasts. For example, it may 
result in an inability to distinguish between the phonemes /ba/ and /da/. There has been 
evidence that individuals with DD may have poor categorical perceptions of sound 
contrasts, indicating that the auditory deficit may be the direct cause of phonological 
deficits which result in a failure to read (Mody et al. 1997; Adlard & Hazan 1998; 
Semiclaes et al. 2001).
1.1.3.4 The Visual Theory
This theory suggests DD is caused by a visual impairment giving rise to difficulties 
in processing letters and words in text (Lovegrove et al. 1980; Livingstone et al. 1991; 
Stein & Walsh 1997). It does not exclude a phonological deficit, but emphasizes a 
visual contribution to reading problems in some individuals with DD. The visual theory
4
suggests that the magnocellular pathway is selectively disrupted in certain dyslexic 
individuals and this leads to deficiencies in visual processing, and, via the posterior 
parietal cortex, to abnormal binocular control and visuospatial attention (Stein & Walsh 
1997; Hari et al. 2001). Support for this theory comes from anatomical studies showing 
abnormalities of the magnocellular layers of the lateral geniculate nucleus (Livingstone 
et al. 1991) and psychological studies have demonstrated decreased sensitivity in the 
magnocellular range, i.e. low spatial frequencies and high temporal frequencies, in 
individuals with DD (Lovegrove et al. 1980; Comelissen et al. 1995). However, 
criticism for this theory has come from failures to replicate findings of a visual deficit 
(Victor et al. 1993; Johannes et al. 1996) or from findings that such a deficit exists in 
only a subgroup of individuals with DD (Comelissen et al. 1995; Witton et al. 1998; 
Amitay et al. 2002).
1.1.3.5 The Cerebellar Theory
The cerebellar deficit theory attempts to tie in the motor deficits often associated 
with DD by recognising that the cerebellum is important in both movement controls and 
the automation of overleamed tasks, such as driving, typing and reading (Nicolson et al. 
2001; Stoodley et al. 2005; Haslum & Miles 2007). A weak capacity to automatise 
would affect the learning of grapheme-phoneme correspondences. Support for this 
theory has come from evidence of individuals with DD performing poorly in a large 
number of motor tasks (Fawcett et al. 1996), in dual tasks demonstrating impaired 
automatisation of balance (Nicolson & Fawcett 1990) and in time estimation, which is a 
non-motor cerebellar task (Nicolson et al. 1995). Brain imaging studies have also shown 
anatomical, metabolic and activation differences in the cerebellum of dyslexics (Rae et 
al. 1998; Nicolson et al. 1999; Brown et al. 2001; Leonard et al. 2001).
This theory does not account for sensory disorders observed in individuals with DD, 
such as auditory and visual deficits, but supporters of the cerebellar theory have 
suggested that there may be two distinct subtypes of DD, one involving the cerebellum, 
the other the magnocellular pathways (Fawcett & Nicolson 2001). However, it is 
uncertain how many individuals with DD have motor problems as some studies have 
failed to find such problems (Wimmer et al. 1998; van Daal & van der Leij 1999; 
Kronbichler et al. 2002) whereas others only find them in subgroups of DD (Yap & van 
der Leij 1994; Ramus et al. 2003a).
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1.1.3.6 The Magnocellular Theory
This theory attempts to integrate all of the findings mentioned above. The 
magnocellular (auditory and visual) theory suggests that a general impairment in 
magnocellular pathways will affect visual, auditory and tactile sensory modalities (Stein 
& Walsh 1997). The cerebellum is also thought to be affected by the general 
magnocellular deficit because it receives a large amount of input from various 
magnocellular systems in the brain (Stein & Walsh 1997). This theory therefore 
manages to account for all aspects of DD, including visual, auditory, motor, tactile and 
phonological difficulties (Ramus et al. 2003b). Evidence specifically relevant to the 
magnocellular theory includes magnocellular abnormalities that have been observed in 
the medial and lateral geniculate nuclei of dyslexic brains (Livingstone et al. 1991; 
Galaburda et al. 1994), poor performance of individuals with DD in the tactile domain 
(Grant et al. 1999; Stoodley et al. 2000) and the co-occurance of visual and auditory 
problems in certain individuals with DD (Witton et al. 1998; Cestnick 2001; Van 
Ingelghem et al. 2001).
Many supporters of the auditory and visual theories now agree that visual and 
auditory disorders in dyslexia are part of a more general magnocellular dysfunction 
(Ramus et al. 2003b). However, this theory still fails to describe why not all deficits are 
observed in all individuals with DD. For example, there have been a number of failures 
to replicate findings of auditory disorders in dyslexia (Heath et al. 1999; Hill et al. 1999; 
McArthur & Hogben 2001). Other studies have found auditory deficits in individuals 
with DD, but only in a subgroup (Tallal 1980; Reed 1989; Manis et al. 1997; Mody et 
al. 1997; Adlard & Hazan 1998; Lorenzi et al. 2000; Marshall et al. 2001; Rosen & 
Manganari 2001). In addition, results have shown inconsistencies with the theory that 
auditory deficit lies in ‘rapid’ auditory processing, and therefore with magnocellular 
function, with ‘rapid’ auditory processing remaining intact with some tasks while 
‘slow’ auditory processing is found to be impaired with others (Reed 1989; McAnally & 
Stein 1996; Adlard & Hazan 1998; Schulte-Kome et al. 1998b; Witton et al. 1998; 
Nittrouer 1999; Lorenzi et al. 2000; Rosen & Manganari 2001; Share et al. 2002). It has 
also been argued that auditory deficits do not predict phonological deficits (Mody et al. 
1997; Schulte-Kome et al. 1998a; Bishop et al. 1999; Marshall et al. 2001; Rosen & 
Manganari 2001; Share et al. 2002). The visual side of the magnocellular theory has 
also been criticised because visual impairments observed in individuals with DD tend to
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be in a whole range of stimuli rather than those that specifically tap into the 
magnocellular system (Skottun 2000; Amitay et al. 2002; Farrag et al. 2002). 
Kronbichler and colleagues (2002) found significant differences between DD cases and 
controls in phonological tests but not in visual, auditory or motor tasks, supporting the 
idea of a phonological deficit but not a deficit in the magnocellular system.
1.1.3.7 The Attentional Deficit theory
The neural process which allows for the processing of stimuli relevant to a particular 
task, while inhibiting irrelevant stimuli, is referred to as attention. When reading text, 
the attention needs to be shifted between individual letters and letter groups, as well as 
rapid and accurate integration of visual and auditory (if reading aloud) cues. Accurate 
reading also requires filtering out information from the periphery. Individuals with DD 
have been found to have deficits in suppressing interfering peripheral information and 
focusing their attention on the text (Geiger et al. 1994; Steinman et al. 1998; Facoetti et 
al. 2000). Individuals with DD have also been found to be easily distracted and often 
have problems maintaining attention on one task for prolonged periods (Keogh & 
Margolis 1976). Further support for this theory comes from the observation that 
attentional deficit hyperactivity disorder (ADHD) is often found to be comorbid with 
DD (see Section 1.1.5.1)
It is possible that all these theories are true, with different individuals having 
partially overlapping subtypes of DD (Ramus et al. 2003b). However, it could be that 
one theory accounts for every case of DD and that the other manifestations observed are 
different markers for DD (i.e. they are associated with DD but are not the cause of DD) 
(Ramus et al. 2003b).
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1.1.4 Neurobiology of Developmental Dyslexia
Evidence for a neurobiological basis for DD comes from post-mortem examinations 
and brain imaging of individuals with DD.
1.1.4.1 Post Mortem Studies of Individuals with DD
The planum temporale is located within the sylvian fissure on the superior-posterior 
surface of the temporal lobe and it functions in auditory comprehension and possibly 
phonologic processing (Frank & Pavlakis 2001). Generally the planum temporale is 
larger on the left side and this asymmetry forms as early as 33 weeks gestation. Post 
mortem examinations of 7 brains from individuals with DD revealed that there was an 
increase in abnormalities of the left hemisphere, particularly around the perisylvian 
region, and the planum temporale was nearly symmetrical which has been suggested to 
be the result of enlargement of the right side (Galaburda & Kemper 1979; Galaburda et 
al. 1985; Humphreys et al. 1990). The abnormalities consisted of neuronal ectopias, 
dysplasias and vascular micro-malformations. The ectopias were often found in layer I 
of the left inferior frontal and superior temporal gyri, suggesting that these occurred at a 
time of peak neuronal migration during embryonic development (Galaburda et al.
1985). It should be noted however, that some individuals showing these abnormalities 
reported oral language delay as well as DD (Cohen et al. 1989).
Subsequent visual processing and auditory processing experiments suggested 
hypotheses which led to re-examination of these brains, revealing disorganisation of the 
magnocellular layers of the lateral geniculate nuclei (LGN) (Galaburda & Kemper 
1979; Galaburda et al. 1985; Humphreys et al. 1990; Livingstone et al. 1991). These 
observations are consistent with the visual processing deficiencies observed in 
individuals with DD as this region of the brain forms part of the primate visual system 
(Livingstone et al. 1991). It was also noticed that the cell bodies making up the 
magnocellular layers of the LGN from the brains of individuals with DD appeared 
smaller than in control brains. As the medial geniculate nuclei (MGN) are involved in 
the auditory processing system, these regions of the dyslexic brains were also examined 
(Galaburda & Kemper 1979; Galaburda et al. 1985; Galaburda et al. 1994; Humphreys 
et al. 1990). The dyslexic brains showed greater asymmetry between the left and right
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MGN than in control brains, and in general, the left MGN had a higher number of 
smaller neurons and less larger neurons (Galaburda et al. 1994).
In addition to these studies on DD brains, studies on mice and rats with ectopia and 
microgyri have found that they exhibit a number of learning deficits (Denenberg et al. 
1991; Schrott et al. 1992; Rosen et al. 1995; Balogh et al. 1998). Mice with ectopia in 
layer I of the cortex were found to learn differently compared to non-ectopic mice and 
since the ectopia that were observed are structurally similar to those of dyslexic 
individuals, this suggest that individuals with DD may learn differently to those without 
the learning disability. The specific location of the cortical disruption (e.g. in the pre- 
fontal cortex or motor cortex) also influenced the type of learning disability exhibited 
by the mouse and this may reflect the variability in the extent of learning disability 
found in individuals with DD (Hyde et al. 2001).
1.1.4.2 Brain Imaging Studies of Individuals with DD
Functional neuroimaging of brains unaffected by DD has taught us more about the 
processes behind reading. These studies suggest that two posterior pathways are 
involved in reading, the dorsal and ventral pathways, along with an anterior component. 
The dorsal pathway is centred in the left temporoparietal regions and includes the 
angular and supramarginal gyri as well as the left posterior end of the superior temporal 
gyrus (Simos et al. 2000b). This pathway deals with linking graphemes of a visual word 
with phonemes and an underactivation in this pathway is considered to be linked with a 
phonological deficit. The ventral pathway is centred on the left inferior 
occipitotemporal region, including the posterior fusiform gyrus. It is thought to be 
required for the quick automatic processing of familiar words or frequent letter strings 
within words and an underactivation of this pathway in individuals with DD is thought 
to be linked with slow and inaccurate word recognition. The anterior component is 
centred on the left inferior frontal gyrus and is involved in the articulation of speech 
sounds (Richlan et al. 2009).
Functional neuroimaging studies on individuals with DD have shown altered 
activity of these regions (Demonet et al. 2004). Corina and colleagues (2001) found that 
phonological and lexical tasks resulted in activation of the left inferior temporal gyrus in 
most controls brains, but very few of the DD showed any activation in this region. Other 
studies have also shown reduced activity of the left temporoparietal regions on tasks of
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word reading, non-word reading and letter rhyming (Simos et al. 2000a; Simos et al. 
2000b; Temple et al. 2001) and left occipitotemporal regions on tasks of letter matching 
(Temple et al. 2001).
Shaywitz and colleagues (2002) conducted a neuroimaging study comparing 70 
individuals with DD to 74 controls and found that individuals with DD had reduced 
activity in the left inferior frontal, left superior temporal, left occiptotemporal and left 
temporoparietal regions on several reading related tasks. They also found a correlation 
between reading skill and activity in left posterior regions (Shaywitz et al. 2002).
Neuroimaging studies have also identified that DD brains have greater asymmetry 
and less grey matter content of the cerebellum (Brown et al. 2001; Eckert et al. 2003; 
Leonard et al. 2001). Leonard and colleagues (2001) also found that phonological 
deficits correlate with a smaller right anterior lobe.
As well as this decreased activity in the left hemisphere of the brain in individuals 
with DD, increased activity in the right hemisphere is often observed, possibly as part of 
a compensatory mechanism. For example, studies have found that the right 
temporoparietal regions of the brains of individuals with DD showed greater activity in 
response to both word and non-word reading (Simos et al. 2000a; Simos et al. 2000b). 
Corina and colleagues (2001) also demonstrated that there was increased activity in the 
right inferior temporal gyrus relative to the left in the brains of individuals with DD 
during a phonological task.
These neuroimaging studies have indicated that there seems to be a reduction in 
activity of the left temporal areas which is consistent with the results from post-mortem 
brain studies of individuals with DD. Together, these results suggest that reading 
requires a number of brain areas, including posterior (phonological processes) and 
anterior brain regions (syntactic processing).
It is important to note that many of these neurobiological studies involve small 
numbers of participants which often included only adults and controls which were not 
well matched in terms of sex, handedness, intelligence or educational experience. 
Schlaug and colleagues (1995) have suggested that intensive training in language skills 
can modify the symmetry observed in individuals with DD, resulting in ‘normalisation’ 
of the brain and so studies need to be conducted on larger, homogenous samples of 
children, rather than adults.
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1.1.4.3 Neuronal Migration and DD
A number of studies have suggested that impaired neuronal migration may be a 
functional cause of DD. The developmental progression of the cerebral cortex is unique 
to mammals and is fairly conserved throughout species (Ayala et al. 2007). Neuronal 
migration is a key step in the development of the neocortex, resulting in the organisation 
of neurons in to six specialised laminar layers (Hatten 1999). It is achieved through the 
rearrangement of cytoskeletal components in response to extracellular cues and is 
mediated by numerous intracellular pathways (Ayala et al. 2007).
Cortical neurones arise from proliferative pseudostratified epithelium at the margin 
of the embryonic cerebral vesicles (Rakic 1982). During each cell cycle, progenitor 
cells undergo a pattern of oscillation in the ventricular zone, termed interkinetic nuclear 
migration, shown in Figure 1.1. Projection neurons are bom from radial glial cells in the 
ventricular zone. These migrate radially along radial glial fibres towards the pial 
surface. The S phase of the cell cycle occurs at the basal surface of the ventricular zone, 
with mitosis occurring at the apical surface. Once a cell has exited the cell cycle, it must 
migrate out of the ventricular zone to its final resting place in the developing neocortex. 
The first set of neurons that migrate out of the ventricular zone make up the preplate 
with the next wave of migration splitting the preplate into two layers: the marginal zone 
and the deeper subplate. The development of the cerebral cortex progresses with 
successive waves of migration that position neurons within the different layers in the 
cortical plate (Hatten 1999). These layers are established according to an inside-out 
pattern where the earliest waves of neuronal migration will go on to form the deeper 
layers of the cortical plate while the last waves of neurons will be localised to the more 
peripheral layers (Marin & Rubenstein 2001).
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Figure 1.1: Diagram illustrating the migration o f neurons from the ventricular zone, along glial fibres 
towards the pial surface, at different stages o f the cell cycle. Taken from Ayala et al. (2007).
The general model for neuronal movement consists of three repetitive and highly 
regulated steps. In the first step, the cell extends a leading neurite which is preceded by 
a growth cone which extends and contracts as it explores the microenvironment. The 
growth cone is a very dynamic structure, showing extension and retraction of the 
filopodia as well as ruffling and transient advance or collapse of lamellipodia as it 
detects signals providing information on the direction that the cell should migrate in. 
The next step involves translocating the nucleus into the leading neurite, before the 
trailing process is retracted in the final step. This last step is still poorly understood 
(Ayala et al. 2007). The molecular mechanisms involved in regulating neuronal 
migration consist of extracellular guidance cues which are interpreted by receptors. 
These receptors then relay signals to a large network of intracellular signalling 
pathways, converging to the cytoskeleton. Both microtubule and actin networks are 
believed to operate synergistically to mediate migration (Ayala et al. 2007).
Defects in neuronal migration are the cause of several human syndromes with 
symptoms of epilepsy and mental retardation (Bielas et al. 2004; McManus & Golden 
2005). As mentioned previously, Galaburda and colleagues (1979; 1985) undertook 
microscopic analysis of brain tissue, and they showed the presence of ectopia, dysplasia 
and vascular micro-malformations in cortical parietal regions of the brains from 
individuals with DD, suggesting impairments in neuronal migration. Further support for 
the involvement of impaired neuronal migration in DD has come from behavioural 
studies conducted on individuals with periventricular nodular heterotopias (PNH) which
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is a neuronal migration disorder caused by a mutation in the filamin A (FLNA) gene 
(Fox et al. 1998). Chang and colleagues (2005) tested 10 patients with PNH and 
epilepsy and found that 8 of these had deficits in reading skills despite normal 
intelligence. They also found that in those individuals with more wide-spread 
heterotopias, the deficits in reading skills were more severe (Chang et al. 2005).
Providing further support for a role of neuronal migration within DD, a number of 
putative susceptibility genes for DD have been found to have possible roles in neuronal 
migration and these are discussed in Chapter 3.
1.1.5 Comorbidity of DD with Other Neurodevelopmental Disorders
A number of disorders have been found to exist in individuals with DD more often 
than in matched controls.
1.1.5.1 Attentional Deficit Hyperactivity Disorder (ADHD)
ADHD is characterised by inattention, overactivity and impulsiveness. Studies have 
estimated that 15-40% of individuals diagnosed with DD also have ADHD (Gilger et al. 
1992; Willcutt & Pennington 2000; Willcutt et al. 2007). Twin and family studies on 
DD and ADHD have suggested that these disorders have shared genetic underpinnings 
(Willcutt et al. 2000; Willcutt et al. 2007). When ADHD is subdivided into its symptom 
dimensions, twin studies also predict a stronger relationship between DD and symptoms 
of inattention compared with symptoms of hyperactivity/impulsivity (Willcutt et al. 
2000).
Results from linkage studies of DD and genome scans of ADHD have indicated 
several regions that overlap. Willcutt and colleagues (2002) have suggested that the 
comorbidity between DD and ADHD may be partly due to the effects of the 
quantitative trait locus (QTL) on chromosome 6p (see section 1.4.4). Overlapping loci 
on 15q, 16p, 17p, lOq, 14q32, 13q32 and 20ql 1 have also been suggested by additional 
studies (Loo et al. 2004; Gayan et al. 2005; Wigg et al. 2004; Wigg et al. 2008).
1.1.5.2 Developmental Dyscalculia (DC)
DC is generally defined as a specific impairment in arithmetic abilities, despite any 
deficits in intelligence, socioeconomical background, general motivation, emotional
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stability, educational opportunity or sensory acuity. Studies have estimated that 25-37% 
of individuals with DD also have DC (Knopik et al. 1997; Lewis et al. 1994) and 17 - 
70% of individuals with DC also have DD (Gross-Tsur et al. 1996; Knopik et al. 1997; 
Lewis et al. 1994).
1.1.5.3 Developmental Coordination Disorder (Dyspraxia)
Dyspraxia is an impairment in the development of motor coordination which is not 
attributable to a general medical condition or mental retardation. It has been estimated 
that there is an overlap of 30-50% between DD and dyspraxia (Kadesjo & Gillberg 
1999; Richardson & Ross 2000). Whilst a relationship between lower motor ability, 
such as hand motor skill and DD has been observed, the genetic effects in motor skill 
are largely distinct from DD (Francks et al. 2003).
1.1.5.4 Specific Language Impairment (SLI) and Speech-Sound Disorder (SSD)
SLI is an impairment in the ability to acquire adequate language skills, despite 
normal intelligence and development. Studies have estimated that 20-60% of 
individuals with DD also have SLI (McArthur et al. 2000) and 40-80% of individuals 
with SLI also have DD (McArthur et al. 2000).
SSD (or phonological disorder) is characterised by speech-sound production errors 
associated with deficits in articulation, phonological processing and cognitive linguistic 
processing. There is not much evidence of increased co-morbidity between DD and 
SSD alone, but in conjunction with language impairments there is significant co­
morbidity with DD, particularly with deficits in spelling (Bishop & Adams 1990; Lewis 
et al. 1994). Stein and colleagues (2004) found that 21.6 % of individuals with SSD also 
have DD and also found linkage of SLI to a region of chromosome 3, a region 
implicated in linkage studies of DD as discussed in section 1.4.5.
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1.2 Genetic Basis of Developmental Dyslexia
1.2.1 Familiality of Developmental Dyslexia
The first step in determining whether or not a disorder may have a genetic aetiology 
is to establish that the disorder runs in families (familiality). This is measured by 
comparing the rate of a disorder in relatives of probands to the baseline rate found in the 
general population.
Familial clustering of DD was observed over 100 years ago (Hinshelwood 1907; 
Stephenson 1907; Thomas 1905). Since then, a number of large studies have confirmed 
DD familiality. An early study by Rutter and Yule (1975) found that 9% of control 
children had a sibling or parent with a reading problem, compared with 34% of children 
with DD. More recently, it has been shown that 20-33% of siblings of affected 
individuals, with unaffected parents, are themselves also affected (Gilger et al. 1996). 
This percentage increased to 54-63% if either parent was also affected (Gilger et al.
1996).
The probability of an individual being affected with DD given that a sibling is 
already affected (regardless of parental affection status) is estimated to be between 38% 
and 60% (Hallgren 1950; Finucci et al. 1976; Vogler et al. 1985; Gilger et al. 1991; 
Gilger et al. 1996). These sibling recurrence risk estimates are considerably higher than 
the general population risk (5 to 10%) (Pennington 1990).
Gilger and colleagues (1991) also studied the probability of a mother or father being 
affected if they had affected offspring in three population samples from Iowa and 
Colorado. They found that the risk of a father being affected if their son was affected 
was between 30% and 35% and between 12% and 15% for mothers. For those parents 
with an affected daughter, the risk was between 17% and 41% for fathers and 30% and 
42% for mothers. Whereas the risk for parents of a normal control proband was 4% for 
fathers and 3% for mothers, which is close to the general population risk (Pennington 
1990).
From these studies, it is clear that the risk of having DD is greater among first 
degree relatives than in the general population. However, as families tend to share their 
environments, this alone does not imply that DD is strictly influenced by genetic 
factors. Twin studies have therefore been used to try to differentiate the genetic and 
environmental factors that influence DD and estimate the heritability of this disorder.
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1.2.2 Heritability of Developmental Dyslexia
Typically, twin studies consist of large sets of monozygotic (MZ) and same sex 
dizygotic (DZ) twins. The concordance rate for DD is then compared between the two 
sets of twins, with a higher concordance rate for DD in the MZ twins being suggestive 
of some genetic aetiology for DD.
Early twin studies of DD showed significantly greater MZ than DZ concordance for 
DD (Hallgren 1950; Hermann 1956; Bakwin 1973), but these suffered from 
methodological problems including ascertainment bias, inconsistent definitions of DD, 
failure to determine zygosity adequately and failures to limit DZ twin samples to same 
sex twins (Stevenson et al. 1987; Pennington 1989). The first compelling evidence that 
DD is influenced by genetic factors came from two large twin studies in the 1980s: the 
London Twin Study (Stevenson et al. 1987) and the Colorado Twin Reading Study 
(DeFries et al. 1987). Stevenson and colleagues (1987) examined the reading skills of 
285 pairs of 13 year old twins identified from the general population on the basis of 
birth records and from the registers of schools in the London area. They did not find any 
evidence supporting the heritability of reading in general, but did find significant 
heritability for phonological coding (82%). In a later study of this twin sample, 
Stevenson (1991) observed significant heritability for impaired spelling (62%) and 
found that deficits in phonological processing were more heritable than deficits in 
orthographic coding.
DeFries and colleagues (1987) used multiple regression analysis of twin data in their 
analysis of 64 MZ and 55 DZ twin pairs in which at least one member of the pair (the 
proband) had DD. These twins were ascertained from schools in Colorado. The reading 
ability of both twins was then assessed by a standard battery of tests that had been 
previously shown to discriminate between individuals with DD and normal readers.
This study found highly heritable components to reading (44%), spelling (62%) and 
deficits in phonological processing (75%), but did not identify a significant heritable 
component for orthographic processing (31%).
Gayan and Olson (1999) used a larger sample from the Colorado Twin Study and 
reported significant heritabilities of 61% for phonological decoding, 56% for 
phonological awareness and 58% for orthographic processing. This suggests that 
phonological and orthographic deficits in DD have similar levels of heritability, in
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contrast with the studies by Stevenson (1991) and DeFries and colleagues (DeFries et 
al. 1987) which observed lower heritability for orthographic deficits.
The concept of heritability is not a fixed one as the variance that can be attributable 
to genes is partly dependent on the variance in exposure to relevant (but unknown) 
environmental risk factors and on the characteristics of the population studied (Williams 
& O'Donovan 2006). In a further study of the Colorado twin sample, DeFries and 
colleagues (1997) demonstrated that reading had a higher heritability in younger 
compared with older children, whereas the heritability of spelling increased with age. 
Another study on this sample by Wadsworth and colleagues (2000) found that 
heritability estimates increase with increasing levels of IQ. They reported a heritability 
of 43% for a group of twins with the average IQ of each twin pair below 100 and a 
heritability of 72% for a group of twins with an average IQ above 100, suggesting that 
genetic factors may be more important in DD in individuals with higher IQs. However, 
they did not determine whether the genetic factors that influenced DD differed as a 
function of IQ. It may be that the same genetic factors are involved in DD, regardless of 
IQ but the proportion of variance accounted for by these genetic factors may differ 
because the degree and nature of environmental influences may vary as a function of 
IQ.
1.2.3 Mode of Transmission
Pennington and colleagues (1991) performed segregation analysis of DD in order to 
establish a mode of transmission. They examined the relatives of DD probands in four 
independent samples from Colorado, Washington and Iowa, producing a sample of 204 
families and 1,698 individuals. Three of the four samples showed evidence for major 
locus transmission. In the first three samples, the estimates of penetrance of the AA, Aa 
and aa genotypes (where A is the risk allele) were, respectively, 1, 1 and 0.001-0.039 in 
males and 0.56-1, 0.55-0.897, and 0 in females. Therefore these samples were 
consistent with models of dominant or additive transmission, with sex-dependent 
penetrance. The fourth sample showed evidence of a multifactorial-polygenic 
transmission. Pennington and colleagues (1991) noted that they may have 
underestimated the multifactorial background of DD; the ascertainment procedures for 
two of the three samples showing evidence of major gene effect may have created bias. 
They also noted that the male penetrance estimates of 1.0 for homozygotes and
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heterozygotes were inconsistent with male MZ twin concordance rates, which are 
substantially less than 1.0 (Pennington et al. 1991).
Gilger and colleagues (1994) followed up this study by carrying out segregation 
analysis on a quantitative reading phenotype in 125 families which had been ascertained 
through normal probands. The results of this study suggested that a major gene with 
dominance was responsible for a significant amount of variance in reading scores 
(54%).
Wijsman and colleagues (2000) conducted segregation analysis on two phonological 
phenotypes (non-word memory and digit span) in 102 families with a DD affected 
proband. They found evidence in support of a Mendelian mode of inheritance with an 
intermediate heterozygous phenotype with a dominance of -0.8 for non-word memory. 
The inheritance of digit span was best described by a dominant gene model.
As discussed in section 1.1.2, a higher proportion of males than females appear to be 
affected by DD, suggesting that there may be sex effects on the transmission of this 
disorder. However, none of the family studies or segregation analyses found evidence 
for X-linked transmission (Pennington et al. 1991) or for mitochondrial transmission as 
transmission rates from each parental sex were essentially equal.
There does not appear to be a consensus mode of transmission of DD as yet. The 
findings that the MZ concordance rates and heritabilities for DD from twin studies are 
substantially less than 1.0 makes it unlikely that there is a major locus transmission. 
There may be a mixed model of a small number of susceptibility loci operating against a 
multifactorial background, or there may be a polygenic multifactorial model with a 
small number of Mendelian subforms of the disorder also existing.
1.3 Methods for Identifying Susceptibility Variants
As there is strong evidence for a genetic component influencing susceptibility to 
DD, the next logical step is to attempt to identify genes which confer susceptibility to 
DD. The two main methods that have been used to locate such susceptibility genes for 
DD so far are linkage and association analysis. They can be used to test specific 
candidate genes, or in a systematic scan of a chromosome or the entire genome. Linkage 
is only able to detect genes of major effect, but allows scanning of the entire genome 
with only a few hundred markers (Sham & McGuffin 2002). Association analysis can 
detect genes of more moderate effect, although until recently, only relatively small
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regions could be analysed at one time due to the number of markers required as these 
needed to be much more densely spaced compared to linkage. The advent of genome- 
wide association studies (GWAS) have now enabled the whole genome to be 
systematically scanned for association with a disorder. In the last few years, analysis of 
structural variants has also been employed to identify susceptibility variants for 
complex disorders.
1.3.1 Linkage Analysis
Linkage analysis has been particularly successful at detecting genes that cause 
Mendelian traits and is based on the phenomenon known as genetic linkage. During 
meiosis, homologous pairs of chromosomes can exchange genetic material in a process 
known as recombination which occurs at crossover points and chiasma. This process 
generates increased diversity among the human species, restructuring genes and their 
alleles (Sham & McGuffin 2002). If two loci are on different chromosomes, the 
probability that their alleles will be inherited together is 0.5, a phenomenon which 
Mendel described as independent assortment. For loci on the same chromosome, the 
nearer that two genes are to one another, the less likely it is that a crossover point will 
occur between them and the more likely it is that they will be inherited together. This 
departure from the law of independent assortment is known as genetic linkage.
Linkage analysis tests for cosegregation of a genetic marker and disease phenotype 
within many independent families or over many generations in an extended pedigree. 
Although the marker itself may not be causing the disease or phenotype, genetic linkage 
indicates that a susceptibility locus causing the phenotype is within the same 
chromosomal region as the segregating marker. The traditional approach for calculating 
the statistical evidence for linkage is the LOD score (Morton 1955). This score is a 
logarithm of the odds ratio of the likelihood that the observed co-segregation of marker 
and illness is due to linkage, against the likelihood that the observed co-segregation 
occurs by chance. It has been suggested that a cumulative LOD score exceeding 3 can 
be regarded as good evidence for linkage, while a cumulative LOD score below -2 
should be regarded as strong evidence against linkage.
19
1.3.1.1 Parametric and Non-parametric Analysis
Classic linkage analysis (known as parametric analysis) involves the specification of 
a genetic model and is a powerful method for detecting loci segregating in a Mendelian 
fashion (Sham & McGuffin 2002). However, DD is a complex disease and as discussed 
in section 1.2.3, the mode of transmission in unknown. In the case of complex diseases, 
non-parametric linkage analysis is a more appropriate method, albeit a less powerful 
one. Parametric linkage analysis follows the cosegregation of markers and 
disease/phenotype over a number of generations in large multiplex families, whereas 
non-parametric linkage analysis usually examines allele sharing in affected relatives, 
such as affected sib-pairs. Allele sharing can either be defined by identity-by-state (IBS) 
or identity-by-descent (IBD). If two alleles have the same DNA sequence at the 
polymorphic site then they are characterised as IBS. If these alleles are also both 
descended from a recent common ancestor then they are said to be IBD. The IBD 
measure of allele sharing is more informative and less dependent on knowledge of the 
exact marker allele frequency (Sham & McGuffin 2002).
1.3.1.2 Limitations of Linkage Analysis
For most common diseases, linkage analysis has only achieved limited success 
(Altmtiller et al. 2001; Hirschhom & Daly 2005), which can be attributed to a number 
of factors. For linkage analysis to succeed, markers that flank the disease gene must 
segregate with the disease in families. Linkage studies have been successful for 
mapping genes which underlie Mendelian traits because variants that cause monogenic 
disorders are often rare and so each segregating disease allele will be found in the same 
10-20cM chromosomal background within each family (Hirschhom & Daly 2005). In 
addition, Mendelian diseases are caused by highly penetrant variants and so markers 
within 10-20cM of the disease causing alleles will co-segregate with disease status 
(Hirschhom & Daly 2005). Advocates of the common disease, common variant 
hypothesis argue that many of the alleles affecting susceptibility to common complex 
traits (such as DD) will themselves be common (Reich & Lander 2001; Lohmueller et 
al. 2003). Most common diseases also have complex architectures in which the 
phenotype is determined by interactions between multiple genetic and environmental 
factors (Wang et al. 2005) and as such, any individual genetic variant will generally 
have a relatively small effect on disease risk (Hirschhom & Daly 2005). Linkage
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analysis is less powerful at identifying common genetic variants which have modest 
effects and prohibitively large sample sizes would be needed to detect small effects 
(Risch & Merikangas 1996). In addition, the standard set of microsatellites used in 
linkage analysis are spaced ~10cM apart and are therefore unlikely to extract complete 
inheritance information (Hirschhom & Daly 2005). Increasing the density of the marker 
map does not have a great effect on the resolution (Teare & Barrett 2005). Finally, 
whilst the linkage region identified may contain a susceptibility gene, such regions often 
contain hundreds of genes, many of which are biologically plausible candidates (Teare 
& Barrett 2005).
1.3.2 Association Studies
Genetic association studies aim to detect association between one or more genetic 
polymorphisms and a trait by looking for a significant difference in marker allele 
frequencies between a group of disease affected cases and unaffected controls. 
Association differs from linkage in that the same marker allele (or alleles) is associated 
with the trait in a similar manner across the whole population, while linkage allows 
different marker alleles to be linked with the trait in different families (Cordell & 
Clayton 2005). Association studies have greater power than linkage studies to detect 
small effects, but they require many more markers to be examined (Cordell & Clayton 
2005).
Allelic association describes a significant difference in marker allele frequency 
between cases and controls, whereas genotypic association refers to a significant 
difference in genotype frequency. There are 3 reasons why an association between a 
genetic marker and a trait might exist in a population. The polymorphism may itself be 
the causal variant and this is referred to as direct association. Alternatively, the 
polymorphism may not have a causal role but is associated with a nearby causal variant 
and this is referred to as indirect association. Finally, the association may also be due to 
some underlying stratification or admixture in the population being studied.
1.3.2.1 Linkage Disequilibrium
Indirect association arises due to linkage disequilibrium (LD) which refers to the co­
occurrence or correlation between two loci on the same chromosome. The reshuffling of
21
genes in meiosis will tend to reduce the level of LD between all pairs of loci from one 
generation to the next. However, as discussed earlier, markers that are close together are 
less likely to be separated by recombination and so the degree of LD between such 
alleles will decay at a slower rate over time. The degree of LD existing between two 
loci is usually calculated by one of two measures, D ’ or r2 (Devlin & Risch 1995). Both 
measures are based on the pairwise-disequilibrium coefficient D which is a measure of 
the co-variance between two loci. The value of D between two alleles (i.e. A and B) is 
calculated using the frequencies of the two alleles (pA and qs) and the haplotype 
frequency ( oiab)-
D a b  =  oia b  " P a 9 b
However, a limitation of using D as a measure of LD between two markers is that its 
possible value is constrained by the frequencies of each marker allele. In order to 
compare values of D between different pairs of markers with different allele 
frequencies, D is normalised to D ’ (Mueller 2004). Unlike D, D ’ lies on a scale of 0-1 
and is calculated using the theoretical maximal and minimal values of D (Dmax and Dmjn) 
(Devlin & Risch 1995; Mueller 2004):
I f D > 0 , D '  = D/Dmax 
If D < 0, D ’ = D/Dmin
A  D ’ value of 0 indicates there is no correlation between two loci, while a value of 
1 indicates complete LD, where all copies at one locus occur exclusively with one of the 
two possible alleles at the second marker. D ’ is an important measure for the 
identification of regions in which there has been little recombination and, therefore, in 
regions where there is the potential to map causal loci by indirect association studies 
(Cordell & Clayton 2005). However, a limitation of this measure is that where a 
difference in allele frequency between two markers exists, a D ’ of 1 can occur even 
though the two markers are not in perfect correlation since it reflects the correlation 
only since the most recent mutation occurred (Zondervan & Cardon 2004). For 
example, allele A of one locus may always occur with allele B of a second locus. 
However, allele B of the second locus may occur with both allele A and a of the first 
locus.
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The alternative measure, r2, accounts for this. It is measured using D plus the 
product of the allele frequencies at the two loci:
? =  D 2
f(A)f(a)f(B)f(b)
As with D \ r2 values lie between 0 and 1, but an r2 of 1 indicates a perfect 
correlation between the genotypes of two markers, where the occurrence of an allele at 
one marker perfectly predicts the allele at a second locus (Zondervan & Cardon 2004).
1.3.2.2 Association Due to Population Stratification
As well as direct and indirect association, another possible reason for a marker 
showing association with a disease or trait may be due to some underlying stratification 
or admixture in the population being studied. This may arise if the cases and controls 
being studied are not ethnically comparable as differences in allele frequency may arise 
whether the alleles are causally related to a disease or not. Meta-analyses (Ioannidis et 
al. 2003) have indicated that causal variants for complex disease are likely to have small 
effect sizes and so large studies will be required to detect them (Dahlman et al. 2002).
In this situation, even modest confounding by stratification and admixture could have a 
large effect on the results (Cordell & Clayton 2005). It is therefore vital to ensure that 
cases and controls are well matched for ethnicity and other confounding factors. One 
method to deal with this is to use unaffected family members as controls, such as 
parents or siblings. However, using siblings results in a loss of power as they are over­
matched to the cases. In addition, family studies are difficult to conduct on a sufficiently 
large scale to detect associations reliably (Cordell & Clayton 2005). Therefore, well 
chosen unrelated controls may be the best option.
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1.3.2.3 Association Study Design
To guarantee detection of all possible disease-associated variants at a given gene or 
locus, every base at which variation might conceivably alter gene function or expression 
would need to be examined in very large samples (Hattersley & McCarthy 2005). This 
is currently unrealistic and so research groups have used various strategies in the design 
of their association studies in order to retain as much power as possible to detect true 
causal variants for a disease, but without the study becoming prohibitively expensive.
Association studies can be conducted using a hypothesis-led candidate gene 
approach or using a more systematic approach which may involve testing 
polymorphisms in a chromosomal segment or conducting a genome-wide association 
study (GWAS). They can also be conducted using a case control sample, or using a 
family based sample.
1.3.2.3.1 Tag Marker Selection
Advocates of the common disease, common variant hypothesis argue that many of 
the alleles affecting susceptibility to common complex traits (such as DD) will 
themselves be common (Reich & Lander 2001; Lohmueller et al. 2003). If this is true, 
then typing of regional ‘tag-markers’ which are selected specifically to capture such 
common alleles should provide an efficient approach for detecting complex trait 
susceptibility alleles (Zondervan & Cardon 2004; Gabriel et al. 2002) .
The presence of LD in the human genome allows for the selection of these tag 
markers when conducting association studies. If an association signal is detected then 
the polymorphisms tagged by the significant marker are considered to be potential risk 
variants along with the significant marker itself. In order to identify these tag markers, it 
is first necessary to genotype all polymorphisms at a locus within either a subset of the 
association sample or a representative population. This allows estimation of the LD 
structure of the association sample and so tag markers can be selected. The HapMap 
database (www.hapmap.org) is a research tool which often allows the researcher to 
avoid this initial step. It is a publically available database created by the International 
Haplotype Map Consortium (The International HapMap Consortium 2007). It contains 
details of over 5.5 million single nucleotide polymorphisms (SNPs) (HapMap phase II) 
which have been genotyped in 270 individuals from four populations, West European 
(CEU), West African (ASW), Han Chinese (CHB) and Japanese (JPT). The more recent
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phase III of the HapMap project now contains genotype information for individuals 
from populations across the world including Chinese in Colorado (CHD), Gujariti 
Indians in Texas (GIH), Luhya in Kenya (LWK), those with Mexican ancestry in 
California (MEC), Maasai in Kenya (MKK), Tuscan in Italy (TSI) and Yoruban in 
Nigeria (YRI).
The selection of tag SNPs is based on a number of factors. The researcher needs to 
decide how much of the genetic variation in a region they want to cover (e.g. common 
variation versus rare variation) and how thoroughly (i.e. the degree of LD between the 
genotyped marker and the tagged SNP). Due to the large sample sizes that are needed to 
detect an association with rare SNPs, a minor allele frequency (MAF) > 0.05 is often 
chosen. The ideal tag SNP selection strategy would also genotype all markers where the 
alleles are not in an r2 of 1 with any other genotyped marker. However, this could still 
result in a prohibitively large number of SNPs to genotype so this threshold is often 
reduced to r2 > 0.8.
1.3.2.3.2 Case Control Studies
The simplest type of association study involves comparing individuals with a 
disease (cases) with unaffected subjects from the same population (controls) (Sham & 
McGuffin 2002). Because family data are not required, case control samples are 
relatively easy to collect and this allows for the collection of larger samples, giving the 
study greater power to detect true association variants (see section 1.3.2.4). As 
mentioned earlier, the one drawback of a case control study is that spurious association 
can arise in the presence of population stratification. To protect against this, it is 
important to ensure that the sample is ethnically homogenous and that the cases are 
matched to the controls for possible confounding factors such as age and sex. It is often 
not possible to obtain perfectly matched case control samples however, and often 
unknown confounding factors can remain. In these instances, epidemiological methods 
of adjustment such as stratified analysis or logistic regression can be used to correct for 
confounding factors as much as possible (Sham & McGuffin 2002). Logistic regression 
is particularly useful in also allowing the analysis of potential interaction between 
genotype and demographic or environmental factors.
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1.3.2.3.3 Family Based Studies
As mentioned previously, one way to prevent population stratification producing 
confounding effects is to use family based samples, in which unaffected family 
members are used as controls, such as parents or siblings. The most popular family 
based association study design uses parent-proband trios in which both parents and their 
affected offspring are genotyped (Sham & McGuffin 2002). If there is a distortion in the 
number of times an allele is transmitted to the affected offspring from a heterozygote 
parent that is greater than expected by chance, then the allele is said to be associated.
However, there are two additional costs to using this type of study design. Firstly, 
complete families will inevitably be more difficult to identify and recruit, especially for 
late-onset diseases such as Alzheimer’s disease. Secondly, for equivalent power, the trio 
design is relatively more expensive than a case/control approach, requiring multiples of 
three individuals to be genotyped compared to two individuals of a case-control pair. A 
drawback of using unaffected siblings is the resulting loss of power as they are over­
matched to the controls, as mentioned earlier.
1.3.2.3.4 Pooling Studies
Another option to reduce the cost of association studies is to carry them out in the 
form of a pooled study. These involve mixing equal amounts of DNA from each sample 
to form a pool of case samples and another of control samples. Thus, the allele 
frequencies in a sample of 200 cases and 200 controls can be measured from two pooled 
samples, rather than 400 individual samples. However, as allele frequencies can only be 
estimated from such studies, replicates of pooled samples are often run in order to 
calculate the average allele frequencies.
Unfortunately, the increase in efficiency gained by genotyping fewer samples is 
somewhat reduced due to a loss of detailed information that could have been obtained 
through individual genotyping (Sham et al. 2002). Pooling studies and their caveats are 
discussed in more detail in Chapters 5 and 6 of this thesis.
1.3.2.3.6 Candidate Gene Studies
This type of association study involves testing variants within interesting genes for 
an association with a disease or trait, as opposed to systematically testing the whole 
genome or a chromosomal segment. In these hypothesis based studies, genes are 
selected for further study on the basis of evidence that might affect disease risk.
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Evidence from a range of sources can be used to identify candidate genes (Hattersley & 
McCarthy 2005). These may include: biological evidence which shows that the function 
of the protein encoded by the gene is implicated in the disease or trait; the gene may 
encode a protein which is implicated in the mechanism-of-action of a disease-modifying 
drug; animal homologues of the gene may be implicated in related traits in animal 
models; genome-wide scans for linkage or association could indicate regions with a 
high probability of containing a susceptibility gene. A major problem in selecting 
candidate genes is that if the precise biology underlying the trait is unknown, it is 
possible to find evidence connecting almost any gene to the disease of interest. 
Therefore a combination of evidence from different sources is often required when 
selecting candidate genes.
An additional caveat of candidate gene is that detection of a true association would 
not only require that the gene product is involved in pathways relevant to the 
development of the trait of interest, but also that the gene contains variants that are 
capable of influencing its regulation or function (Hattersley & McCarthy 2005).
1.3.2.3.5 Genome Wide Association Studies
Genome wide association studies (GWAS) involve systematically testing variants 
across the genome for association with a particular trait or disease. This enables a 
hypothesis-free approach to identifying susceptibility variants, and therefore does not 
require prior knowledge of the biology of the disease.
The increasing knowledge of common polymorphisms in the genome in different 
populations through the HapMap project (The International HapMap Consortium 2007) 
has enabled the development of commercial arrays which currently allow the researcher 
to genotype over 2.5 million markers across the human genome. The two main 
manufacturers of these arrays are Illumina (www.illumina.com) and Affymetrix. These 
companies use different methods to select markers for inclusion in their arrays. The 
probes on the Affymetrix arrays are spaced evenly throughout the genome without 
taking inter-SNP LD into account whereas Illumina selected tag SNPs to maximise 
genetic coverage. The earlier Illumina arrays (e.g. HumanHap300) contained probes for 
over 300,000 tag SNPs, whereas the newest arrays (e.g. HumanOmni2.5-Quad) contain 
probes for -2.5 million markers, including probes for common (MAF > 0.05) as well as 
rare (MAF > 0.025) SNPs and non-polymorphic probes to capture common copy 
number variation (see section 1.3.3 and Chapter 7).
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As the older arrays provide less coverage of the genome, a modest boost to their 
power can be achieved by using computational approaches to improve the detection of 
associations that are attributable to SNPs that are known but have not themselves been 
directly genotyped (Browning 2008). This is referred to as ‘imputation’. Imputation can 
also enable results from two or more studies that have been genotyped on differing sets 
of markers to be compared or meta-analysed. Imputation is carried out using a reference 
panel of samples. Traditionally this reference panel has come from HapMap II but 
recently reference panels from the 1000 Genomes Project can be used as this panel 
contains most of the variation occurring at a population frequency >1%  (Via et al. 
2010). Imputation is related to tagging, in that HapMap data can be used to infer LD 
between alleles at each SNP. If genotyped SNP(s) are correlated with another un- 
genotyped SNP, the missing genotype data can be imputed using the haplotype structure 
defined by the reference panel. A larger sample size is needed to achieve comparable 
power to genotyping the imputed SNPs directly because imputation is typically less 
accurate than genotyping (Anderson et al. 2008). A number of imputation algorithms 
have been developed to carry out imputation of missing genotype data (Browning 
2008). The degree of accuracy that can be achieved when imputing un-genotyped 
markers varies greatly depending on the extent of LD between the un-genotyped marker 
and the nearby genotyped markers (Browning 2008). Imputation algorithms are able to 
estimate the accuracy of an imputed SNP and so the researcher can discard those that 
have low estimated accuracies before carrying out association analysis. However, it is 
important to bear in mind that there will still be some degree of inaccuracy in the 
remaining imputed SNPs (Browning 2008).
GWAS have produced strongly significant evidence that common polymorphisms 
influence genetic susceptibility in more than 40 different phenotypes (Manolio et al. 
2008) and in the last 3 years, almost 1000 variants associated with a range of human 
traits and common diseases have been identified using genome-wide methods (Visscher 
& Montgomery 2009). One of the landmark GWAS to be conducted so far has been the 
Wellcome Trust Case Control Consortium’s (WTCCC) study which scanned 17,000 
individuals for seven diseases, including type 2 diabetes (T2D) and bipolar disorder 
(WTCCC 2007). This study was conducted using the Affymetrix GeneChip 500K 
Mapping Array, comparing -2000 cases for each of the disease against a shared sample 
of -3000 controls. 24 independent significant association signals were identified in the
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diseases with P-values < 1 x 10'7, enabling the identification of a number of novel 
susceptibility genes.
1.3.2.4 Issues of Multiple Testing in Association Studies
In a test of statistical significance, a P-value of 0.05 or less is typically used to 
indicate that the null hypothesis of no association can be rejected (Sham & McGuffin 
2002) as such a value is likely to occur by chance on only 5% of occasions. However, if 
testing more than 20 SNPs, such a P-value can be expected to occur by chance for at 
least one variant, assuming all SNPs are independent. In order to reduce the number of 
false positives, methods are used to adjust the probability estimate for multiple tests.
The most commonly used methods are Bonferroni correction, experiment or gene wide 
adjustments and permutation methods (Hirschhom & Daly 2005). However, it is likely 
that these methods are over conservative in the presence of weak, but true genetic 
effects (Salyakina et al. 2005). The Bonferroni correction, for example, assumes that all 
tests are independent. This is considered to be too conservative for genetic association 
tests as there is likely to be a certain degree of LD between some SNPs, and so the P- 
value should be adjusted for the number of independent SNPs.
Permutation testing provides an empirical method to correct P-values for multiple 
testing in a way that retains the correlation present in the actual data (Doerge & 
Churchill 1996). This approach creates a simulated dataset identical to the original 
except that the case/control labels are randomly permuted in the artificial dataset. By 
randomly permuting just the individual identifiers, the correlation among genotypes is 
preserved, as is the number of cases and controls, but any association between genotype 
and phenotype is broken. The complete set of association tests is then performed on the 
permuted data, and the permutation process is repeated a preset number of times. This 
generates a distribution of the best P-value expected in the entire experiment under the 
null model of no association between genotype and phenotype. For example, if an 
association has a P-value of 0.001 and a P-value 0.001 or lower is observed 60 times in 
1000 permutations, then the corrected empirical experiment-wide P-value is 0.06.
Bayesian methods have also been proposed that can take into account pre-test 
estimates of the likelihood that a particular variant is truly associated with a phenotype 
(Wacholder et al. 2004). However, the mathematics behind these methods require
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knowledge of not only the prior probability of association, but also of the distribution of 
the size of effects that will be encountered (Cordell & Clayton 2005).
For GWAS, in which many hundreds of thousands of SNPs are tested, it has been
o
suggested that an appropriate threshold for genome-wide significance is P < 5 x 10' 
(Pe'er et al. 2008). This is based upon an estimate of 1 million independent tests 
genome-wide in Europeans (i.e. P = 0.05/1000000 = 5 x 10'8).
However, even after correcting for multiple testing false positives may still remain 
and so the ideal method for assessing whether a reported association is a true effect or 
not is for the association to be replicated in an independent sample (Hattersley & 
McCarthy 2005).
1.3.2.5 Power of Association Studies
In an association study, the power of a study to detect a significant association is 
affected by the sample size, the significance level required, the effect size and the risk 
allele frequency in the general population. The more common a risk allele and/or the 
larger the effect size, the greater the power a study of a fixed sample size has to find a 
significant association with that variant at a fixed value of P. The odds ratio (OR) of a 
variant is a measure of its effect size and is defined as the odds of exposure to a 
susceptibility variant in cases compared to controls. For example, if a variant has an OR 
of 3, the odds of an individual with a copy of the risk allele being affected by the 
disease is three times higher than someone without the risk allele.
As discussed previously, DD is a common, complex disease. The common 
disease/common variant (CDCV) hypothesis has proposed that common diseases are the 
result of common variants (Reich & Lander 2001). Under this model, disease 
susceptibility is suggested to result from the joint action of several common variants, 
and unrelated affected individuals share a significant proportion of disease alleles. Due 
to their common nature, however, these variants are also likely to be of weak effect 
(Wang et al. 2005). This means that large sample sizes will be required within 
association studies of DD in order to be sufficiently powered to detect these variants of 
small effects.
As an example of how MAF and OR can affect the power of a study, a sample of 
500 cases and 500 controls would be needed to have an 80% chance of detecting a risk 
allele with an OR of 1.5 and a MAF of 0.1 at a P-value < 0.05 (Dupont & Plummer
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1990). However, if the variant had the same effect size but a MAF of 0.01, 4000 cases 
and 4000 controls would be required to achieve the same level of power. If the MAF 
remained the same but the OR was 1.3, over 1000 cases and 1000 controls would be 
required.
These may seem like reasonably manageable samples, however these figures 
assume a multiplicative model of risk and that either the disease variant is assayed itself 
or that there is perfect LD with the genotyped marker and the disease variant. If this is 
not the case then even larger sample sizes may be required to achieve the same power 
(Wang et al. 2005). Also, multiple testing requires far more stringent P-values to be 
confident that a true association is being observed, as mentioned previously. With 
GWAS, a P-value < 5 x 10'8 is deemed to be genome-wide significant (Pe'er et al.
2008). At this level of significance very large sample sizes of more than 5,000 cases and 
5,000 controls would be required for 80% power to achieve convincing support for an 
association with a variant that has a MAF of 0.1 and an OR of 1.3 (Wang et al. 2005).
1.3.3 Identifying Structural Variants
SNPs identified through PCR-based sequencing methods were once thought to be 
the main source of genetic and phenotypic variation, but the advent of genome scanning 
technologies has enabled the identification of an unexpectedly large amount of 
structural variation (e.g. copy number variants or CNVs) in the human genome (Feuk et 
al. 2006; Stankiewicz & Lupski 2010). In the last few years, this has led to a number of 
studies investigating the association of CNVs with complex diseases. These types of 
association studies are discussed in detail in Chapter 7.
31
1.4 Linkage and Association Studies o f Developmental Dyslexia
In order to identify the genes that underlie the genetic predisposition to DD, a 
number of linkage and association studies have been conducted. The earlier linkage 
studies have identified a number of regions which may harbour DD susceptibility 
gene(s). Regions showing replicated evidence of linkage to DD have been named 
DYX1-DYX9 by the Human Gene Nomenclature Committee (www.genenames.org). The 
evidence for linkage and association of each of these regions with DD is discussed 
below.
1.4.1 DYX1 (Chromosome 15)
15p l3
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1 5 p l l .2  -
1 5 p l l . l  
15*11 .1  
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------- Grigorenko et al. 1997
------ NOthen et al. 1999
------ Morris et al. 2000
------ Nopola-Hemmi etal. 2000
------ Chapman et al. 2004
------ Marino et al. 2004
------ Bates et al. 2007
------ Schumacher et al. 2008
DYX1C1 (Taipale etal. 2003; Scerri
etal. 2004; Wigg etal. 2004; Marino
et al 2007; Dahdouh et al. 2009;
Bates et al. 2009)
Figure 1.2: Regions on chromosome 15 showing evidence o f linkage/association with DD.
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Study Type Sample Main Findings
Smith et al. 
(1983) Linkage
9 American families 
(n = 84)a Cen15 (LOD = 3.2)
Smith et al. 
(1991) Linkage
9 American families 
(n = 84)a Qualitative analyses: ynz90 (P = 0.0085)
Grigorenko 
etal. (1997) Linkage
6 American Families 
(n = 94) SWR (LOD = 3.15)
NOthen et 
al. (1999) Linkage 7 German Families
D15S143 (Parametric LOD = 1.26; NPL 
2.19), D15S132 (Parametric LOD = 1.78)
Morris et al. 
(2000) Association
101 (stage 1) and 77 
(stage 2) UK trios
D15S994/D15S214/D15S146 haplotype 
(P<0.001 stage 1, P = 0.009 stage 2)
Taipale et 
al. (2003) Association
109 cases vs. 195 
controls, Finland
DYX1C1 SNPs -3A (P = 0.002) and 1249T 
(P = 0.006), -3A/1249T haplotype (P  = 
0.015)
Chapman et 
al. (2004) Linkage
111 American 
families (n = 898) Linkage with SWR (D15S143, LOD = 2.34)
Marino et al. 
(2004) Association 158 Italian families0 D15S214/D15S508/D15S182 (P = 0.005)
Scerri et al. 
(2004) Association
264 UK families (n = 
1153)
DYX1C1 -3G/1249G haplotype (P = 0.015) 
with OC choice
Wigg et al. 
(2004) Association
148 Canadian 
families
rs11629841 (P = 0.018, Corrected P = 
0.036), -3G/1249G (P = 0.026)
Bates et al. 
(2007) Linkage
403 Australian 
families (n = 980)d
Regular spelling linked with D15S994 (P = 
0.002)
Marino et al. 
(2007) Association
114 Italian probands 
and 50 sibings0
Association of the -3A/1249T haplotype 
with short term memory (P = 0.0114)
Schumacher 
et al. (2008) Linkage
82 German families 
(n = 331)b
D15S182 (LOD = 1.246), D15S143 (LOD 
1.310) and D15S1032 linked with spelling
Dahdouh et 
al. (2009) Association 66 German triosb
rs3743205/rs3743204/rs600753 (G/G/G) 
(P = 0.006)
Bates et al. 
(2009) Association
789 Australian 
families'1
rs17819126 with reading (P = 0.0003) and 
spelling (P = 0.0086); rs3743204 with 
reading (P = 0.009); rs685935 with short 
term memory (P = 0.04)
Table 1.2: Evidence for association/linkage with DYX1 (SWR = single word reading, NPL = non- 
parametric LOD score, OC = orthographic). Letters (a,b,c,d) indicates overlapping samples.
The first study to report linkage of chromosome 15 to DD was carried out by Smith 
and colleagues (1983). Linkage analysis between reading disability and chromosomal 
heteromorphisms in American families produced a LOD score of 3.2 for the marker 
cenl5. In an extension of this study, analyses were carried out using both qualitative 
and quantitative phenotype measures (Smith et al. 1991). Qualitative analyses showed 
significant linkage of DD with the marker ynz90 (P = 0.0085), however this was not 
replicated in the quantitative analyses. Grigorenko and colleagues (1997) went on to 
genotype 6 extended American families (n = 94) using markers in the 15pter-qter 
region. Five theoretically derived phenotypes were used in the linkage analysis: 1) 
phonological awareness (PA); 2) phonological decoding (PD); 3) rapid automatized
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naming (RAN); 4) single-word reading (SWR); 5) discrepancy between intelligence and 
reading performance (DISC). Significant linkage was found for a marker on 
chromosome 15q21.1 (D15S143, LOD = 3.15) with the SWR phenotype. Linkage of 
this particular phenotype to the same region was also found in an American sample by 
Chapman and colleagues (2004), with a single point LOD score of 2.34 for the 
D15S143 marker. A previous study also found linkage to this marker (Nothen et al. 
1999). This study used a spelling phenotype to diagnose dyslexic patients in a German 
sample and genotyped 13 microsatellite markers across chromosome 15. Significant 
linkage was found using both parametric (LOD = 1.78, P = 0.0042) and non-parametric 
analysis (LOD = 2.19, P = 0.03). Although different phenotypes have been used in these 
studies, it is perhaps not surprising that they have both shown linkage to the same 
region because spelling and reading disability have been shown to be strongly 
correlated (Malmquist 1958).
Morris and colleagues (2000) found association between DD and a 3-marker 
haplotype on chromosome 15ql5.1 (D15S994/D15S214/D15S146; P <0.001, corrected 
P = 0.03) in a UK sample. This was then replicated in another sample from the UK (P = 
0.0091). The marker D15S944 was also found to be linked to DD in a genome-wide 
study using an Australian sample (LOD = 1.89, P = 0.002) (Bates et al. 2007). Another 
3 marker haplotype in this region (D15S214/D15S508/D15S182) was shown to be 
associated with DD in an Italian population (P = 0.005) (Marino et al. 2004). Although 
this study did not find any significant association with the marker D15S994, this marker 
lies within the region covered by the significant haplotype and therefore still provides 
further evidence for an association with DD within this region. D15S994 is within a 
phospholipase gene, Phospholipase C p 2 (PLCB2) and is 1.6 Mb from another 
phospholipase gene, Phospholipase A2, group IVB (PLS2G4B). Morris and colleagues 
(2004) went on to test sequence variants within these genes for an association with DD 
in their UK case-control (164 cases vs 174 controls) and family-based samples (178 
trios). In the case-control sample, one variant within PLCB2 (PCLB2 no.9, P = 0.038) 
and two variants within PLA2G4B (PLA2G4B no.8, P = 0.049; PLA2G4B no. 26, P = 
0.048) showed association with DD, but none of the variants showed association in the 
trios. This difference in results may have been due to low power of the trios sample to 
detect significant association. However as it was this sample that had previously shown 
replication for a significant association between DD and D15S944, it should have been
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powerful enough to detect the variants causing this association, therefore these variants 
cannot account for the association signal originally observed.
The region surrounding the marker D15S143 was linked with dyslexia through a 
study by Nopola-Hemmi and colleagues (2000). They identified 2 Finnish families with 
different balanced translocations, the breakpoints of which were both mapped to a 6-8 
Mb region between markers D15S143 and D15S1029. In one family, the translocation 
t[2;15][ql 1 ;q21 ] was present in the father and two of his children who had DD. The 
mother and other child had normal karyotypes and normal reading abilities. However, it 
should be noted that one of the children diagnosed with DD also had low intelligence. 
The second family showed the translocation t[2;15][pl3;q22] in the father and all three 
children. The evidence for a link between this translocation and DD is less convincing. 
The father and the oldest child had cornea plana, and the oldest child had reading 
disability whereas the two younger siblings carrying this translocation had no symptoms 
of DD. There was also no history of learning difficulties in the father. As the 
translocation does not completely segregate with the presence of DD, even in this 
family alone, it is unlikely to be linked to the disease.
The translocation in the first family (t[2;15][ql 1 ;q21]) was shown to disrupt the 
gene DYX1C1 (Taipale et al. 2003). 8 SNPs within this gene were tested for an 
association with DD using 109 cases and 195 controls from Finland. Two of the SNPs 
were found to be significantly associated. The SNP rs3743205 (-3 G>A) gave an OR of
3.2 (95% Cl 1.5 - 6.9, P = 0.002). This SNP is three bases 5’ to the ATG translational 
start site and disrupts a predicted Elk-1 transcription factor binding site. The SNP 
rs57809907 (1249 G>T) gave an OR of 2.3 (95% Cl 1.2 - 4.2, P = 0.006). This SNP 
introduces a premature stop codon and is predicted to truncate the protein by 4 amino 
acids. These SNPs also showed significant association when present as the haplotype - 
3A:1249T (P = 0.015). Further studies have provided conflicting results for the 
association of rs3743205 and rs57809907 with DD. They were also found to be 
associated with an orthographic choice (OC) measure by Scerri and colleagues (2004) 
in a UK sample, but as the haplotype -3G:1249G (P = 0.0158). This was again found to 
be the case in a Canadian sample by Wigg and colleagues (2004). Dahdouh and 
colleagues (2009) identified a 3 marker haplotype with these SNPs and rs3743204 
(G/G/G, P = 0.006) in the female subset of their German trio sample. Four other studies 
tested these SNPs for an association with DD in Italian (Bellini et al. 2005; Marino et al. 
2005), UK(Cope et al. 2005b), American (Meng et al. 2005a) and Australian (Bates et
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al. 2007) samples, but none of them found significant evidence. However, a later study 
by Marino and colleagues (2007) on the same Italian sample found association for the 
haplotype -3A:1249T (P = 0.0114) with a measure of short term memory, but did not 
find significant association with other subphenotypes of DD. The case control sample 
used by Taipale et al. (2003) came from just 23 families, 33 unrelated case/control pairs 
and 1000 population controls, but no adjustment for relatedness was carried out. The 
non-independence of alleles in different related individuals from the same family may 
have distorted the evidence for association and so this may be why this result has not 
yet been convincingly replicated in subsequent studies.
Wigg and colleagues (2004) also found significant association to a SNP in DYX1C1 
that had not been tested in the previous studies. The SNP rsl 1629841 showed 
association with DD both alone (P = 0.036 corrected for multiple testing) and as part of 
a haplotype with rs3743204 (haplotype C/G, P = 0.0089) and with rs692691 (T/T, P = 
0.0058; G/T, P = 0.0389). However, this was not replicated by Cope and colleagues 
(2005b). They genotyped the marker rsl 1629841 in a sample of 247 UK parent proband 
trios and did not find any significant association with DD. This sample had previously 
shown association with a marker outside of DYX1, D15S994 (Morris et al. 2000), so 
Cope and colleagues (2005b) carried out LD analysis between this marker and the SNPs 
rs3743205, rsl 1629481 and rs57809907 within DYX1C1, but no significant LD was 
observed (P-values all >0.25). Together with the fact that D15S994 is 15 Mb away from 
DYX1C1, it is unlikely that the observed association between chromosome 15 and DD 
in this particular sample is due to DYX1C1.
Recently, Bates and colleagues (2009) looked for association with subphenotypes of 
reading ability in their sample of 789 Australian families that had not been selected for a 
DD phenotype. They found association of three other SNPs within DYX1C1 with 
measures of irregular-word reading (rsl 7819126, P = 0.02), non-word reading 
(rsl7819126, P = 0.0003; rs3743204, P = 0.0089), irregular-word spelling (rsl7819129, 
P = 0.0086) and short term memory (rs685935, P = 0.04). The SNP rs l7819129 has not 
been typed in previously reported studies and codes for a non-synonymous protein 
sequence alteration. This SNP is in complete LD with SNPs in two nearby genes,
RAB27 and C15orf5 suggesting that these genes may also warrant further investigation 
within this linkage region.
The evidence for DYX1C1 as a susceptibility gene for DD has not been convincingly 
replicated. It seems that this gene is only significantly associated in certain populations,
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such as Finland. Due to the small sample size studied and the large number of related 
individuals in that sample, it could be that the results were false positives. However, it is 
also possible that different causal variants within this gene exist in the different 
populations that have been studied so far and differences in language or variations in 
LD could be causing the differences in results. The association for the -3A/1249T 
haplotype was originally found in a Finnish population (Taipale et al. 2003). This 
population is a genetic isolate that was established around 10,000 years ago, with a 
limited number of founders, and has since gone through several bottlenecks (Arcos- 
Burgos & Muenke 2002). In such populations, regions of linkage disequilibrium will 
generally extend further. This could result in a causal genetic variant in a Finnish 
population being in significant LD with a particular genetic background (such as the - 
3A/1249T haplotype) that is relatively far away. Other more heterogeneous populations 
would have weaker LD in these regions and so would not necessarily pick up these 
associations. Another explanation is that these risk alleles may be in LD with a causal 
variant that has different founders, which could account for an association in different 
directions being observed in different populations.
Further evidence supporting DYX1C1 as a possible susceptibility gene for DD 
comes from functional studies which have suggested that this gene may have a role 
within neuronal migration, as discussed in Chapter 3, section 3.1.1.
Two other neurodevelopmental disorders have been linked with chromosome 15q. 
Bakker and colleagues (2003) carried out a genome wide scan using 164 Dutch sib pairs 
diagnosed with ADHD which shares comorbidity with DD (see section 1.1.5.1). The 
most promising chromosome region was 15q, with the marker D15S944 producing the 
highest single point LOD score (3.37). This particular marker had been found to show 
significant association with DD in the study by Morris and colleagues (2000). Smith 
and others (2005) used a sample of 86 sib pairs from 65 families in a study that linked 
this region to phonological memory (D15S1017-D15S1029, Zmax = 2.31) and 
articulation (D15S1017-D15S1029, Zmax= 2.719). Speech-sound disorder (SSD) is a 
common childhood disorder which is characterised by ‘developmentally inappropriate 
errors in speech production that greatly reduce intelligibility’ (Smith et al. 2005). There 
is evidence to suggest that children with SSD also have phonological processing 
problems as discussed in section 1.1.5.5. Stein and colleagues (2006) also analysed the 
15ql4-q21 region for linkage with SSD, and obtained the most significant results at the 
marker D15S214 (P = 0.0072) which again showed significant association with DD in
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the study by Morris and others (2000). These results suggest that DD, ADHD and SSD 
share some genetic aetiology within this region and further investigation of the genes 
affected may be able to provide more information about why these disorders share a 
high level of comorbidity.
1.4.2 DYX2 (Chromosome 6p)
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Figure 1.3: Regions on chromosome 6p showing evidence o f linkage/association with DD
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Study Type Sample Main Findings
Smith et al. 
(1991) Association 18 American families8 Qualitative analysis, GLO P = 0.0153; Quantitative analysis, BF P < 0.001
Cardon et al. 
(1994) Linkage
Sibling sample from 19 American families (n 
= 358)a, dizygotic twin sample from Colorado 
twin study (n = 50 pairs)15
QTL between D6S105 and TNFB (sibling P = 0.066, twin P < 0.00001,
combined P <0.0001)
Grigorenko et 
al. (1997) Linkage 6 extended American families (n = 94)°
Multipoint P < 10^ for PA for markers D6S108, D6S461, D6S299, D6S464 and
D6S306
Fisher et al. 
(1999) Linkage 181 sib pairs from 82 nuclear UK families'1 Linkage in D6S1660-D6S291 for OC and PC (P = 0.038 to 0.00035)
Gay£n et al. 
(1999) Linkage 79 American families (126 sib pairs)15
Linkage in region D6S276-D6S105 with OC (LOD = 3.10), PD (LOD = 2.42),
PA (LOD = 1.46)
Grigorenko et 
al. (2000) Linkage 8 American families (n = 171)°
Significant P-values within D6S464-D6S306 for the SWR, vocabulary and
spelling (IBD analyses)
Fisher et al. 
(2002) Linkage
89 UK families (195 sibling pairs)d Linkage with PD (D6S276, singlepoint P = 0.00006; D6S1610, single point P =0.00001)
119 American families (180 sibling pairs) from 
Colorado twin study15 Linkage with PD (D6S276, singlepoint P = 0.002)
Kaplan et al. 
(2002) Linkage 104 American families (n = 392)b Linkage with OC and PD in JA04 region (P = 0.05 - 0.00049)
Grigorenko et 
al. (2003) Linkage 8 American families (n = 176)c
Linkage with D6S299 (LOD = 2.01 for the PA/PD/SWR pathway) and D6S222
(LOD = 2.57 for PA)
Deffenbacher 
et al. (2004)
Linkage 349 American families (n = 1559)b Linkage with 5 phenotypes (PA, PD, SWR, OC, DISC) over interval D6S1597to D6S1571
Association 114 American families15 VMP (P = 0.05-0.004), DCDC2 (P = 0.05-0.001), KIAA0319 (P = 0.03), TTRAP (P = 0.03-0.008) and THEM2 (P = 0.008).
Francks et al. 
(2004) Association
89 UK families® rs1061925 (P = 0.0269 for OC)
175 UK families® rs9467247 (P = 0.0006 for OC-irreg, P =0.0003 for READ); rs1061925 (P = 0.0005 for OC-choice, P = 0.0008 for READ)
159 American families15 rs9467247 (P = 0.0038 for READ, P = 0.042 for PA); rs3033236 (P = 0.0023 for READ, P = 0.015 for SPELL)
Table 1.3: Evidence for association/linkage with DYX2 (PA = phonological awareness, PD = phonological decoding, OC = orthographic coding, NWR = non word reading, 
SWR = single word reading, DISC = discrepancy between IQ and reading ability). N.B some of these studies have overlapping samples. Letters (a,b,c,d,e,f) indicate sample 
overlap.
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Study Type Sample Main Findings
Cope et al. 
(2005a) Association
240 cases vs. 312 controls, UK1 15 SNPs associated in KlAA0319/TTRAP/THEM2 locus (P £ 0.05)
223 cases vs. 273 controls, UKr 7 SNPs associated in KIAA0319/TTRAP/THEM2 locus (P £ 0.05)
143 parent-proband trios and 223 cases vs 
273 controls, UKf
KIAA0319 (rs4504469, P = 0.002; rs2173515, P = 0.007; rs6935076, P = 
0.006), MRS2L (rs2793422, P = 0.003), THEM2 (rs3777664, P = 0.008), 
intergenic (rsl 053598, P = 0.02)
Meng et al. 
(2005b) Association 153 American families (n = 536)b rs807724 in DCDC2 (P = 0.0003) associated with DISC
Harold et al. 
(2006) Association
264 nuclear families and 350 cases vs. 273 
controls, UKe'f Association within intron 1 of KIAA0319 (rs2038137, P = 0.00002)
Schumacher 
et al. (2006a) Association
137 triads, Germany rs793862 in DCDC2 (P = 0.011) and D6S276 (P = 0.004)
239 triads, Germany Association with haplotype A-C at rs7938620-rs807701 (P = 0.001)
Luciano et al. 
(2007) Association
440 Australian families unselected for DD (n = 
858)
TTRAP (rs2143340; P = 0.009), KIAA0319 (rs6935076; P = 0.008), haplotype 
spanning KIAA0319 and TTRAP (rs4504469/rs2038137/rs214340)
Paracchini et 
al. (2008) Association
10,261 UK children unselected for reading 
ability
rs2143340 with reading (P = 0.003), spelling (P = 0.008) and NWR (P = 0.03); 
rs4504469/rs2038137/rs2143340 (A/A/C) haplotype with reading (P = 0.009)
and spelling (P = 0.03)
Couto et al. 
(2010) Association 291 Canadian families
Qualitative analysis: VMP (rs9356928 P = 0.034; rs4285310, P = 0.048; rs3178 
P = 0.043), KIAA0319 (rs6935076 P = 0.014), TTRAP (rs3181238 P = 0.031). 
Quantitative analysis: KIAA0319 (rs6935076, P = 0.025 for spelling), VMP 
(rs3178, P = 0.043 for PD)
Haplotype analysis: KIAA0319, rs4504469-rs6935076 (G-A) P = 0.018
Dennis et al. 
(2009) Association 264 UK families, 126 in severe subset®
Association of rs9461045, rs3212236 and rs9467247 with measures of OC,
PD, reading and spelling
Table 1.3 Continued.
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An association of chromosome 6p21 with DD was first identified by Smith and 
colleagues (1991). They used a sample of 18 American families and looked for linkage 
between four markers (BF, GLO, thhl57 and 2C5) and DD using both quantitative and 
qualitative measures of the trait. For the qualitative analysis, the marker GLO 
(glyoxylase 1) showed significance (P = 0.0153). However, for the quantitative 
analyses, the marker BF (properdin factor) rather than GLO was significant (P < 
0.0001).
Cardon and colleagues (1994) targeted the 6p21 region in their study which used an 
American kindred sample comprising 358 individuals from 19 families, and a twin 
sample consisting of 50 families from the Colorado twin study. They genotyped the 
markers used by Smith and colleagues (1991), as well as five other markers that were 
more informative due to higher heterozygosities. They found significant linkage in this 
region between the markers D6S105 and TNFB (tumour necrosis factor beta) in the 
twin sample (twin P < 0.00001; kindred P = 0.066). Combining both the twin and 
kindred samples reinforced this finding (P < 0.0001). Grigorenko and colleagues (1997) 
used six extended American families and genotyped markers in the 6p23-p21.3 region 
using the 5 phenotypes described earlier. Two point nonparametric analyses revealed 
significant P-values for five markers relatively close to each other (D6S109, D6S461, 
D6S464, D6S306, and D6S276). However, the results varied with the phenotype used 
and the most statistically significant results were obtained for the PA phenotype. In an 
extension of this study involving another 2 families (Grigorenko et al. 2000), IBD 
analyses showed significant P-values in the region D6S464-D6S306 but only for the 
phenotypes SWR, vocabulary and spelling with little evidence for PA and PD. 
Grigorenko and colleagues later went on to use this sample of 8 American families to 
identify linkage to 6 phenotypes; PA, PD, RAN and SWR as before and the 
PA/PD/SWR and PA/RAN/SWR pathways (Grigorenko et al. 2003). They observed the 
most significant linkage with the markers D6S299 (LOD = 2.01 for the PA/PD/SWR 
pathway) and D6S222 (LOD = 2.57 for PA). Overall, this study highlighted three 
interesting regions within 6p21.3, all of which have been replicated in other studies. The 
first is the D6S109-JA01 region (replicated by Turic et al. (2003)), the second being the 
D6S299-D6S1261 region (also implicated by Kaplan et al. (2002)) and the third is the 
D6S105-D6S265 (as found by Cardon et al. (1994), Fisher et al. (1999) and Grigorenko 
etal. (2000)).
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Fisher and colleagues (1999) also used quantitative phenotypes in their study 
involving 181 sib pairs from 82 families in the UK. They found evidence of linkage in 
the D6S1660 - D6S291 region for OC and PC phenotypes (P-values between 0.038 and 
0.00035), with the highest significance observed for the marker D6S276. Gayan and 
colleagues (1999) also found evidence for these phenotypes in a sample of 79 American 
families. They obtained large LOD scores for OC (LOD = 3.10), PD (LOD = 2.42) and 
PA (1.46) within the region D6S276-D6S105. An extension of these studies, involving a 
whole genome linkage study of both the US and UK samples, was carried out by Fisher 
and colleagues (2002). In the 6p21 region, the most significant results from the single 
point analyses were obtained for PD in the UK sample (D6S276, P = 0.00006;
D6S1610, P = 0.00001). These were replicated in the US sample, although with less 
significance (D6S276, P = 0.002). Kaplan and colleagues (2002) used this US sample 
and 11 quantitative phenotypes in their analyses of 29 markers in the 6p21.3 -  6p22 
region. All phenotypes yielded evidence for association to 6p (P < 0.05), however they 
obtained the most significant results for orthographic and phonological processes (P- 
values between 0.05 and 0.00049), with the most likely location of the quantitative trait 
locus being within a 4-Mb region surrounding the marker JA04 (P = 0.0021 for OC). 
Turic and colleagues (2003) used two separate samples of UK proband/parent trios in a 
two-stage study involving 21 microsatellite markers covering an 18 cM region on 
chromosome 6p. The three marker haplotypes D6S109/D6S422/D6S1665 and 
D6S506/D6S1029/D6S1660 showed the most association across both of the samples, 
with the most significant haplotype (D6S109/D6S422/D6S1665) showing association 
with subphenotype measures of SWR, spelling, PA, PD, orthographic accuracy and 
RAN. These results suggest a broad region of association spanning the markers D6S109 
to D6S1260.
The region 6p21.3-22.3 has been widely replicated in American and UK samples 
(see Figure 1.3 and Table 1.3). Several of these studies have focused on quantitative 
sub-phenotypes of dyslexia, and those involving orthographic and phonological 
processes have shown the most amount of evidence for an association with this region. 
However, a number of other studies have been carried out that have not found 
significant association of this region with phenotypes of DD. Field and Kaplan (1998) 
used a sample of 79 Canadian families and a qualitative diagnosis of ‘Phonological 
Coding Dyslexia’ (PCD). Subjects were assigned to one of five categories: definitely
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affected, probably affected, uncertain, probably unaffected, and definitely unaffected. 
However no significant results were found. This may have been due to the qualitative 
nature of the phenotype they used, whereas other studies have used more quantitative 
analyses for subphenotypes. This group then extended their study and used four 
quantitative measures: PA, PD, RAN and spelling (Petryshen et al. 2000), but still no 
significant association was found. Chapman and colleagues (2004) attempted to confirm 
linkage in this region using a sample of 111 American families and continuous 
measures of PD and SWR in a genome wide scan. Their results showed only weak 
evidence of linkage of PD with chromosome 6p in a region that was -10 cM distal to 
the regions previously reported. Studies in other populations have also failed to find an 
association of this region to DD, including a genome-wide study carried out using a 
Norwegian sample showing impaired orthographic and phonological processing 
abilities (Fagerheim et al. 1999), and a study using a German sample (Nothen et al. 
1999). These differences are again likely to be due to population heterogeneity and 
differences in diagnostic criteria, especially when considering the German sample 
which was selected on the basis of spelling ability rather than difficulties in reading.
There is still a great deal of evidence for this region however, and a number of 
studies have sought to identify possible candidate genes lying within this region. 
Deffenbacher and colleagues (2004) used a sample of 1,559 individuals from 349 
nuclear families from the Colorado twin study to refine the region of linkage. Both 
single-point and multi-point analyses showed significant linkage with all of five 
phenotypes (PA, PD, SWR, OC and DISC) over the interval D6S1597 to D6S1571, 
with maximal linkage converging between markers D6S276 and D6S1554. Of 12 genes 
within this region, 10 were tested for an association with DD in a subset of 114 families. 
Five of these genes showed evidence of association: VMP (P = 0.05-0.004), DCDC2 (P 
= 0.05-0.001), KIAA0319 (P = 0.03), TTRAP (P = 0.03-0.008) and THEM2 (P = 0.008). 
All of these genes are expressed in the central nervous system and so would make good 
candidates for further screening. VMP is a neuron-specific vesicular membrane protein 
thought to play a role in vesicular organelle transport and neurotransmission (Cheng et 
al. 2002). DCDC2 is expressed ubiquitously and contains two doublecortin peptide 
domains that were originally described in the doublecortin gene (DCX) encoded on the 
X chromosome. DCX  encodes a cytoplasmic protein that directs neuronal migration by 
regulating the organisation and stability of microtubules and is mutated in X-linked
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lissencephaly (a neuronal migration defect) (Dobyns et al. 1999) and double cortex 
syndrome, which is caused by arrested migration halfway to the cortex, producing a 
‘double cortex’. KIAA0319 is highly expressed in the brain and codes for a novel 
protein of an unknown function. The predicted KIAA0319 protein contains four 
polycystic kidney disease (PKD) domains that have an immunoglobulin-like fold, 
originally found in the PKD1 protein (Bycroft et al. 1999). PKD domains have been 
implicated in cell-cell adhesion processes (Ibraghimov-Beskrovnaya et al. 2000). 
TTRAP encodes a tumour necrosis factor receptor-associated protein known to inhibit 
the activation of nuclear factor-kappa B (NF-kB) and subsequent down-stream 
activation of transcription (Pype et al. 2000). Activation of NF-kB transcription has 
been shown to play a role in long-term potentiation and synaptic plasticity associated 
with learning and memory. THEM2 encodes a protein belonging to the thioesterase 
superfamily that catalyses the hydrolysis of long-chain fatty acyl-CoA thioesters. 
Abnormal fatty acid metabolism has been suggested to play a role in a spectrum of 
neurodevelopmental disorders, including dyslexia.
The Colorado sample (159 families) was also used by Francks and colleagues 
(2004), as were two samples from the UK (89 and 175 families). They first refined the 
linked region on chromosome 6p to 5.8Mb (LOD = 3.48). Within this region, 8 genes 
are expressed in the brain which separate into 4 clusters. Cluster 1 contains the genes 
ALDH5A1, KIAA0319, TTRAP, and THEM2. Cluster 2 contains the gene C6orf32, 
cluster 3 contains the gene SCGN and cluster 4 contains the genes BTN3A1 and 
BTN2A1. Francks and colleagues (2004) analysed 15 SNPs within these genes using a 
sample of 89 UK families, with significant association being found for the SNP 
rs 1061925 (P = 0.0269 for OC). 42 additional SNPs surrounding this SNP were then 
analysed with the combined UK samples, revealing evidence of association for 21 SNPs 
which were then typed in the Colorado sample. In these analyses, evidence for 
association was found when the samples were selected for more extreme ends of the 
phenotype. A specific haplotype (tagged by the SNPs rs4504469, rs2034469, and 
rs2143340) spanning the genes KIAA0319, TTRAP and THEM2, was found to be 
associated with DD in both the UK and US families. Francks and colleagues (2004) 
then tried to identify variants within these genes using 32 probands with severe DD, 
however the only SNP identified that had an effect on protein sequence was rs4504469
44
within exon 4 of KIAA0319. The minor allele frequency of this SNP was 0.47 in these 
samples and was not unique to the risk haplotype identified.
Cope and colleagues (2005a) also analysed this region, using 137 SNPs. A UK case 
control sample of 240 cases and 312 controls was used to identify significant markers 
and these were followed up in a sample of 143 parent-proband trios. In both samples, 
Cope and colleagues (2005a) found evidence for association with three SNPs in 
KIAA0319 (rs4504469, P = 0.002; rs2173515, P = 0.007; rs6935076, P = 0.006), with 
one SNP in MRS2L (rs2793422, P = 0.003) and in THEM2 (rs3777664, P = 0.008) and 
with an intergenic SNP (rs 1053598, P = 0.02). They also found strong evidence that the 
association observed within this region was due to the KIAA0319 SNPs rs4504469 and 
rs6935076. A haplotype of these two SNPs (A/G) was found to be highly significantly 
associated with DD in both the case-control sample (P = 0.00003) and the trio sample (P 
= 0.006). A recent study conducted by Couto and colleagues (2010) also found evidence 
for a significant association of these two SNPs with DD in their sample of 291 Canadian 
families, but as the haplotype G/A only (P = 0.018). This particular haplotype was also 
associated with DD in the study by Cope and colleagues (P = 0.02), but was not as 
significant as the A/G haplotype.
Luciano et al. (2007) genotyped 10 SNPs in or near to the KIAA0319 gene using a 
sample of 440 Australian families that were unselected for DD but were tested using 
reading and spelling tasks. They found significant association with reading ability for 
SNPs within the TTRAP (rs2143340; P = 0.009) and KIAA0319 (rs6935076; P = 0.008) 
genes, and for a three-SNP haplotype that spans K1AA0319 and TTRAP 
(rs4504469/rs2038137/rs2143340, global P = 0.005). This is the same 3 marker 
haplotype that was found to be associated with DD by Francks and colleagues (2004). 
Franks and colleagues found the most significant association with the 1-1-2 individual 
haplotype and a measure of orthographic coding (P = 0.0007). Luciano and colleagues 
(2007) also found significant association with this haplotype (P = 0.04 for a bivariate 
analysis of whole word reading), but in the opposite direction. Luciano and colleagues 
(2007) found a higher level of significance with the 1/1/1 and 2/2/2 haplotypes with a 
univariate analysis of principle components of reading (P = 0.02 for both haplotypes). 
The 1/1/1 haplotype was found to be associated with phonological decoding in the UK 
sample studied by Francks and colleagues (2004) (P = 0.031) and was also associated in 
the study by Cope and colleagues (P = 0.03).
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Another study conducted using individuals that had been not been selected for DD 
was carried out in the UK by Paracchini and colleagues (2008). They also found 
significant association of the TTRAP SNP rs2143340 with measures of reading (P = 
0.003), spelling (P = 0.008) and non-word reading (P = 0.03) as well as association with 
the same three marker haplotype rs4504469/rs2038137/rs2143340 as the 1-1-2 
haplotype with measures of reading (P = 0.009) and spelling (P = 0.03). The other forms 
of this three marker haplotype were not tested in this study. Whilst this three marker 
haplotype has shown association in a three independent samples, the individual risk 
haplotypes do not appear to be the same in all samples. The 1-1-2 risk haplotype had an 
opposite direction of effect in the Australian sample (Luciano et al. 2007) compared 
with the two UK samples (Francks et al. 2004; Paracchini et al. 2008). This may be 
indicative of a false positive in the Australian sample or it could be a consequence of 
the sample being ethnically heterogeneous as only -82% of this sample was reportedly 
of Anglo-Celtic origin (Luciano et al. 2007). Despite this, Paracchini and colleagues 
(2006) showed that this risk-haplotype reduces the expression of K1AA0319, making it a 
good functional candidate for increasing an individual’s susceptibility to DD.
Dennis and colleagues (2009) tried to identify variants upstream of KIAA0319 
within the region spanned by the TTRAP/KIAA0319 haplotype that may affect the 
expression of KIAA0319. They identified 7 risk SNPs within this haplotype region and 
found significant association of 3 of these SNPs (rs9461045, rs3212236 and rs9467247) 
with orthographic choice and spelling in their sample of 264 families in the UK. When 
they selected for a subset of severe cases (126 families), the significance of these SNPs 
increased and they were also found to be significantly associated with measures of 
phonological decoding and reading. Dennis and colleagues (2009) produced luciferase- 
expressing constructs containing the region upstream of KIAA0319 to demonstrate that 
the minor allele of rs9461045 confers reduced luciferase expression in both neuronal 
and non-neuronal cell lines. This suggests that the minor allele of this associated variant 
reduces the expression of KIAA0319 and is therefore likely to be functionally relevant 
for the development of DD (Dennis et al. 2009).
Another study using subjects from the Colorado sample (153 nuclear families) 
found association with another gene in this region (Meng et al. 2005b). 147 SNPs in the
1.5 Mb region surrounding the marker JA04 (the marker that this group previously 
found to be associated with DD (Kaplan et al. 2002)) were genotyped. The strongest
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evidence was found for the SNP rs807724 located in intron 6 of the gene DCDC2 (P = 
0.0003). This gene is 500 kb away from the JA04 marker, so is within the replicated 
DYX2 region.
Schumacher and colleagues (2006a) used a categorical definition of DD based on 
spelling abilities. Using two independent trio samples of German families, they found 
association with extreme spelling disability in two SNPs within the DCDC2 gene 
(rs793862, P = 0.011; rs807701, P = 0.058), most significantly as a two-marker 
haplotype in intron 7 (P < 0.0001).
A collaboration of groups from Oxford and Cardiff attempted to replicate the 
association of DCDC2 to DD using two UK samples (Harold et al. 2006). The sample 
from Oxford included 264 unrelated nuclear families, while the Cardiff sample included 
350 cases and 273 controls. Both samples were used to genotype those polymorphisms 
that showed the most significant association in the previous US (Meng et al. 2005b) and 
German (Schumacher et al. 2006a) samples. In the Oxford sample, nominally 
significant associations were detected with several traits, with the strongest association 
being found between the marker rs 1087266 and the PA phenotype (P = 0.005). 
However, when this sample was selected for more severe phenotypes, these associations 
were no longer significant. No association with DD was observed for any of the 
DCDC2 polymorphisms in the Cardiff sample. These groups then went on to genotype 
new polymorphisms in or flanking the KIAA0319 gene. In total, 5 SNPs were 
significantly associated with DD in both samples. After combining the P-values of these 
five SNPs, the most significant association with DD was with the SNP rs2038137 in 
intron 1 (P = 0.00002). Another 4 SNPs in the 5’ flanking region or intron 1 showed 
association, but only in one of the two samples. Despite finding no association with 
DCDC2 in their samples, these groups tested for statistical interactions between markers 
in this gene and the five SNPs in KIAA0319 that showed association in both samples. 
They found significant interactions between variants of the two genes, the most 
significant being between rs793862 in DCDC2 and rs761100 in KIAA0319 (P = 0.007).
The association of variants in this region with reading ability in populations that 
have not been selected for DD suggests that variants within the genes in this region may 
influence reading ability in the general population. However, the findings that the 
significance of the associations within these genes increase when selecting a sub-set of 
samples containing the more severe cases of DD (Francks et al. 2004; Harold et al.
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2006; Schumacher et al. 2006a; Dennis et al. 2009) suggests that there may also be 
specific functional variants within these genes that can cause DD.
Overall, the genes KIAA0319 and DCDC2 have received the most support in this 
region, being widely replicated in a number of studies. Evidence for an association 
between DD and KIAA0319 has been found in UK, US and Australian samples, while 
evidence for an association to DC DC2 has been found in UK, US and German samples. 
The differences in results across studies may be due to the different populations studied, 
differing ascertainment criteria, and different marker sets being used, making 
comparisons between them difficult. Even those studies that have used subsets from the 
same population in Colorado have obtained different results. Francks and colleagues 
(2004) found association with KIAA0319, Meng and colleagues (2005b) found 
association with DCDC2, while Deffenbacher and colleagues (2004) found association 
with both genes. These differences may have been due to different sampling criteria 
being used by these groups when deciding on which subsets to use.
KIAA0319 and DCDC2 share a number of similarities; they are physically close on 
chromosome 6p, are both expressed in the brain and have similar putative functions. As 
these genes are so close together, it could be the case that the associations detected in 
both genes are due to a single mutation that has not yet been identified (Paracchini et al. 
2007). This would explain why this particular region has been widely replicated in 
samples from different populations. However, Harold and colleagues (2006) reported 
that there is a significant lack of LD across and between these two genes, so this theory 
is unlikely to be true. It could be that different subgroups of individuals with DD are 
determined by the effects of either one or the other gene.
Recently, Couto and colleagues (2010) attempted to map acetylated histones in this 
region using chromatin immunoprecipitation coupled with genomic tiling arrays (ChlP- 
chip). Acetylated histones are frequently associated with accessible chromatin at 
genomic regions containing regulatory elements (Eberharter & Becker 2002; Kurdistani 
et al. 2004; Roh et al. 2005; Heintzman et al. 2007; Roh et al. 2007) and therefore 
identifying these regions provides functional clues as to the location of genomic 
sequences involved in gene regulation. Couto and colleagues (2010) identified several 
regions marked by acetylated histones that mapped near to associated markers in this 
locus, including intron 7 of DCDC2 and the 5’ region of KIAA0319.
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Both genes have been implicated in neuronal migration (discussed in Chapter 3, 
section 3.1.1), making them good functional candidate genes and overall, these genes 
have received the most support as candidate genes for DD across the whole genome. At 
this stage no gene within this region can be ruled out and the consistent replication of 
findings in this region make it a worthwhile area of the genome to explore further.
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Figure 1.4: Region on chromosome 2p showing evidence o f linkage/association with DD
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Study Type Sample Main Findings
Fagerheim 
etal. (1999) Linkage
1 Norwegian 
family (n = 36)
D2S2183 (Z = 5.53, 6 = 0.00), D2S393 (Z = 
2.93, 6  = 0.0) and D2S378 (Z = 4.32, Q = 0.0).
Petryshen 
et al. 2002 Linkage
96 Canadian 
families (n = 877)
Linkage with spelling (D2S2352-D2S378, LOD 
= 3.82), PC (D2S378, LOD = 1.13) and PA 
(D2S378, LOD = 1.01)
Fisher et al. 
(2002) Linkage
89 UK families 
(195 sibling pairs)
OC (D2S2211, P = 0.001; D2S391, P = 
0.0007) and reading (D2S391, P = 0.007) in 
single point analysis
119 American 
families (180 
sibling pairs)3
Reading (D2S2368, P = 0.013), PA 
(D2S2368, P = 0.001; D2S286 P = 0.0003) 
and OC (D2S2368, P = 0.005) in the single 
point analysis, 2p15 with reading (P = 0.006), 
PA (P = 0.001) and OC (P = 0.005) in 
multipoint analysis
Francks et 
al. (2002) Linkage
119 American 
families (180 
sibling pairs)3
OC (D2S2240, P = 0.003), SWR (D2S2378, P 
= 0.004) PD (D2S2378, P = 0.004)
Kaminen et 
al. (2003) Linkage
11 Finnish 
families (n = 97)b
D2S2216 (LOD = 2.55, non-parametric); 
D2S286 (LOD = 3.01, parametric)
Peyrard- 
Janvid et al. 
(2004)
Linkage 11 Finnish families (n = 97)b D2S2216 (LOD = 3.0, non-parametric)
Anthoni et 
al. (2007) Association
11 Finnish 
families (n = 97)b
rs1000585/rs917235/rs714939 (GGG, P = 
0.0076)
251 German 
families
rs917235/rs714939/rs6732511 (GGC, P = 
0.036)
Bates et 
al.(2007) Linkage
403 Australian 
families (n = 980)
Non-word spelling (D2S1360, LOD = 0.83); 
SWR (D2S2972, LOD 1.04); spelling 
(D2S1360, LOD = 1.13)
Table 1.4: Evidence for association/linkage with DYX3 (PA = phonological awareness, PD = 
phonological decoding, OC = orthographic coding, SWR = single word reading). N.B some of these 
studies have overlapping samples. Letters (a,b) indicate the same samples.
The first evidence for a region on chromosome 2 showing linkage with DD came 
from a genome wide study using 36 members of a Norwegian family (Fagerheim et al. 
1999). At first the screen did not show any significant linkage, but marker D2S1356 on 
2pl5-pl6 gave a slightly significant LOD score of 0.8. Fagerheim and colleagues 
(1999) then analysed 17 additional microsatellite markers around this region and found 
significant LOD scores for the markers D2S2183 (Z = 5.53, using a model of complete 
linkage: 6 = 0.0), D2S393 (Z = 2.93, 0 = 0.0) and D2S378 (Z = 4.32, 6 = 0.0).
Petryshen and colleagues (2002) replicated this linkage in a sample of 96 Canadian 
families, each containing two or more siblings diagnosed with phonological coding 
dyslexia (PCD). They used both categorical and quantitative definitions of PCD in their 
study. Using nonparametric analysis and a categorical diagnosis of PCD, evidence for
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linkage was found within the DYX3 region (P = 0.009). Using variance components 
analysis and a quantitative definition, peak LOD scores were found for spelling (3.82 
between D2S2352 and D2S378), PD (1.13 at D2S378) and PA (1.01 at D2S378).
Fisher and colleagues (2002) carried out a genome wide scan using a UK sample of 
89 families and an American sample of 119 families from the Colorado twin study. The 
UK sample showed linkage on 2p25 with the OC phenotype (P = 0.001) and 2pl6 with 
reading (P = 0.007) and OC (P = 0.0007) in the single point analysis, but gave little 
evidence with multipoint analysis. The US sample showed linkage on 2pl5 with reading 
(P = 0.013), PA (P = 0.001) and OC (P = 0.005) in the single point analysis. In the 
multipoint analysis, the US sample showed evidence of 2pl5 being linked to reading (P 
= 0.006), PA (P = 0.001) and OC (P = 0.005).
Francks and colleagues (2002) used the US sample to fine-map the 2pl2-17 region 
using 21 microsatellite markers. They refined the linkage region to 12 cM between the 
markers D2S337 and D2S286 (see Figure 1.4), with the peak significance of linkage 
very similar to that reported by Fisher and colleagues (2002). This linkage was 
replicated in a genome-wide study by Bates and colleagues (2007), using a sample of 
403 Australian samples that were not selected for reading ability. They identified 
nominally significant peaks within the region reported by Francks and colleagues 
(2004), with a LOD of 0.83 at the marker D2S1360 for nonword spelling and a second 
peak of 1.04 at marker D2S2972 for SWR. They also found linkage on chromosome 2p 
outside of the DYX3 region (see Figure 1.4). Regular-word spelling was found to be 
linked to D2S1360 on chromosome 2p24.2 (LOD = 1.13, P = 0.030). This could 
represent an alternative DD locus on chromosome 2p, but as yet has not been reported 
by any other studies.
Kaminen and colleagues (2003) carried out a whole genome scan using 11 Finnish 
families, and obtained a linkage peak for the marker D2S2216 on 2pl 1 (NPL = 2.55, P 
= 0.004). The marker D2S2216 is about 34 cM centromeric from the DYX3 locus 
implicated in other studies (Fagerheim et al. 1999; Francks et al. 2002; Petryshen et al. 
2002). This result could represent a different locus, or the difference could be due to 
different populations, diagnostic criteria and markers being used in the studies. Peyrard- 
Janvid and colleagues (2004) used this same sample to fine map the region further.
They used 24 markers in a 40 cM region. Their highest NPL score was 3.0 (P = 0.001) 
for the marker D2S2216, replicating the result found by Kaminen and colleagues
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(2003). They refined their region of linkage to a 12 cM region between D2S2216 and 
D2S181, supporting other evidence of a DD susceptibility locus in this region. Anthoni 
and colleagues (2007) also used this sample of Finnish families in a study that used 8 
microsatellites and 43 SNPs to refine the location of linkage to a 157 kb region on 2pl2. 
This was then replicated in an independent set of 251 German families. Two 
overlapping risk haplotypes were identified in the two sample sets. The haplotype 
rsl000585/rs917235/rs714939 was found to be significantly associated in the Finnish 
sample (GGG, P = 0.0076), while the haplotype rs917235/rs714939/rs6732511 was 
significantly associated in the German sample (GGC, P = 0.036). In a joint analysis of 
the two sample sets, these risk haplotypes were still significant (P = 0.0049 for the 
Finnish haplotype, P = 0.0013 for the German haplotype). These haplotypes span a 16.6 
kb region, located in an intergenic region between the hypothetical gene FLJ13391 and 
the genes MRPL19 (mitochondrial ribosomal protein 19) and C20RF3 (chromosome 2 
open reading frame 3). The haplotype block structure of the region revealed a 62 kb 
block of strong LD containing MRPL19 and C20RF3. Both of these genes were shown 
to be co-expressed across a panel of tissues from regions of adult brains, as well as 
showing correlation of expression with four other putative dyslexia susceptibility genes 
(DYX1C1, ROBOl, DCDC2 and KIAA0319). Anthoni and colleagues (2007) went on to 
sequence the coding exons and the flanking sequences of these two genes in one 
affected individual from each of the 19 Finnish families. Several non-synonymous 
variants were identified, but none of these were seen to be over-transmitted in affected 
individuals and so did not show significant association with DD. However, they did 
observe a reduction in the expression of both MRPL19 and C2orf3 from chromosomes 
carrying both rs917235(G) and rs714939(G) (Anthoni et al. 2007).
The DYX3 region seems to be a promising region for harbouring DD susceptibility 
loci, being widely replicated in samples from Norway (Fagerheim et al. 1999), Canada 
(Petryshen et al. 2002), UK (Fisher et al. 2002), US (Fisher et al. 2002; Francks et al. 
2002), Australia (Bates et al. 2007), Finland (Kaminen et al. 2003; Peyrard-Janvid et al. 
2004; Anthoni et al. 2007) and Germany (Anthoni et al. 2007). However, further work 
on this region now needs to concentrate on identifying candidate genes for DD and 
testing these for an association in larger samples.
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1.4.4 DYX4 (Chromosome 6q)
Petryshen et al. 2001 
Bates et al. 2007
Figure 1.5: Region on chromosome 6q showing evidence o f linkage/association with DD
Study Type Sample Main Findings
Petryshen et al. 
(2001) Linkage
96 Canadian families 
(n = 877)
PC (D6S965, LOD = 2.08), Spelling 
(D6S865, LOD = 3.34)
Bates et a I. 
(2007) Linkage
403 Australian families 
(n = 980)
Irregular word spelling at D6S462 
(LOD = 1.59, P = 0.003)
Table 1.5: Evidence for association/linkage with DYX4 (PC = phonological coding).
Petryshen and colleagues (2001) carried out a linkage study using a sample of 96 
Canadian families and a qualitative PCD phenotype (affected, unaffected or uncertain) 
and found suggestive evidence of linkage with chromosome 6ql 1.2-12 (see Figure 1.5). 
Two-point parametric analyses found evidence for linkage between PCD and the 
markers D6S254, D6S965, D6S280 and D6S251 (LODmax scores = 2.4 to 2.8) across an 
11 cM region. Multipoint parametric analysis supported this linkage with a peak LOD 
score of 1.6 between markers D6S20 and D6S286. Petryshen and colleagues (2001)
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then used separate reading measures (PA, PC, spelling and RAN speed) and found 
evidence of linkage between this region and spelling (D6S865, peak LOD = 3.34), PC 
(D6S965, peak LOD = 2.08) and PA (D6S455, P = 0.026).
Bates and colleagues (2007) also found evidence for linkage in this region in their 
genome wide study using 403 Australian families that were not selected for reading 
ability. They found linkage for irregular word spelling at D6S462 (LOD = 1.59, P = 
0.003).
No other studies have replicated the linkage reported in this region, despite several 
genome-wide linkage scans being conducted (de Kovel et al. 2004; Fagerheim et al. 
1999; Fisher et al. 2002; Igo Jr et al. 2006; Kaminen et al. 2003; Marlow et al. 2003; 
Nopola-Hemmi et al. 2001; Norton et al. 2000; Raskind et al. 2005). However, several 
genes are located near this region that still make strong candidates for a DD 
susceptibility gene (Petryshen et al. 2001). The serotonin neurotransmitter receptor 
genes HTR1B and HTR1E and the gamma-aminobutyric acid (GABA) receptor rho- 
subunit genes GABRR1 and GABRR2 make good candidates due to their involvement in 
brain development (Levitt et al. 1997). The cannabinoid receptor gene (CNR1) is also a 
good candidate since studies suggest that the endogenous cannabinoid system plays a 
role in neural development (Femandez-Ruiz et al. 2000).
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1.4.5 DYX5 (Chromosome 3)
5 .3  -
3p21.33 -  
3p 21.32
3 p 2 1 .3 1  -
3^ 1 1 .2
Nopola-Hemmi et al. 2001 
Fisher et al. 2002 
Hannula-Jouppi et al. 2005 
Bates et al. 2007
R0B01
3<25.1
3a2S,2
Figure 1.6: Regions on chromosome 3 showing evidence o f  linkage/association with DD
Study Type Sample Main Findings
Nopola-Hemmi 
etal. (2001) Linkage
1 Finnish 
family (n = 74) D3S1595-D3S3655 (LOD = 3.84)
Fisher et al. 
(2002) Linkage
89 UK families 
(195 sibling 
pairs)
PD (D3S1566, P = 0.044), OC-irreg (D3S1566, 
P = 0.001; D3S1311, P = 0.0008)
119 American 
families (180 
sibling pairs)
D3S1278 linked to reading P = 0.002, PA P = 
0.097, PD P = 0.0004, and OC P = 0.026 
(single-point); linked to reading P = 0.003, PA P 
= 0.072, PD P = 0.0003, and OC P = 0.025 
(multipoint
Bates et al. 
(2007) Linkage
403 Australian 
families (n = 
980)
Irreg word spelling (D3S1292, LOD = 1.66, P = 
0.003)
Table 1.6: Evidence for association/linkage with DYX5 (PA = phonological awareness, PD = 
phonological decoding, OC = orthographic coding).
Linkage of DD to the 3pl 2-ql 3 region was first identified by Nopola-Hemmi and 
colleagues (2001). They carried out a genome-wide scan using 74 members of a four 
generation Finnish family, of which 21 were affected with dyslexia. In the first part of
the study, part of the sample, family A, was genotyped using 320 markers spanning the 
whole genome. This revealed non-parametric linkage in the 3pl2-ql3 region (Z= 5.8, P 
= 0.0017) (see Figure 1.6). The other part of the sample, family B, were then genotyped 
using 7 microsatellite markers that spanned the 60 cM region of linkage implicated in 
the first sample, and both samples were genotyped using 11 additional markers in this 
region. Haplotype analysis revealed that 19 out of 21 dyslexic subjects shared identical 
copies of chromosome 3 and parametric multipoint linkage analysis resulted in a 
maximum LOD score of 3.84 between the markers D3S1595 and D3S3655.
Hannula-Jouppi and colleagues (2005) identified a patient within the Finnish family 
(Nopola-Hemmi et al. 2001) that had DD and the translocation t[3;8][pl2;ql 1] which is 
within the DYX5 region. The translocation breakpoint localised within the orthologue of 
the Drosophila roundabout (robo) gene ROBOl, disrupting ROBOl between exons 1 
and 2. They then sequenced this gene and the region surrounding it in the original 
Finnish sample used by Nopola-Hemmi and colleagues (2001) and found that the 
haplotype present in 19 of the dyslexic individuals spanned ROBOl and was not 
detected in the other samples examined, including controls and the remaining family 
members. Gene expression analysis was carried out using lymphocytes from four 
affected members of the family and this showed that the transcription of ROBOl from 
this haplotype was absent or attenuated, suggesting that in this family, DD may be 
caused by a reduction in the expression of ROBOL However, reduction in expression 
varied across the four individuals, so there does not seem to be a uniform phenotype. 
Also, as the expression analysis was only carried out in 4 individuals, it is not known if 
this reduction in expression occurs in all members carrying the haplotype. Another 
important point is that a sibling of a translocation carrier was diagnosed with severe DD 
but did not carry the translocation themselves, so there must also be other variants 
causing the disorder, perhaps on different chromosomes. Functionally, ROBOl is a 
good candidate gene for DD. It is widely expressed in the brain and the robo gene in 
Drosophila was found to be involved in controlling the decision by axons to cross the 
central nervous system midline (Kidd et al. 1998). In robo mutants, it was found that 
too many axons cross the midline (Seeger et al. 1993), and so ROBOl appears to play a 
role within axon guidance/neuronal migration (see Chapter 3).
In another genome-wide scan, Fisher and colleagues (2002) found linkage to several 
regions on chromosome 3 using quantitative trait analysis in US and UK samples. As
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shown in Figure 1.6, some of these regions were not close to the DYX5 region 
(D3S1311 at 3q29 linked to OC of irregular words in UK sample, P = 0.0008; D3S1263 
at 3p25 linked to reading, PA and OC in US sample, P = 0.016, 0.023 and 0.001, 
respectively) while others were just outside of the region. A marker on 3pl3 was linked 
to PD and OC of irregular words in the UK samples (D3S1566, PD P = 0.044; OC P = 
0.001), while the region 3ql3 was linked to DD in the US samples using both single 
point analysis (D3S1278 linked to reading P = 0.002, PA P = 0.097, PD P = 0.0004, and 
OC P = 0.026) and multipoint analysis (linked to reading P = 0.003, PA P = 0.072, PD P 
= 0.0003, and OC P = 0.025). The DYX5 region was also linked to DD in a genome- 
wide scan by Bates and colleagues (2007) using 403 Australian families unselected for 
reading ability. A linkage peak for irregular word spelling was found in the 3pl2-ql3 
region for irregular word spelling (LOD = 1.66, P = 0.003). This is within 20 cM of the 
linkage peak reported by Nopola-Hemmi and colleagues (2001).
So far, the region on chromosome 3 that shows evidence of linkage with DD is quite 
broad. More studies need to be carried out on this region, perhaps with denser panels of 
markers and larger sample sets. However, ROBOl appears to be a promising candidate 
gene for DD.
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1.4.6 DYX6 (Chromosome 18)
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Figure 1.7: Regions on chromosome 18 showing evidence o f linkage/association with DD
Study Type Sample Main Findings
89 UK families (195 
sibling pairs)3
SWR (Single point - D18S53, P = 0.0002; 
D18S464, P = 0.0006; Multipoint - P = 
0.00001)
Fisher et al. 
(2002) Linkage
119 American families 
(180 sibling pairs)
SWR (Single point - D18S53, P = 0.0004; 
D18S1102, P = 0.0005; Multipoint - P = 
0.0004)
84 UK families (143 
sibling pairs)
PA (Singlepoint - D18S452, P = 0.005; 
D18S464, P = 0.0001; Multipoint - P = 
0.0005)
Marlow et 
al. (2003) Linkage 173 UK familiesa+b Multivariate analysis P = 0.0011
Bates et al. 
(2007) Linkage
403 Australian families 
(n = 980) Reading (D18S464, LOD = 1.70, P = 0.03)
Table 1.7: Evidence for association/linkage with DYX6 (SWR = single word reading; PA = phonological 
awareness). Letters (a,b) indicate sample overlap.
The first study implicating the DYX6 region in DD was the first whole-genome scan
carried out by Fisher and colleagues (2002). The strongest evidence for linkage in this
study was found in the 18pl 1 region (see Figure 1.7 and Table 1.7). Linkage was found
in both the US and UK samples, and was replicated in a separate UK sample. However,
the first UK sample had shown the strongest linkage to the SWR measure (P = 0.0001),
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whereas the second sample gave the most significant results for the PA measure (P = 
0.0005), raising concerns over whether this finding represents a true replication. The 
second UK sample was also used by Marlow and colleagues (2003) who applied a 
multivariate approach in their linkage analysis rather then the univariate approach used 
by Fisher and colleagues (2002). This involved analysing all the correlated trait 
measures together when conducting linkage analysis, rather than looking at each 
measure separately. This approach gave a less significant result (P = 0.0011) for 
18pl 1.2. These findings were replicated in a genome-wide scan by Bates and colleagues 
using 403 Australian families. They found linkage with SWR for a marker on 18pl 1.2 
(D18S464, LOD = 1.70, P = 0.003).
Two other studies have failed to replicate these results. Chapman and colleagues
(2004) used 8 markers in the 18pl 1.3 -  ql2.3 region to genotype 111 American families 
(n = 898), but did not find any positive linkage signals. Another study used 14 markers 
in the same region to genotype 82 German families, but again failed to find any 
significant linkage (Schumacher et al. 2006b). These differences could well be due to 
differing sample sets and ascertainment criteria, particularly as Schumacher and 
colleagues (2006b) used a spelling measure as their ascertainment criteria, whereas 
Fisher and colleagues (2002) measured reading ability. However, the American sample 
used by Chapman and colleagues (2004) is larger than that used by Fisher and 
colleagues (2002) and so would have more power to detect linkage. It could be that the 
putative disease gene in the DYX6 locus confers a smaller risk to DD than originally 
suggested.
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Figure 1.8: Regions on chromosome 11 showing evidence o f linkage/association with DD
Study Type Sample Main Findings
Fisher et al. 
(2002) Linkage
89 UK families (195 
sibling pairs) PA (D11S1338 (P = 0.001)
Hsuing et al. 
(2004) Linkage
100 Canadian 
families (n = 914)
Linkage between DRD4-exon 3 
repeat and HRAS (LOD = 3.57, P = 
0.00005)
Table 1.8: Evidence for association/linkage with DYX7 (PA = phonological awareness).
Evidence for linkage of a region on chromosome 11 to DD was first identified in 
the genome-wide scan conducted by Fisher and colleagues (2002). In their UK sample, 
they found linkage with the marker DllS1338 o n l l p l 5  with the PA measure.
However, no significant linkage on this chromosome was identified in the US sample.
Hsiung and colleagues (2004) also studied this region for linkage with DD. They 
looked at this region due to the presence of an ADHD candidate gene, the dopamine D4 
receptor (DRD4). This gene contains several polymorphic elements, including a 48-bp
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variable number tandem repeat (VNTR) in exon 3 which is in the region previously 
found to be associated with ADHD (see meta analysis by Faraone et al. (1999)). As 
discussed previously, ADHD and DD share some comorbidity, therefore Hsiung and 
colleagues (2004) used 14 markers in and around the DRD4 locus to genotype their 
sample of 100 Canadian families, diagnosed with PCD (as previously used by Field and 
Kaplan (1998) and Petryshen et al. (2001)). The DRD4 gene is a member of the 
dopamine D2-like receptor family and is expressed in the hippocampus and frontal 
cortex (Defagot et al. 1997; Primus et al. 1997). These regions are known to be involved 
in executive functions, attention processing, memory formation and language 
processing, making it a good DD susceptibility candidate gene, aside from the link with 
ADHD. Evidence for linkage was found at the DRD4-cxon 3 repeat (LOD = 2.27) and 
at several nearby markers (D1 IS 1984, LOD = 2.32; D11 SI363, LOD = 2.13; HRAS, 
LOD = 2.68). Three point analysis identified a significant peak LOD score of 3.57 (P = 
0.00005) between the DRD4~exon 3 repeat and HRAS. Pairwise non-parametric sib-pair 
analyses also generated a significant P-value within the DRD4-qxon 3. However, 
subsequent association analysis did not detect a significant association between DD and 
the DRD4 VNTR (P = 0.30). As this region has been found to be linked with DD in a 
previous study (Fisher et al. 2002), it could be that this is indeed a susceptibility locus, 
but that DRD4 is not involved in causing the susceptibility to DD. As DD is common in 
the general population, another possibility is that there are multiple DRD4 variants 
contributing to susceptibility (Hsiung et al. 2004).
Another genome-wide study conducted using 51 American families found 
suggestive evidence for linkage on a different region of chromosome 11. Raskind and 
others (2005) obtained a LOD score of 2.32 for the marker D11S1314 using two-point 
parametric analysis. However, this marker is on the other arm of chromosome 11 as 
shown in Figure 1.8. This region has not yet been found to be linked with DD in any 
other studies and the result from this study isn’t highly significant, especially when 
considered on a genome-wide scale, so may not be a true finding. Alternatively, it could 
represent a second DD susceptibility locus on chromosome 11 that has only been 
highlighted in this particular sample so far.
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Figure 1.9: Regions on chromosome 1 showing evidence o f  linkage/association with DD
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Study Type Sample Main Findings
Rabin et al. 
(1993) Linkage 9 American Families
Rh (Zmax = 1.95); D1S165 (Zmax = 
2.33)
Grigorenko 
etal. (2001) Linkage
8 multiplex American 
families (n = 165 
individuals)
PD (D1S199, max NPL = 2.623); RN 
(D1S470, max NPL = 5.737)
Tzenova et 
al. (2004) Linkage
100 Canadian families (n 
= 914)
Qualitative: D1S507 (LOD = 3.65). 
Quantitative: Spelling D1S552 - 
D1S622 (LOD = 4.01)
Franke et 
al. (2006) Linkage 108 Dutch families Linkage to 1p36 (NPL-LOD = 2.0_
Bates et al. 
(2007) Linkage
403 Australian families 
(n = 980) NWR (D1S234, LOD = 1.2, P = 0.009)
Couto et al. 
(2008) Association
263 Canadian families 
(263 subjects and 101 
siblings)
Qualitative: rs7523017 (P = 0.035). 
Quantitative: Spelling rs7523017 (P = 
0.036)
Table 1.9: Evidence for association/linkage with DYX8 (PA = phonological awareness, PD = 
phonological decoding, RN = rapid naming, NWR = non-word reading). N.B. These are all independent 
samples.
Linkage of a region on chromosome 1 to DD was first identified by Rabin and 
colleagues and Froster and colleagues in 1993. Rabin and colleagues (1993) carried out 
linkage analyses with the polymorphic protein marker Rh in 9 three-generation 
American families in which DD appeared to be inherited as a dominant trait. This 
rhesus blood group CcEe antigens locus (RHCE) maps to the region lp34-36 and 
showed significant linkage in all the families (Zmax = 0.95, 0 < 0.2). Linkage was also 
found for the markers FUCA1 (Zmax = 0.950, 0 = 0) and D1 SI65 (Zmax = 2.33, 0 = 
0.2). Froster and colleagues (1993) identified a co segregation of severely delayed 
speech development and the reading and writing disability with a balanced translocation 
(t[l ;2][lp22;2p31]) in a German family that had a history of learning difficulties. A 
father and two of his sons carried the translocation and showed evidence of learning 
difficulties as well as severely delayed speech development. The members of the family 
with normal karyotypes had normal phenotypes.
Bache and colleagues (2006) also found evidence for a translocation on 
chromosome 1 being linked with DD, but this translocation involved the lp36.1 region 
of the chromosome. They found that the balanced translocation t[ 1; 18] [p36.1 ;q21 ] 
cosegregated with DD in 5 members of a Dutch family. However, diagnosis of DD was 
based on the family members self reporting their disease status, rather than carrying out 
any tests so this result is not completely reliable.
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Grigorenko and colleagues (2001) found evidence for linkage of DD with 
chromosome lp by examining the region around Rh (Ip36-lq23) using eight extended 
American families who possessed at least four individuals with dyslexia (n = 165). 
Again, this group used five theoretical phenotypes for DD in their search for linkage: 1) 
PA; 2) PD; 3) RAN; 4) SWR; 5) vocabulary. A “lifetime” diagnosis (LD) was also used 
as a phenotype. An individual (adult or child) was diagnosed as having DD if it had 
beat reported that they had difficulty acquiring initial reading skills (n = 68). If they 
still showed impairment in their reading or still required specialist instruction, they were 
classed as clearly impaired (n = 33 out of the 68 DD cases). If however they had 
managed to obtain literacy level or no longer required ongoing reading help, they were 
diagnosed as “borderline” (n =* 35). Individuals were classed as normal if they had no 
reported history of difficulty with reading and if there was a deficiency in no more than 
one aspect of reading. Single point analysis indicated two broad regions of linkage: 1) 
D1S253 (6.3 Mb) to D1S478 (21.3 Mb); 2) MATN1 (30.9 Mb) to PPT (40.2 Mb). 
However, multipoint analyses gave an inconsistent pattern and may be invalid due to 
two of the markers used in the analysis being in the wrong order. The PD phenotype 
showed linkage to the marker D1S199 (NPL score = 2.623) and the RAN phenotype 
showed linkage to the marker D1S470 (NPL score = 5.737).
Tzenova and colleagues (2004) found further evidence for linkage of DD to the 
region lp34-36. This involved a larger sample than the previous studies, with analyses 
being carried out on 100 Canadian families (n = 914). The group used both qualitative 
and quantitative definitions of DD in their linkage analysis. The qualitative definitions 
used were ‘affected’, ‘unaffected’ or ‘uncertain’ using the scores on phonological 
coding tasks as the primary determinant of affection status. Under these phenotypes, the 
strongest evidence for linkage was found at the marker D1S507 (max LOD = 3.65).
This marker is ~5Mb away from D1S199, which had previously been found to be linked 
to DD by Grigorenko and colleagues (2001). For the quantitative phenotype analysis, 
psychometric tests were conducted to assess four components of DD: 1) PA; 2) PD; 3) 
spelling; 4) RAN. Using multipoint analysis, the maximum LOD score for spelling was
4.01 and occurred between D1S552 and D1S622. PD and RAN speed showed non­
significant evidence for linkage to the same region (max LOD scores of 1.65 and 0.37 
respectively), while the LOD scores for PA were close to zero throughout the region.
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However, again these results are unreliable due to two markers being in the wrong 
order.
A linkage study carried out on a Dutch population also looked at DD as both a 
categorical trait and as a number of different quantitative traits (Franke et al. 2006). The 
categorical trait showed the strongest linkage to lp36 (NPL-LOD = 2.0). The LOD 
scores for the quantitative traits: SWR, NWR and RAN were found to be correlated and 
peaked near the same location as the categorical trait.
A gene within the lp34-36 region shows homology to the KIAA0319 gene on 
chromosome 6 and is called KIAA0319-Like (KIAA0319-L) (see Figure 1.9). Couto and 
colleagues (2008) genotyped a sample of 156 Canadian families using 5 SNPs within 
this gene. Evidence for an association was found with the marker rs7523017 (P = 0.042) 
when DD was defined as a categorical trait. They also identified a significant haplotype 
with the markers rsl203138, rsl203148, rsl2408030, and rs7523017 (C/A/A/A; P = 
0.031). When using quantitative measures of DD and their whole sample of 291 families 
(the 156 previous families plus an additional 135 families that had been ascertained 
through a proband who had reading difficulties but did not meet the categorical criteria), 
this haplotype showed significant association with measures of word-reading efficiency 
(P = 0.032) and rapid object and colour naming (P = 0.047). However, as the authors 
point out, these results would not withstand correction for multiple testing. These results 
correlate with those of Tzenova and colleagues (2004) who also found linkage on 
chromosome lp for spelling in a region that is 5 kb from rs7523017. In the genome 
wide study carried out by Bates and colleagues (2007) on 403 Australian families, the 
region lp34-36 also showed some evidence of linkage to NWR (max LOD = 1.2).
Further evidence supporting linkage of the DYX8 region to DD has come from 
studies focusing on SSD. Smith and colleagues (2005) tested whether SSD is linked to 
risk loci for DD, including those on chromosome lp36. Although only suggestive 
evidence for linkage was found in this particular study (P = 0.053 at D1S620), another 
study on SSD supported this evidence by obtaining highly significant evidence for 
linkage (Miscimarra et al. 2007). This group obtained significant linkage signals for 
articulation (P = 0.0009) and listening comprehension (P = 0.0019) in two separate 
regions on chromosome 1.
However, studies using subjects sampled from other populations have failed to 
replicate linkage of DD to chromosome 1. For example, Cardon and colleagues (1994)
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typed markers in the Rh region in 358 individuals from the Colorado twin study and 
failed to find significant linkage. Several genome wide studies have also failed to 
identify linkage to DD on chromosome 1. Fagerheim and colleagues (1999) conducted a 
genome wide search with an average 20 cM marker density in a Norwegian population. 
This search included 12 markers on chromosome lp, but no linkage was found to DD.
A genome scan using a Finnish population of 140 families conducted by Nopola- 
Hemmi and colleagues (2001) used 320 microsatellite markers, but found no association 
with DD on chromosome 1. Fisher and colleagues (2002) carried out two complete 
quantitative trait locus-based (QTL-based) genome wide linkage studies in large 
samples from the United Kingdom (195 total sibling pairs) and United States (180 total 
sibling pairs). This group used over 400 microsatellite markers spaced at about 10 cM 
intervals throughout the genome. Again, this study failed to replicate an association of 
chromosome 1 with DD.
The evidence so far seems to suggest that a region on chromosome 1 is linked with 
DD, with the most widely replicated region being lp34.2 to lp36.13 as shown in 
Figure 1.9. However, while evidence for linkage in this region has been found in 
American (Rabin et al. 1993; Grigorenko et al. 2001), Canadian (Tzenova et al. 2004; 
Couto et al. 2006), Australian (Bates et al. 2007) and Dutch (Franke et al. 2006) 
populations, genome-wide scans carried out on populations in Norway (Fagerheim et 
al. 1999), Finland (Nopola-Hemmi et al. 2001), UK and a different American 
population (Fisher et al. 2002), have failed to support these results. It is possible that 
this region may be involved in DD, but only in certain populations.
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Figure 1.10: Regions on chromosome X showing evidence o f linkage /association with DD.
Study Type Sample Main Findings
Fisher et 
al. (2002) Linkage
89 families (195 sib pairs), 
UK
Xq26 linked to reading (P = 0.001), PD 
(P = 0.018), OC-irreg (0.038)
de Kovel 
et al. 
(2004)
Linkage 1 Dutch family (n -  29) DXS8043 (multipoint LOD = 3.68; NPL = 1.95, P = 0.0014)
Bates et 
al. (2007) Linkage
403 Australian families (/? = 
980)
Non-word spelling (DXS9908 LOD = 
1.09, P = 0.012)
Table 1.10: Evidence for association/linkage with DYX9 (PD = phonological decoding, NPL = non- 
parametric LOD score)
The genome-wide study conducted by Fisher and colleagues (2002) was again the 
first study to identify linkage to DD on the X chromosome. They found linkage of the 
Xq26 region with measures of reading (P = 0.001), PD (P = 0.018) and OC using 
irregular words (P = 0.038) in their UK sample. However, no significant linkage was 
found between this chromosome and DD in the US sample.
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Another genome-wide study found evidence of linkage 12 cM away from the region 
identified by Fisher and colleagues (2002). This study used 400 markers to genotype 29 
members of a single Dutch family of which 5 males and 10 females (1 of which was an 
unrelated spouse) were classified as dyslexic (de Kovel et al. 2004). The most 
significant evidence for linkage was found with the marker DXS8043 on chromosome 
Xq27.3 (multipoint lod score = 3.68, 6 = 0.00; non-parametric lod = 1.95, P = 0.0014). 
As two key recombinants flanked the region surrounding this marker, the group tested 
three extra markers (DXS8028, DXS8084 and DXS8106) between the two breakpoints 
in the key recombinants and their ancestors, narrowing the region down to ~8 cM 
between the markers DXS1227 and DXS8091. All four males and 8 of the 9 women 
diagnosed with DD carried the risk haplotype. This suggests that the risk allele has a 
dominant effect, but it could be that heterozygous females are less severely affected 
than hemizygous males.
Bates and colleagues (2007) also found linkage within this region in their genome- 
wide study using 403 Australian families. They found linkage of the non-word spelling 
measure with the marker DXS9908 on chromosome Xq27 (LOD = 1.09, P = 0.012) 
using multipoint linkage analysis.
As discussed in section 1.1.2, epidemiological studies have observed that DD is 
often found in males at a greater rate than in females, with a ratio of ~2:1 (Flannery et 
al. 2000). A possible cause for this could be the involvement of X linked loci, backed up 
by evidence of a susceptibility locus on chromosome X as shown here. However, other 
explanations for this skewed ratio could involve male specific hormonal differences 
during development that may interact with an autosomal locus (James 1992).
Geschwind and Behan (1982) have hypothesised that gender differences could be 
explained by an excess of, or sensitivity to, androgens such as testosterone.
1.4.10 Other Possible DD Susceptibility Loci
Other loci have also been found to be linked or associated with DD but have not 
been designated a DYX region by the Human Gene Nomenclature Committee 
(http://www.gene.ucl.ac.uk/nomenclature/). Two of these have shown replication and 
are worth mentioning.
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Figure 1.11: Regions on chromosome 2q showing evidence of linkage/association with DD.
Chromosome 2q22.3 first showed evidence of linkage with DD in a genome scan 
carried out on a total of 874 individuals from 108 American families (Raskind et al. 
2005). This study found that a phonemic decoding efficiency measure (PDE) was 
significantly linked with the marker D2S1399 (LOD = 3.0). Igo Jr and others (2006) 
used this same sample in a genome scan using measures of single-word reading 
efficiency (SWE) and word identification (WID). The same region showed linkage with 
SWE for the three marker combination D2S1334-D2S1326-D2S1399 (LOD = 1.88). 
WID, which is a measure of accuracy alone, did not show any evidence of linkage to 
this region, suggesting that this locus is involved in the speed rather than accuracy of 
phonological decoding. Further evidence of linkage in this region comes from the 
genome-wide scan by Bates and others (2007). The scan of 403 Australian families
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showed linkage with regular-word spelling for the marker XRCC5 (LOD = 2.18, P = 
0 .001).
1.4.10.2 Chromosome 7q
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Figure 1.12: Regions on chromosome 7q showing evidence o f linkage/association with DD.
The FOXP2 gene on 7q31 was first associated with speech and language disorder in 
a study on 30 members from 4 generations of a family (KE) in which half of the family 
members were affected by a severe speech and language disorder (Pennington et al.
1991). Those affected mainly showed difficulties in articulation and grammar, but they 
also showed deficits in phonological processing (Vargha-Khadem et al. 1995). Lai and 
colleagues (2001) found that a G—>A nucleotide transition in exon 14 of FOXP2 co­
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segregated perfectly with the speech and language disorder in the KE family. A region 
15 Mb from this gene showed linkage to DD in a genome wide scan using 88 subjects 
from 11 Finnish families (D7S530, NPL = 2.77, P = 0.003) (Kaminen et al. 2003). This 
was also replicated in a genome wide scan using 403 Australian families (Bates et al. 
2007). The marker D7S530 showed evidence of linkage with nonword spelling (LOD = 
2.05), irregular word reading (LOD =1.91), regular word reading (LOD =1.13) and 
nonword reading (LOD = 1.21). However, after sequencing the whole coding region of 
FOXP2 in six subjects with DD and 3 controls, no mutations in this gene were found, 
including the G—>A transition on exon 14 (Kaminen et al. 2003). This suggests that the 
FOXP2 gene specifically affects the speech disorder, and may not be involved in DD. 
Although individuals with the speech disorder showed phonological processing deficits, 
these may have been a secondary effect of the speech disorder, rather than being related 
to an actual reading deficit. Even if FOXP2 isn’t a likely candidate gene for DD, the 
region of linkage identified by Kaminen et al. (2003) and Bates et al. (2007) is still 
worthy of further investigation.
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1.5 Aim of Thesis
The aim of this thesis was to identify susceptibility variants for DD using several 
approaches:
• A candidate gene study was conducted selecting genes within the DYX 
linkage regions that either have a possible role within neuronal migration or 
share homology to putative DD susceptibility genes identified so far. This is 
presented in Chapter 3 of this thesis.
• The first GWAS of DD was carried out in collaboration with other DD 
research groups in Europe (NeuroDys collaboration) in an effort to identify 
new susceptibility variants for DD and this is presented in Chapters 4 and 5 
of this thesis.
• An additional GWAS in the form of a pooling study was conducted using the 
Cardiff case-control sample in order to identify new variants that show 
association for DD in this homogeneous sample and this is presented in 
Chapter 6.
• Finally, a CNV analysis was conducted using data from the initial NeuroDys 
GWAS in order to identify if these types of structural variants may have a 
significant association with DD. This is presented in Chapter 7 of this thesis.
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Chapter 2: Materials and Methods
2.1 Sample Ascertainment and Collection
2.1.1 Collection of the Cardiff Sample
The collection of DNA samples and phenotypic information for this study was 
undertaken by Dr Gary Hill and colleagues under the supervision of Prof. Julie 
Williams. The study has ethical approval obtained from local ethics committees in the 
UK and informed written consent was obtained for all participants in the study. Written 
consent for children under the age of 18 years was obtained from parental guardians.
DD-probands and their families were ascertained through contacts with Local 
Education Authorities (LEA) in South Wales and schools specialising in the education 
of children with reading difficulties in England. All English schools, with the exception 
of one, were members of Crested (the Council for the Registration of Schools Teaching 
Dyslexic Pupils).
A pro-rated full-scale IQ score was calculated using four subtests from the WISC III 
UK, including vocabulary, similarities, block design and picture completion (Weshler
1992). Reading disability was assessed using either the Neale Analysis of Reading 
Disability (NARA) (Neale 1989) or the British Ability Scale (BAS) single word reading 
test (Elliot 1983) depending on age and ability of the proband. Whilst NARA is based 
on prose reading, the BAS single word reading is based on reading a list of words 
(correlation coefficient between NARA and BAS tests, r = 0.89). The measure used to 
assess reading disability is comparable to other definitions of DD used in molecular 
genetic studies including those of Grigorenko and colleagues (1997) and others (Fisher 
et al. 1999; Gayan & Olson 1999). Probands were required to have an IQ of 85 or above 
and a reading age 2.5 years or more behind their chronological age. This criterion 
represents a severe degree of reading disability and is likely to represent the lower 5th 
percentile of children. English was the first language of all participants.
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2.1.2 1958 Birth Control Cohort
Some studies presented in this thesis also used population controls from the 1958 
British Birth Cohort (or the National Child Development Study (NCDS). This began as 
a study of Perinatal Mortality focussing on just over 17,000 births in the UK in a single 
week in 1958 (Power & Elliott 2006). Members of the cohort were then followed-up by 
parental interview and examination at ages 7,11, and 16 years and by cohort member 
interview at 23,33 and 42 years. The first biomedical assessment in adulthood was 
conducted at 44-45 years. Genetic data for this cohort has been made available to 
researchers, and the data presented in this thesis was based on genetic data from the 
cohort genotyped on the Illumina HumanHap500 array.
2.13 Ascertainment Tests
2.13.1 British Ability Scales (BAS) Single Word Reading
The BAS single word reading involves reading single words from a list rather than 
prose text. The test is divided into 9 blocks of 10 words and is discontinued when one 
block is failed. Each block contains two lines of five words. Individuals read the words 
across each line before proceeding to the next. Words get progressively more difficult. 
Failure of a block occurs when five words on one line have been read incorrectly. The 
test has a retest reliability of 0.96 and a heritability of 0.44 (Hohnen & Stevenson 1999)
2.13.2 Neale Analysis of Reading Ability (NARA)
The NARA reading test consists of a set of graded prose passages that allow the 
testing of rate, comprehension and accuracy of oral reading. Test material is presented 
in the form of a book, which consists of short, graded narratives, each constructed with 
a limited number of words and with a central theme, action and resolution. Pictures 
accompany the narrative however these set the scene rather than tell the story.
Within the book there are six passages of increasing difficulty. Comprehension 
questions are available after the oral reading of the passage, which tap into the child’s 
use of contextual cues, pictures and prompts. They also test the immediate recall of the 
main idea of the narrative, the sequence of events and other details. In order to answer 
some questions inference is required.
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The NARA tests are only suitable for children up to the age of 12 years. As a result, 
analysis undertaken using measures from this test are only done on children aged 12 
years and under.
2.13J2.1 Reading Accuracy
Children start reading the passages but at a level below expected by their age (since 
they are poor readers), but which is not too low that they lose interest. Children move to 
the next level of passage until 16 mistakes have been made (20 on level 6). At this point 
the reading test is discontinued. The accuracy score is based on the number of words 
correct out of the number read. The accuracy score is converted to reading age based on 
population norms.
2.1.3.2.2 Reading Comprehension Task
Reading comprehension was measured on the number of correct questions answered 
by the child based on the number of passages they read and at what level. Like reading 
accuracy, a reading comprehension age is calculated and a discrepancy measure 
calculated between this and the child's chronological age.
2.1.3.23 Reading Rate Task
Whilst undertaking the prose reading task, the child is timed. Question answering is 
not included in the timing of individuals. A time is calculated and used in the following 
equation:
Total number of words
Words per minute = ------------------------------- x 60
Total time (seconds)
From this equation a reading rate age is calculated based on child norms. An age 
discrepancy is calculated between the reading rate age and the child’s chronological 
age.
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2.2 Samples Used In Thesis
The Cardiff case-control sample consisted of 357 cases with DD and 269 screened 
controls. The cases consisted of 281 males and 76 females and the controls consisted of 
124 males and 145 females. The sample demographics are described in Table 2.1.
Cases Controls
Variable Mean SD Minimum Maximum Mean SD Minimum Maximum
Age (years) 13.93 2.17 7.8 17.49 12.2 2.2 5.08 16.67
IQ* 102.05 11.8 85 141 109.5 12.15 85 137
RD (years) -4.58 1.56 -2.5 -9.13 1.64 1.55 -1.75 5.67
Table 2,1: Demographics of the Cardiff case-control sample. RD = Reading Disability, i.e. the 
discrepancy between their reading age and their chronological age at time of testing. * Not all controls 
were tested for IQ therefore demographics are based on the 102 participants tested for IQ
Different sample sets are used throughout this thesis. Figure 2.1 and Figure 2.2 
explain these sample sets and show the terms which will be used when referring to these 
sample sets in this thesis.
3751 population controls
1958 Birth Cohort
Cardiff Pooling Sample
302 cases & 219 controls
55 cases & 50 controls
Additional Cardiff 
Samples
Cardiff Case Control Sample
357 cases & 269 controls
Cardiff Individual 
Genotyping sample
357 cases & 269 controls
357 cases & 4020 controls
Cardiff Sample With 
Population Controls
Figure 2.1: Flow diagram explaining the different sample sets of the Cardiff case-control sample that are 
used in this thesis.
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Combined NeuroDys GWAS 
Sample
1868 cases & 4316 controls
Whole NeuroDys Individual 
Genotyping Sample
1526 cases and 2261 controls
NeuroDys GWAS Sample
• 410 UK cases & 1437 UK 
population controls
• 200 German cases & 905 
German population controls
From UK pools: 461 cases & 219 controls
From Central European pools: 527 cases & 902 controls
NeuroDys Individual Genotyping Sample
Additional NeuroDys 
Samples
• UK: 53 cases & 359 controls
• Central Europe: 246 cases & 423 
controls
• France: 161 cases & 204 controls
• Hungary: 78 cases & 154 controls
UK pools = 461 cases & 219 controls
Central European Pools = 532 cases & 912 controls
Finnish Pools = 286 cases & 321 controls
NeuroDys Pooling Sample
UK: 537 cases & 556 controls 
Germany: 308 cases & 879 Controls 
Switzerland: 26 cases & 43 controls 
Netherlands: 115 cases & 106 controls 
& 201 controls 
Finland :156 cases & 189 controls
Austria: 116
NeuroDys Replication Sample
Figure 2.2: Flow diagram explaining the different sample sets used within the NeuroDys studies that 
presented in this thesis.
2.3 DNA and Sample Extraction
2.3.1 DNA Extraction
Venous blood was taken from participants willing to give blood and DNA extracted 
from lymphocytes using standard procedures. If blood samples could not be given, 25ml 
saline mouthwashes were obtained. DNA was extracted from buccal cavity epithelial 
cells by centrifugation at 3000g for 15 minutes, followed by incubation with proteinase 
K (Sigma, USA), SET buffer (Qiagen, UK) and SDS (Invitrogen, UK) at 50°C for 12 
hours. The DNA was then isolated by standard phenol-chloroform extraction. Stock and 
diluted samples were stored in water at -20°C.
2.3.2 DNA Quantification
2.3.2.1 Quantification via Spectrophotometer
Extracted DNA was initially quantified using a Beckman DU 640B 
spectrophotometer (Beckmann Instruments, UK). Each DNA sample was diluted to a 
5% solution in sterile water. The absorbance (A) of UV light at 260nm and 280nm 
wavelengths (A) were measured and DNA concentrations were calculated on the 
assumption that an A260nm value of 1 was equivalent to 50pg of DNA. A ratio of A260nm 
to A28Qnm above a value of 1.8 indicated a suitable level of DNA and the absence of 
contaminating protein.
All DNA stocks were kept at -20°C in individual Eppendorf tubes. Working 
dilutions of DNA, diluted to 8ng/pl, were kept in 96-deep-well plates at 4°C.
23.2.2 Pico Green DNA Quantification
A more accurate quantification of DNA samples was also performed using a 
Fluoroskan Ascent fluorometer (Thermo Labsystems) and PicoGreen (Invitrogen). 
Samples were first diluted to less than 50ng/pl based on spectrophotometer readings. 
Aliquots of the samples were then diluted by a constant factor with IX TBE in a white 
96 well cliniplate such that the DNA concentration was expected to lie in the range of 
0.2-1.6ng/pl. A PicoGreen working solution was prepared in parallel by adding 5pi of 
pico green to 995pi of IX TE.
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In order to measure DNA concentration, lOOpl of the PicoGreen working dilution 
was dispensed into lOOpl of each diluted sample. The fluorometer measures the 
concentration of a sample using an UV excitation wavelength of 485nm and an 
emission wavelength of 538 nm. A standard curve was then used to calculate the 
concentration of DNA for each sample. All DNA stocks were kept at -20°C in 
individual Eppendorf tubes. Working dilutions of DNA, diluted to 8ng/pl, were kept in 
96-deep-well plates at 4°C.
2.4 Constructing Pools
DNA pooling was used in order to allow the estimation of allele frequency 
differences between cases and controls using fewer genotyping reactions that would be 
necessary if individual samples were individually assessed. DNA concentration was 
determined using PicoGreen (as described in section 2.3.2.2). To make sure that high 
quality DNA samples were used, only those which had genotyping call rates > 98% in 
previous genotyping studies were included. To produce pools, water was added to 
produce a target DNA concentration of 40ng/pl. Samples were allowed to equilibrate at 
4 °C for 48 hours before quantification using PicoGreen. Each sample was then further 
diluted to lOng/pl, allowed to equilibrate at 4 °C for 48 hours, and then quantified again. 
Based on the final quantification, equimolar amounts of the DNA samples were 
combined to form the DNA pools.
2.4.1 Concentrating Pooled Samples
After construction, the concentration of the UK pools was lOng/pl so they were 
concentrated using Microcon YM-100 Centrifugal Filter tubes (Millipore). The 
Microcon sample reservoirs were inserted into the vials and the 500pl DNA samples 
were pipetted into the sample reservoir. The tubes were the sealed and spun at 500g for 
~40 minutes until the volume of remaining sample in the reservoir was ~100|il. The 
sample reservoirs were then placed upside down in a new vial and spun at lOOOg for 3 
minutes to transfer the concentrate to the vial. The concentrated samples were then 
quantified using PicoGreen and subsequently diluted to 50ng/pl.
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2.4.2 Validating Pooled Samples.
To test the accuracy of the case and control pools in estimating allele frequency 
differences, the pools were genotyped using SNaPshot, as described in section 2.9.2.
2.5 Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PGR) is an enzymatic in vitro cycling technique for 
the amplification of a specific region of DNA that lies between two regions of known 
sequence. Thermostable Taq polymerase enzyme was used which synthesises a 
complementary strand from the DNA template in the presence of suitable buffers and a 
mix of adenine (abbreviated A), cytosine (C), guanine (G) and thymine (T) 
deoxyribonucleotide triphosphates (dNTPs). Two oligonucleotide primers are designed 
to flank the specific region of DNA to be amplified. These primers anneal to the 
template and provide the double stranded starting point for Taq polymerase to begin 5’ 
to 3’ synthesis. A PCR reaction is comprised of three steps, a denaturation step which 
produces a single stranded DNA template, a primer annealing step where the primers 
bind their complementary sequence and an elongation step when the synthesis of DNA 
occurs. Each step is accompanied by controlled temperature changes and there are 
typically 30-45 cycles per reaction.
The methods given below were used for general PCR reactions. Specific PCR 
conditions for other techniques are described in the relevant sections.
2.5.1 PCR Primer Design
PCR primers were designed in silico using the Primer 3 web resource (http//www- 
genome.wi.mit.edu/cgi-bin/primer/primer3-www.cgi). If possible PCR primers were 
designed using the default Primer 3 settings of an average length of 20bp, an annealing 
temperature of ~60°C and a GC content less than 80%. In general, and specifically 
where PCR products were required to be sequenced, amplimers were restricted to 
<500bp.
2.5.2 PCR Optimisation
All PCRs were performed on MJ thermocyclers (MJ Research, UK). To find the 
optimum temperature for primer annealing, optimisation reactions were undertaken for 
each primer-pair on control DNA using a temperature gradient. PCR reactions were
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carried out using the following mix shown in Table 2.2 (note: the amount of each 
reagent is given per single PCR reaction).
Reagent Company Volume (pi)
Buffer (10X containing 15mM MgCI2) Qiagen 1.2
dNTPs (2.5 mM) Amersham 1.2
Forward Primer (10pmol/|jl) Eurogentec 0.6
Reverse Primer (10pmol/|jl) Eurogentec 0.6
ddH20 4.34
HotStarTaq Polymerase (5units/pl) Qiagen 0.06
Genomic DNA (8ng/|jl) 4
Table 2.2: Reagents required for PCR reactions
The PCR cycling conditions were as follows:
94°C for 15 minutes 
94°C for 30 seconds
56-66°C for 30 seconds (depending on amplimer)
72°C for 45 seconds 
Go to step 2 for 34 cycles 
72°C for 10 minutes.
2.6 Agarose Gel Electrophoresis
The negative phosphate groups within DNA allow DNA fragments to be separated 
electrophoretically. When a potential difference is applied through a porous substance 
such as an agarose gel, DNA will move towards the anode, at a rate dependent on the 
fragment size. Analysis of pre -or post- PCR samples was performed using 1-2% 
agarose gels, depending on the fragment size and resolution required.
To construct a 1% gel, lg of agarose (Sigma-Aldritch) was dissolved in 100ml 0.5x 
TBE buffer (Ultra pure electrophoresis grade, National Diagnostics). The solution was 
heated until it became clear. Once the solution had cooled slightly, lpl Ethidium 
Bromide solution (lOmg/ml) was added. This solution was then poured into a gel- 
former with appropriate gel combs added and left to cool until it formed a solid.
In order to run a specific sample in a gel, each PCR product was mixed with loading 
buffer. 6x loading buffer was made by creating a solution of 15% ficoll, 0.25% 
bromophenol blue, 0.25% xylene cyanel in water. An appropriate volume of PCR
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product was mixed with loading buffer and pipetted into a formed well. 3pi of size 
standard (for example lkb plus DNA ladder, Invitrogen) was also run alongside samples 
to allow size comparison. Each gel was run at between 100-120V in an electrophoresis 
tank for the appropriate amount of time needed to see the DNA size expected. Samples 
were visualised using a UV transilluminator (UVP) and photographs taken using a 
Kodak Electrophoresis Gel analysis system.
2.7 Mutation Detection
Mutation detection was carried out using High Resolution DNA Melting Analysis 
(HRMA) on the Lightscanner (Idaho Technologies). HRMA is based on the observation 
that the melting temperature (Tm) of a PCR amplimer can be largely dependent on its 
specific sequence composition (Ririe et al. 1997). By slowly melting a PCR amplimer in 
the presence of a suitable fluorescent dye, which binds specifically to double stranded 
DNA (dsDNA), it is possible to monitor the amplimer’s melting curve via the change in 
fluorescence as the dye is released. When compared with a wild type sequence, the 
presence of both homo and heteroduplexes (caused by PCR products with heterozygous 
loci) can generate detectable changes in the shape of the melting curve (Graham et al. 
2005). The fluorescent dye LC green is particularly suited to HRMA because it can be 
used at concentrations high enough to saturate the dsDNA binding sites during PCR 
without inhibiting Taq polymerase (Wittwer et al. 2003). Saturation of the dsDNA 
reduces the potential of dye molecules released during HRMA being redistributed to 
dsDNA. This increases the sensitivity of the HRMA to detect subtle changes in 
fluorescence and LC green can efficiently detect single nucleotide variants in PCR 
products (Reed & Wittwer 2004).
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2.7.1 HRMA PCR
PCRs were performed in a 12pl reaction using the reagents shown in 
Table 2.3.
Reagent Volume (|il)
LCgreen Plus PCR buffer (10X containing 20mM MgCI2) 1.2
LCgreen Plus (10X) 1.2
dNTPs (5 mM) 0.96
Forward Primer (5pmol/|jl) 0.66
Reverse Primer (5pmol/|jl) 0.56
ddH20 3.46
HotStarTaq Polymerase (5units/|jl) 0.06
Genomic DNA (8ng/ul) 4
Table 2.3: Reagents and volumes required for HRMA PCR 
The PCR cycling parameters were as follows:
1. 95°C for 10 minutes
2. 94°C for 20 seconds
2. 56-66°C for 30 seconds (depending on amplimer)
3. 72°C for 1 minute
4. Go to step 2 for 44 cycles
5. 72°C for 10 minutes
6. 15°C forever
2.7.2 Mutation Detection by HRMA
HRMA was performed according to the manufactures instructions: each 12ul sample 
was denatured by increasing the temperature to 98°C at a rate of 0.1°C/s with 
fluorescent data points being acquired continuously at a rate of 14 points/°C.
Melting profiles were analysed using a semi-automated analysis (Dwyer et al.
2010). This involved normalising the melting curves by manually defining the 
temperature interval before and after the major change in fluorescence that corresponds 
to 100% and 0% fluorescence respectively. The samples were then analysed using the 
Lightscanner HRMA software Call-IT™ (Idaho Technologies) using the high sensitivity
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setting. The automatic calls of the software were inspected by the user and manually 
clustered according to the similarity of the ‘difference curve’ plots.
2.8 Sequencing
PCR products from individuals showing alternative melt profiles by HRMA (and 
therefore suggestive of heteroduplex formation) were sequenced in both directions 
using the fluorescent Sanger sequencing method via Big-Dye termination chemistry.
The fluorescent sequencing reaction involves the incorporation of four fluorescently 
labelled dideoxynucleotides (ddATP, ddCTP, ddGTP, ddTTP) in addition to unlabelled 
dNTPs. Unlike dNTPs, ddNTPs terminate after extending one base during a primer 
extension reaction. After an appropriate number of cycles, such a reaction produces a 
series of DNA fragments which have been terminated at each successive base position. 
When these fragments are electrophoresed in a capillary sequencer, such as the 
ABI3100, each base of the sequence will be fractionated by size and under laser 
detection, fluoresce according to the base at that site.
In order to reduce errors and improve consistency an Agencourt semi-automated 
protocol was employed for the clean-up of PCR and Sequencing products using the 
Beckman-Coulter NX liquid handler.
2.8.1 PCR Clean-Up
PCR clean-up is needed when the product to be sequenced has been amplified via a 
PCR reaction as it removes unincorporated dNTPs, primers, DNA polymerase and salts. 
The PCR product (1 Ojxl) was mixed with 21.6pl of AMPure reagent (Agencourt). This 
reagent contains magnetic beads which adhere to the DNA. The products not fixed to 
the beads were removed by successive 85% ethanol wash steps. The PCR amplimeres 
were then eluted in 195pi H20 in a new 96-well skirted plate.
2.8.2 Sequencing Reaction
5 pi of the cleaned PCR product was added to a 5 pi sequencing reaction mix which 
was made as shown in Table 2.4.
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Reagent Volume (pi)
5x BigDye sequencing buffer 0.917
BigDye termination mix 0.116
Forward or reverse PCR primer (4pmol/|jl) 1
H20 1.917
Table 2.4: Reagents and volumes required for the sequencing reaction mix.
The BigDye reaction mix contains the four fluorescently labelled ddNTPs, 
unlabelled dNTPs and a Sequenase enzyme. The sequencing reaction was performed on 
a MJ thermocycler using the following conditions:
1. 96°C for 2 minutes
2. 96°C for 30 seconds
3. 55°C for 15 seconds
4. 60°C for 4 minutes
5. Repeat steps 2-4 23 times
6. 4°C for 4 minutes
2.8.3 Post Sequencing Clean Up
The post-sequencing clean-up removes any unwanted impurities from the 
sequencing reaction such as unincorporated ddTTPs. The post-sequencing clean-up 
involves a CleanSEQ chemistry protocol which, like the AmPure reagent used in the 
PCR clean-up, contains magnetic beads. lOpl of sequencing product is added to 7.5pl of 
CleanSEQ reagent along with 36.39pl of 85% ethanol. As with the AMPure protocol 
the sequencing product binds to magnetic beads and the non-bound contaminants are 
removed by successive 85% ethanol wash steps. The cleaned sequencing product is 
eluted in 75pi of H20 which can be read directly via a capillary sequencer.
2.8.4 Sequencing Analysis
Samples were then run on the ABB 100 PRISM through a 36cm capillary using 
polyacrylamide POP6 (Applied Biosystems). The ABB 100 PRISM genetic analyser 
automatically analyses the raw data generated through electrophoresis using its 
Sequence Analysis Software (Applied Biosystems). This software calls each nucleotide 
based on the fluorescence at each base. The sequence analysis software package 
Sequencher (Gene Codes) was used to identify any polymorphisms within the
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amplimers. This package aligns multiple sequencing traces and will highlight 
differences between the traces and/or a reference sequence. The user can then manually 
inspect these differences to judge whether a polymorphism exists.
2.9 Genotyping
Genotyping of candidate genes and follow up SNP panels was conducted using 
Sequenom MassARRAY genotype platform. The GWAS were conducted using 
Illumina SNP arrays and SNaPshot genotyping was used to validate the pooling 
samples.
2.9.1 Genotyping Using Sequenom MassArray
The Sequenom MassARRAY genotyping system allows the highly accurate 
genotyping of simple polymorphisms by combining iPlex GOLD primer extension 
chemistry with MALDI-TOF (Matrix Assisted Laser Desorption Ionisation -  Time Of 
Flight) Mass Spectrometry (MS). iPlex GOLD involves primer extension over the 
polymorphism of interest and the examination of the mass of the extended product to 
discern the genotype of the sample. Results are stored and analysed using the software 
Typer (Sequenom). The main advantage of this genotyping system is the high accuracy 
combined with a high multiplexing level (up to a 40-plex).
The initial step of MassARRAY genotyping involves the design of a multiplex assay 
using Sequenom Design Assay software. For each polymorphism the flanking DNA 
sequence is obtained and additional features of the sequence that may confound any 
assay are highlighted (for example known SNPs or repetitive sequence) to prevent assay 
design over these regions. From this information the Sequenom Assay Design software 
designs PCR and extension primers to the highest multiplex level possible. Details of 
these are provided in the design output file. In order to ensure extension peaks are 
detected at the MALDI-TOF MS stage, the design software may add a non-specific 
sequence to the extension primer. A 10 nucleotide non-specific tag sequence is also 
added to the 5’ end of the PCR primers to ensure they are detected in the MADLI-TOF 
MS spectrum.
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2.9.1.1 Sequenom Reactions
The software designs the PCR primers so as to create the shortest amplimer possible 
that will allow efficient PCR at an annealing temperature of 56°C. This allows a 
universal PCR condition to be used. Each PCR was performed with 3 pi of dried 
genomic DNA (8ng/pl) in a 384 microtitre plate (ABgene) with the addition of a 5 pi 
PCR mix. The reagents for this mix and the volumes require per sample are shown in 
Table 2.5.
Reagent Volume (pi)
10x PCR Buffer 0.625
MgCI2 (25mM) 0.325
dNTPs (25mM) 0.1
HotStarTaq (5units/|jl) 0.2
Forward and Reverse PCR primers (Ipmol/pl) 0.5
Water 3.25
Table 2.5: Reagents and volumes required per sample for the Sequenom PCR
The following PCR was then performed:
1. 95°C for 15 minutes
2. 94°C for 20s
3. 56°C for 30s
4. 72°C for 1 minute
5. Repeat steps 2-4 for 44 cycles
6. 72°C for 3 minutes
7. 15°C for 10 minutes
A number of negative control samples and genomic DNA positive control samples 
were electrophoresised on a 2% gel to check for both PCR efficiency and 
contamination. If the assays passed this quality control (QC), a 2pl Shrimp Alkaline 
Phosphatase (SAP) mix was added to the 5 pi PCR reaction. The SAP mix is shown in 
Table 2.6.
Reagent Volume (ul)
SAP 0.3
SAP Buffer 0.17
Water 1.53
Table 2.6: Reagents and volumes required for the SAP mix.
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This 7(4,1 reaction mix then underwent the following thermocyclic conditions:
1. 37°C for 30 minutes
2. 85°C for 10 minutes
3. 95°C for 5 minutes
4. 15°C for 10 minutes
The extension reaction involves the addition of optimised concentrations of 
unextended extension primers, along with ddNTPs, to the 7pi PCR and SAP reaction 
product. The extension primer mix containing a mix of all unextended extension 
primers was defined by an optimisation procedure involving a small number of DNA 
samples. The extension primers were split into four groups dependent upon their mass 
(lowest to highest mass) which were diluted initially to final concentrations of 0.938pM, 
1.17pM, 1.425pM and 1.875pM. The extension primers were divided in this way as 
lower mass products generate a lower signal to noise ratio when detected by MALDI- 
TOF. After an initial test run the extension primer concentrations were adjusted 
according to their peak height. For example if a peak height was low then the final 
concentration was increased. At the optimisation stage, failed or abnormal assays (for 
example self priming assays) were also removed. The 2pl extension mix was made up 
as shown in Table 2.7
Reagent Volume (|il)
iPLEX GOLD Reaction Buffer 0.2
iPLEX GOLD Termination Mix 0.2
iPLEX GOLD Enzyme 0.041
Adjusted Unextended Primer Mix 1.559
Table 2.7: Reagents and volumes required for the extension mix.
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The 9pl reaction then underwent the following thermocyclic conditions:
1. 94°C for 30 seconds
2. 94°C for 5 seconds
3. 52°C for 5 seconds
4. 80°C for 5 seconds
5. Repeats steps 3 and 4, 4 times
6. Repeat steps 2 to 5 39 times
7. 72°C for 3 minutes
8. 15°C for 10 minutes
After the extension reaction, desalting of the solution using Clean Resin (Sequenom) 
was performed by the addition of 6mg of the resin using the Sequenom dimple plate 
followed by 25 pi of water to the reaction mix. The reaction sample was then mixed on a 
rotor for ~1 hour. The resin removes all ions that may alter the spectra of the sample and 
therefore affect the subsequent analysis. After mixing, the samples were spun in 
centrifuge for 15minutes at 3000rpm to separate the resin from the solution.
2.9.1.2 Sequenom Analysis
Samples were automatically spotted onto the Sequenom MassARRAY SpectroCHIP 
using a nanodispenser liquid handler (Sequenom). Each chip contains 384 spots which 
are composed of a combustible matrix (3 -hydroxypicolinic acid) that allows ionisation 
of the product when excited by a laser. Each ionised extended and unextended 
MassEXTEND primer product differs in mass and is therefore amenable to MALDI- 
TOF MS analysis using MassARRAY RT software (SpectroAcquire, Sequenom). The 
software estimates genotypes for each sample based upon the assay design output and 
certain parameters such as the peak heights (intensity of mass signal) of each allele and 
also the extension primer yield (successful extension of the primer compared to residual 
unextended primer). These genotypes can then be viewed and manually revised by the 
user using the Typer software, as shown in Figure 2.3.
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Figure 2.3: Screenshot from Typer analysis software (Sequenom) for rs2550360. TT homozygotes are 
shown in green, C homozygotes in blue and CT heterozygotes in yellow. No Calls are shown in red.
2.9.1.3 Accurate Genotyping
All assays were initially optimised by genotyping DNA from 30 CEPH parent- 
offspring trios from Utah with ancestry from northern and western Europe (CEU). All 
plates for genotyping contained a mixture of cases, controls, blanks, and 46 CEU 
samples. “Double-genotyping”, where another experienced user of the Sequenom 
genotyping system and Typer software checks the genotypes for every assay, was used. 
Genotypes were called blind to sample identity and affected status. Genotypes of CEU 
samples were compared to those available on the HapMap to provide a measure of 
genotyping accuracy. Genotyping assays were only considered suitable for analysis if a) 
during optimisation, genotypes for CEU individuals were the same as those in the 
HapMap when available and b) all subsequent duplicate genotypes from the CEU 
samples were consistent with the HapMap data.
2.9.2 Genotyping Using SNaPshot
A polymorphism which varies at one particular nucleotide can be genotyped via 
oligonucleotide primer mediated extension of a single fluorescently labelled ddNTP 
using SNaPshot chemistry (Applied Biosystems). The SNaPshot reaction consists of the 
PCR of a sample of interest, which is then cleaned before primer extension by a single 
fluorescent ddNTP (ddATP, ddCTP, ddGTP, ddTTP) corresponding to the next 3’ base 
(the polymorphic site of interest). This is followed by another clean-up strep to remove 
excess ddNTPs and analysis using an ABB 100 PRISM Genetic Analyser (Applied
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Biosystems). Genotyping was performed by manual inspection of the extension peaks 
using Genotyper software (Appied Biosystems). Oligonucleotide extension primers 
were designed using the internet based algorithm FP primer designed by Dobril Ivanov 
(http://m034.pc.uwcm.ac.uk/FP_Primer.html). For SNaPshot genotyping, each sample 
underwent a standard 12pl PCR reaction using the reagents and volumes shown in 
Table 2.8.
Reagent Volume (pi)
10x Buffer 1.2
dNTPs (5mM) 0.96
Forward primer (5pmol/p) 0.28
Reverse primer (5pmol/|j) 0.28
HotStarTaq (5un its/pl) 0.06
dH20 6.22
Genomic DNA (8ng/pl) 3
Table 2.8: Reagents and volumes required for the SNaPshot PCR Reaction 
The PCR cycling conditions are outlined below:
1. 94°C for 15 minutes
2. 94°C for 20 seconds
3. Ta°C for 20 seconds
4. 72°C for 30-45 seconds
5. Repeat steps 2-4 for 35-45 cycles
6. 72°C for 10 minutes
7. 15°C for ever
Ta°C is a function of the melting temperature of each primer set.
SAP (Amersham) and exonuclease I (Amersham) were then added to each PCR 
product to degrade unincorporated dNTPs and unextended primers. The reaction 
involved the addition of a 5pl SAP mix described in Table 2.9 to the 12pl PCR product.
Reagent Volume (pi)
SAP 0.5
Exonuclease I 0.1
Water 4.4
Table 2.9: Reagents and volumes required for the SAP mix in the SNaPshot reaction.
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The reaction conditions were as follows:
1. 37°C for 1 hour
2. 80°C for 15mins
3. 15°C for ever
For SNaPshot primer extension an 8pl reaction mix shown in Table 2.10 was added 
to 2pl of the cleaned PCR product.
Reagent Volume (pi)
SNaPshot Reagent 1.25
Reaction buffer 3.75
Extension primer 1
Water 2
Table 2.10: Reagents and volumes required for the SNaPshot extension mix. The SNaPshot reagent 
contains fluor-labelled ddNTPs and a sequenase.
Typically extension primers were used at a 0.5pmol/pl concentration, although this 
was altered in some cases to obtain optimum peak heights using the equation:
Concentration = Y7 (Y/X)
Here, Y’ is the required peak height (typically 3000 fluorescence intensity units as 
displayed by the Genotyper software (Applied Biosystems), Y is the initial peak height 
and X is the initial primer concentration (Norton et al. 2002).
The following reaction was then performed:
1. 96°C for 2 minutes
2. 96°C for 5 seconds
3. 43 °C for 5 seconds
4. 60°C for 5 seconds
5. Repeat steps 2-4 for 24 cycles
6. 15°C for ever
A further stage of SAP clean-up was then performed to degrade the unincorporated 
ddNTPs. A 5pi reaction mix comprising of 0.5pl SAP and 4.5pi water was added to the 
SNaPshot reaction product and the same conditions as the SAP PCR clean-up were
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performed. After this reaction, 3 pi of the product was added to lOpl of HiDi formamide. 
The samples were then run through a 36cm capillary using POP4 polyacrylamide 
(Applied Biosystems). The raw data were analysed using the Genescan Analysis v3.7 
software (Applied Biosystems) and imported into Genotyper software (Applied 
Biosystems).
The Genotyper software allows firstly the discrimination of correct genotypes and 
secondly the amount of each allele present in a sample. The latter is indirectly measured 
via the peak height of the fluorescence. The amount of each allele present is given as a 
numerical value (arbitrary absorbance units) and can be exported to an Excel file for 
further analysis. Individual samples are then genotyped based on the presence of 
fluorescence for the corresponding nucleotide (Figure 2.4). Along with genomic DNA, 
negative controls are added at the PCR and SNaPshot stages to check for contamination.
A:
B:
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Figure 2.4: Individual genotyping via SNaPshot using Genotyper software (Genecodes). Part A shows a 
GG homozygote and part B shows a GC heterozygote.
In the analysis of bi-allelic markers in DNA pools, the primer extension products 
may not be represented with equal efficiency, thus not providing an accurate basis for 
the calculation of allele frequencies. To allow for the unequal representation of alleles, 
the estimated allele frequencies from pools were corrected by using the mean of the 
ratios obtained from measurements taken from heterozygous samples. Since 
heterozygous individuals contain one of each allele at a known polymorphism,
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fluorescence corresponding to each allele of a SNP should be the same (under perfect 
conditions) resulting in a 1:1 ratio of fluorescence units for each allele. Any deviation 
away from 1:1 fluorescence ratio can be determined and so pooled assays can be 
corrected for any unequal representation of the alleles from the known heterozygote 
ratio. The correction could be made using the following equation:
/  (a) = A/(A+kB)
Where A and B are the peak heights of the primer extension products representing 
alleles A and B in a pool and k is the mean of the replicates of A/B ratios observed in a 
heterozygote (Hoogendoom et al. 2000). J(sl) is the frequency of allele A. The frequency 
of allele B (/(b)) was then calculated from the formula:
X b )= l- /a )
2.9.3 Genotyping Using Illumina SNP Arrays
Genotyping on the Illumina HumanHap300 array for the initial NeuroDys GWAS 
(Chapter 4) and genotyping of the NeuroDys pools on the Illumina Human lM-Duo 
array (Chapter 5) were both carried out elsewhere as outlined in the respective chapters. 
Genotyping of the Cardiff pools was carried out on the Illumina Human lM-Duo array 
in Cardiff following the manufacturer’s protocol described below and using the reagents 
provided in the array kits. This array interrogates nearly 1.2 million loci per sample, 
consisting of tagSNPs, SNPs in genes, as well as non-polymorphic markers in known 
CNV regions.
2.9.3.1 Preparation of DNA Samples for Array Genotyping
The first step involved denaturing the DNA samples using NaOH. 8 pi of DNA at 
50ng/pl was mixed with 8pi of 0.1 NaOH and incubated for 10 minutes at room 
temperature. 135pl the Illumina MP1 reagent was then added to neutralise the DNA.
To perform uniform whole-genome amplification of the DNA, 150pl of the Illumina 
AMM was added to each sample before incubating at 37°C for 20-24 hours.
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The samples were then split into two, each containing 150pl. 50pl of the Illumina 
FRG reagent was then added before heating at 37°C for an hour. This step 
enzymatically fragments the DNA, using an end-point method to avoid over 
fragmentation. The DNA was then precipitated by adding lOOpl of the Illumina PA1 
reagent, followed by incubation at 37°C for 5 minutes before the addition of 300pl of 
100% 2-propanol. The samples were mixed and then incubated at 4°C for 30 minutes 
and then spun at 3000g at 4°C for 20 minutes. The supernatant was removed and the 
remaining DNA pellets were left to dry at room temperature for 1 hour. The DNA 
pellets were then resuspended by adding 46pl of the Illumina RA1 reagent before 
incubation at 48°C for 1 hour.
2.9.3.2 Hybridisation of DNA to BeadChips
This process involved hybridising the fragmented DNA to locus specific 50-mer 
oligos which were covalently linked to one of over 1,100,000 bead types on the surface 
of the array. These carefully designed 50-mer probes selectively hybridize to the loci of 
interest, stopping one base before the interrogated marker.
The samples were first denatured at 95°C for 20 minutes, before rejoining the 
previously split samples. The BeadChips were then placed into hybridisation chamber 
inserts and 84pl of each DNA sample was dispensed into each BeadChip inlet port (2 
samples loaded for each BeadChip). The BeadChips were visually inspected to ensure 
that the DNA samples covered all of each of the chips. The chips and their hybridisation 
chamber inserts were then loaded into hybridisation chambers containing 400pl of the 
Illumina PB2 reagent in the humidifying buffer reservoirs. The chambers were then 
closed securely and incubated at 48°C for 16-24 hours.
The BeadChips were removed from the hybridisation chambers and the IntelliHyb 
seals were removed from the surface of the chips. The chips were then washed in two 
washes of the Illumina PB1 reagent in order to remove any unhybridised DNA. The 
chips were then immediately assembled into flow-through chambers in preparation for 
single base extension and staining.
2.9.3.3 Single-base Extension
The next process involved carrying out single-base extension of the oligos on the 
BeadChip using the captured DNA as a template. This incorporated detectable labels on
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the BeadChip in order to determine the genotype call of the sample. C and G 
nucleotides were biotin labelled (stained green) and A and T nucleotides were 
dinitrophenol labelled (stained as red).
The assembly of the chips within flow-through chambers allows for a series of 
reagents to be flowed evenly across the surface of the chip whilst the chip is incubated 
at certain temperatures in a chamber rack. Each chip within its flow-through chamber 
was placed in a chamber rack heated to 44°C. 150pl of the Illumina RA1 reagent was 
first added to the reservoir of each flow-through chamber to wash away unhybridised 
and non-specifically hybridised DNA sample. The chips were left to incubate at 44°C 
for 30 seconds before this step was repeated another 5 times. To prepare the chips for 
the extension reaction, 450pl of the Illumina XC1 reagent was then added before 
incubating for 10 minutes. 450pl of the Illumina XC2 reagent was added next followed 
by another 10 minute incubation. To extend the primers hybridised to the DNA on the 
BeadChip and incorporate labelled nucleotides into the extended primers, 200pl of the 
Illumina TEM reagent was added to the flow-through chamber and left to incubate for 
15 minutes. 450pl of 95% formamide/lmM EDTA was then added twice at 1 minute 
intervals in order to remove the hybridised DNA. The chips were then left to incubate at 
44°C for 5 minutes before adding 450pl of the Illumina XC3 reagent twice at 1 minute 
intervals to neutralise the chips.
2.9.3.4 Staining of the BeadChips
The next process involved dual-colour staining so that the nucleotides incorporated 
during the extension step could be detected by the Illumina iScan imaging system.
The temperature of the chamber rack was lowered to 37°C. The multi-layer staining 
process was carried out by adding a sequence of Illumina staining reagents (STM and 
ATM) and washing with Illumina XC3, with incubation steps in between, as described 
below:
250pl of STM, incubate for 10 minutes.
450pl of XC3, incubate for 1 minute. Repeat once and then wait 5 minutes.
240pi of ATM, incubate for 10 minutes.
450pi of XC3, incubate for 1 minute. Repeat once and then wait 5 minutes.
Repeat steps 1-4 twice more.
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After staining, the flow-through chambers were immediately removed from the 
chamber rack and placed horizontally on the lab bench. The BeadChips were removed 
from the flow-through chambers and placed into a staining rack before being washed 
with PB1 reagent to thoroughly remove any remaining staining reagents. The staining 
rack was then submerged in XC4 and allowed to soak for 5 minutes in order to coat the 
surface of the BeadChips. The chips were then left to dry on a tube rack inside a 
vacuum dessicator at 508 mm Hg (0.68 bar) for 50-55 minutes. The undersides of the 
chips were then carefully cleaned with ethanol in order to remove any excess XC4 and 
ensure that the chips would lie flat in the iScan Reader tray.
2.9.3.5 Processing the BeadChips and Extracting Normalised Intensities
The BeadChips were then imaged using the iScan system. The iScan Reader uses a 
laser to excite the fluor of the single-base extension product on the beads of the 
BeadChip. Light emissions from these fluors are then recorded in high-resolution 
images. If fluorescence could not be detected from all sections of the chip then the 
samples hybridised to these chips were excluded from further analyses. Data from the 
images produced by the iScan was then exported into the BeadStudio Genotyping 
Module v3.2.
The BeadStudio Genotyping Module v3.2 enables the user to normalise the signal 
intensities obtained from the BeadChips. Because the performance of external controls 
can vary from sample to sample, Illumina have developed a self-normalisation 
algorithm that uses information contained within the array itself (www.illumina.com). 
This algorithm is designed to adjust for channel-dependant background and global 
intensity differences.
The normalised signal intensities of each SNP were then used to estimate allele 
frequencies in the pooled samples, as described in Chapters 5 and 6.
2.10 Sample Processing
For large scale PCR and post-PCR reactions involving many DNA samples, reagent 
master mixes and samples were aliquoted using robotic liquid handling systems. DNA 
samples were typically stored within shallow well DNA boxes (ABgene). These are 
compatible with the Beckman-Coulter FX and NX microdispensers. DNA samples were
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aliquoted into suitable (96 or 384 well) microtitre plates (ABgene). Both machines were 
also used to dispense reaction master mixes in the same manner. All programs for use 
with the Beckman-Coulter FX and NX were written by Sarah Dwyer.
2.11 Statistical/Bioinformatic Analysis
2.11.1 Tag SNP Determination
Tag SNP identification was performed using Haploview 
(http://www.broad.mit.edu/haploview/haploview), a software program designed for 
genetic association studies (Barrett et al. 2005). The program allows the user to import 
marker genotype data such as a CEU HapMap dataset or case-control genotype data. 
The quality of this data can then be assessed via a display of the percentage of 
individuals genotyped, Hardy-Weinberg equilibrium P-values and non-Mendelisations. 
The LD {r2 and D ’) between markers can also be identified. The Tagger function within 
Haploview uses the LD values to select “tag” markers for an association study via user 
defined parameters (r2, minor allele frequency and the type of analysis to be performed; 
pairwise, haplotype). In addition to LD analysis, Haploview can also be used test for 
marker or haplotype association.
2.11.2 LD Estimation
The LD between markers was determined using the SNP Annotation and Proxy 
Search tool (http://www.broadinstitute.org/mpg/snap/ldsearch.php) (Johnson et al.
2008). SNAP finds proxy SNPs based on LD, physical distance and/or membership in 
selected commercial genotyping arrays (e.g. Illumina arrays). Pair-wise LD is pre­
calculated based on phased genotype data from the International HapMap Project. SNPs 
were considered to be in highly correlated if the r2 value between them was >0.8 and a 
value < 0.5 was considered to indicate low correlation.
2.11.3 Sample Size Power Calculations
Power calculations for the mutation detection sample was determined using the 
equation: l-(l-f)", where f  = minor allele frequency and n = number of chromosomes 
examined (i.e. 2x number of individuals).
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The power of an association sample to detect susceptibility variant(s) with a specific 
MAF and odds ratio (OR) at a given P-value were calculated using the software PS 
Power and Sample Size Calculations (Dupont & Plummer 1990).
2.11.4 Statistical Analysis Using PLINK
Several types of statistical analyses were performed in this thesis. The majority were 
carried out using the analysis software PLINK
(http://pngu.mgh.harvard.edu/purcell/plink) (Purcell et al. 2007). These included tests 
for single marker association (additive and genotypic), and haplotype analysis. Analysis 
of variants for deviations from Hardy-Weinberg equilibrium were also performed using 
PLINK. Statistical analyses that did not use the PLINK software are found within the 
methods section of the relevant chapter.
2.11.4.1 Tests for Deviation from Hardy-Weinberg Equilibrium
The Hardy-Weinberg principle states that if an infinitely large, random mating 
population is free from outside evolutionary forces (i.e. mutation, migration and natural 
selection), the gene frequencies will not change over time and the allele frequencies of 
A and a in the next generation will be p for the AA genotype, 2pq for the Aa genotype
<y
and q for the aa genotype.
Departures from the Hardy-Weinberg equilibrium (HWE) can be due to inbreeding, 
population stratification, selection or they can be a symptom of disease association 
(Balding 2006). Deviations from HWE can arise in the presence of a common deletion 
polymorphism, because of a mutant PCR-primer site or because of a tendency to miscall 
heterozygotes as homozygotes. This has led to researchers testing for HWE as a data 
quality check. In this study, SNPs were tested for deviations from Hardy-Weinberg in 
the control samples using PLINK. PLINK tests for deviations from the Hardy-Weinberg 
equilibrium using the Exact test described by Wigginton and colleagues (2005). This 
test is more accurate for rare genotypes compared with the y? goodness-of-fit test 
(Wigginton et al. 2005).
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2.11.4.2 Association Tests
Genotypic tests were carried out in PLINK which uses a x2 test with 2 degrees of 
freedom to test the null hypothesis that there is no association between rows and 
columns of a 2 x 3 matrix containing the counts of the three genotypes among cases and 
controls as shown in Table 2.11.
Genotypes
AA Aa aa Total
Cases i">iaa fllAa n-|aa n i
Controls r»2AA r>2Aa ^2aa n2
Total Haa nAa naa N
Table 2.11: An example of a 2 x 3 contigency table to present genotype data in cases and control.
As the x? genotypic test cannot be reliably used when the counts for a particular 
genotype are less than 5, the CLUMP programme was also used to test for genotypic 
association in some instances using 1000 permutations (Sham & Curtis 1995). This 
method calculates the x2 based on the 2 x 3 contigency table but uses Monte Carlo 
simulations in order to test the significance.
For complex traits, it is widely thought that the contributions to disease risk from 
individual SNPs will often be roughly additive - i.e. the heterozygote risk will be 
intermediate between the two homozygote risks (Balding 2006). Additive tests were 
conducted using the Cochran-Armitage trend test in PLINK. This test was used instead 
of the x2 allelic test as it is more robust to departures from the HWE. The trend test tests 
the hypothesis of zero slope for a line that fits the three genotypic estimates best, as 
shown in Figure 2.5.
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Figure 2.5: Cochran-Armitage trend test. The dots indicate the proportion o f the cases, among cases and 
controls combined, at each o f three SNP genotypes (coded as 0,1, and 2). The Cochran-Armitage trend 
test corresponds to testing the hypothesis that the line has zero slope. Adapted from Balding (2006).
Logistic regression within PLINK was also used to test for association in some 
instances so that covariates could be included. Both the additive and genotypic tests 
were performed within the logistic regression framework.
2.11.5 Imputation
Imputation of SNPs which had not been genotyped in the intial NeuroDys GWAS 
was carried out using PLINK. A reference panel of genotypes was obtained from Phase 
II of the International HapMap Project (The International HapMap Consortium 2007) 
and merged with the GWAS data, after ensuring that both sets of data were aligned on 
the positive strand. Only those imputed SNPs with an INFO score >0.8 were included 
in further analyses, as recommended in the PLINK documentation.
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Chapter 3: Candidate Gene Study
3.1 Introduction
Candidate genes studies can represent a cost-efficient approach to identifying 
variants that may be associated with a complex disease (Jorgensen et al. 2009). The 
power of such studies can be improved by focusing on genes in regions that have 
already shown good evidence of linkage or association and whose possible functions 
indicate a plausible role within the disease.
This candidate gene study focuses on a small number of genes that are in well 
replicated linkage regions for DD, have interesting functions in terms of neuronal 
migration and on those that show homology or correlated expression with previously 
identified DD candidate genes.
As discussed in Chapter 1, impaired neuronal migration has been previously linked 
with DD through the identification of neocortical malformations in the post-mortem 
brains of individuals with DD (Galaburda & Kemper 1979; Galaburda et al. 1985; 
Humphreys et al. 1990) and also through behavioural studies on patients with the 
neuronal migration disorder PNH (Chang et al. 2005). Neuronal migration involves the 
rearrangement of cytoskeletal components in response to extracellular cues, mediated 
by numerous intracellular signalling pathways resulting in the organisation of neurons 
into six specialised laminar layers (Ayala et al. 2007). Notably, four genes that have 
received support for an association with DD are thought to be involved in controlling 
neuronal migration.
As discussed in section 1.4.2, KIAA0319 is in the DYX2 linkage region on 
chromosome 6p21.2-6p22.3 and has shown association with DD in several studies 
(Deffenbacher et al. 2004; Francks et al. 2004; Cope et al. 2005a; Harold et al. 2006; 
Luciano et al. 2007; Paracchini et al. 2008). Functional studies on KIAA0319 have 
highlighted a possible role for this gene in neuronal migration. Paracchini et al. (2006) 
showed that the risk haplotype spanning TTRAP and KIAA0319 is associated with a 
reduction of KIAA0319 gene expression in cell line models and demonstrated that 
knocking down Kiaa0319 through in utero RNAi in the developing rat neocortex 
significantly reduces the distance migrated by neurons. Peschansky et al. (2009)
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recently demonstrated that the disruption in neuronal migration caused by reduced 
expression of KIAA0319 results in specific types of anomalies in the postnatal brain, 
such as periventricular heterotopias (PVHs) and abnormal laminar locations. These 
anomalies are similar to the anomalies identified by Galaburda and others in their post­
mortem studies on the brains of individuals with DD (Galaburda & Kemper 1979; 
Galaburda et al. 1985; Humphreys et al. 1990).
DCDC2 is also within the DYX2 region and, as discussed in section 1.4.2, has 
shown association with DD in many studies (Deffenbacher et al. 2004; Francks et al. 
2004; Meng et al. 2005b; Schumacher et al. 2006a; Harold et al. 2006; Wilcke et al.
2009). DCDC2 contains two doublecortin peptide domains. These protein domains were 
originally described in the doublecortin gene (DCX), which has a well-recognised role 
in neuronal migration. Defects in DCX have been shown to cause the neuronal 
migration disorders X-linked lissencephaly and double cortex syndrome (des Portes et 
al. 1998; Gleeson et al. 1998). In X-linked lissencephaly, DCX mutations in males result 
in a severe disruption to cortical neuronal migration, leading to a rudimentary four- 
layered cortex (Berg et al. 1998). Mutations in DCX heterozygous females lead to a less 
severe disease, double cortex, in which some neurons form a relatively normal cortex, 
while a second population of neurons apparently arrests, leading to a collection of 
neurons beneath the outgrowth cortex (Gleeson & Walsh 1997). Gleeson and colleagues 
(1999) have shown that DCX is expressed in migrating neurons throughout the central 
and peripheral nervous system and may direct neuronal migration by regulating the 
organisation and stability of microtubules. Meng et al. (2005b) used in utero RNAi in 
developing rat neocortex to test for a functional role of DCDC2 in neuronal migration 
and found that a loss of function of Dcdc2 resulted in abnormal migration during the 
prenatal period. Burbridge et al. (2008) found that knocking down Dcdc2 resulted in 
neocortical malformations such as PVHs in the cerebral cortices of the brains of 
postnatal rats.
As the name suggests, DYX1C1 lies within the DYX1 region and has shown 
association with DD in a number of studies (Taipale et al. 2003; Scerri et al. 2004;
Wigg et al. 2004) although this association was not supported by others (Bellini et al. 
2005; Cope et al. 2005b; Marino et al. 2005; Meng et al. 2005a; Bates et al. 2007) (see 
section 1.4.1 for more detail on this region). Functional studies on DYX1C1 have found 
that in utero RNA interference (RNAi) of Dyxl cl in the developing rat neocortex
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prevents correct neuronal migration and this results in heterogeneous malformations 
that appear to be associated with distinct impairments in auditory processing and spatial 
learning (Threlkeld et al. 2007; Wang et al. 2006). When examining these 
malformations in the adult rat brain, Rosen et al. (2007) found that they resemble 
malformations identified in the brains of post mortem dyslexics. Other functional 
studies have suggested that DYX1C1 interacts with the U-box protein CHIP (Carboxy 
terminus of Hsc70-Interacting Protein) (Hatakeyama et al. 2004), and regulates the 
levels of estrogen receptors alpha (ERa) and beta (ER(3) (Massinen et al. 2009). ER 
receptors been shown to be important in brain development and to be involved in 
cognitive processes and memory. This suggests that DYX1C1 may affect neuronal 
migration via interactions with ERs.
ROBOl is within the DYX5 region and has shown association with DD, although 
only in one study (Hannula-Jouppi et al. 2005) (see section 1.4.5). The Drosophila 
homolog of this gene, Robo, is thought to be a neuronal axon guidance receptor gene 
involved in brain development and controls whether or not axons cross the central 
nervous system midline (Kidd et al. 1998).
This section of the thesis sought to identify genes encoding proteins with a possible 
role in neuronal migration that also lie within major DD linkage regions. The gene cell 
division cycle 42 (CDC42) lies on chromosome lp36.12 within the DYX8 region. This 
region has been linked with dyslexia in several studies (Rabin et al. 1993; Grigorenko et 
al. 2001; Tzenova et al. 2004; Franke et al. 2006; Bates et al. 2007). The protein 
encoded by this gene is a member of the Rho family of GTPases and has been shown to 
regulate the formation of filopodia. These occur at the leading edge of migratory 
neurons and sense environmental cues, enabling the neurone to migrate to the correct 
place (Kozma et al. 1995; Nobes & Hall 1995; Luo 2000). BioGPS 
(http://biogps.gnf.org) (Wu et al. 2009) shows that CDC42 is highly expressed in the 
fetal brain and possesses a similar expression pattern to that of KIAA0319 (r = 0.913).
Protogenin (PRTG) lies on chromosome 15q21.3 within the DYX1 region. This 
region showed linkage to dyslexia in a large number of studies (Smith et al. 1983; Smith 
et al. 1991; Grigorenko et al. 1997; Schulte-Kome et al. 1998; Nothen et al. 1999; 
Bakker et al. 2003; Chapman et al. 2004; Smith et al. 2005; Bates et al. 2007). Its name 
is based on the fact that it is expressed during early development of the nervous system 
(‘proto’) and is structurally similar to Neogenin. The protein encoded by this gene is
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most closely related to the DCC-Neogenin subclass of the Ig superfamily of proteins 
(Toyoda et al. 2005). Functional studies on DCC and Neogenin have revealed important 
roles in axonal guidance in a number of species (Culotti & Merz 1998). Expression 
studies on the chicken (Toyoda et al. 2005), murine and zebrafish (Vesque et al. 2006) 
homologues of PRTG have suggested that Prtg may have a conserved role in axis 
elongation. In a recent study by Wigg et al. (2008), 20 markers across PRTG were 
genotyped in 253 families with proband diagnosed with ADHD. They found association 
with this gene and ADHD as both a categorical trait and with symptoms of ADHD 
measured as quantitative traits, but failed to find evidence for association with two key 
components of reading. As discussed in section 1.1.5.1, previous twin studies have 
found evidence for shared genetic factors between ADHD and DD, particularly for 
inattention and reading phenotypes (Willcutt et al. 2007). Further support for genetic 
overlap between these disorders comes from overlapping chromosomal regions that 
have been identified for by linkage and association studies (Wigg et al. 2008).
Therefore, a gene that has previously shown evidence for an association in one of the 
disorders may also by associated with symptoms of the other.
In addition to those genes that may be involved in neuronal migration, this study 
sought to identify candidate genes based on their homology with genes that have shown 
convincing evidence of association with DD previously. Two genes within the DYX8 
susceptibility locus show homology with KIAA0319 and DCDC2 which have both 
shown replicated evidence for a role within DD.
The protein sequence of KIAA0319-like (KIAA0319L) shows a 61% similarity to 
that of KIAA0319. It also contains PKD domains, which are thought to mediate cell-cell 
adhesion. Two of the four PKD domains in KIAA0319L show a 69% and 75% protein 
sequence similarity with the two PKD domains of KIAA0319 suggesting a similar 
function for these genes. KIAA0319L has already shown nominal association with DD 
in a previous study. Couto and colleagues (2008) genotyped 5 SNPs within KIAA0319L 
in a sample of 156 Canadian families. Evidence for association was found with the 
marker rs7523017 (P = 0.042) when DD was defined as a categorical trait (< 1.5 
standard deviations below the population mean on two of three standardised reading 
tests or < 1 standard deviation on the average of the three tests). They also identified a 
significant haplotype with the markers rsl203138, rsl203148, rsl2408030, and 
rs7523017 (C/A/A/A; P = 0.031). When using quantitative measures of DD and their
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whole sample of 291 families (the 156 previous families plus an additional 135 families 
that had been ascertained through a proband who had reading difficulties but did not 
meet the categorical criteria), this haplotype showed significant association with 
measures of word-reading efficiency (P = 0.032) and rapid object and colour naming (P 
= 0.047). However, as the authors point out, these results would not withstand 
correction for multiple testing.
DCDC2b is on chromosome lp35.1 and shows a 34% protein sequence similarity to 
DCDC2. Its DCX domain shows 48% protein sequence similarity to the DCX domain 
of DCDC2 and so may prove to have a similar role within neuronal migration.
Myers and colleagues (2007) conducted a survey of gene expression on 193 
neuropathologically normal human brain samples using the Affymetrix Gene Chip 
Human Mapping 500K array set and Illumina HumanRefseq-8 Expression BeadChip 
platforms. This survey has provided a resource that allows for the assessment of genetic 
effects on normal human cortical gene expression. This study showed that the minor 
alleles of two SNPs within the KIAA0319 gene were both associated with the expression 
of the gene RIOK3 (Myers et al. 2007). This suggests that SNPs within KIAA0319 may 
have a trans-acting effect on the expression of RIOK3 and as SNPs within KIAA0319 
have shown association with DD previously, this makes RIOK3 a potential candidate 
gene for DD. In addition, this gene is on chromosome 18 and lies just outside the DYX6 
linkage region. The specific function of this gene has not yet been determined and it 
shows ubiquitous expression.
3.1.2 Aims
As these genes are within or near to the Z)7X linkage regions and have putative roles 
in neuronal migration/axonal guidance (CDC42 and PRTG), show homology to 
previously associated DD genes (DCDC2b and KIAA0319L) or because their expression 
appears to affected by SNPs in a convincing candidate gene for DD (RIOK3), variants 
within these genes were tested for association with DD in the Cardiff case-control 
sample.
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3.2 Methods
3.2.1 Sample
Variants within the candidate genes were genotyped in the Cardiff case-control 
sample, consisting of 357 DD cases and 269 screened controls. As previously described 
in Chapter 2, the criteria for cases is an IQ > 85 and a reading age that is > 2.5 years 
below their chronological age. DNA for these samples were extracted from either blood 
or saliva samples using phenol/chloroform methodology as previously described (see 
Chapter 2). DNA quantification and dilution was also as described (Chapter 2), with a 
final sample dilution of 8ng/pl.
3.2.2 Genotyping
For the genes CDC42, PRTG, KIAA0319L and RIOK3, SNPs were identified using 
HapMap (Rel 22). The regions to be tagged were extended at either ends of the genes to 
reach the edges of blocks of LD using Haploview v4.01. For CDC42 the region of 
chromosome 1 that was tagged extends from 22,218,596-22,309,033, for PRTG the 
tagged region on chromosome 15 extends from 53,676,324-53,834,838bp, for 
KIAA0319L the region of chromosome 1 that was tagged extends from 35,491,743- 
35,854,982 bp, and for RIOK3 the tagged region on chromosome 18 extends from 
19,278,296-19,325,923 bp (NCBI build 36.1). The Tagger function in Haploview was 
then used to select a panel of tagSNPs for each gene based on pairwise tagging, using an 
r2 threshold of > 0.8 and a minor allele frequency (MAF) threshold of > 0.05. 12 
tagSNPs were selected for CDC42, 35 for PRTG, 13 for KIAA0319L and 10 for RIOK3. 
One of the SNPs within KIAA0319 (rsl6889511) that had been shown to be associated 
with reduced expression of RIOK3 (Myers et al. 2007) was also genotyped. An assay 
for the other SNP that showed an association with the expression of RIOK3 could not be 
designed alongside the other SNPs in the panels, however this SNP was in perfect LD 
with rs16889511 (£>’= 1, r2 = 1).
At the time of designing this study, DCDC2b did not have any known SNPs with a
minor allele frequency > 0.05 in the HapMap CEU population (HapMap Release 22).
Therefore this gene was screened for polymorphisms using high resolution melting
analysis (HRMA). 23 primer pairs were designed using the Primer 3 software (Rozen &
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Skaletsky 2000) to amplify the length of DCDC2b, plus an extra 2000 bp of sequence in 
the 5’ direction and 300 bp in the 3’ direction (chrl :32445282-32454285; NCBI Build 
36.1) (see Table A.l in Appendix for primer sequences). After amplification by PCR, 
each amplimer was screened for polymorphisms using HRMA using the LightScanner 
and a sample of 15 DD subjects (see Chapter 2 for protocol). Any polymorphisms were 
then characterised by DNA sequencing on the ABI3100 PRISM (see Chapter 2 for 
sequencing protocol). This method for mutation detection has been tested, optimised 
and automated in the department by Sarah Dwyer (Dwyer et al. 2010).
All SNPs were genotyped using the Sequenom MassARRAY iPlex GOLD system 
in accordance with the manufacturers’ instructions (see Chapter 2 for description). PCR 
primers and extensions probes for each SNP were designed using the Assay Design v3.1 
software and genotype calling was carried out using the Typer 3.4 Software (see Table 
A.2 in Appendix for primer sequences). All SNP assays were initially optimised by 
genotyping DNA from 30 CEPH parent-offspring trios. Cluster plots for all SNPs were 
inspected manually, and SNP assays that did not produce distinct clusters were 
excluded. All plates for genotyping contained a mixture of cases, controls, blanks, and 
46 CEU samples. “Double-genotyping”, where another experienced user of the 
Sequenom genotyping system and Typer software checks the genotypes for every assay, 
was used. Genotypes were called blind to sample identity, affected status, and blind to 
the other raters. Genotypes of CEU samples were compared to those available on the 
HapMap to provide a measure of genotyping accuracy. Genotyping assays were only 
considered suitable for analysis if a) during optimisation, genotypes for CEU 
individuals were the same as those in the HapMap when available and b) all subsequent 
duplicate genotypes from the CEU samples were consistent with the HapMap data.
After genotyping, samples were removed if their call rate was less than 70% in 
order to exclude poor quality samples. SNPs were tested for Hardy-Weinberg 
equilibrium in controls and their MAFs were calculated using PLINK vl.05 (Purcell et 
al. 2007). PLINK was also used to test for association using the ‘model’ function to 
perform genotypic and Cochran-Armitage trend tests. Haplotype analysis was 
performed using the Unphased programme (Dudbridge 2003).
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3.3 Results
3.3.1 CDC42 Analysis
Out of 22 markers at the CDC42 locus, 12 SNPs tagging CDC42 at r2 > 0.8 and a 
MAF > 0.05 in the HapMap CEU population were selected. These were genotyped in 
the Cardiff case-control sample, of which 355 cases and 268 controls passed QC. One 
of the SNPs was dropped due to a poorly performing assay. No proxy for this tag SNP 
could be found at an r2 value > 0.8. The remaining 11 SNPs had a call rate above 98% 
and were all in HWE in the controls (P > 0.05) as shown in Table A.3 in the Appendix. 
As shown in Table 3.1 and Figure 3.1, none of these variants showed significant 
association with DD in this sample, with the lowest P-value being obtained for 
rsl0917139 (additive test P = 0.145). Haplotype analysis was also carried out for all 
possible haplotype combinations, but none were significant (see Table A.4 in Appendix 
for the haplotype combinations with the lowest global haplotype P-values).
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P-values
SNP Position (bp) Minor Allele MAFCases
MAF
Control OR 95% Cl Genotypic Additive
rs11577378 22293036 T 0.137 0.110 1.279 0.91-1.81 0.370 0.159
rs2501275 22247652 C 0.223 0.195 1.180 0.90-1.56 0.421 0.227
rs2501276 22246211 T 0.094 0.084 1.142 0.77-1.70 0.780 0.527
rs1534949 22298774 C 0.410 0.380 1.131 0.90-1.42 0.566 0.294
rs10917139 22274125 A 0.138 0.111 1.289 0.91-1.82 0.345 0.145
rs2473317 22267838 G 0.145 0.127 1.161 0.84-1.62 0.647 0.375
rs17837965 22267212 G 0.048 0.045 1.078 0.63-1.84 0.917 0.785
rs12035094 22257300 T 0.023 0.024 0.933 0.45-1.96 0.983 0.852
rs2473323 22261914 C 0.062 0.062 0.998 0.63-1.60 0.352 0.993
rs2056975 22281114 A 0.062 0.061 1.011 0.64-1.61 0.347 0.964
rs2268177 22287997 T 0.185 0.185 1.002 0.75-1.34 0.924 0.988
Table 3.1: Results of CDC42 genotyping. MAF -  minor allele frequency, OR -  odds ratio, Cl -  confidence interval.
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3.3.2 PRTG Analysis
Out of 69 markers at the PRTG locus, 35 SNPs tagging PRTG at r2 > 0.8 and a MAF 
> 0.05 in the HapMap CEU population were selected. These were genotyped in the 
Cardiff case control sample, of which 350 cases and 266 controls passed QC. Two were 
dropped due to poorly performing assays, and no proxies could be found at an r2 value 
>0.8. As shown in Table A.3 in the Appendix, the remaining 33 SNPs had a call rate 
>89%, 32 of which were in HWE (P > 0.05). The SNP rs4774217 had a HWE P-value 
of 0.024 for the control sample (P-values > 0.05 for the case sample and in the whole 
sample), and so the result for this SNP should be interpreted with caution. None of the 
variants showed a significant association with DD in this sample. As shown in Table 3.2 
and Figure 3.2, the lowest P-value was for rs4774217 (genotypic test P = 0.099). 
Haplotype analysis was carried out on 1-, 2-, 3-, and 4-marker combinations. This gave 
nominally significant results with the lowest P-value being 0.0027 for the haplotype 
rs9920546/rs8025445/rs1530087 (C/C/G) as shown in Table 3.3. However, this analysis 
involved carrying out nearly 47,000 tests, and thus no results remain significant 
following correction for multiple testing.
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P-Values
SNP Position (bp) Minor Allele MAFCases
MAF
Control OR 95% Cl Genotypic Additive
rs552292 53676324 T 0.330 0.316 1.066 0.84-1.36 0.764 0.609
rs4774217 53680603 A 0.460 0.491 0.881 0.69-1.12 0.099 0.283
rs7175728 53681850 T 0.384 0.344 1.185 0.93-1.50 0.390 0.170
rs617137 53691536 T 0.137 0.138 0.992 0.72-1.37 0.713 0.962
rs1438915 53699820 A 0.088 0.094 0.935 0.63-1.38 0.931 0.733
rs16976432 53703325 C 0.097 0.078 1.258 0.84-1.88 0.498 0.259
rs12591646 53706431 G 0.192 0.182 1.064 0.80-1.42 0.809 0.682
rs7165971 53708305 C 0.294 0.279 1.079 0.84-1.38 0.710 0.550
rs16976436 53711247 T 0.243 0.233 1.055 0.81-1.37 0.512 0.691
rs581287 53711901 T 0.343 0.331 1.055 0.83-1.34 0.703 0.653
rs7164393 53715424 T 0.104 0.099 1.054 0.73-1.53 0.961 0.788
rs1550326 53720491 A 0.435 0.413 1.090 0.86-1.38 0.230 0.475
rs492363 53730834 A 0.241 0.249 0.959 0.74-1.25 0.596 0.755
rs9920246 53732745 A 0.275 0.260 1.082 0.84-1.40 0.734 0.541
rs9920546 53734024 C 0.380 0.369 1.048 0.83-1.33 0.522 0.693
rs17819156 53742397 A 0.056 0.056 1.011 0.62-1.65 0.938 0.966
rs12903822 53745709 T 0.383 0.383 1.003 0.80-1.26 0.876 0.981
rs8025445 53753934 A 0.344 0.331 1.059 0.84-1.34 0.819 0.623
rs8030790 53754689 G 0.241 0.230 1.059 0.81-1.38 0.515 0.663
rs2118781 53755208 C 0.102 0.095 1.090 0.74-1.60 0.575 0.656
rs12373006 53755831 A 0.225 0.218 1.037 0.79-1.36 0.534 0.793
rs16976466 53760089 C 0.105 0.098 1.084 0.75-1.58 0.751 0.665
rs7176699 53761062 C 0.098 0.091 1.078 0.72-1.61 0.880 0.717
rs687128 53771897 A 0.406 0.402 1.017 0.81-1.28 0.108 0.881
rs9920680 53773093 C 0.085 0.086 0.987 0.66-1.48 0.888 0.952
rs1011061 53774790 A 0.499 0.494 1.017 0.81-1.27 0.791 0.882
rs1530087 53777321 A 0.129 0.121 1.080 0.77-1.52 0.837 0.666
Table 3.2: Results o f PRTG genotyping. MAF -  minor allele frequency, OR -  odds ratio, Cl -  confidence interval.
P-Values
SNP Position (bp) Minor Allele MAFCases
MAF
Control OR 95% Cl Genotypic Additive
rs11858195 53785887 A 0.326 0.318 1.037 0.82-1.32 0.881 0.766
rs2414424 53787355 T 0.149 0.134 1.136 0.82-1.57 0.750 0.457
rs4377101 53804814 C 0.079 0.081 0.978 0.63-1.51 0.958 0.921
rs7163167 53824295 C 0.349 0.339 1.045 0.82-1.33 0.842 0.716
rs2414433 53831481 T 0.179 0.173 1.042 0.78-1.40 0.917 0.789
rs8036481 53834838 C 0.459 0.472 0.948 0.76-1.19 0.597 0.626
Table 3.2 continued
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Figure 3.2: LD plot and results of tag SNPs in PRTG that were genotyped in the candidate gene study. The black bars show the position o f the tag SNPs and the -L ogi0
their additive P-value.
SNPs in Haplotype Haplotype Frequency in Cases
Frequency in 
controls x2
Individual
Haplotype
P-value
rs9920546/rs8025445/rs1530087 CCG 0.0031 0.0207 8.97 0.0027
rs9920546/rs8025445/rs1530087/rs2414424 CCGC 0.0031 0.0208 8.96 0.0028
rs1438915/rs9920546/rs8025445/rs2414424 CCCC 0.0032 0.0210 8.84 0.0029
rs9920546/rs8025445/rs2414424 CCC 0.0032 0.0208 8.82 0.0030
rs9920546/rs8025445/rs2414424/rs4377101 CCCT 0.0036 0.0219 8.77 0.0031
rs16976432/rs9920546/rs8025445/rs2414424 TCCC 0.0033 0.0209 8.76 0.0031
rs9920546/rs8025445/rs1530087/rs4377101 CCGT 0.0036 0.0217 8.63 0.0033
rs9920546/rs8025445/rs7176699/rs1530087 CCTG 0.0045 0.0231 8.45 0.0037
rs7164393/rs9920546/rs8025445/rs1530087 CCCG 0.0038 0.0216 8.39 0.0038
rs16976436/rs9920546/rs8025445/rs1530087 CCCG 0.0041 0.0222 8.34 0.0039
rs581287/rs9920546/rs8025445/rs2414424 CCCC 0.0034 0.0207 8.28 0.0040
rs9920546/rs8025445/rs7176699/rs2414424 CCTC 0.0046 0.0232 8.25 0.0041
rs16976432/rs9920546/rs8025445/rs1530087 TCCG 0.0040 0.0217 8.22 0.0042
rs16976436/rs9920546/rs8025445/rs2414424 CCCC 0.0041 0.0221 8.18 0.0042
rs7164393/rs9920546/rs8025445/rs2414424 CCCC 0.0040 0.0219 8.12 0.0044
rs1438915/rs9920546/rs8025445/rs1530087 CCCG 0.0041 0.0217 8.12 0.0044
rs492363/rs8030790/rs7176699/rs4377101 AATT 0.0057 0.0258 8.11 0.0044
rs9920546/rs8025445/rs8030790/rs1530087 CCAG 0.0042 0.0218 8.10 0.0044
rs617137/rs492363/rs7176699/rs4377101 CATT 0.0094 0.0328 8.09 0.0044
rs9920546/rs8025445/rs8030790/rs2414424 CCAC 0.0042 0.0218 8.03 0.0046
rs16976436/rs12903822/rs 1011061 /rs2414424 CTAC 0.0088 0.0302 7.71 0.0055
rs9920246/rs2118781/rs7176699/rs687128 GTTA 0.0221 0.0508 7.30 0.0069
rs617137/rs492363/rs8030790/rs4377101 CAAT 0.0059 0.0243 7.25 0.0071
rs9920246/rs16976466/rs687128/rs2414433 GTAT 0.0109 0.0327 7.21 0.0073
rs16976436/rs2118781 /rs 1011061 /rs2414424 CTAC 0.0342 0.0677 7.18 0.0074
rs492363/rs9920246/rs8030790/rs4377101 AGAT 0.0076 0.0267 6.83 0.0090
rs8030790/rs2118781 /rs687128/rs2414424 ATAC 0.0258 0.0542 6.70 0.0096
rs492363/rs8030790/rs12373006/rs4377101 AAGT 0.0075 0.0261 6.68 0.0098
Table 3.3: Results o f the haplotype analysis o f  PRTG SNPs for those haplotypes with P-values <0.01.
3.3.3 KIAA0319L Analysis
Out of 44 markers at the KIAA0319L locus, 13 SNPs tagging PRTG at r2 > 0.8 and a 
MAF > 0.05 in the HapMap CEU population were selected. These were genotyped in 
the Cardiff case control sample, of which 355 cases and 267 controls passed QC. Two 
SNPs were dropped due to poorly performing assays, and no proxies could be found at 
an r2 value >0.8. The remaining 11 SNPs had a call rate >98% (as shown in Table A.3 
in the Appendix). None of the variants showed a significant association with DD in 
this sample. As shown in Table 3.4 and Figure 3.3, the lowest P-value was for 
rsl 188633 (genotypic test P = 0.065). Haplotype analysis was carried out on all 
possible haplotype combinations, but none were significant (see Table A.5 in Appendix 
for a list of the haplotypes with the lowest global P-values).
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P-Values
SNP Position (bp) Minor Allele MAFCases
MAF
Control OR 95% Cl Genotypic Additive
rs12122296 35547202 C 0.110 0.112 0.979 0.69-1.40 0.470 0.908
rs3814302 35673202 C 0.018 0.028 0.644 0.30-1.36 0.503 0.241
rs1188633 35676499 c 0.063 0.086 0.719 0.47-1.10 0.065 0.122
rs1203138 35723292 T 0.121 0.110 1.114 0.78-1.59 0.561 0.536
rs2486297 35734324 G 0.041 0.058 0.691 0.41-1.16 0.071 0.165
rs1203148 35741486 C 0.228 0.238 0.947 0.73-1.24 0.716 0.694
rs1635718 35747056 C 0.020 0.025 0.805 0.38-1.73 0.852 0.572
rs12408030 35783621 G 0.263 0.285 0.894 0.70-1.15 0.490 0.388
rs7523017 35787598 A 0.048 0.062 0.774 0.47-1.27 0.146 0.307
rs6426949 35821996 C 0.018 0.028 0.645 0.30-1.37 0.508 0.244
rs6668196 35841791 G 0.045 0.056 0.791 0.47-1.32 0.349 0.362
Table 3.4: Results of KIAA0319L genotyping. MAF -  minor allele frequency, OR -  odds ratio, Cl -  confidence interval.
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3.3.4 DCDC2b Analysis
As no HapMap SNPs with a MAF > 0.05 were identified in DCDC2b, high 
resolution DNA melting analysis on the LightScanner was used to detect 
polymorphisms within the DCDC2b region in 15 DD cases. A change in melting curve 
indicated a different DNA sequence in that particular sample compared to the others 
(see Figure 3.4 for an example). A total of three samples showed polymorphisms, two 
of which were in the same amplimer of DCDC2b.
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Figure 3.4: Temperature shifted melting curves and difference curves produced by the third amplimer of 
DCDC2B. The two red lines indicate that two samples have a DNA sequence different to the others
These samples were then sequenced to identify the polymorphisms causing the 
change in melting temperature. The sample producing a different curve for the eighth 
amplimer showed a C to T transition at chrl: 32,447,903 (NCBI Build 36.1) (see Figure
3.5).
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Figure 3.5: Section o f the DNA sequence o f the eighth amplimer. The bottom trace shows the C to T 
transition at chr 1: 32,447,903.
Two samples producing a different melting curve for the third amplimer showed a G 
to C transversion at chrl: 32,446,453 (NCBI Build 36.1) in their sequences (see Figure
3.6).
ACTAGTGOGOCCAAGAOAAGCTOGAGCAGAGAGCTGOCATOAQTATAGGGAAGGAGGV6GACACATTTTCAATCCTCTOCCTGTAGCTCMTCCAMTTTG1
I T T
Figure 3.6: Section o f the DNA sequence o f the third amplimer in two samples. The traces at the top and 
bottom show the same G to C transversion at chr 1: 32,446,453 in both samples.
The G to C transversion shown in the third amplimer (-829G>C) is situated 829 bp 
upstream of the DCDC2b gene, and the C to T transition (IVS1+355C>T) in the eighth 
amplimer occurs within intron 1 of the DCDC2b gene. Both of these SNPs were 
genotyped in the case control sample and had a call rate > 99%. 355 cases and 267 
controls passed QC. As shown in Table 3.5, none of these variants showed a significant 
association with DD in this sample, with the lowest P-value being obtained for - 
829G>C (genotypic test P = 0.214). However, the SNP IVS1+355C>T shows a very
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low MAF of 0.007 in the controls, and as this variant is rare a sample of this size is 
insufficiently powered to detect a significant association with such a variant.
3.3.5 RIOK3 Analysis
Out of 22 markers at the RIOK3 locus, 10 SNPs tagging RIOK3 at r2 > 0.8 and a 
MAF > 0.05 in the HapMap CEU population were selected. These were genotyped in 
the Cardiff case control sample of which 354 cases and 265 controls passed QC. All 
SNPs had a call rate > 96%. As shown in Table 3.6, only one variant showed nominally 
significant association (rsl 1659196, genotypic test P = 0.046), however this association 
would not remain significant after correction for multiple testing. This SNP is in the 3’ 
UTR of the gene, as shown in Figure 3.7. Haplotype analysis was carried out on all 
possible haplotype combinations. No haplotypes were significantly associated with DD 
with the lowest global P-value being 0.110 for the haplotype
rsl 1659196/rsl995329/rs7241000 (see Table A.6 in Appendix). The SNP in KIAA0319 
shown to be correlated with RIOK3 expression (rsl6889511) did not show a significant 
association with DD in this sample as shown in Table 3.7.
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P-Values
SNP Position (bp) MinorAllele
MAF
Cases
MAF
Controls OR 95% Cl Genotypic Additive
-829G>C 32446253 C 0.055 0.058 0.943 0.58-1.53 0.214 0.816
IVS1+355C>T 32447903 T 0.003 0.007 0.375 0.07-2.05 0.499 0.238
Table 3.5: Results of DCDC2b genotyping. MAF -  minor allele frequency, OR -  odds ratio, Cl -  confidence interval.
P-Values
SNP Position (bp) MinorAllele
MAF
Cases
MAF
Control OR 95% Cl Genotypic Additive
rsl 995329 19291516 C 0.381 0.351 1.140 0.90-1.44 0.500 0.292
rs8083331 19295223 C 0.086 0.095 0.894 0.60-1.32 0.461 0.559
rsl 7202653 19296516 T 0.151 0.155 0.964 0.71-1.32 0.211 0.817
rsl 7187071 19297687 G 0.047 0.032 1.501 0.83-2.77 0.354 0.179
rs2291993 19298605 A 0.323 0.342 0.922 0.73-1.17 0.104 0.513
rs2047683 19303801 C 0.066 0.066 1.011 0.64-1.59 0.503 0.963
rsl 1663375 19312080 C 0.462 0.485 0.912 0.73-1.14 0.378 0.440
rs2270885 19312965 A 0.087 0.096 0.906 0.61-1.34 0.490 0.604
rsl 1659196 19316693 T 0.124 0.140 0.875 0.63-1.22 0.046 0.430
rs7241000 19318372 T 0.200 0.188 1.077 0.81-1.43 0.383 0.605
Table 3.6: Results of RIOK3 genotyping. MAF -  minor allele frequency, OR -  odds ratio, Cl -  confidence interval.
P-Values
SNP Position (bp) MinorAllele
MAF
Cases
MAF
Controls OR 95% Cl Genotypic Additive
rs16889511 24714015 G 0.2044 0.2271 0.8745 0.66-1.16 0.631 0.3373
Table 3.7: Results of the SNP in KIAA0319 that is associated with expression of RIOK3. MAF -  minor allele frequency, OR -  odds ratio, Cl -  confidence interval.
Overview of Chr18
S2.00
.00 J
< »■» ♦ « i »■* « ♦ 4 « « <
on ion ........... ...............20H
1 . . 4 * \ . . f « t . ♦ » « f ♦ ♦ ■>
3on 4oh son 6on ?on
Ideogran M 1 ■ ■■ )
21.013K
 ^nn I . . . . . . .  .
21.027K
. 1 .....................
21.041K
■ ■ ■ i .............................
21,0S5K
■ I . * . .
21.069K
.................i . . . .
21.083K
• 1
RJOK3
OT.THtfMMQOMttlTMiCtteiHK IFUQK3.QT I HUMOQQQQQ 1318131
I--------------- H H +
Figure 3.7: LD plot and results o f tag SNPs in RIOK3 that were genotyped in the candidate gene study. The black bars show the positions o f the tag SNPs and the -L o g 10 of
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3.4 Discussion
Variants within 5 genes were tested for an association with DD due to their 
hypothesised roles within neuronal migration (CDC42 and PRTG), their homology with 
genes that have shown convincing evidence for association with DD previously 
(DCDC2b and KIAA0319L) or because their level of expression has been associated 
with SNPs in one of the replicated candidate genes for DD (RIOK3). 68 SNPs in these 
genes were genotyped in the Cardiff sample consisting of 357 cases and 269 controls. 
However, none of the variants tested showed significant association with DD after 
correction for multiple testing.
CDC42 lies in the central region of DYX8, a region of chromosome 1 in which a 
number of studies have found evidence for linkage or association with DD (Rabin et al. 
1993; Grigorenko et al. 2001; Tzenova et al. 2004; Bache et al. 2006; Franke et al.
2006; Bates et al. 2007). However, none of these studies have looked for an association 
between DD and CDC42 and none of the markers that were genotyped in linkage 
studies of the DYX8 region lie within this gene. The results from this study suggest that 
variation within CDC42 cannot explain the observed linkage of DD with this region.
PRTG lies on the edge of the DYX1 susceptibility region in an area of chromosome 
15 that has been linked with DD in a previous study (Smith et al. 2005). This study 
found linkage of chrl5q21 to a DD sub-phenotype of phonological memory using a 
sample of American children affected with speech sound disorder (SSD). One of the 
significantly linked markers, D15S1029, lies within intron 11 of PRTG. It is possible 
that this gene is significantly associated with a phonological subtype of DD, rather than 
reading disability in general which maybe why variants within this gene did not show 
significant association with DD in this study. Wigg et al. (2008) used a sample of 253 
families with a proband diagnosed with ADHD and found evidence of association of 
variants within PRTG with ADHD using both categorical and quantitative trait analysis. 
However, when carrying out quantitative analyses using two key components of reading 
(word identification and decoding), none of the SNPs genotyped were found to be 
significantly associated. Out of the 20 SNPs genotyped in that study, 8 SNPs were typed 
directly in this study, and a further 6 were typed indirectly via proxies. Thus, it appears 
that although variation within PRTG may be associated with a phonological sub­
phenotype of DD in a SSD sample, it does not appear to be associated with reading
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ability when defined categorically in this study, or through reading components in an 
ADHD sample.
KIAA0319L lies within the DYX8 susceptibility locus and has been previously tested 
for an association with DD by Couto and colleagues (2008). All of the SNPs that made 
up the significant haplotype identified in that study
(rs1203138/rs1203148/rs12408030/rs7523017; C/A/A/A haplotype, P = 0.03; global P 
= 0.339) were genotyped here, but failed to show a significant association (C/A/A/A 
haplotype P = 0.3069; global P = 0.266). The SNP showing a significant association by 
Couto and colleagues (rs7523017; P = 0.042) was also not significant in this study (P * 
0.307). The difference in results may be due to the different populations studied. 
However, 68.1% of the families used in the sample in Couto and colleagues’ study 
described their descendants’ ethnicity as being European or British, with another 26% 
describing them as “Caucasian Canadians” so the populations between the two studies 
should not differ dramatically. Both studies also used similar tests and inclusion criteria 
to define subjects as ‘affected’. Further studies in other independent samples will need 
to be carried out to determine if an association between variants within KIAA0319L and 
DD exists or not.
DCDC2b is on chromosome lp35.1 within the well replicated DYX8 region. 
Although this region has shown linkage to DD in a number of studies, no variants 
within DCDC2b have been tested for association with the disorder previously. Two 
novel variants were identified in DCDC2b through high resolution DNA melting 
analysis but neither of these variants were significantly associated in this sample. The 
mutation detection sample used in this study had a power of 96% to detect a variant 
with a MAF >0.1 and 79% power to detect a variant with a MAF > 0.05. It is therefore 
possible that variants within DCDC2b may exist that are associated with DD but are 
either too rare and/or do not have large enough effect sizes in order to be identified in 
this study. The SNP IVS1+3550T showed a very low MAF of 0.007 in the controls, 
and as this variant is not highly polymorphic, a sample of this size is unlikely to pick up 
a significant association with such a rare variant. As there are no SNPs in the HapMap 
CEU population within this gene that have a MAF > 0.05, it is likely that any variants 
within DCDC2b are too rare for association with DD to be detected in small samples.
RIOK3 is on chromosome 18ql 1.2, just outside of the DYX6 linkage region. One of 
the two SNPs within the KIAA0319 gene that were shown to be correlated with
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expression of RIOK3 (Myers et al. 2007) was also genotyped in this study but did not 
show a significant association with DD (rsl6889511, P -  0.3373). The other SNP that 
showed a correlation with the expression of this gene (rsl 6889506), has also been 
genotyped in this sample in a previous study but failed to show a significant association 
(P = 0.8673) (Harold et al. 2006), which supports the results in this current study as 
these SNPs are in perfect LD with each other. As the KIAA0319 SNPs that are 
correlated with the expression of RIOK3 are not significantly associated with DD in this 
sample, it implies that the expression of this gene may not affect an individual’s 
susceptibility to this disorder. Neither of the KIAA0319 SNPs are present in more recent 
eQTL databases (Dixon et al. 2007; Dimas et al. 2009). Although the KIAA0319 SNP 
was not significantly associated with DD in this study, variation within RIOK3 may 
contribute to DD susceptibility, i.e. an association of rsl 1659196 with DD was observed 
(genotypic P = 0.046). This result does not survive correction for multiple testing 
however, and genotyping in a larger, independent sample is required to either confirm 
or refute the association.
However, no single study of this size can exclude a gene from involvement in 
disease susceptibility and there could be a number of reasons why no association was 
found for these genes in this particular study. It is possible that these genes do have a 
role within DD, but their effect sizes are too small for association to be detected in a 
sample of this size. For example, for a susceptibility variant with an OR of 1.3 and a 
MAF of 0.4, this sample had 62% power to detect a significant association (P < 0.05).
Another possibility is that while CDC42 and PRTG may have roles within neuronal 
migration (Luo 2000; Wang et al. 2006), the roles they play in this pathway do not have 
an effect on reading ability and so are not associated with DD. These genes are far from 
an exhaustive list of neuronal migration genes that lie within DD susceptibility regions. 
Neuronal migration is a complex process involving a large network of pathways and it 
is still a biological process that is worth exploring further within the context of reading 
ability.
In summary, variants within five candidate genes which lie within the DD 
susceptibility regions were genotyped in the Cardiff case control sample but did not 
show a significant association with DD. However, further studies in independent 
samples need to be carried out before these genes can be confidently discounted as DD 
susceptibility genes.
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Chapter 4: NeuroDys Genome-wide 
Association Study
4.1 Introduction
Genome-wide association studies (GWAS) involve testing a large number of 
common genetic variants across the human genome for association with a disease or 
trait. Because no hypotheses are made about the location of the susceptibility variants or 
their biology, this method provides an unbiased approach to identifying new 
susceptibility loci for disease (Hirschhom Sc Daly 2005), as opposed to candidate gene 
studies which are often based on an imperfect understanding of biological pathways and 
can yield associations that are difficult to replicate (Manolio et al. 2009). GWAS have 
become possible through the development of commercial arrays that can capture most 
of the known single nucleotide polymorphism (SNP) variation with a minor allele 
frequency (MAF) greater than 5% in the general population (The International HapMap 
Consortium 2007). This has been achieved by exploiting the linkage disequilibrium that 
exists between SNPs in the human genome. For example, the Illumina HumanHap300 
array consists of 317,503 SNPs which capture 76% of the SNPs with MAF > 0.05 in 
Phase II of HapMap at an r2 threshold > 0.8 (in the Caucasian population) (Magi et al. 
2007). The Illumina HumanHap550 array consists of >550,000 SNPs which capture 
86% of the SNPs in Phase II of HapMap (MAF > 0.05, r2 > 0.8) (Magi et al. 2007).
As discussed in section 1.3.2.4, multiple testing issues in GWAS require stringent P- 
values in order for an association to be considered to be genome-wide significant. It has 
been suggested that an appropriate threshold for genome-wide significance is P < 5 x
o
10' (Pe'er et al. 2008). In order to be sufficiently powerful enough to identify common 
genetic variants with small effect sizes at this genome-wide level of significant 
association, GWAS of complex diseases require thousands of case and control samples 
in the initial stages in order to be powerful enough to identify common genetic variants 
with small effect sizes at genome-wide levels of significant association (Risch 2000; 
Cardon Sc Bell 2001). This results in high costs that are often beyond the budgets of 
many research groups. GWAS are most commonly carried out in the form of case- 
control studies, as it is often more time consuming and expensive to collect large
family-based samples (Craddock et al. 2008). In addition, case-control based studies can 
take advantage of data from large population based samples that have become publicly 
available by using such samples as controls against cases for a disease of interest. For 
example, whole-genome genotype data for participants that were recruited as part of the 
National Child Development Study (otherwise known as the 1958 birth cohort) has been 
made available. Using such population data in a study means that only the case samples 
need to be genotyped, thus reducing costs.
Taking a multi-stage approach to the design of a GWAS can also improve the 
efficiency of the study by reducing the amount of genotyping required without 
sacrificing too much power (Hirschhom & Daly 2005). In the first stage, the full set of 
genome-wide SNPs (i.e. all SNPs on a genome-wide SNP array) is genotyped in a 
subset of the samples (often referred to as the ‘discovery sample’). A P value threshold 
(e.g. < 1 x 10"4) is used to identify a subset of SNPs with putative associations, which 
are then re-tested in a larger independent sample (the ‘follow-up’ or ‘replication 
sample’) in the second or sometimes third stages. This allows researchers to distinguish 
the true-positive associations identified in the first stage from the false-positives which 
may be identified in the first stage by chance.
In recent years, GWAS have improved our understanding of complex diseases and 
have resulted in the identification of a large number of novel susceptibility loci in a 
range of human diseases, including type 1 and type 2 diabetes mellitus, prostate cancer 
and breast cancer (McCarthy et al. 2008). For example, five separate GWAS of type 2 
diabetes (T2D) identified six new gene regions on top of the five that were already 
known (Frayling 2007). This a remarkable result when taking into account the weak 
genetic component of this disease compared with many other common diseases - the 
sibling relative risk is at the most 3 - 4 for T2DM, compared with 15 for type 1 diabetes 
(WTCCC 2007). In comparison, DD has an estimated sibling relative risk of 4-6 
(Ziegler et al. 2005). The success of these studies can be partly attributed to the large 
sample sizes that were used, with a total of approximately 55,000 cases and controls in 
the combined discovery and follow up samples across the five studies (Frayling 2007).
As discussed in Chapter 1, a total of 19 independent linkage studies have been 
carried out in an effort to identify susceptibility variants for DD and these have 
identified nine DD susceptibility regions ([DYX1 to DYX9). Eight of these linkage 
studies were genome-wide screens (de Kovel et al. 2004; Fagerheim et al. 1999; Fisher
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et al. 2002; Igo Jr et al. 2006; Kaminen et al. 2003; Marlow et al. 2003; Nopola-Hemmi 
et al. 2001; Raskind et al. 2005). Another genome-wide linkage screen for general 
reading and spelling ability has been carried out using samples that were not specifically 
selected for DD (Bates et al. 2007). However, these linkage studies have only achieved 
limited success. The limited success of linkage studies in complex diseases in general 
can be attributed to their low power and resolution for variants with small effect sizes 
(Hirschhom & Daly 2005), as discussed in section 1.3.1.2. A powerful GWAS of DD 
may have more success in identifying the common susceptibility variants underlying 
this complex disease.
While no GWAS of DD have been published as yet, a GWAS of general reading 
ability has been performed. Meabum and colleagues (2008) used samples from the UK 
that had been recruited as part of the Twins Early Development Study (TEDS) (n = 
3043, one member from each twin pair). They selected two subsets from the 3043 
individuals based on their reading scores, with one subset in the lower 25% of the 
reading distribution (n = 755) and the other in the top 25% of the distribution (n = 747). 
They formed pools with these two subsets and genotyped them on the Affymetrix 
GeneChip Human Mapping 100K Array Set. They then selected another 4258 
individuals from the TEDS cohort and individually genotyped 75 of the top SNPs in a 
subset of individuals in the lower 10% of the reading distribution (n = 452) and another 
subset in the higher 10% (n = 452). 9 of these SNPs showed a significant association 
with reading ability and another 14 showed low versus high allele frequency differences 
in the predicted direction. Out of these 23 SNPs, 10 showed significant association with 
reading ability when genotyped in the remaining 3,408 individuals from the second 
TEDS cohort that had not been selected for reading ability. However, these SNPs were 
only nominally significant at the 0.05 level, and would not survive correction for 
multiple testing. Seven SNPs within the DYX1 and DYX2 linkage regions were among 
the 300 most significant SNPs in the first stage of this study of which five showed 
association with a low reading ability, but they were not selected for individual 
genotyping. However, this study was carried out using the 100K Affymetrix GeneChip 
array and testing 100,000 SNPs (-30% coverage of the genome) cannot be considered 
to be a comprehensive genome-wide scan and many of the susceptibility variants for 
reading ability may have been missed in these studies.
130
The NeuroDys consortium (www.neurodys.com) have recently undertaken the first 
GWAS of DD involving research groups from the UK and Germany in the first stage 
and then additional groups from Switzerland, Netherlands, Austria, Finland, France and 
Hungary in the replication stages. The overall aim of the NeuroDys project is to gain a 
better understanding of DD by investigating the correlations between candidate genes 
and brain functions that are found to be relevant for learning to read and to spell, such 
as grapheme-phoneme association. The genotyping and quality control for the 
NeuroDys GWAS was conducted by the consortium before this PhD project was 
started, but I was involved in subsequent follow-up studies.
4.1.2 Aims
The aim for this section of the thesis was to use the data from the NeuroDys GWAS 
to identify new susceptibility variants for DD as well as compare the results with 
previous findings. The first stage of the study tested over 300,000 SNPs and highlighted 
a number of interesting variants which were then selected for follow up in an 
independent, larger sample in an effort to replicate these findings.
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4.2 Materials and Methods
4.2.1 First Stage of GWAS
4.2.1.1 Sample Ascertainment and Criteria
The first stage of the GWAS involved 410 cases from the UK (made up of 200 cases 
from the University of Oxford and 210 cases from Cardiff University) and 200 cases 
from Germany (see Table 4.1). The criteria for determining affection status differed 
slightly between centres. The Cardiff case criteria is an IQ > 85 and a reading age that is 
> 2.5 years below their chronological age (see Chapter 2). Samples from Oxford were 
identified from the dyslexia clinic at the Royal Berkshire Hospital in Reading. 
Participants were classed as cases if they had an IQ > 90 and discrepancy of > 1.5 SD 
between the average score obtained from British Abilities Scales (BAS) II matrices and 
similarities subtests (a test for IQ) compared with BAS II Word Reading Test, provided 
reading age was no higher than chronological age (Marlow et al. 2001; Fisher et al. 
2002). German cases were recruited from the Departments of Child and Adolescent 
Psychiatry and Psychotherapy at the Universities of Marburg and Wurzburg.
Participants were classed as cases if they had observed spelling scores that were > 1 SD 
below that predicted based on an assumed correlation between IQ and spelling of 0.40 
(Schulte-Kome et al. 2001; Schumacher et al. 2006a).
DNA for these case samples were extracted from either blood or saliva samples 
using phenol/chloroform methodology as previously described (see Chapter 2). DNA 
quantification and dilution was also as described (Chapter 2), with a final sample 
dilution of 50ng/pl.
The UK control sample consisted of 1437 population controls recruited as part of 
the 1958 British Birth Cohort (Power & Elliott 2006) (see Chapter 2 for more 
information on this sample) and the German control sample consisted of 905 samples 
from the Heinz Nixdorf Recall Study (an epidemiological study with a focus on risk 
factors for coronary heart disease (Stang et al. 2005; Kroger et al. 2006)) and the 
Munich Antidepressant Response Signature Project (Hennings et al. 2009).
4.2.1.2 Genotyping and Analysis
All German cases and 102 of the Cardiff cases were genotyped on the Illumina 
HumanHap300 array according to manufacturer’s instructions at the University of
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Bonn. The Oxford cases and the rest of the Cardiff case sample were genotyped at 
Oxford University. The Oxford cases and 32 of the Cardiff cases were genotyped on the 
Illumina HumanHap550 array, with the remaining Cardiff cases (76) genotyped on the 
Illumina HumanHap300 array. The population controls had previously been genotyped 
on the Illumina HumanHap550 arrays.
QC filtering was performed by Andrew Morris from Oxford University and Bertram 
Miiller-Myhsok from the Max Planck Institute of Psychiatry in Munich. Individuals 
were excluded if they had a SNP call rate < 98%, if their autosomal heterozygosity was 
< 33.5 % or > 36.5%, or if they showed non-European ancestry. Potential duplicate 
individuals were removed by calculating identity by state (IBS) distances for all 
possible pairs of individuals in PLINK vl .04 (Purcell et al. 2007) using those SNPs that 
passed QC filters (see below), and removing one of each pair with an IBS distance > 
98%. After QC filters were applied, a total of 585 cases and 2326 controls remained, as 
shown in Table 4.1.
Cases Controls
UK Sample 389 1421
German Sample 196 905
Total 585 2326
Table 4.1: Sample genotyped in the first stage of the GWAS
As samples were genotyped on both the Illumina HumanHap300 and 
HumanHap550 arrays, only those autosomal SNPs that were common to both arrays 
were used in the analysis. Additional SNPs were excluded if their call rate was < 98%, 
if their minor allele frequency was < 0.05 and if their Hardy-Weinberg P-value was < 1 
x 10"5 in cases or controls. 297,650 SNPs passed these QC filters.
SNPs were tested for an association with DD using logistic regression carried out in 
PLINK vl.05 (Purcell et al. 2007). To correct for possible population stratification, the 
genome-wide average IBS distance was calculated in PLINK between each pair of 
individuals in the resulting dataset using those SNPs that passed the QC filters 
mentioned above. Multidimensional scaling (MDS) analysis was then performed on the 
resulting matrix of IBS distances to extract four components. MDS is a method of 
analysis that provides a visual representation of the pattern of similarities between 
datasets. For example, given a matrix of IBS distances between various individuals, 
those individuals that are perceived to be similar are plotted close together, whereas 
those who are perceived to be different are plotted far apart from each other.
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Components can then be extracted which are able to explain the genetic variation 
occurring between individuals, with the first component explaining most of the 
variation and the remaining components explaining the rest of the variation. The 
components can then be used as covariates in order to control for differences between 
individuals that may be the result of population stratification. The impact of including 
the components as covariates was evaluated by calculating the genomic control inflation 
factor (A,). Including the first component as a covariate with centre of origin (shown in 
Table 4.3) had the maximum impact on A as shown in Table 4.2 and Figure 4.1. 
Therefore, these covariates were used when carrying out logistic regression. Both the 
additive and genotypic tests of association were performed within the logistic regression 
framework.
Component with Country 
of Origin X
0 1.042
1 1.041
2 1.042
3 1.044
4 1.041
Table 4.2: Table shows the effect o f varying the number o f components extracted from the MDS 
analysis, on the genomic control inflation factor (A). These values are based on analysis o f 297,650 SNPs 
that passed QC filters.
a
o
o
0 5 10 15 20
Expected Chisquare
Figure 4.1: Quantile-quantile (QQ) plot o f 297,650 observed genome wide association y? test statistics 
(y-axis) against those expected under the null expectation (x-axis) using country o f origin and MDS 
component 1. The line o f equality is coloured red (A = 1.041).
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Set-based analysis was also carried out on SNPs within the DD linkage regions, 
DYX1-DYX8, that had been genotyped in the GWAS. Set-based analysis may offer a 
number of possible advantages over single locus tests (Neale & Sham 2004). For 
example, if there is more than one independent association signal within a gene or set of 
markers, such as where there is more than one functional variant, combining these into a 
single statistic might offer enhanced power over single SNP analysis (Moskvina et al. 
2009). All SNPs located within the regions DYX1 to DYX8 that had been genotyped in 
the GWAS were identified, and logistic regression using the additive model was carried 
out as before. Two region-wide tests were then performed using PLINK vl .05 (Purcell 
et al. 2007). The first was based on the most significant single P-value within each of 
the DYX regions, correcting this value based on the number of independent SNPs within 
the region. The second analysis was based on the product of the P-values within each 
region. The significance in both tests was obtained by comparing the test statistic in the 
observed data to that obtained when disease status was randomly permuted among 
individuals, thereby accounting for inter-SNP LD. For each permutation, the smallest P- 
value and the product of P-values were obtained as performed in the original data set. 
The final empirical P-value was determined by the number of times the permuted P- 
value exceeded the original value. 1000 permutations were performed.
4.2.2 Replication Study
4.2.2.1 Replication Sample Ascertainment and Criteria
A total of 1258 cases and 1974 screened controls from 6 European countries formed 
the replication sample (see Table 4.3). The inclusion criteria for the replication sample 
were slightly different to that used in the initial GWAS. All cases were between 8 and 
12 years of age, were of European ethnicity, had an IQ > 85 and had a performance 
level of at least 1.25 standard deviations below the expected age-based norms on a 
standardised test of reading (a test with established norms for the population being 
tested) administered in the child’s native language.
Participants were recruited from the UK by Cardiff University and Oxford 
University, from Germany by the University of Bonn and University of Munich, from 
Switzerland by the University of Zurich, from the Netherlands by the University of
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Maastricht, from Austria by the University of Salzburg and from Finland by the 
University of Jyv&skyl&.
DNA was extracted from saliva or blood samples using phenol/chloroform 
methodology as mentioned previously. It was then quantified using PicoGreen (see 
Chapter 2) and diluted to 5ng/pl.
Country/Centre Cases Controls Centre
UK:
Cardiff 209 268 1
Oxford 328 288 2
Germany:
Bonn 200 685 3
Munich 108 194 4
Switzerland 26 43 5
Netherlands 115 106 6
Austria 116 201 7
Finland 156 189 8
Total 1258 1974
Table 4.3: Replication sample
4.2.2.2 Genotyping of Replication Panel and Analysis
SNPs were chosen based on their minimum P-value from the additive and genotypic 
association tests in the GWAS. The top 65 hits were put through the Sequenom 
MassARRAY Assay Design 3.1 software in order to design a multiplex panel of SNPs 
that contained most of the top hits from the GWAS. A panel of 29 SNPs was designed 
which included 17 SNPs from the top 25 hits, and another 12 that were in the top 65 hits 
(P-min < 1 x 10*4). Table 4.8 shows all SNPs entered into this panel (see Table B.2 in 
Appendix for primer sequences).
This panel of SNPs was genotyped in the replication sample using the Sequenom 
MassARRAY iPlex GOLD system as described in Chapter 2. Genotype calling was 
carried out using the Typer 3.4 software. All SNP assays were initially optimised by 
genotyping DNA from 30 CEPH parent-offspring trios. Cluster plots for all SNPs were 
inspected manually, and SNP assays that did not produce distinct clusters were 
excluded. All plates for genotyping contained a mixture of cases, controls, blanks, and 
46 CEU samples. “Double-genotyping”, where another experienced user of the 
Sequenom genotyping system and Typer software checks the genotypes for every assay, 
was used. Genotypes were called blind to sample identity, affected status, and blind to
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the other rates. Genotypes of CEU samples were compared to those available on the 
HapMap to provide a measure of genotyping accuracy. Genotyping assays were only 
considered suitable for analysis if a) during optimisation, genotypes for CEU 
individuals were the same as those in the HapMap when available and b) all subsequent 
duplicate genotypes from the CEU samples were consistent with the HapMap data.
After genotyping, SNPs were tested for Hardy-Weinberg equilibrium in controls and 
their MAFs were calculated using PLINK vl.05 (Purcell et al. 2007). Samples with a 
call rate < 70% were excluded.
SNPs were tested for an association with DD using logistic regression carried out in 
PLINK vl .05 (Purcell et al. 2007) using both the additive and genotypic association 
tests. To correct for possible population stratification, a covariate was applied as shown 
in Table 4.3. It was not possible to carry out MDS analysis at this stage because 
genome-wide SNP data was not available for the replication sample. Additional logistic 
regression analysis was carried out combining the genotypes for the SNPs in both the 
replication and initial GWAS samples. Due to the change in ascertainment criteria and 
to control for artefacts that may be present as a result of the samples being collected and 
extracted at different times and being genotyped in different centres, the UK cases and 
controls in the GWAS sample were assigned a different covariate to the UK cases and 
controls in the replication sample. The German cases and controls in each sample set 
were also analysed in this way. The samples from the other countries were all assigned 
a covariate according to their centre as these were not included in the initial GWAS.
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4.3 Results
4.3.1 First Stage of GWAS
A total of 585 cases and 2326 controls from the UK (389 cases, 1421 controls) and 
Germany (196 cases, 905 controls) were included in further analyses (see Table 4.1) 
following sample QC. A total of 297,650 SNPs passed QC. The results from the logistic 
regression analyses are shown in Figure 4.2 for the additive test and Figure 4.3 for the 
genotypic test (see Table B.l in Appendix for a list of the 200 most significant SNPs).
o
No SNPs achieved genome-wide significance (P < 5 x 10’ ). Alternatively, the 
Bonferroni corrected P-value based on the number of SNPs analysed in this study is P < 
1.7 x 10’7 and the top hit had a P-value that was just below this threshold (rsl 0513829, 
additive P = 1.2 x 10'7, OR = 0.68), as shown in Table 4.4. Another 35 SNPs showed a 
suggestive level of significance (P < 5 x 10'5) based on their minimum P-value when 
using either the additive or genotypic test.
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Figure 4.2: Manhattan plot o f the additive P-values from the logistic regression analysis on all samples using country and MDS component 1 as a covariates. The blue line
indicates a P-value o f 5 x 10 '.
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Figure 4.3: Manhattan plot o f the genotypic P-values from the logistic regression analysis on all samples using country and MDS component 1 as a covariates. The blue line
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indicates a P-value o f 5 x 10"5
UK Sample German Sample Whole Sample
Rank SNP Chr Position(BP)
Minor
Allele
Closest
RefSeq
Gene
P-Gen P-Add OR P-Gen P-Add OR P-Gen P-Add OR 95% Cl
1 rs10513829 3 189971026 C LPP 3.9 x 10-6 4.5 x 10-® 0.66 0.0241 0.0063 0.71 2.0x1 O'7 1.2 x 1 0 7 0.68 0.59-0.79
2 rs6796074 3 103316739 T LOC152225 5.7x1 O'9 2 .8x1 O’9 1.74 0.5842 0.9352 0.99 5 .6x1 O’7 4.8 x 10* 1.45 1.24-1.71
3 rs7840675 8 34075413 C DUSP26 1.3 x 10* 6.7 x 10'7 1.86 0.1212 0.1334 1.33 4.8 x 10* 8.1 x 107 1.67 1.36-2.04
4 rs3742673 14 89805459 T PSMC1 0.0070 0.9254 0.99 3.5x10-® 0.9512 0.99 1.6x10"® 0.9597 1.00 0.88-1.13
5 rs747783 11 15670131 T SOX6 7.1 x 10"* 1.8x10"* 1.39 0.0095 0.0027 1.44 1.1 x 10* 1.8x10* 1.41 1.22-1.62
6 rs11117425 16 84529771 T IRF8 9.3x10"* 3.1 x 10"* 0.72 0.0101 0.0036 0.69 8.8 x 10* 3.1 x 10* 0.71 0.61-0.82
7 rs2836341 21 38656626 A ERG 5.2x10-® 0.2107 1.11 0.0526 0.8496 0.98 5.4x10* 0.3474 1.06 0.94-1.21
8 rs10123957 9 110900238 C C9orf5 7.4 x 10"* 1.9x10"* 1.36 0.0134 0.0071 1.35 1.6x10* 5.9 x 10* 1.35 1.19-1.54
9 rs10518444 4 125945653 G ANKRD50 5.8x10-® 9.0x1 O'7 1.97 0.4366 0.4280 1.18 3.7 x 10* 7.9x10* 1.67 1.33-2.08
10 rs10816767 9 110822490 A C9orf5 0.0015 5.9x10"* 1.33 0.0088 0.0034 1.39 1.9x10* 8.9 x 10* 1.34 1.18-1.53
11 rs4678029 3 123391123 C CASR 7.3 x 10"* 0.0202 1.25 0.0117 0.0757 1.25 9.1 x 10* 3.4x10* 1.25 1.08-1.45
12 rs4887111 15 71815337 G LOC388135 7.3x10"* 6.7 x 10"4 0.75 0.0115 0.0027 0.70 2.5 x 10* 9.3 x 10* 0.73 0.64-0.84
13 rs7202472 16 84535002 T IRF8 0.0050 0.0037 0.74 0.0036 5 .7 x 1 0"4 0.59 3.6 x 10* 9.7 x 10* 0.68 0.58-0.81
14 rs1181841 5 128580604 G ISOC1 0.0025 6.4x10"* 1.32 0.0325 0.0089 1.35 6.2 x 10* 1.1 x 10* 1.34 1.18-1.53
15 rs4327894 8 1740903 T MIRN596 0.0121 0.0038 0.75 0.0033 7.8x10"* 0.59 5.4 x 10* 1.4x10* 0.70 0.59-0.82
16 rs10512712 5 39728088 C DAB2 0.0017 3.9 x 10"* 1.34 0.0489 0.0214 1.29 8.2 x 10* 1.4x10* 1.33 1.17-1.52
17 rs1429411 2 197852246 C ANKRD44 3.4x10"* 0.0075 0.80 0.0358 0.0448 0.79 1.6x10* 7.8 x 10* 0.80 0.70-0.91
18 rs7623540 3 189972233 c LPP 0.0010 2.4x10"* 1.38 0.0412 0.0195 1.33 9.0x10* 1.6x10* 1.36 1.18-1.56
19 rs6136213 20 17798339 G SNX5 4.8 x 10* 1.0x10"* 0.69 0.0530 0.0489 0.77 4.1 x 10* 1.6x10* 0.72 0.62-0.83
20 rs4747165 10 72969307 G CDH23 0.0264 0.0108 1.22 7.2x10"* 1.4x10"* 1.53 7.7 x 10* 2.1 x 10* 1.32 1.16-1.49
21 rs11855844 15 96462744 A LOC728459 2.9x1 O'® 1.3x10-® 1.64 0.2937 0.2019 1.22 9.4x10* 2.1 x 10* 1.47 1.23-1.76
22 rs2894536 6 43909855 C VEGFA 0.0026 6.1 x 10"* 1.43 0.0296 0.0091 1.49 1.1 x 10* 2.4x10* 1.44 1.22-1.70
23 rs9465637 6 20222086 T MBOAT1 0.0028 0.0331 0.83 0.0079 0.1720 0.85 2.4x10* 0.0125 0.84 0.73-0.96
24 rs2727822 7 36627947 T AOAH 0.0072 0.7097 0.97 0.0019 0.7006 1.05 2.5 x 10* 0.9239 0.99 0.87-1.14
25 rs1465234 2 151493615 A RBM43 6.0x10"* 1.2x10"* 1.75 0.0777 0.0659 1.47 1.1 x 10* 2.5x10* 1.65 1.31-2.09
Table 4.4: Top 25 hits from the GWAS according to their minimum P-value. P values < 0.05 are in bold. Chr -  Chromosome; UTR -  Untranslated Region; P-Gen -  
Genotypic P-value; P-Add -  Additive P-value; OR - Odds Ratio with respect to the minor allele; Cl - confidence interval.
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Table 4.4 shows the top 25 hits from the first stage of the GWAS, based on their 
minimum P-value. Two of these top hits are in the gene LIM domain containing 
preferred translocation partner in lipoma (LPP) on chromosome 3, as shown in Figure 
4.4. Both of these SNPs lie close together within intron 8 of the gene and are in high LD 
with each other, although the r2 between them is low (r2 = 0.2, D ’ = 0.92). While these 
SNPs were significantly associated in the German sample set alone (rs 10513829 P-add 
= 0.0063, OR = 0.71; rs7623540 P-add = 0.0195, OR = 1.33), they showed much 
stronger association in the UK sample set (rs10513829 P-add = 3.9 x 10"6, OR = 0.66; 
rs7623540 P-min = 2.4 x 10"4, OR = 1.38). Both of these SNPs had slightly higher effect 
sizes in the UK sample. The UK sample was also larger than the German sample, 
therefore it would have had greater power to detect a significant association with these 
SNPs. Four other SNPs within this gene also had P-values < 0.05 in the combined 
GWAS sample, indicated by the red bars in Figure 4.4 and shown in Table 4.5. None of 
the significant SNPs in this gene are in a high level of LD with each other, with the 
highest level of LD existing between the two top SNPs, rsl0513829 and rs7623540.
Two other SNPs in the top hits shown in Table 4.4 are downstream of the gene 
interferon regulatory factor 8 (IRF8) as shown in Figure 4.5. These SNPs and are in LD 
with each other (D’= 1), although the r2 between them is low (r2 = 0.57). The SNP 
rsl 1117425 (P-min = 8.8 x 10‘6) lies ~16 Kb downstream of IRF8 and rs7202472 (P- 
min = 9.7 x 10*6) lies ~21 Kb downstream and both SNPs are outside of the LD blocks 
of IRF8. The SNP rsl 1117425 showed a higher level of significance in the UK sample 
(P-add = 3.1 x 10-4, OR = 0.72) compared with the German sample (P-add = 0.0036,
OR = 0.69), while the opposite is true of rs7202472 (UK sample: P-add 0.0037, OR = 
0.74; German sample: P-add = 5.7 x 10-4, OR = 0.59). Both of these SNPs had larger 
effect sizes in the German sample. The reason that rsl 117425 showed a higher level of 
significance in the UK sample even though it had a smaller effect size is likely to be due 
to the greater amount of power that the larger UK sample had. Three other SNPs in this 
region had P-values < 0.05 (see Table 4.6), and these were in LD with other (D ’ > 0.9) 
although the correlation between them all was low (r2 < 0.57).
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Figure 4.4: LD plot and results o f SNPs in LPP that were genotyped in the GWAS. Red bars denote P-values <0.05. The two most significant SNPs are not in high LD with
each other.
143
UK Sample German Sample All Samples
SNP Position(bp)
Position 
in LPP P-gen P-add OR P-gen P-add OR P-gen P-add OR 95% Cl
rsl 0937357 189780599 Intron 5 0.0225 0.1113 0.82 0.5275 0.6901 0.93 0.0165 0.1288 0.86 0.71-1.04
rs9837401 189802757 Intron 5 0.0770 0.0351 1.20 0.6373 0.3544 1.12 0.0874 0.0273 1.17 1.02-1.34
rs4322991 189822630 Intron 6 0.3141 0.1411 0.87 0.0769 0.0679 0.77 0.0671 0.0268 0.84 0.71-0.98
rs13314127 189952657 Intron 7 0.0217 0.1597 1.14 0.3851 0.2601 0.87 0.0447 0.6628 1.03 0.89-1.19
rsl 0513829 189971026 Intron 8 3.9 x 10'* 4.5x10* 0.66 0.0241 0.0063 0.71 2.0 x 10* 1.2 x 10* 0.68 0.59-0.79
rs7623540 189972233 Intron 8 0.0045 2.4 x 10* 1.38 0.0412 0.0195 1.33 9.0 x 10* 1.6 x10 s 1.36 1.18-1.56
Table 4.5: Table of results from all SNPs within LPP that had a minimum P-value < 0.05 in the whole GWAS sample. The results o f these SNPs in the UK and German 
samples are also shown. P-gen -  genotypic P-value; P-add -  additive P-value; OR - odds ratio o f the minor allele; Cl - confidence interval.
UK Sample German Sample All Samples
SNP Position(bp)
Position in 
IRF8 P-gen P-add OR P-gen P-add OR P-gen P-add OR 95% Cl
rs391525 84501939 Intron 3 0.0840 0.0842 1.16 0.0327 0.0103 1.44 0.0630 0.0401 1.15 1.01-1.32
rs366078 84522063 Downstream 0.0435 0.0618 0.81 0.2541 0.0041 0.61 0.0014 0.0012 0.73 0.61-0.88
rsl 1117425 84529771 Downstream 9.3x10* 3.1 x 10* 0.72 0.0101 0.0036 0.69 8.8x10* 3.1 x 10* 0.71 0.61-0.82
rs305061 84533159 Downstream 0.0438 0.0211 1.21 0.3387 0.1489 1.18 0.0051 0.0060 1.21 1.06-1.38
rs7202472 84535002 Downstream 0.0050 0.0037 0.74 0.0036 5.7 x 10* 0.59 3.6 x 10* 9.7x10* 0.68 0.58-0.81
Table 4.6: Table o f results from all SNPs within IRF8 that had a minimum P-value < 0.05 in the whole GWAS sample. The results o f these SNPs in the UK and German 
samples are also shown. P-gen -  genotypic P-value; P-add -  additive P-value; OR - Odds Ratio o f the minor allele; Cl - confidence interval.
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Figure 4.5: LD plot and results o f SNPs in 1RF8 that were genotyped in the GWAS. Red bars denote P-values <0.05. The two most significant SNPs are not in high LD with
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Another gene with multiple SNPs in the top hits is C9orf5. These SNPs are 
rsl0123957 (P-min = 5.9 x 10'6) and rsl0816767 (P-min = 8.9 x 10'6)and are in 
complete LD with each other in the HapMap CEU population (r2 = 1, D ’ = 1). These 
SNPs both showed a higher level of significance in the UK sample (rsl 0123957: P-add 
= 1.9 x 10-4, OR = 1.36; rsl0816767: P-add = 5.9 x 10"4, OR = 1.33) than in the 
German sample (rsl0123957: P-add = 0.0071, OR = 1.35; rsl0816767: P-add = 0.0034, 
OR = 1.39). These SNPs had similar or higher effect sizes in the German sample, so as 
before, the higher level of significance is likely to be due to the larger size of the UK 
sample. Figure 4.6 and Table 4.7 show the other 7 SNPs in this region that have P- 
values < 0.05. Two of these SNPs are in LD with the two SNPs in the top 25 hits 
(rsl003346 P-min = 2.9 x 10‘5, r2 = 0.76 and D ’= \  with both rsl0123957 and 
rsl0816767; rsl537431 P-min = 2.6 x 104, r2 = 0.76 and D ’ = 1 with both rsl0123957 
and rsl0816767). These SNPs were also in LD with each other (D’ = 1), however the r2 
between them was low (r = 0.58). All of the SNPs in this region were more 
significantly associated in the UK sample than in the German sample, but in general 
their effect sizes were very similar in both samples so this is likely to be due to the 
power of each sample. Two SNPs that did have larger effect sizes in the UK sample 
were rs2271878 (UK sample: P-add = 2.7 x 104, OR = 1.38; German sample: P-add = 
0.42, OR = 1.10) and rs7879057 (UK sample: P-add = 2.2 x 104, OR = 1.38; German 
sample: P-add = 0.49 OR = 1.09).
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Figure 4.6: LD plot and results o f SNPs in C9orf5 that were genotyped in the GWAS. Red bars denote P-values <0.05. The two most significant SNPs are in perfect LD with
each other with an r2 = 1.
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UK Sample German Sample All Samples
SNP Position(bp)
Position
in
C9orf5
P-gen P-add OR P-gen P-add OR P-gen P-add OR 95% Cl
rs7776 110822351 3' UTR 0.0134 0.0722 0.84 0.4556 0.2108 0.85 0.0129 0.0318 0.85 0.73-0.99
rsl 0816767 110822490 3' UTR 0.0015 5.9 x104 1.33 0.0088 0.0034 1.39 1.8 x 10"8 8.9 x 1045 1.34 1.18-1.53
rsl 537431 110828048 Intron 16 0.0168 0.0046 0.79 0.0472 0.0132 0.75 0.0012 2.6 x 10*4 0.78 0.69-0.89
rsl 003346 110855160 Intron 12 0.0031 8.9 x 10"4 1.32 0.0080 0.0087 1.34 4.9 x 10 s 2.9 x 10 s 1.32 1.16-1.50
rsl 0123957 110900238 Intron 3 7.4 xIO’4 1.9 x 10"4 1.36 0.0134 0.0071 1.35 1.6 x10'5 5.9 xIO’6 1.35 1.19-1.54
rs2271878 110908705 Exon 3 0.0013 2.7 x 10"4 1.38 0.7072 0.4240 1.10 0.0028 6.4 x 10-4 1.28 1.11-1.47
rs7870597 110911684 Intron 1 0.0011 2.2 x 104 1.38 0.7657 0.4893 1.09 0.0031 6.4 x 10"4 1.28 1.11-1.47
rs2805888 110920556 Intron 1 0.1043 0.0396 0.81 0.1339 0.1466 0.82 0.0463 0.0141 0.82 0.70-0.96
rs6825 110921747 Exon 1 0.0136 0.0042 1.27 0.0541 0.0158 1.31 9.5 x 10"4 2.3 x 10-4 1.28 1.12-1.46
Table 4.7: Table of results from all SNPs within C9orf5 that had a minimum P-value < 0.05 in the whole GWAS sample. The results of these SNPs in the UK and German 
samples are also shown. P-gen -  genotypic P-value; P-add -  additive P-value; OR - Odds Ratio of the minor allele; Cl - confidence interval.
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4.3.2 Replication Study
A panel of 29 SNPs in the top hits based on their minimum P-values were chosen 
for genotyping in the replication sample. The nearest genes and positions of the SNPs 
relative to these genes are shown in Table 4.8. These SNPs were genotyped in the 
replication sample in which a total of 1244 cases and 1955 controls passed sample QC. 
Two of the SNPs failed the optimisation stage of the genotyping (see Table B.3 in 
Appendix). Of the remaining 27, all SNPs had a call rate > 80% and all had a MAF > 
0.05. Two SNPs were out of Hardy-Weinberg equilibrium in the controls (rs4887111, P 
= 0.011; rs958877, P = 0.002). These were not excluded from the association analyses 
but any association found with these SNPs should be treated with caution.
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SNP
Rank
in
GWAS
Proxy Chr Position(bp)
Closest
RefSeq
Gene
Position 
Relative to 
Gene
rsl 0513829 1 3 189971026 LPP Intronic
rs7840675 3 8 34075413 DUSP26 Intergenic
rs747783 5 11 15670131 SOX6 Intergenic
rsl 1117425 6 rsl 1648084 16 84529771 IRF8 Intergenic
rsl 0123957 8 9 110900238 C9orf5 Intronic
rsl 0518444 9 rs2271081 4 125945653 ANKRD50 Intergenic
rsl 0816767 10 rs7034615 9 110822490 C9orf5 3' UTR
rs4887111 12 15 71815337 LOC388135 Downstream
rs7202472 13 16 84535002 IRF8 Intergenic
rsl 181841 14 5 128580604 ISOC1 Intergenic
rs4327894 15 8 1740903 MIRN596 Intergenic
rs10512712 16 5 39728088 DAB2 Intergenic
rsl 429411 17 2 197852246 ANKRD44 Intronic
rs7623540 18 3 189972233 LPP Intronic
rs6136213 19 20 17798339 SNX5 Intergenic
rs4747165 20 10 72969307 CDH23 Intronic
rs9465637 23 rs13191158 6 20222086 MBOAT1 Intronic
rsl 003346 26 rsl 1792635 9 110855160 C9orf5 Intronic
rs6984900 27 8 128373450 POU5F1B Intergenic
rsl 872285 29 11 15621627 SOX6 Intergenic
rs902025 31 15 61019453 TLN2 Intergenic
rs6498274 35 16 12273876 SNX29 Intronic
rs7541094 40 1 68536861 WLS Intergenic
rs7411544 41 1 206428792 PLXNA2 Intronic
rs2077268 43 15 31661042 RYR3 Exonic
rs4940802 45 18 54861101 ZNF532 Intronic
rs958877 48 2 356409 FAM150B Intergenic
rs3821173 49 2 207186404 ADAM23 Intronic
rs905950 64 16 12265706 SNX29 Intronic
Table 4.8: Table showing all SNPs in the replication panel, their rank in the GWAS, their closest RefSeq 
gene and their position relative to that gene.
Table 4.9 shows the results of the logistic regression using country and centre as a 
covariate for both additive and genotypic tests. SNPs are listed in order of each SNP’s 
rank in the original GWAS. The minimum P-values for these SNPs in the replication 
sample alone ranged from 0.0066 to 0.9530, with only eight of the SNPs giving P- 
values < 0.05 (P-min = 0.0066 -  0.0444). The most significant of these is the SNP 
rsl0512712 on chromosome 5 (P-add = 0.0066, OR =1.15; P-gen = 0.0164). In the 
initial GWAS sample, this SNP had an additive P-value of 1.42 x 10'5 (OR = 1.33), 
ranking it as the 16 most significant hit. None of the SNPs achieved a high level of
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significant association in any of the sample groups individually, with only one SNP 
with P-values < 0.05 in more than one sample group, although showing the opposite 
direction of effect (rs7202472: German sample additive P = 0.019, OR =1.31, Austrian 
sample additive P = 0.048, OR = 0.66) as shown in Table B.4 of the Appendix. It is 
clear that in the replication sample, these SNPs did not approach the level of significant 
association that was seen in the GWAS.
The genotypes for these SNPs when genotyped in the replication sample were 
combined with the genotypes from the discovery GWAS sample, making a total of 1828 
cases and 4274 controls which passed QC. The results from the logistic regression 
analyses on this combined sample are shown in Table 4.9.
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GV/AS Sample Replication Sample Whole Sample
SNP
Rank
in
GWAS
Proxy P-gen P-add OR P-gen P-add OR P-gen P-add OR 95% Cl
rsl 0513829 1 1.98 x 1 0 7 1.2 x10'7 0.68 0.7363 0.5533 1.03 0.0154 0.0111 0.90 0.83-0.98
rs7840675 3 4.75 x10* 8.11 x 10'* 1.67 0.9631 0.9530 0.99 0.0131 0.0033 1.21 1.07-1.38
rs747783 5 1.12x10* 1.78x10* 1.41 0.2723 0.1685 1.09 2.25x10* 4.23 x 10* 1.20 1.10-1.31
rsl 1117425 6 rsl 1648084 8.78 x 10* 3.12x10* 0.71 0.8594 0.6041 1.03 0.0163 0.0070 0.89 0.82-0.97
rsl 0123957 8 1.61 x 10* 5.88 x 10* 1.35 0.3077 0.1282 0.93 0.2955 0.1459 1.06 0.98-1.14
rs10518444 9 rs2271081 3.66 x 10* 7.89x10* 1.67 0.1481 0.3085 0.90 0.1056 0.0413 1.16 1.01-1.35
rs10816767 10 rs7034615 1.85x10* 8.88x10* 1.34 0.4168 0.1860 0.93 0.2681 0.1558 1.06 0.98-1.14
rs4887111 12 2.46 x 10* 9.32x10* 0.73 0.9126 0.9774 1.00 0.0072 0.0022 0.88 0.81-0.96
rs7202472 13 3.64 x 10* 9.67 x 10* 0.68 0.0682 0.0280 1.15 0.4116 0.1898 0.94 0.85-1.03
rsl 181841 14 6.22 x 10* 1.11 x 10* 1.34 0.7085 0.9030 0.99 0.0446 0.0200 1.10 1.02-1.20
rs4327894 15 5.39 x 10* 1.41 x 10* 0.70 0.8580 0.9513 1.00 0.0408 0.0114 0.89 0.81-0.97
rs10512712 16 8.24 x 10* 1.42 x 10* 1.33 0.0164 0.0066 1.15 1.79x10* 3.78 x 10* 1.20 1.11-1.30
rsl 429411 17 1.57x10* 7.79 x 10* 0.80 0.5838 0.3489 0.95 0.0017 0.0018 0.88 0.81-0.95
rs7623540 18 9.02 x 10* 1.59x10* 1.36 0.9644 0.7888 0.98 0.0453 0.0183 1.12 1.02-1.22
rs6136213 19 4.06 x 10* 1.61 x 10* 0.72 0.0832 0.0413 1.12 0.7208 0.4265 0.97 0.89-1.05
rs4747165 20 7.71 x 10* 2.10x10* 1.32 0.0294 0.5281 1.03 1.63x10* 5.77 x 10* 1.15 1.06-1.24
rs9465637 23 rsl 3191158 2.43 x 10* 0.0125 0.84 0.1269 0.0444 0.90 4.00 x 10* 0.0028 0.88 0.82-0.96
rsl 003346 26 rsl 1792635 4.88 x 10* 2.91 x 10* 1.32 0.3857 0.1675 0.93 0.2606 0.1674 1.06 0.98-1.14
rs6984900 27 9.32 x 10* 2.93 x 10* 0.68 0.6355 0.3469 0.94 0.0038 0.0010 0.84 0.76-0.93
rsl 872285 29 1.74x10* 3.17x10* 1.38 0.4199 0.3404 1.06 0.0018 4.95 x 10* 1.18 0.08-1.30
rs902025 31 3.27 x 10* 0.0077 0.78 0.7487 0.4531 1.06 0.0186 0.1302 0.92 0.83-1.03
rs6498274 35 2.46 x 10* 4.47 x 10* 1.31 0.0566 0.0169 1.14 1.32x10* 2.65 x 10* 1.19 1.10-1.28
rs7541094 40 5.37 x 10* 2.15x10* 1.27 0.6017 0.3136 1.05 0.0025 0.0013 1.13 1.05-1.23
rs7411544 41 3.02x10* 5.84 x 10* 1.31 0.0109 0.6942 0.98 0.0097 0.0226 1.10 1.01-1.19
Table 4.9: Comparison of results for the SNPs in the replication panel when genotyped in the GWAS sample, the replication sample and in the total sample. Significant P- 
values (P < 0.05) are in bold. P-add -  additive P-value; P-gen -  genotypic P-value; OR -  odds ratio; Cl -  confidence interval.
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GWAS Sample Replication Sample Whole Sample
SNP Rank in GWAS Proxy P-gen P-add OR P-gen P-add OR P-gen P-add OR 95% Cl
rs2077268 43 2.62 x KT4 6.09 x 10'* 0.60 Failed Optimisation
rs4940802 45 1.45 x 10-4 6.13 x10‘5 0.58 Failed Optimisation
rs958877 48 3.26 X10-4 6.42 x 10 s 1.30 0.1273 0.1101 0.92 0.4726 0.2525 1.05 0.97-1.13
rs3821173 49 1.20 x 10"4 6.47 x 10'* 0.76 0.7360 0.8729 1.01 0.0119 0.0231 0.91 0.84-0.99
rs905950 64 5.19 x 10-4 9.86 x 10 s 1.30 0.0446 0.0134 1.14 2.04 x 10-4 4.52 x 10'5 1.18 1.09-1.28
Table 4.9 continued
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In this large combined sample, none of the SNPs in the replication panel showed 
genome-wide levels of significant association with DD. However, 3 SNPs showed a 
higher level of significance in the whole sample than they had in the initial GWAS 
sample. These are rs l0512712 (GWAS sample minimum P = 1.42 x 10'5; replication 
sample minimum P = 0.0066; whole sample minimum P = 3.78 x 10'6) , rs6498274 
(GWAS sample minimum P = 4.47 x 10‘5; replication sample minimum P = 0.0169; 
whole sample minimum P = 2.65 x 10"5) and rs905950 (GWAS sample minimum P = 
9.86 x 10'5; replication sample minimum P = 0.0134; whole sample minimum P = 4.52 
x 10*5). These 3 SNPs showed the same direction of effect in both the GWAS and 
replication sample, but a number of other SNPs in this replication panel showed a 
different direction of effect in the two samples. The SNP rsl 0512712 is in an intergenic 
region on chromosome 5, 260kb upstream of the nearest gene which is disabled 
homolog 2, mitogen-responsive phosphoprotein (DAB2). The other two SNPs are in 
perfect LD with each other in the CEU HapMap population (r2 = 1, D ’ = 1) and are both 
within intron 7 of the gene sorting nexin 29 (SNX29) on chromosome 16, as shown in 
Figure 4.7. 25 other SNPs in this gene had P-values < 0.05 in the GWAS study but were 
not in the replication panel of SNPs. These are shown in Table 4.10. Many of these 
SNPs are not in LD with the most significant SNP in this gene, but are not independent 
of each other, as shown by the LD blocks in Figure 4.7.
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Figure 4.7: LD plot and results o f SNPs in SNX29 that were genotyped in the GWAS. Red bars denote P-values <0.05. The two most significant SNPs are LD with each
other.
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LD with rs6498274
SNP Position (bp) P-gen P-add OR 95% Cl D ’
rs6498274* 12273876 2 .4 6 x 1 0'4 4.47 x 10'5 1.31 1.15-1.50 1 1
rs830727 12217285 3 .50x1  O'4 6.77 x 10'5 1.30 1.14-1.48 0.506 0.905
rs905950 12265706 5.19 x10 '4 9 .86x1  O'5 1.30 1.14-1.48 1 1
rs7195058 12252684 0.0011 2.16 X10"4 1.28 1.12-1.46 0.759 0.88
rs7191435 12270535 0.0029 0.0012 1.25 1.09-1.42 0.756 0.896
rs4781236 12432914 0.0067 0.0016 0.81 0.71-0.92 0.15 0.654
rs4781223 12399254 0.0073 0.0021 0.82 0.72-0.93 0.172 0.67
rs7201310 12421297 0.0029 0.0022 1.24 1.08-1.41 0.405 0.663
rsl 704147 12142377 0.0106 0.0027 1.23 1.07-1.41 0.066 0.259
rs2941081 12221951 0.0139 0.0038 1.21 1.06-1.38 0.442 0.717
rs209836 12331057 0.0172 0.0044 1.21 1.06-1.37 0.604 0.954
rs4781209 12357278 0.0160 0.0047 1.21 1.06-1.37 0.675 0.956
rs4781214 12369368 0.0172 0.0049 1.20 1.06-1.37 0.502 0.975
rs709423 12212118 0.0114 0.0050 1.40 1.11-1.76 0.057 0.573
rs8043724 12397838 0.0111 0.0053 1.21 1.06-1.37 0.322 0.6
rs209835 12332132 0.0213 0.0059 1.20 1.05-1.36 0.569 0.976
rsl 2599107 12146102 0.0227 0.0067 1.26 1.07-1.49 0.112 0.651
rs2432625 12384723 0.0269 0.0071 1.19 1.05-1.36 0.262 0.697
rs6498294 12417371 0.0202 0.0078 1.19 1.05-1.36 0.269 0.665
rs209834 12334145 0.0278 0.0079 1.19 1.04-1.35 0.522 0.951
rsl 035579 12438659 0.0296 0.0092 0.84 0.74-0.96 0.155 0.621
Table 4.10: SNPs within SNX29 that had a minimum P-value < 0.05 in the GWAS and their LD with the most significant SNP. * These SNPs were genotyped in the 
replication sample. P-gen -  genotypic P-value, P-add -  additive P-value, OR -  Odds ratio, Cl -  confidence interval.
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LD with rs6498274
SNP Position (bp) P-gen P-add OR 95% Cl /* D'
rs830733 12250472 0.0149 0.0132 1.19 1.04-1.37 0.409 0.734
rs7205270 12427699 0.0184 0.0178 1.18 1.03-1.36 0.403 0.675
rs8048462 12441121 0.0202 0.0434 1.14 1.00-1.30 0.201 0.517
rs7188465 12450174 0.0576 0.0240 0.86 0.75-0.98 0.098 0.599
rs4353467 12629947 0.0325 0.0658 0.88 0.78-1.01 0.013 0.155
rsl 472979 12206734 0.0419 0.0643 0.85 0.72-1.01 0.054 0.673
Table 4.10 continued
4.3.3 Results of Candidate Genes in GWAS
The results of the SNPs within previous candidate genes for DD and for those genes 
that were investigated in Chapter 3 of this thesis were extracted from the GWAS data 
for comparison. Table B.5 of the Appendix show the results of these SNPs in the whole 
GWAS sample, in the UK sample alone and in the Cardiff case-control sample if they 
were genotyped as part the candidate gene study. Only one SNP within KIAA0319 gave 
a P-value < 0.05 (rs2817200, P-add in UK sample = 0.0092, OR = 0.80). This SNP is in 
a high level of LD with the SNP rs4504469 (r2 = 0.90, D ’ = 0.96) which has shown 
association with DD in a number of previous studies (Francks et al. 2004; Cope et al. 
2005a; Paracchini et al. 2008). This SNP was not significant in the whole GWAS 
sample (P-add = 0.057, OR = 0.88). Three other SNPs in KIAA0319 that have shown 
significant association with DD previously were all in LD with the SNP rs3756819 
(rsl061925, ^ = 0 .72 , D ’= 1; rs9461045, r* = 0.76, D ’= 1; rs2143340, 1 ,D ’= 1).
This SNP was not significant in the GWAS (P-gen = 0.549, P-add = 0.955, OR =1.01) 
(see Table B.6 of Appendix). The SNPs on the Illumina HumanHap300 array provide 
48% coverage of this gene at an r2 > 0.8 based on phase II of HapMap.
A number of SNPs in DCDC2 showed significant association (see Table B.5 of the 
Appendix). The array provides 77% coverage of the SNPs within this gene. The most 
significant of these SNPs was rs4712804 with an additive P-value of 3.66 x 10"4 in the 
whole sample. This SNP is not in a high level of LD with any previously associated 
SNPs in DCDC2 (r2 < 0.8). However, 2 SNPs show high levels of LD with the SNP 
rs807701, which was previously shown to be significantly associated with DD in the 
German sample as part of a haplotype with rs793862 (Schumacher et al. 2006a). The 
SNPs in high LD with rs807701 are rs870601 (r2 = 0.89,D ’= 1) and rs2274305 (r2 = 
0.93, D ’ = 0.96) and in the GWAS these SNPs had additive P-values of 0.0051 (OR = 
1.21) and 0.0041 (OR = 1.22), respectively. These two SNPs are also in high LD with 
each other (r2 = 0.82, D ’ = 0.96). Another significant SNP in DCDC2 (rs9295619: P- 
add = 0.0051, OR = 1.21) is also in LD with rs807701 (r2 = 0.72, D ’= 1). This SNP is 
also in LD with the previous two SNPs (D ’ > 0.96) but the correlation between these 
SNPs is low (r2 < 0.7). The SNP rs807724 which has also shown previous association 
with DD in DCDC2 (Meng et al. 2005b) was in complete LD with rs2792682 (r2 = 1, 
D ’= 1), but this SNP was not significant in the GWAS (P-gen = 0.32, P-add = 0.15,
OR = 1.12) (see Table B.6 of Appendix).
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One SNP within DYX1C1 (of which 68% is covered by the array) showed 
marginally significant association with DD in the UK sample (rs3759864, P-add = 
0.0456). This SNP was not in high LD with SNPs in these genes that have shown 
association with DD in these genes previously (r2 < 0.8). Three SNPs in DYX1C1 that 
have shown association with DD recently (Dahdouh et al. 2009; Bates et al. 2009) were 
genotyped directly in this GWAS, but none of these were significantly associated 
(rs3743204, P-add = 0.48, OR = 1.06; rs600753, P-add = 0.65, OR = 0.97; rs685935 P- 
add = 0.92, OR =1.01). Another two SNPs in DYX1C1 that have shown association 
with DD (Taipale et al. 2003; Wigg et al. 2004; Marino et al. 2007; Dahdouh et al. 
2009) are in LD with SNPs in this GWAS (see Table B.6 of Appendix). These were 
rs3743205, which is in LD with rs7181226, (r2 = 0.614, D ’ = 1) andrsl7819126, which 
is in LD with rsl 1857829 (r2 = 1, D ’ = 1). Neither of these SNPs were significantly 
associated in this GWAS (rs7181226: P-add = 0.68, OR =1.05; rsl 1857829: P-add = 
0.61, OR =1.07).
No other SNPs in the other DD candidate genes showed a significant association in 
the GWAS. Those SNPs that were typed in the candidate gene study and were not 
found to be associated in the case control sample (see Chapter 3) were not significantly 
associated with DD in the GWAS sample either.
4.3.4 Results of Main DYX  Linkage Regions in GWAS
The results of those SNPs within the main DYX linkage regions were extracted from 
the GWAS data and Manhattan plots were produced for each region as shown in Figure 
4.8 to Figure 4.15 (see Chapter 1 for more information on these regions). All of these 
regions have a large number of SNPs with P-values < 0.05 as would be expected by 
chance. For example, the DYX1 region had 68 SNPs with P-values < 0.05. 1767 SNPs 
were tested in this region, so 88 SNPs would be expected to have P-values < 0.05 by 
chance. DYX5 is the only locus that harbours a SNP with an additive P-value < 5 x 10‘5 
(rs6796074: P-add = 4.8 x 10'6, OR = 1.45). After correcting for the number of 
independent SNPs in this region using the SET based analysis, this SNP had a P-value 
of 0.008 and the product of the P-values in this region was 0.007 (see Table B.7 of the 
Appendix). The SNP rs6796074 lies within an intergenic region towards the edge of 
DYX5, 117kb downstream from the nearest gene LOCI 52225. No other SNPs in the
linkage regions were significant after correcting for the number of SNPs in the regions.
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However, DYX3 and DYX4 both had significant product of P-values (P = 0.016 and 
0.041, respectively). This indicates that these regions are likely to contain multiple 
independent signals of modest effect, rather than a single marker of strong effect.
Results of GWAS SNPs Within The DYX1 Region
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Figure 4.8: Manhattan plots o f the additive (P-add) P-values from the logistic regression analyses o f  
SNPs in the GWAS within the DYX1 region when using country as a covariate. The blue line indicates a 
P-value o f 0.05 and the red line indicates a P-value o f 5 x 10‘5. The arrows show the positions of the DD 
candidate genes in this region, DYX1C1 and PRTG.
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Results of GWAS SNPs Within The DYX2 Region
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Figure 4.9: Plots o f the additive (P-add) P-values from the logistic regression analyses o f SNPs in the 
GWAS within the DYX2 region when using country as a covariate. The blue line indicates a P-value o f 
0.05 and the red line indicates a P-value o f 5 x 10'5. The arrows show the positions o f the DD candidate 
genes in this region, DCDC2 and KIAA0319.
Results of GWAS SNPs Within in DYX3 Region
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Figure 4.10: Plots o f the additive (P-add) P-values from the logistic regression analyses of SNPs in the 
GWAS within the DYX3 region when using country as a covariate. The blue line indicates a P-value o f 
0.05 and the red line indicates a P-value o f 5 x 10'5.
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Figure 4.11: Plots o f the additive (P-add) P-values from the logistic regression analyses o f SNPs in the 
GWAS within the DYX4 region when using country as a covariate. The blue line indicates a P-value o f 
0.05 and the red line indicates a P-value o f 5 x 10'5.
Results of GWAS SNPs Within the DYX5 Region
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Figure 4.12: Plots o f the additive (P-add) P-values from the logistic regression analyses o f SNPs in the 
GWAS within the DYX5 region when using country as a covariate. The blue line indicates a P-value o f 
0.05 and the red line indicates a P-value o f  5 x 10'5. The arrow shows the position o f the DD candidate 
gene in this region, ROBOl.
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Results of GWAS SNPs Within the DYX6 Region
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Figure 4.13: Plots o f the additive (P-add) P-values from the logistic regression analyses o f SNPs in the 
GWAS within the DYX6 region when using country as a covariate. The blue line indicates a P-value o f 
0.05 and the red line indicates a P-value o f  5 x 10'5.
Results of GWAS SNPs Within the DYX7 Region
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Figure 4.14: Plots o f the additive (P-add) P-values from the logistic regression analyses o f SNPs in the 
GWAS within the DYX7 region when using country as a covariate. The blue line indicates a P-value o f 
0.05 and the red line indicates a P-value o f  5 x 10‘5.
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Results of GWAS SN Ps Within the DYX8 Region
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Figure 4.15: Plots o f the additive (P-add) P-values from the logistic regression analyses o f SNPs in the 
GWAS within the DYX8 region when using country as a covariate. The blue line indicates a P-value o f 
0.05 and the red line indicates a P-value o f 5 x 10'5. The arrows show the positions o f the DD candidate 
gene in this region, CDC42, DCDC2b and KIAA0319L.
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4.4 Discussion
This is the first GWAS to be carried out on DD, with 297,650 SNPs genotyped in 
585 cases and 2326 controls. The power of this sample to detect a significant 
association at the 0.05 level with loci that have effect sizes of the same magnitude to 
those commonly observed in complex traits (i.e. OR between 1.2 and 1.5 (WTCCC 
2007)) is modest. It has 98% power to detect a significant association (P < 0.05) with a 
variant that has a MAF of 0.4 and an OR of 1.3. However, to detect an association at P 
< 1 x 1CT4 (i.e. the level of significance for the SNPs selected in the replication panel), 
the power drops substantially to 54%. Therefore it is perhaps unsurprising that none of 
the SNPs showed significant association at the genome-wide significance level. Despite 
this lack of power, a number of SNPs showed suggestive significance with P-values less 
than 5 x 10'5 in the whole sample. The majority of the top hits showed a higher level of 
significance in the UK sample alone compared to the German sample. As the effect 
sizes of the top hits are generally similar in each of the two samples, the higher level of 
significance observed in the UK subset is likely to have been due to the larger size of 
this sample. This sample alone has 90% power to detect a significant association (.P < 
0.05) with a variant that has a MAF of 0.4 and an OR of 1.3, while the German sample 
has 65% power.
Three genes had multiple hits within the SNPs that had P-values < 5 x 10‘5. LPP had 
two SNPs in the top 25 hits, which were significantly associated in the whole sample, as 
well as in the UK and German samples individually. This gene is on chromosome 3 and 
is thought to play a structural role at sites of cell adhesion in maintaining cell adhesion 
and motility (Petit et al. 2000), but is only expressed at very low levels in the brain. 
Another two SNPs in the top hits lie just outside of IRF8; this gene is on chromosome 
16 and is a transcription factor of the interferon (IFN) regulatory factor (IRF) family 
(Weisz et al. 1992). The IRF family of proteins control expression of IFN-a and IFN-0- 
regulated genes that are induced by viral infection and so play regulatory role in cells of 
the immune system. This gene is predominantly expressed in lymphoid tissues. The 
other gene with multiple hits is C9orf5 on chromosome 9. The function of this gene is 
unknown, but it is highly expressed in the brain, especially in fetal brain tissue and the 
hypothalamus. Based on what is known about the functions of these genes, they do not
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appear to be obvious candidates for DD, however they cannot be discounted and may be 
involved in biological processes that have not yet been linked to DD.
In an attempt to replicate the findings of the initial GWAS, 27 SNPs were selected 
from the top hits (P-min < 5 x 10-4) and were genotyped in a large independent sample 
consisting of 1244 cases and 1955 controls. This sample had 100% power to detect a 
significant association (P < 0.05) with a variant that has a minor allele frequency of 0.4 
and an odds ratio of 1.3, and 88% power to detect association with the same variant at P 
< 1 x 10"4. When genotyped in the replication sample, none of the SNPs approached the 
same level of significant association seen in the initial GWAS. 19 of these SNPs were 
not significant at the 0.05 level. This is often seen in GWAS and is thought to be caused 
by an overestimation of effect sizes of the variants in the original study in comparison to 
their effect sizes observed in the follow up study. This is referred to as the ‘winner’s 
curse’ and can result in a failure to replicate the initial results (Ioannidis 2008). 11 SNPs 
had smaller effect sizes and the remaining 16 showed a different direction of effect in 
the replication sample. This suggests that many of the top hits in the initial GWAS were 
actually false positives arising out of chance due to the large number of SNPs tested 
rather than due to the presence of a true association. This finding highlights the need to 
adopt stringent P-value cut offs when selecting SNPs for follow up in order to reduce 
the chance that they are false-positives. This in turn demonstrates the requirement for 
large, well-powered studies in order to achieve these highly significant associations in 
the initial GWAS.
Combining the GWAS and replication samples produced a total of 1828 cases and 
4274 controls, providing 100% power to detect an association with a variant that has a 
MAF of 0.4 and an OR of 1.3 at the 0.05 significance level and 99% power at the 1 x 
1CT4 level of significance. Combining both samples resulted in an increase in 
significance for 3 SNPs compared to the initial GWAS study. The most significant of 
these was rs10512712 which is in an intergenic region on chromosome 5, with the 
nearest gene being DAB2 over 260kb away. The next two SNPs to show an increased 
significance in the whole sample were rs6498274 and rs905950 which are in complete 
LD with each other and are both within the gene SNX29. Not much is known about the 
function of this particular gene, but it is ubiquitously expressed and is a member of the 
sorting nexin family. Members of this family contain phosopholipd-binding motifs (PX 
domains) and are thought to facilitate membrane trafficking and protein sorting (Worby
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& Dixon 2002). PX domains have also been found in yeast proteins that are involved in 
cell polarity (Ago et al. 2001), which could suggest a possible link for this gene in 
neuronal migration. However, the PX domains in the nexin family of proteins evolved 
independently from other PX domains (Teasdale et al. 2001) and are therefore likely to 
have unique cellular functions.
The results of this GWAS were compared with previous findings in DD. Only one 
SNP (rs2817200) within the DD candidate gene KIAA0319 showed marginal 
significance in the UK sample. Interestingly, this SNP is in high LD with rs4504469 (r2 
= 0.90), which was previously found to be associated with DD in 3 independent UK 
samples (Francks et al. 2004; Cope et al. 2005a; Paracchini et al. 2008), as presented in 
Chapter 1. Two of these samples overlap with the Oxford (Francks et al. 2004) and 
Cardiff (Cope et al. 2005a) samples used in this GWAS and so the significant 
association of rs2817200 in the UK sample of the GWAS cannot be regarded as an 
independent replication. This SNP was not significant in the German subset. The 
sample used in the study by Paracchini and colleagues (2006) was independent of this 
GWAS and was unselected for reading ability. Three other SNPs in this gene that have 
shown association with DD previously (Francks et al. 2004; Cope et al. 2005a; Luciano 
et al. 2007; Paracchini et al. 2008; Dennis et al. 2009; Couto et al. 2010) were in LD 
with the SNP rs3756819 which was genotyped in this GWAS but was not significant. 
Two of the previously associated SNPs, rsl061925 and rs2143340 have shown previous 
association in UK samples that share some overlap with the UK case sample in this 
GWAS. Both of these SNPs were significantly associated in the UK sample used by 
Francks and colleagues, particularly with measures of orthographic choice. Cope and 
colleagues (2005a) also found significant association with rs2143340 in a subset of this 
UK case sample as part of a haplotype that spans KIAA0319 and TTRAP. However, 
these studies used screened controls, whereas this GWAS used population controls and 
this may explain why rs3756819 did not show significant association with DD despite 
being in LD with these previously associated SNPs. Just 48% of KIAA0319 was covered 
by the SNPs on the array and so even though none of the SNPs in this gene achieved 
genome-wide significance in this study, it still remains a plausible candidate gene for 
DD.
A number of SNPs in DCDC2 showed significant association in both the UK and 
the whole GWAS sample. The most significant SNP in DCDC2 was rs4712804, which
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has not shown significant association with DD in any previous studies, nor is it in LD 
with any previously associated SNPs in DCDC2. However, three of the SNPs that 
showed a significant association (namely rs2274305, rs870601 and rs9295619) are in 
LD with rs807701 which was previously shown to be significantly associated with DD 
in the German sample as part of a haplotype with rs793862 (Schumacher et al. 2006a). 
Interestingly, this SNP was also tested for association in the Cardiff cases and a severe 
subset of the Oxford cases in a previous study (Harold et al. 2006) but was not 
significantly associated with DD. All three SNPs in LD with rs807701 showed nominal 
levels of significant association with DD in the UK sample alone of this GWAS (P > 
0.02), which may have been down to chance due to the large number of SNPs tested or 
may be because of the increased power of this GWAS as a result of the large population 
control sample. Of all the replicated candidate genes for DD, DCDC2 showed the most 
association with DD in this GWAS. This may have been because the SNPs on the 
Illumina HumanHap300 array cover this gene more densely than either of the genes 
KIAA0319 or DYX1C1.
None of the SNPs in the genes that were tested for association in Chapter 3 of this 
thesis were significant in the GWAS. The Cardiff case sample in the GWAS overlaps 
with the cases that were genotyped in the candidate gene studies, and even though these 
genes were not as well covered in the GWAS, this backs up the previous findings that 
none of these genes appear to be significantly associated with DD.
A large number of SNPs across all of the DYX susceptibility loci that were 
genotyped in this GWAS were significant at P < 0.05 level, as would be expected by 
chance. However, one SNP showed a P-add value < 5 x 10’5, which was still significant 
after correcting for the number of SNPs tested in this region (corrected P = 0.0080). The 
SNP rs6796074 lies within an intergenic region towards the edge of DYX5, 129kb away 
from D3S3665 which was found to be linked with DD in one of the first studies that 
showed evidence for linkage in DYX5 (Nopola-Hemmi et al. 2001). None of the other 
regions had significant P-values after correcting for the number of SNPs tested, 
however DYX3 and DYX4 both had significant product of P-values (DYX3 P = 0.016; 
DYX4 P = 0.041) suggesting that these regions may contain multiple susceptibility 
variants of weak effect rather than a single variant of strong effect.
The only similar GWAS that has been carried out previously was that by Meabum 
and colleagues (2008) using the TEDS cohort. None of the 65 most significant SNPs in
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this particular GWAS were in their 300 most significant SNPs which may have been 
due to the difference in the genotyping platforms used in each study.
This GWAS was limited by the size of the SNP array that was used. The Illumina 
HumanHap300 array has been estimated to cover 76% of the genome in the CEU 
population (based on Phase II of the HapMap project) (Magi et al. 2007), and therefore 
it is possible that some susceptibility variants for DD were missed. The coverage of 
some of the previously associated DD candidate genes such as KIAA0319 was even 
lower than this. In addition, this study was under-powered to detect susceptibility 
variants due to the size of the sample. Despite employing a two-stage design and 
forming collaborations with other groups as well as using population controls to 
substantially increase the sample, this GWAS was still under-powered to detect SNPs 
that have small effect sizes (which are commonly observed in complex traits such as 
DD) with a genome-wide level of significance.
Future work for this GWAS could include carrying out imputation to highlight 
additional susceptibility variants for follow up, and pathway analysis (e.g. testing for 
over-representation of gene ontology (GO) categories amongst the most significantly 
associated SNPs) could be used to identify interesting gene networks which should be 
prioritised for investigation. The increase in significance of the SNPs in the 
chromosome 5 intergenic region and within the SNX29 gene in the whole sample also 
warrants further investigation. The latter in particular could be fine mapped in order to 
identify any functional variants, or it could be sequenced in a number of DD cases to 
identify novel common variants.
In conclusion, this GWAS has not found any new convincing susceptibility variants 
for DD. While some SNPs showed a high level of significance and some SNPs within 
previously associated regions were significant, none achieved genome-wide 
significance. Larger sample sizes and larger arrays need to employed in order to 
improve the chances of identifying convincing susceptibility variants for this complex 
disease.
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Chapter 5: NeuroDys Genome-wide Pooling 
Study
5.1 Introduction
As discussed in Chapter 4, GWAS of complex diseases require large sample sizes in 
order to be powerful enough to detect genome-wide significant levels of association. 
One approach to reducing the cost, time and labour involved in performing a GWAS is 
to pool DNA samples into case and control pools (Kirov et al. 2006; Docherty et al. 
2007; Macgregor et al. 2008). This commonly involves combining equal amounts of 
DNA from each sample to form pools containing cases and controls. Alternatively, 
individuals with trait values at the two extremes of a quantitative trait can also be 
pooled into two samples (Sham et al. 2002). These pools are then genotyped to estimate 
the difference in allele frequency for each variant. The results from these pooling 
studies are then used to select a smaller number of SNPs to be genotyped in the samples 
individually and tested for association with a particular disease at a fraction of the cost 
of a typical GWAS (Sham et al. 2002; Norton et al. 2002). For example, the allele 
frequencies in a sample of 500 cases and 500 controls can be measured from two pooled 
samples, rather than by genotyping 1000 samples, which represents an increase in 
efficiency of 500-fold (Sham et al. 2002). However, in order to achieve accurate 
estimates of allele frequencies, most studies run replicates of the pooled samples and so 
this increase in efficiency would be closer to 100-fold (based on 5 replicates of each 
pool being genotyped).
Unfortunately, this increase in efficiency is achieved at the cost of detailed 
information that could have been obtained through individual genotyping (Sham et al. 
2002) and a loss in statistical power due to imprecise estimates of allele frequencies 
(Barratt et al. 2002). Pooling studies are subject to experimental errors that do not apply 
to individual genotyping and which result in an overall variance in the allele frequency 
estimation. Quantitative errors can be introduced during the formation of the pools, due 
to inaccuracies in PCR reactions and also during allele frequency estimation (Barratt et 
al. 2002). However, these errors can be taken into account during association analysis 
by using an appropriate test, such as the combined Z-test (Sham et al. 2002). Further
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information is lost because haplotypes cannot be constructed and epistasis and heterosis 
cannot be studied (Norton et al. 2002). In addition, when using pooled samples to study 
quantitative traits, even more information is lost because within-pool differences cannot 
be explored (Sham et al. 2002). However, these issues may be offset in part by the 
ability to test many more SNPs than would be feasible if genotyping the same number 
of samples individually (Norton et al. 2002). In order to reach a compromise between 
the cost savings of a pooling study and the full information that is provided by 
individual genotyping, pooling studies are often conducted using a two-stage design in 
which SNPs that show a significant association in a pooling study are then followed up 
with individual genotyping.
Several genome-wide pooling studies have been published which have been 
successful in either identifying new susceptibility loci for diseases or replicating 
previously known loci (Melquist et al. 2007; Steer et al. 2007; Stokowski et al. 2007; 
Abraham et al. 2008; Kirov et al. 2008; Shifman et al. 2008), providing proof of 
principle that DNA pooling can provide an effective alternative to a large and expensive 
GWAS. For example, in an Alzheimer’s disease (AD) case-control pooling study using 
the Illumina HumanHap 300 and Illumina Sentrix HumanHap240S arrays carried out by 
Abraham and colleagues (2008), APOE showed the most significant association with 
AD. The association of this locus with the late-onset form of AD has been well 
replicated in studies previously (Saunders et al. 1993; Farrer et al. 1995; Coon et al. 
2007) and has also shown the most significant association with AD in more recent 
genome-wide studies of Alzheimer’s disease (Harold et al. 2009; Lambert et al. 2009; 
Seshadri et al. 2010). A genome-wide pooling study of schizophrenia by Kirov and 
colleagues (2009) also illustrated that Illumina arrays can provide highly reproducible 
results. They used a parent-offspring trios design to screen SNPs on the Illumina 
HumanHap550 array and identified a significant SNP within RBP1. This gene inhibits 
PI3K/Akt signalling (Farias et al. 2005) and genes in this pathway have been implicated 
in schizophrenia pathogenesis (Kalkman 2006).
171
5.1.2 Aims
As significant SNPs in the initial NeuroDys GWAS did not show strong evidence of 
replication in the follow-up sample (see Chapter 4), the aim of this section of the thesis 
was to undertake another GWAS which would test a much larger number of SNPs for 
an association with DD. Since the initial GWAS was undertaken, Illumina released the 
HumanlM-Duo array which allows nearly 1.2 million markers to be genotyped, 
capturing 95% of the common variation in the HapMap CEU population at an t L> 0.8 
(InfiniumHD Data Sheet, www.illumina.com), whereas the Illumina HumanHap 300 
array has been estimated to cover just 76% of the genome in the CEU population (based 
on Phase II of the HapMap project) (Magi et al. 2007). Therefore, the Illumina 
Human lM-Duo array was selected for this GWAS and as Illumina arrays have been 
shown to produce reliable results when using pooled DNA (Abraham et al. 2008; Kirov 
et al. 2009), this study was undertaken using pooled DNA samples to reduce the cost.
As discussed above, pooling studies can only provide estimates of allele frequencies so 
selected SNPs were followed up with individual genotyping in an attempt to confirm the 
findings. In addition, the results of this pooling study were compared with the initial 
GWAS in order to ascertain the concordance between the two.
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5.2 Methods
5.2.1 NeuroDys Pooling Study
5.2.1.1 Pooled Samples
Samples from the NeuroDys replication sample (see Chapter 4) were combined to 
form 3 case pools and 3 control pools corresponding to different geographical locations 
as shown in Table 5.1. This sample is referred to as the NeuroDys pooling sample from 
now on. Only those samples that had a call rate > 98% in the replication panel of SNPs 
and which had sufficient DNA available were included.
Country/Centre Case Pool Control Pool
UK NeuroDys Pool: 461 219
Cardiff 187 219
Oxford 274 0
Central European NeuroDys Pool: 532 912
Bonn 196 400
Munich 104 188
Switzerland 25 40
Netherlands 100 103
Austria 107 181
Finnish NeuroDys Pool 286 321
Total 1279 1452
Table 5.1: Samples from the replication sample that were pooled to form 3 pooled sample sets; UK, 
Central European and Finnish.
The UK NeuroDys pool was constructed at the University of Cardiff, the Central 
European NeuroDys pool was constructed at the University of Bonn and the Finnish 
pool was constructed at the University of Jyvaskyla (see Chapter 2 for method). After 
construction, the concentration of the UK pools was 10ng/pl so they were concentrated 
using Microcon tubes (see Chapter 2 for method) and subsequently diluted to a 
concentration of 50ng/pl. To test the accuracy of the pool construction, primers for the 
SNPs rsl 1648084 and rs1892577 from the GWAS replication panel of SNPs were 
designed using primer 3 software (http://ffodo.wi.mit.edu/primer3/) and the extension 
primers were designed using FP PRIMER 1.0.1b
(http://m034.pc.uwcm.ac.uk/FP_Primer.html) (see Table C.l of the Appendix for 
primer sequences). These were then used to genotype the case and control pools using 
the SNaPshot method in order to estimate the allele frequencies for these SNPs (see 
Chapter 2 for method). The estimated differences in allele frequencies between the case
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and control pools for these SNPs were then compared to the actual differences in allele 
frequencies when the pooled samples were genotyped individually.
5.2.1.2 Genotyping
Genotyping was performed using the Illumina Human lM-Duo chip at the 
University of Bonn according to the manufacturer’s protocol (see Chapter 2 for 
description). Each case pool and each control pool were run in replicates of 6. Chips 
were scanned using the Illumina iScan system and the raw intensities were normalised 
using BeadStudio v3.2 software. The normalised intensities were then extracted for 
statistical analysis.
To exclude poorly performing replicates, replicate arrays were excluded if the 
estimated allele frequencies produced a Pearson correlation of r < 0.991 with at least 
two other replicate arrays for that pool as these appeared to be outliers (see Table C.2 in 
Appendix for Pearson correlations between all arrays).
An approximation of allele A frequencies for each replicate were calculated by 
Valentina Moskvina using the normalised intensities and the following equation, where 
Xnorm is the normalised intensity of allele A and Ynorm is the normalised intensity of 
allele B:
Frequency of allele A = Xnorm / (Xnorm + Ynorm).
These frequencies were then averaged over the number of replicates in each pool.
SNP QC was carried out by Valentina Moskvina and SNPs were excluded from the 
analysis if they had a MAF < 0.05 in either cases or controls. In order to exclude those 
SNPs whose allele frequencies appeared to be poorly predicted by the pooling analysis, 
the MAFs of SNPs in the control pools were also compared with their frequencies in the 
CEPH population of the HapMap project. This is a filter that has also been used by 
Kirov et al.(2006), which assumes that the frequency of these SNPs in the CEPH 
population approximates to their true frequency in the control sample and that 
differences between the two are the result of a bias in estimating the frequency of the 
alleles in the pooling experiment. The correction coefficient, k, was calculated using the 
following formula:
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In this formula, Ha is the frequency of allele A in the controls, HB is the frequency 
of allele B in the controls^ is the frequency of allele B in the HapMap CEPH 
population and / a is the frequency of allele A in the HapMap CEPH population. If k = 1 
then the frequency estimated in the control pool is identical to the frequency in the 
CEPH population. It has previously been shown that the use of SNPs with extreme 
values of k results in high error rates (Moskvina et al. 2005). Therefore, the SNPs with 
the worst 10% of k values (5% in each direction) were filtered out in order to remove 
SNPs with extreme values of k without excluding a large proportion of true positive 
results. The coefficient of variation for each SNP across replicates was calculated by 
dividing the standard deviation of the allele frequencies by the mean allele frequency. 
Those SNPs that had a coefficient of variation > 0.5 across the replicate arrays were 
excluded in order to remove the outlying SNPs that showed the most variance across the 
arrays, indicating poorly performing assays (see Figure C.l in Appendix for histograms 
of coefficient of variation). Finally, SNPs which did not show the same direction of 
effect across all 3 pooled sets were also excluded.
5.2.1.3 Association Analyses
In a pooling study, a standard Pearson ^-test should not be used to test the 
magnitude of the difference in allele frequencies between cases and controls because the 
assumption that any variance is determined entirely by sampling variation is unrealistic 
(Sham et al. 2002). The variance in allele frequencies can be inflated by experimental 
errors that are specific to pooling studies. Therefore, association analyses were carried 
out with the help of Valentina Moskvina using the Combined Z-test (Sham et al. 2002; 
Macgregor 2007; Abraham et al. 2008; Kirov et al. 2008). This test combines a chi- 
square statistic T for testing differences between two proportions (in this situation, allele 
frequencies) in cases and in controls accounting for sampling variance, with Z-statistics 
for testing the differences in mean allele frequencies between cases and controls 
accounting for standard error due to experimental error, as shown in the formula:
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w h e r e /a n d /2) are the allele frequencies in cases and controls, Vi and V2 are the 
sampling variances in cases and controls and s\ and £2 are the standard errors due to 
experimental error in cases and controls.
P-values across all pools were then combined using Fisher’s combined probability
tVitest shown below, where p  is the probability of the i hypothesis test:
X2 = - 2 ^  loge(pi).
1= 1
When all the null hypotheses are true, and the pi (or their corresponding test statistics) 
are independent, x2 has a chi-square distribution with 2k degrees of freedom, where k is 
the number of tests being combined (3 in this case, so there are 6 degrees of freedom).
5.2.2 Individual Genotyping of NeuroDys Pools
5.2.2.1 Sample
Individual genotyping was carried out on those samples that were used to construct 
the pools (the ‘NeuroDys individual genotyping sample’, as well as additional cases and 
controls that fulfilled the replication sample ascertainment criteria (the ‘whole 
NeuroDys individual genotyping sample’), as shown in Table 5.2. The additional 
samples from France were recruited by the University of Toulouse and the Centre 
National de la Recherche Scientifique (CNRS) in Paris. Additional samples from 
Hungary were recruited by the University of Budapest. No individual genotyping was 
carried out on the Finnish pooled samples.
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NeuroDys Individual 
Genotyping Sample
Additional NeuroDys 
Samples
Country/Centre Case Pool Control Pool Cases Controls Centre
UK: 461 219
Cardiff 187 219 1
Oxford 274 0 53 359 2
Central Europe: 527 902
Bonn 196 400 4 285 3
Munich 104 188 103 26 4
Switzerland 25 39 2 5 5
Netherlands 96 95 57 79 6
Austria 106 180 80 28 7
Finland 0 0
France - - 161 204 8
Hungary - - 78 154 9
Total 988 1121 538 1140
Table 5.2: Samples from the pools that were individually genotyped using the follow up panel of SNPs. 
Not all samples that were in the pools were genotyped individually due to lack of available DNA. Some 
additional samples that were not in the pools were also genotyped using this panel.
5.2.2.2 Genotyping of Replication Panel
SNPs were not solely chosen for follow up with individual genotyping based on 
their top ranking significance in the pooling study; SNPs were also chosen if they were 
significant in more than one pool, in genes or regions with multiple hits, of functional 
interest or in a pathway of interest and if they were significant in both the pooling study 
and the initial NeuroDys GWAS, as shown in Table 5.5.
The SNPs selected for follow-up were entered into the Sequenom MassARRAY
Assay Design 3.1 software in order to design a multiplex panel of 40 SNPs (see Table
C.3 in Appendix for primer sequences). This panel of SNPs was genotyped in the
replication sample using the Sequenom MassARRAY iPlex GOLD system as described
in Chapter 2. Genotype calling was carried out using the Typer 3.4 software. All SNP
assays were initially optimised by genotyping DNA from 30 CEPH parent-offspring
trios. Cluster plots for all SNPs were inspected manually, and SNP assays that did not
produce distinct clusters were excluded. All plates for genotyping contained a mixture
of cases, controls, blanks, and 46 CEU samples. “Double-genotyping”, where another
experienced user of the Sequenom genotyping system and Typer software checks the
genotypes for every assay, was used. Genotypes were called blind to sample identity,
affected status, and blind to the other rates. Genotypes of CEU samples were compared
to those available on the HapMap to provide a measure of genotyping accuracy.
Genotyping assays were only considered suitable for analysis if a) during optimisation,
genotypes for CEU individuals were the same as those in the HapMap when available
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and b) all subsequent duplicate genotypes from the CEU samples were consistent with 
the HapMap data.
After genotyping, SNPs were tested for Hardy-Weinberg equilibrium in controls and 
their MAFs were calculated using PLINK vl.05 (Purcell et al. 2007). Samples with a 
call rate < 70% were not included in the analysis.
SNPs were tested for an association with DD using logistic regression carried out in 
PLINK vl.05 (Purcell et al. 2007) using both the additive and genotypic models. To 
correct for possible population stratification, a covariate corresponding to centre was 
applied as shown in Table 5.2. This analysis was performed for those samples that were 
in the DNA pools alone and also with the additional samples indicated in Table 5.2.
In order to ascertain the concordance across studies for those SNPs that were 
individually genotyped, their association results in this study were compared with those 
in the initial NeuroDys GWAS (in both the UK GWAS sample and the whole 
NeuroDys GWAS sample). As the initial NeuroDys GWAS was carried out on the 
smaller Illumina HumanHap300 array, not all of the SNPs that were individually 
genotyped in this pooling study had been genotyped in the initial GWAS as well. For 
those SNPs, imputation was carried out on the NeuroDys dataset using PLINK vl .05 
(Purcell et al. 2007), as described in Chapter 2. Association analysis was then carried 
out in the same way as in the GWAS (see Chapter 4) using imputed genotypes for 
SNPs that had an information score greater than 0.8 as recommended in the PLINK 
documentation.
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5.3 Results
5.3.1 NeuroDys Pooling Study
Due to the lack of convincing evidence for associations with DD from the initial 
GWAS, a larger GWAS was carried out using pooled DNA from the NeuroDys 
replication sample to form case and control pools from the UK, Central Europe and 
Finland. Table 5.3 shows the results of validating these pooled samples using SNaPshot. 
For the SNP rsl 1648084, the UK pool had an error rate of 0.97% and for rsl892577 
there was an error rate of 1.07%. This gave an overall average error rate of 1.02%. The 
Central European and Finnish pools were validated in a similar way by Kerstin Ludwig 
and colleagues at the University of Bonn and Myriam Peyrard-Janvid and colleagues at 
the University of JyvaskylS.
Genome-wide pooled genotyping was carried out on the Illumina lM-Duo chip. 
Predicted frequencies for each SNP were averaged over the replicate case and replicate 
control assays.
SNP
Difference in allele 
frequencies from individual 
genotyping (%)
Difference in allele 
frequencies estimated from 
pools (%)
% Error rate
rsl 1648084 4.14 3.17 0.97
rsl 892577 6.62 5.55 1.07
Table 5.3: Comparison of difference in allele frequencies when sample were genotyped individually and 
in the UK pools.
For two of the case replicates and two of the control replicates of the Central 
European pools, the chips had sections that could not be imaged by the iScan system 
(either due to hybridisation or staining issues) so were not included in subsequent 
analysis. The remaining replicates all passed QC with a Pearson’s correlation r > 0.993, 
as shown in Figure C.2 of the Appendix.
Following stringent QC filters, 501,409 SNPs were analysed. Figure 5.1 shows the 
results of these SNPs when their P-values were combined across all pools using the 
Fisher’s combined probability test. Two of these SNPs achieved a genome-wide level of 
significance, rsl 1686995 on chromosome 2 (P-Fisher = 1.74 x 10'10) and rsl2743401 on 
chromosome 1 (P-Fisher = 3.37 x 10'9). A further 109 SNPs had P-values < 1 x 10"4 (see 
Table C.4 of the Appendix for a list of the 200 most significant SNPs).
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Results of NeuroDys Pooling Study
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Figure 5.2: Manhattan plot of combined P-values (-loglO) from the UK pool in the NeuroDys Pooling Study. The red line indicates genome-wide significance with a P-value 
of 5 x 10'8, the blue line indicates a P-value of 5 x 10"5
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Results of UK Pool In NeuroDys Pooling Study
Figure 5.2 shows the P-values in the UK NeuroDys pools for those SNPs that passed 
QC. In this sample, only 1 SNP showed a genome-wide level of significant association 
with DD: rs6865447 on chromosome 9, P-value from combined test = 3.30 x 10"9. This 
SNP had a P-Fisher value of 4.6 x 10'7 in the NeuroDys pooling sample, but was not 
significant in the other individual pools with P-values of just 0.87 and 0.73 in the 
Central European and Finnish NeuroDys pools, respectively. In the UK NeuroDys 
pool, another 59 SNPs had P-values < 1 x 10‘4.
5.3.2 Individual Genotyping of Selected SNPs
Genotyping pooled DNA can only provide an estimate of allele frequency and any 
interesting results need to be confirmed by genotyping the samples individually before 
they can be relied upon.
As shown in Table 5.5, a total of 40 SNPs were selected for individual genotyping 
based on their level of significance in the pooling study and if they were significant in 
more than one pool (29 SNPs), if they were functional or were located in a gene in a 
pathway of interest (3 SNPs), if they were in a gene that had multiple significant hits (4 
SNPs) or if they were significant in both the pooling study and the initial GWAS (4 
SNPs). Unfortunately, Sequenom assays for the two SNPs that achieved genome-wide 
significance could not be designed.
The SNPs rs5063, rs945386 were chosen because they are functionally interesting as 
they cause an amino acid change in the genes they are in. As shown in
Table 5.4, the non-synonymous SNP rs5063 (32Val —>Leu) is within the first exon 
of the gene natriuretic peptide precursor A (NPPA) and rs945386 is a non-synonymous 
SNP (38Met—►Thr) within exon 2 of KIAA1984.
The SNP rs420121 was selected for follow-up because it is within intron 1 of the 
gene glutamate receptor ionotropic kainate 1 (GRIK1). Glutamate receptors are the 
predominant excitatory neurotransmitters in the mammalian brain and play a role in 
short- and long-term synaptic plasticity (Headley & Grillner 1990). GRIK1 is mainly 
expressed in the cerebellum and the suprachiasmatic nuclei (SCN) of the hypothalamus 
and its expression is developmentally regulated with a peak of expression during early 
postnatal development at a stage of intense synaptogenesis (Bettler & Mulle 1995). This
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suggests that this gene may be functionally interesting within DD and is worthy of 
follow-up.
The gene protein phosphatase 1, regulatory (inhibitor) subunit 12B (PPP1R12B) had 
multiple significant hits in the pooling study. The top hit, rs l2743401 (P-Fisher = 3.37 x 
10'9) in this gene was selected for follow up with individual genotyping. Two more 
SNPs in this gene were in the top 200 hits: rs3817222 (P-Fisher = 6.23 x 10‘6, rank = 
24) and rsl2734338 (P-Fisher = 2 x 10"4, rank = 199). It is important to note that in the 
HapMap CEU population, rsl2734338 is in perfect LD (r2 = 1, D ’ = 1) with rsl2743401 
and so these SNPs are likely to be picking up the same association. The top hit within 
the gene prostaglandin E receptor 3 (subtype EP3) (.PTGER3) was also selected for 
follow up (rs6687859, P-Fisher = 1.78 x 10-4, rank = 12). Another SNP in this gene, 
rs l7131481, was in the top 20 hits (P-Fisher = 4.4 x 10'6, rank = 20) and is in high LD 
with rs6687859 (r2 = 0.98). The gene isoleucyl-tRNA synthetase 2 (IARS2) contains 2 
SNPs within the top 270 SNPs. The top hit, rs2289191 (P-Fisher = 1.79 x 10-4, rank = 
171) was selected for follow up and is in high LD {D’ = 0.88) with the other significant 
hit in this gene, rsl7007135 (P-Fisher = 4 x 10*4, rank = 269), although these SNPs are 
not highly correlated (r2 = 0.56). The gene WD-repeat domain 78 (WDR78) has two 
SNPs within the top 350 hits: rs2454320 (P-Fisher = 6.21 x 10‘6, rank = 23) and 
rs4655653 (P-Fisher = 5.11 x 10"4, rank 341). These SNPs are in perfect LD (r2 = 1, D ’
= 1) with each other and rs4655653 was put in the panel for follow up because the assay 
for the more significant SNP, rs2454320, could not be designed alongside the other 
SNPs in the panel.
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SNP Rank Reason for inclusion Chr
Position
(bp)
Nearest 
RefSeq Gene
Position 
Relative 
to Gene
rsl 0932727 7 2 218313957 DIRC3 Intronic
rsl 0509910 9 10 111991750 MXI1 Intronic
rsl 2290752 13 11 115939639 BUD13 Intergenic
rs6812487 14 4 183697713 ODZ3 Intronic
rs2189167 31 4 104953292 TACR3 Intergenic
rs12344734 44 9 74383363 TMC1 Intronic
rsl 1232875 48 11 81191362 FAM181B Intergenic
rs7934218 51 11 72884377 FAM168A Intronic
rsl 7615558 65 6 12463160 EDN1 Intergenic
rs705790 70 6 166286499 C6orf176 Intronic
rs7904542 75 10 95245571 CEP55 Upstream
rsl 6932422 87
Most significant
8 67103552 DNAJC5B Intronic
rsl 2352208 100 9 14563137 ZDHHC21 Intergenic
rsl 0821663 103 in pooling study 10 61480286 ANK3 Intronic
rs4436151 105 and significant 8 114902482 CSMD3 Intergenic
rs4510693 109 in more than 6 156270620 NOX3 Intergenic
rs2311445 135 one pool 16 17456460 XYLT1 Intronic
rs9916926 138 18 12908318 SEH1L Intergenic
rsl 6900429 140 8 90845430 RIPK2 Intronic
rs2817764 143 6 111087345 CDK19 Intronic
rs7381 159 22 44375446 FBLN1 3' UTR
rs9535442 172 13 49821641 FAM10A4 Intergenic
rsl 546929 184 6 81104278 BCKDHB Intronic
rs9397276 185 6 156298468 NOX3 Intergenic
rs4330611 220 7 94109934 SGCE Intronic
rs9324005 246 14 98565680 BCL11B Intergenic
rs3736403 302 2 219613491 CCDC108 Exonic
rs7686728 372 4 184541581 CDKN2AIP Upstream
rs34871518 401 19 63046077 ZNF587 Upstream
rs5063 178 Functional / In 1 11830235 NPPA Exonic
rs945386 316 pathway of 9 138813417 KIAA1984 Exonic
rs420121 79 interest 21 30068479 GRIK1 Intronic
rsl 2743401 2 1 200743271 PPP1R12B Intronic
rs6687859 12 In gene with 1 71135175 PTGER3 Intronic
rs2289191 171 multiple hits 1 218366658 IARS2 Intronic
rs4655653 341 1 67104024 WDR78 Intronic
rs1569012 27 Significant in 
pooling and 
GWAS studies
14 80923160 STON2 Intronic
rs1350317 53 4 183649628 ODZ3 Intronic
rs268598 173 8 71677425 TRAM1 Intronic
rs1581413 217 3 158532859 VEPH1 Intronic
Table 5.4: Table showing the position (based on NCBI b36) of the SNPs chosen for individual 
genotyping, their neareast gene (in RefSeq) and their location relative to this gene. Chr -  
chromosome; UTR -  un-translated region.
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UK Pool Finnish Pool Central Europe Pool All Samples GWAS
SNP Rank Reason for inclusion Chr Pos (bp) P OR P OR P OR P-Fisher P-add OR
rsl0932727 7 2 218313957 5.89x1 O'4 1.97 0.0749 1.42 6.51 x 10 s 1.62 6.15 x10‘7 0.290 1.13
rsl 0509910 9 10 111991750 0.0024 1.89 0.0033 L 1.73 4.44 x 10"* 1.56 7.13 x10'7 0.930 1.01
rsl 2290752 13 11 115939639 1.60 X10-® 2.62 0.0567 1.53 0.156 1.27 2.58x1 O'6
rs6812487 14 4 183697713 0.216 1.29 3.30x10 ■" 2.23 0.0200 1.36 2.61 x 1045
rs2189167 31 4 104953292 0.0216 0.59 7.45 x10 s 0.54 0.0313 0.82 8.01 x 10-®
rsl 2344734 44 9 74383363 0.0012 1.65 0.0637 1.33 0.0015 1.36 1.61 x 10 s
rsl 1232875 48 11 81191362 0.882 0.97 7.17 x 10"4 0.45 2.38x1 O'4 0.60 2.11 x 10 s
rs7934218 51 11 72884377 0.664 0.93 5.32x1 O'6 0.52 0.0485 0.80 2.36 x10 s
rsl 7615558 65 6 12463160 0.0655 1.37 7.05x1 O'5 1.97 0.0629 1.32 3.76x10’5
rs705790 70 6 166286499 0.0798 1.51 0.0403 1.38 9.80 x 10'5 1.73 4.04x1 O'5
rs7904542 75 10 95245571 9.19 xIO-4 0.62 0.00145 0.67 0.271 0.91 4.55 x10 s
rsl 6932422 87 Most significant in 8 67103552 0.332 1.22 1.03 X10-4 2.18 0.0175 1.41 7.09 x10 s 0.484 1.11
rsl 2352208 100 pooling study and 
significant in more than 
one pool
9 14563137 0.414 1.15 2.21 x 10-4 1.79 0.0075 1.35 7.89 x10 s 0.813 1.03
rsl 0821663 103 10 61480286 2.65x1 O'4 0.53 0.00450 0.65 0.617 0.94 8.46 x10 s 0.079 0.85
rs4436151 105 8 114902482 0.438 0.90 0.00907 0.72 1.93 X10-4 0.72 8.76 x 10 s
rs4510693 109 6 156270620 0.695 0.95 1.69 X10-4 0.60 0.0072 0.75 9.50 x 10 s 0.961 1.00
rs2311445 135 16 17456460 0.190 0.81 3.43x1 O'4 0.61 0.0177 0.78 1.25 x 10"4 0.974 1.00
rs9916926 138 18 12908318 4.12 x10 4 1.68 0.0217 1.34 0.131 1.19 1.27 x 10"4 0.073 1.15
rsl 6900429 140 8 90845430 0.952 0.99 4.29x1 O’4 0.62 0.0030 0.76 1.31 X10-4 0.508 0.91
rs2817764 143 6 111087345 0.989 1.00 0.00231 1.55 5.48x1 O'4 1.37 1.34 x 10"4 0.414 1.08
rs7381 159 22 44375446 0.0303 1.43 0.0563 1.42 9.03x1 O'4 1.44 1.60 x 10^ 0.426 1.11
rs9535442 172 13 49821641 0.0094 1.67 0.248 1.22 7.55x1 O’4 1.49 1.80 xIO-4 0.981 1.00
rsl 546929 184 6 81104278 0.953 0.99 7.11 x 10* 0.52 0.0298 0.74 2.02x1 O'4 0.780 0.98
rs9397276 185 6 156298468 0.801 1.03 2.53 x10‘4 1.58 0.0101 1.25 2.04 x 10"4 0.734 1.03
rs4330611 220 7 94109934 1.63 X10-4 0.49 0.294 0.87 0.0591 0.82 2.70x1 O'4 0.790 0.97
rs9324005 246 14 98565680 2.10 X10-4 2.15 0.246 1.26 0.0675 1.26 3.22x1 O'4
rs3736403 302 2 219613491 0.0761 0.76 7.38x1 O'4 0.61 0.0851 0.84 4.22 x 10-4 0.460 0.92
Table 5.5: SNPs in follow-up panel for individual genotyping. Results o f imputed SNPs are presented in italics.
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UK Pools Finnish Pools German Pools All Samples GWAS
SNP Rank Reason for inclusion Chr Pos (bp) P OR P OR P OR P-Fisher P-add OR
rs7686728 372 Most significant in pooling 
study and significant in 
more than one pool
4 184541581 1.66 x 10* 1.79 0.0676 1.30 0.617 1.06 5.77x1 O'4 0.189 0.84
rs34871518 401 19 63046077 0.886 1.02 5.16 X10-4 1.66 0.0173 1.26 6.46x1 O'4
rs5063 178 Functional / In pathway of 
interest
1 11830235 0.249 1.23 4.11 x 10* 2.09 0.0182 1.40 1.89 x 10*
rs945386 316 9 138813417 0.0711 0.78 0.0011 0.63 0.0663 0.82 4.57x10* 0.963 1.00
rs420121* 79 21 30068479 0.0051 1.42 0.167 1.19 0.0173 1.33 5.20x10* 0.371 1.06
rsl 2743401 2
In gene with multiple hits
1 200743271 3.70x1 O'5 0.57 0.225 0.86 1.16x10* 0.63 3.37 x 10*
rs6687859 12 1 71135175 0.0498 1.31 4.91 x 10 s 1.87 0.0038 1.32 1.78 x 10*
rs2289191 171 1 218366658 0.0649 0.71 5.98x10‘5 0.41 0.451 0.87 1.79x10* 0.654 0.95
rs4655653 341 1 67104024 0.0152 1.44 5.54x1 O'4 1.61 0.711 1.04 5.11 x 10*
rs1569012 27
Significant in pooling and 
GWAS studies
14 80923160 0.426 1.19 4.90x1 O'4 1.81 1.98x10* 1.60 6.71 x 10* 0.027 1.27
rs1350317 53 4 183649628 0.0285 0.51 2.09 x 1C4 0.47 0.0303 0.73 2.48x10* 0.049 0.78
rs268598 173 8 71677425 0.0264 1.58 0.130 1.36 5.16x10* 1.73 1.81 x 10* 0.028 1.32
rs1581413 217 3 158532859 0.878 0.98 9.40 x10 s 0.60 0.0332 0.82 2.63x10* 0.006 0.83
Table 5.5 Continued. *rs420121 genotyped via proxy SNP rs461119.
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5.3.2.1 Individual Genotyping of Samples Included in Pools
The panel of follow-up SNPs were genotyped in all of those samples that had been 
pooled, except for the Finnish pool (NeuroDys individual genotyping sample). They 
were also genotyped with some additional samples (whole NeuroDys individual 
genotyping sample) to ascertain if any SNPs showed a higher level of significance when 
they were genotyped in a larger sample (see next section of this Chapter).
Out of the NeuroDys individual genotyping sample, a total of 988 cases and 1121 
controls passed QC when they were genotyped individually. As shown in Table C.5 in 
the Appendix, two SNPs in the panel (rsl2743401 and rs4510693) failed optimisation. 
All remaining SNPs had a call rate > 70% in both the UK and Central European subsets 
and in the entire sample. 2 SNPs had MAFs < 0.05 but were still included in the 
analysis (rsl2290752, MAF = 0.04 in UK subset, 0.02 in Central European subset and 
0.03 in entire sample; rs9324005, MAF = 0.04 in UK sample, 0.049 in Central 
European subset and 0.046 in the whole sample). Nine of the SNPs were out of Hardy- 
Weinberg equilibrium in the control sample. These were not excluded from the 
association analyses but any association found with these SNPs should be treated with 
caution.
The results from the individual genotyping of the NeuroDys individual genotyping 
sample are shown in Table 5.6, in order of their additive P-value in the complete 
sample. A total of 14 SNPs gave significant P-values (<0.05) in the complete sample, 
with the top hit being rs2189167 (P-add = 5.0 x 10‘5, OR =1.41, P-gen = 2.7 x 10-4). 
This SNP was also the most significant hit in the Central European subset (P-add = 6 x 
10"4, OR = 1.37) but was not quite as significant in the UK subset despite having a 
larger effect size (P-add = 0.0264, OR = 1.60), which may have been due to a lack of 
power in this smaller sample. However, this SNP showed highly significant departure 
from Hardy-Weinberg equilibrium and had relatively low call rates, suggesting that this 
may have been a poor assay, even though it passed optimisation and QC filters.
The next most significant SNP in the NeuroDys individual genotyping sample was 
rs7381 (P-add = 8.1 x 10"4, OR = 1.58, P-gen = 0.0118). This SNP was also significant 
in the Central European subset alone (P-add = 0.0037, OR = 1.58) but was not 
significantly associated in the UK subset (P-add = 0.0964, OR = 1.59). Apart from the 
top hit rs2189167 (which, as indicated previously, should be interpreted with caution), 
two SNPs showed significant association with DD in both the UK subset and the
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Central European subset. The most significant of these is rsl 0932727 (UK subset: P-add 
= 0.0304, OR = 2.04; Central European subset: P-add = 0.0135, OR = 1.45) and the 
other SNP is rs461119 (UK subset: P-add = 0.0177, OR =1.5; Central European subset: 
P-add = 0.0191, OR = 1.22). Both of these SNPs had relatively high effect sizes in the 
UK sample, which may be explain why these were significant in both sample subsets 
whereas other SNPs with lower effect sizes were only significant in the larger Central 
European subset. Overall, the SNPs selected for individual genotyping did not reach the 
level of significant association with DD that was found in the pooling study. In addition, 
the four SNPs that had shown a significant association in both the initial NeuroDys 
GWAS and in the pooling study were not significantly associated when genotyped in 
this sample (rsl350317, P-add = 0.2119; rsl569012, P-add = 0.2937, rs268598, P-add = 
0.4003, rsl581413, P-add = 0.601).
188
Pooling
Study
NeuroDys Individual Genotyping Sample
UK Subset Central European Su bset Complete Sample
SNP P-Fisher P-gen P-add OR 95% Cl P-gen P-add OR 95% Cl P-gen P-add OR 95% Cl
rs2189167 8.0 x 10'6 0.0248 0.0264 1.60 1.06-2.43 0.0026 6.0 x 10-4 1.37 1.15-1.64 2.7 x 10"* 5.0 x 10** 1.41 1.19-1.66
rs7381 1.6 xKT4 0.4832 0.0964 1.59 0.92-2.74 0.0236 0.0037 1.58 1.16-2.14 0.0118 8.1 x 10^ 1.58 1.21-2.06
rsl 0932727 6.2 x 10'7 0.0641 0.0304 2.04 1.07-3.90 0.0260 0.0135 1.45 1.08-1.94 0.0028 0.0015 1.54 1.18-2.01
rs461119 5.2 x KT4 0.0161 0.0177 1.50 1.07-2.08 0.0621 0.0191 1.22 1.03-1.44 0.0041 0.0015 1.27 1.10-1.47
rs6687859 1.8 x104 0.2108 0.0778 1.36 0.97-1.92 0.0621 0.0224 1.24 1.03-1.49 0.0149 0.0044 1.27 1.08-1.49
rs4436151 8.8 x 10 * 0.0836 0.1789 0.78 0.53-1.12 0.0153 0.0112 0.76 0.62-0.94 0.0021 0.0041 0.77 0.64-0.92
rsl 2344734 1.6 x 10"5 0.1524 0.1765 1.44 0.85-2.46 0.0861 0.0268 1.31 1.03-1.66 0.0292 0.0100 1.33 1.07-1.65
rsl 0509910 7.1 x 10‘7 0.2780 0.1229 1.48 0.90-2.43 0.1033 0.0527 1.25 1.00-1.57 0.0324 0.0160 1.29 1.05-1.58
rs5063 1.9 x 10"4 0.9909 0.4463 1.27 0.69-2.32 0.0465 0.0135 1.58 1.10-2.28 0.0387 0.0122 1.49 1.09-2.04
rs7686728 5.8 x 10"4 0.0307 0.0317 0.63 0.41-0.96 0.2798 0.1823 0.86 0.68-1.08 0.0868 0.0270 0.80 0.65-0.97
rs4330611 2.7 x 10"4 0.0324 0.0099 0.56 0.36-0.87 0.1402 0.2213 0.87 0.70-1.09 0.0181 0.0232 0.80 0.66-0.97
rsl 6900429 1.3 X10-4 0.1400 0.6929 1.09 0.71-1.68 0.0634 0.0267 1.32 1.03-1.68 0.0249 0.0343 1.26 1.02-1.56
rsl 1232875 2.1 x 10"* 0.7986 0.5251 1.17 0.72-1.89 0.1349 0.0453 1.31 1.01-1.70 0.1199 0.0396 1.27 1.01-1.61
rs2311445 1.3 x 10"4 0.6025 0.6629 0.90 0.57-1.43 0.1326 0.0497 0.78 0.61-1.00 0.1170 0.0518 0.81 0.65-1.00
rs9397276 2.0 x 10"4 0.8814 0.6265 0.93 0.69-1.25 0.0036 0.0133 1.23 1.05-1.46 0.0249 0.0539 1.15 1.00-1.33
rs945386 4.6 x 10"4 0.1365 0.0815 1.35 0.96-1.90 0.5403 0.2672 1.12 0.92-1.35 0.1529 0.0666 1.17 0.99-1.38
rs9535442 1.8 X10-4 0.9891 0.8825 1.05 0.54-2.06 0.0728 0.0679 1.30 0.98-1.73 0.0760 0.0827 1.26 0.97-1.64
rs9916926 1.3 x 10"4 0.0191 0.0048 0.62 0.44-0.86 0.3259 0.7401 0.97 0.80-1.17 0.1320 0.0893 0.87 0.74-1.02
rsl 546929 2.0 x 104 0.6287 0.4600 1.16 0.78-1.74 0.1670 0.1238 1.17 0.96-1.43 0.1778 0.0878 1.17 0.98-1.40
rs9324005 3.2 x 10"* 0.4281 0.1281 0.59 0.29-1.17 0.4765 0.2388 0.80 0.55-1.16 0.2091 0.0768 0.74 0.54-1.03
rs4655653 5.1 x 10"* 0.0192 0.0049 1.72 1.18-2.52 0.5255 0.8614 1.02 0.83-1.24 0.1514 0.1330 1.14 0.96-1.36
rs705790 4.0 x 10'5 0.1662 0.3653 1.32 0.72-2.41 0.4225 0.2012 1.22 0.90-1.65 0.1648 0.1209 1.24 0.95-1.62
Table 5.6: Results of individual genotyping of the NeuroDys Individual Genotyping Sample, sorted by the additive P-value in the complete sample. OR -  odds ratio; Cl -  
confidence interval; P-add -  P-value from additive test; P-gen -  P-value from genotypic test. Significant P-values (<0.05) are in bold. N.B the most significant SNP, 
rs2189167, is not in Hardy Weinberg equilibrium.
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Study
NeuroDys Individual Genotyping Sample
UK Subset Central European Subset All Pooled Samples
SNP P-Fisher P-gen P-add OR 95% Cl P-gen P-add OR 95% Cl P-gen P-add OR 95% Cl
rs34871518 6.5 x KT4 0.3811 0.643 1.10 0.73-1.66 0.1527 0.1014 1.19 0.97-1.46 0.2302 0.0945 1.17 0.97-1.40
rsl 2290752 2.6 x 104 0.3239 0.0751 2.27 0.92-5.61 0.7932 0.7181 1.10 0.66-1.83 0.5717 0.2058 1.32 0.86-2.03
rs2817764 1.3 xIO*4 0.3428 0.5701 0.90 0.62-1.30 0.1269 0.0614 1.21 0.99-1.48 0.1686 0.1726 1.13 0.95-1.35
rsl 2352208 7.9 x 10'5 0.4306 0.2164 1.42 0.81-2.49 0.3664 0.3316 1.16 0.86-1.57 0.2079 0.1476 1.22 0.93-1.59
rs1350317 2.5 x 10b 0.8076 0.5133 1.25 0.64-2.47 0.3043 0.2789 1.16 0.89-1.52 0.2462 0.2119 1.17 0.91-1.51
rs7934218 2.4 x 10'5 0.8850 0.9777 1.01 0.64-1.60 0.0382 0.2333 0.86 0.67-1.10 0.1158 0.3000 0.89 0.71-1.11
rsl 569012 6.7x10* 0.3801 0.1640 1.47 1.86-2.51 0.1359 0.6178 1.07 0.83-1.37 0.1261 0.2937 1.13 0.90-1.41
rs7904542 4.5 x 10'5 0.2825 0.1116 0.69 0.44-1.09 0.1792 0.7649 0.97 0.77-1.21 0.1779 0.3168 0.90 0.74-1.10
rs3736403 4.2 x 104 0.1308 0.1294 1.45 0.90-2.34 0.9061 0.6966 1.05 0.82-1.35 0.4735 0.2913 1.13 0.90-1.40
rs268598 1.8 x 10"4 0.7333 0.9787 0.99 0.55-1.78 0.5302 0.3410 0.85 0.61-1.19 0.2864 0.4003 0.88 0.66-1.18
rsl 0821663 8.5 x 10* 0.4309 0.5564 0.90 0.64-1.27 0.7049 0.6670 0.96 0.78-1.17 0.4172 0.5015 0.94 0.79-1.12
rs1581413 2.6 x 10-4 0.4685 0.9188 1.02 0.77-1.35 0.1032 0.5254 0.95 0.82-1.11 0.0506 0.6101 0.97 0.84-1.11
rs2289191 1.8 X10-4 0.5651 0.2854 1.33 0.79-2.24 0.5179 0.9949 1.00 0.72-1.39 0.5164 0.5682 1.08 0.82-1.43
rsl 6932422 7.1 x 10 s 0.7968 0.5002 1.27 0.63-2.55 0.8905 0.8762 1.03 0.73-1.45 0.7907 0.6621 1.07 0.79-1.45
rsl 7615558 3.8 x 10'5 0.5555 0.6520 1.11 0.70-1.77 0.8523 0.5729 0.92 0.69-1.23 0.7776 0.8053 0.97 0.76-1.24
rs6812487 2.6 x 10'6 0.5547 0.7267 0.90 0.48-1.66 0.5226 0.8282 1.03 0.77-1.39 0.2052 0.9641 1.01 0.77-1.31
Table 5.6 continued.
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5.3.2.2 Genotyping of Whole NeuroDys Individual Genotyping Sample
When genotyping the whole NeuroDys individual genotyping sample, a total of 
1518 cases and 2261 controls passed QC. The results of the QC tests on the panel of 
follow up SNPs when the additional samples are included are shown in Table C.6 in the 
Appendix. As stated previously, 2 SNPs failed optimisation (rs12743401 and 
rs4510693). All remaining SNPs had a call rate > 70% in each individual sample group 
and in the whole sample combined. As with the NeuroDys individual genotyping 
sample, nine SNPs were out of Hardy-Weinberg equilibrium when the additional 
samples were included. As before, these were not excluded from the association 
analyses at this stage but any association found with these SNPs should be treated with 
caution.
The results from the individual genotyping when including the additional samples 
are shown in Table 5.7, in order of their additive P-value in the whole sample. With the 
additional samples, 9 SNPs gave significant P-values (< 0.05), with the top hit now 
being rs461119 (P-add = 3.0 x 10"4, OR = 1.23). This SNP was included in the panel of 
follow-up SNPs as a proxy for the SNP rs420121, which had a Fisher P-value of 5.2 x 
1 O'4 in the NeuroDys pooling study. Both of these SNPs are within the first intron of 
GR1K1, as shown in Figure 5.3. As mentioned previously, the SNP in this gene was 
selected for individual genotyping because GRIK1 encodes a glutamate receptor, and 
these receptors are the predominant excitatory neurotransmitters in the mammalian 
brain (Headley & Grillner 1990). The SNP rs461119 showed a higher level of 
significance when the NeuroDys additional samples were included, compared to the 
NeuroDys individual genotyping sample alone (P-add = 0.0015, OR = 1.27).
Another 5 SNPs showed a higher level of significance when including the 
NeuroDys additional samples. Of these, the next most significant SNP was rs 12344734 
(P-add = 0.0021, OR = 1.25). This SNP had a P-add value of 0.01 when genotyped in 
the NeuroDys individual genotyping sample alone (OR = 1.33). This SNP is in the 
transmembrane channel-like 1 gene (TMC1) on chromosome 9 as shown in Figure 5.4. 
The specific function of this gene in unknown but mutations in this gene have been 
associated with progressive postlingual hearing loss and profound prelingual deafness 
(Kurima et al. 2002; Meyer et al. 2005; Santos et al. 2005; Kitajiri et al. 2007b; Tlili et 
al. 2008; Kitajiri et al. 2007a; Kalay et al. 2005; Vreugde et al. 2002).
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The next most significant SNP was rs16900429 (NeuroDys individual genotyping 
sample: P-add = 0.034, OR = 1.26; whole NeuroDys individual genotyping sample: P- 
add = 0.009, OR =1.21). This SNP is within the gene receptor-interaction serine- 
threonine kinase 2 (RIPK2) on chromosome 8, as shown in Figure 5.5. RIPK2 encodes a 
component of signalling complexes in both the innate and adaptive immunity pathways 
and overexpression of this gene can lead to cell death (McCarthy et al. 1998).
The fourth SNP to show an increase in significance was rs4655653 (NeuroDys 
individual genotyping sample: P-add = 0.133, OR =1.14; whole NeuroDys individual 
genotyping sample: P-add = 0.015, OR =1.15) which is an intronic SNP within the 
gene (WDR78\ as shown Figure 5.6. The exact function of this gene is unknown, but 
the family of WD-repeat domain containing proteins play key roles in the formation of 
protein-protein complexes and are critical for a wide range of biological functions 
including transduction, transcription regulation, cytoskeletal assembly and apoptosis (Li 
& Roberts 2001; Smith 2008). As mentioned previously, this SNP was selected for 
follow up as this gene had two significant SNPs in the top 350 hits (rs4655653 and 
rs2454320, as shown in Figure 5.6).
The fifth SNP that showed an increase in significance was rs7686728 (NeuroDys 
individual genotyping sample: P-add = 0.027, OR = 0.80; whole NeuroDys individual 
genotyping sample: P-add = 0.0201, OR = 0.84). This SNP is in an intergenic region on 
chromosome 4, 61 kb upstream from the CDKN2A interacting protein gene 
(CDKN2AIP) which is thought to be involved the negative regulation of cell growth and 
the regulation of protein stability.
The final SNP was rs 1581413 (NeuroDys individual genotyping sample: P-gen = 
0.051; whole NeuroDys individual genotyping sample: P-gen = 0.005, OR = 0.84) 
within intron 9 of the ventricular zone expressed PH domain homolog 1 gene (VEPH1) 
on chromosome 3, as shown in Figure 5.7. VEPH1 is a homolog of a zebrafish gene but 
its function is unknown.
The majority of the other SNPs showed a decreased level of significance when the 
additional samples were combined with those that had been in the NeuroDys individual 
genotyping sample. For example, the top hit in the NeuroDys individual genotyping 
sample (rs2189167, P-add = 5 x 10'5, OR =1.41) was no longer significantly associated 
with DD when the additional samples were also analysed (P-add = 0.0602, OR =1.12).
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This suggests that the association identified in the in the smaller sample may have been 
a false positive finding.
Only one SNP showed significant association in more than one sample group 
(rs 10932727, P-gen in UK sample = 0.0022, P-add in Central European sample = 
0.0267). This SNP is within intron 1 of the disrupted in the gene renal carcinoma 3 
(DIRC3) on chromosome 2. As the name suggests, this gene has been associated with 
renal cell cancer as it spans a breakpoint that was identified in a family with renal 
cancer (Bodmer et al. 2003). It shows low expression in fetal and adult tissues, with the 
highest level of expression in the placenta (Bodmer et al. 2003). Very little is known 
about the function of this gene as yet.
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Pooling
Study
Whole NeuroDys Individual Genotyping Sample
UK Subset Central European Subset French Subset Hungarian Subset All Samples
SNP P-Fisher P-gen P-add OR P-gen P-add OR P-gen P-add OR P-gen P-add OR P-gen P-add OR 95% Cl
rs461119 5.2 x 10"* 3.7 x 10-4 1.2 x104 1.45 0.2523 0.1104 1.12 0.6884 0.5628 1.10 0.8003 0.5194 1.15 0.0010 3.0 x 10-4 1.23 1.11-1.36
rs12344734 1.6 x 10-6 0.1143 0.0414 1.35 0.0341 0.0146 1.29 0.8169 0.5943 0.87 0.2416 0.1543 1.51 0.0080 0.0021 1.25 1.08-1.46
rs16900429 1.3 x 10-4 0.2548 0.5324 1.09 0.0314 0.0137 1.30 0.5779 0.4451 1.18 0.1943 0.2653 1.51 0.0115 0.0085 1.21 1.04-1.40
rs7381 1.6 x 10"4 0.0958 0.2995 1.19 0.0157 0.0042 1.47 0.9985 0.9566 1.02 0.9163 0.6761 0.83 0.0205 0.0138 1.24 1.03-1.49
rs4655653 5.1 x 104 0.0014 0.0031 1.39 0.5486 0.5678 1.05 0.2966 0.2344 1.26 0.8795 0.7928 0.94 0.0428 0.0149 1.15 1.02-1.29
rs7686728 5.8 x 10^ 0.0365 0.0157 0.73 0.3267 0.2070 0.88 0.3029 0.1433 0.71 0.3805 0.2193 1.39 0.0670 0.0201 0.84 0.73-0.96
rs10932727 6.1 x 10'7 0.0022 0.2451 1.18 0.0528 0.0267 1.33 0.9981 0.8013 1.08 0.2902 0.3007 0.66 0.0041 0.0312 1.20 1.01-1.42
rs4436151 8.8x1  O'6 0.0039 0.0115 0.75 0.2565 0.1554 0.88 0.1749 0.0676 1.44 0.1661 0.1112 0.61 0.0145 0.0353 0.86 0.76-0.97
rs705790 4.0 x 10-6 0.0398 0.2042 1.28 0.1751 0.0664 1.27 0.9678 0.9474 0.98 0.9970 0.8694 0.94 0.0732 0.0506 1.17 0.97-1.42
rs9916926 1.3 x 10-4 0.0560 0.0166 0.79 0.6787 0.5016 0.95 0.7258 0.8751 1.03 0.9708 0.9449 0.98 0.1469 0.0545 0.90 0.81-1.00
rs2189167 8.0 x 10^ 0.2732 0.9424 1.01 0.0109 0.0073 1.24 0.1210 0.8730 1.03 0.0558 0.7589 0.94 0.1534 0.0602 1.12 1.01-1.25
rs1581413 2.6 x 10"4 0.3887 0.1806 0.89 0.0059 0.4653 0.95 0.1597 0.0566 0.75 0.5633 0.6907 1.08 0.0054 0.0707 0.92 0.84-1.01
rs9397276 2.0 x 10"* 0.0204 0.0925 1.16 0.0770 0.0762 1.13 0.2644 0.2271 0.82 0.5415 0.8388 0.96 0.2071 0.0766 1.10 0.99-1.21
rs9535442 1.8x10"* 0.3611 0.1722 1.27 0.2808 0.1653 1.19 0.3284 0.3981 0.79 0.7298 0.4692 1.26 0.0719 0.0846 1.19 1.01-1.42
rs1350317 2.5 x 10-6 0.8671 0.7541 0.95 0.1515 0.1306 1.19 0.4898 0.3610 1.25 0.3072 0.1682 1.49 0.0748 0.0987 1.15 0.98-1.36
rs11232875 2.1 x 10-6 0.6577 0.5954 1.08 0.4106 0.2982 1.13 0.4108 0.2901 1.30 0.5197 0.5507 1.23 0.2476 0.1088 1.09 0.93-1.27
rs2311445 1.2x10"* 0.3422 0.9482 1.01 0.2405 0.1510 0.86 0.2576 0.1053 0.65 0.8689 0.8857 0.96 0.1328 0.1239 0.87 0.75-1.01
rs34871518 6.5x10"* 0.6884 0.4505 1.10 0.1667 0.0673 1.18 0.9975 0.9825 1.00 0.8957 0.7001 0.91 0.2009 0.1324 1.13 1.00-1.27
rs945386 4.6 x 10"* 0.5440 0.4720 1.08 0.9287 0.7503 1.03 0.0350 0.0106 1.59 0.9274 0.9936 1.00 0.3236 0.1361 1.08 0.97-1.21
rs3736403 4.2 x 10"* 0.1211 0.1213 1.26 0.2032 0.1004 1.19 0.9280 0.9338 0.98 0.0907 0.7013 0.88 0.2939 0.1508 1.18 1.02-1.37
rs5063 1.9 x 10-4 0.8405 0.6075 1.10 0.1073 0.0600 1.35 0.8294 0.3849 0.73 0.9516 0.7530 0.84 0.2852 0.1849 1.13 0.92-1.40
rs6687859 1.8 x 10"6 0.6255 0.3869 1.09 0.4488 0.2075 1.11 0.6548 0.6243 0.91 0.9737 0.9637 1.01 0.4219 0.1904 1.06 0.95-1.18
rs17615558 3.8 x 10"5 0.6674 0.4254 0.89 0.8104 0.5189 0.92 0.8958 0.3830 0.79 0.3124 0.7763 0.91 0.4631 0.2285 0.90 0.76-1.06
rs7934218 2.4x1  O'5 0.3898 0.1865 0.83 0.5871 0.7250 0.96 0.4680 0.3505 1.26 0.5030 0.1834 0.60 0.5298 0.2770 0.93 0.80-1.08
rs7904542 4.5x1  O'6 0.2934 0.1178 0.80 0.0233 0.7772 0.97 0.9895 0.8845 0.96 0.9853 0.8807 1.05 0.0909 0.2932 0.95 0.83-1.10
rs16932422 7.1 x 10-5 0.8496 0.2704 1.24 0.8614 0.5905 1.08 0.9914 0.8911 0.96 0.9201 0.9299 1.04 0.6763 0.3782 1.12 0.91-1.37
Table 5.7: Results of individual genotyping in the Whole NeuroDys Individual Genotyping Sample within each sample subset and for all samples combined, sorted by the 
additive P-value for all samples combined. P-add -  P-value from additive test; P-gen -  P-value from genotypic test; OR -  odds ratio; Cl -  confidence interval. Significant P- 
values (<0.05) are in bold.
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Pooling
Study
Whole NeuroDys Individual Genotyping Sample
UK Subset Central European Subset French Subset Hungarian Subset All Samples
SNP P-Fisher P-gen P-add OR P-gen P-add OR P-gen P-add OR P-gen P-add OR P-gen P-add OR 95% Cl
rs1546929 2.0 x 10“* 0.4825 0.4232 1.10 0.7430 0.5339 1.06 0.9014 0.6632 1.09 0.5198 0.2519 0.73 0.4720 0.4174 1.05 0.93-1.19
rs10509910 7.1 x 10‘7 0.4993 0.2408 1.18 0.0507 0.2013 1.13 0.3033 0.1222 0.71 0.7566 0.2941 0.72 0.1963 0.4349 1.06 0.92-1.22
rs12352208 7.9 x 10* 0.2922 0.3692 0.86 0.1809 0.2116 1.18 0.9961 0.3130 1.35 0.9803 0.8418 1.09 0.0615 0.4419 1.07 0.89-1.28
rs1569012 6.7 x 10* 0.8352 0.8951 0.98 0.1232 0.4153 1.09 0.5657 0.2866 1.33 0.6799 0.6568 0.86 0.0815 0.4527 1.11 0.95-1.30
rs9324005 3.2x10* 0.9998 0.8576 0.96 0.4911 0.2541 0.83 0.8630 0.8125 1.08 0.9923 0.9014 1.06 0.6427 0.4875 0.89 0.71-1.11
rs6812487 2.6 x 10* 0.2908 0.7739 0.95 0.2995 0.3526 1.12 0.5568 0.2870 1.31 0.7270 0.4260 0.72 0.2932 0.4966 1.09 0.91-1.30
rs4330611 2.7 x 10* 0.3476 0.1513 0.82 0.1272 0.7132 0.97 0.4831 0.3152 1.25 0.9970 0.9397 0.98 0.1131 0.5223 0.94 0.82-1.08
rs12290752 2.6x10* 0.1621 0.0568 1.55 0.9374 0.5824 0.89 0.9980 0.9499 1.03 0.2706 0.1412 0.21 0.7823 0.5576 1.06 0.80-1.40
rs2817764 1.3x10* 0.6148 0.3396 0.90 0.3151 0.1410 1.14 0.7131 0.4489 1.16 0.2681 0.1051 0.64 0.7994 0.5927 1.00 0.89-1.13
rs10821663 8.6x10* 0.4253 0.3635 0.90 0.7299 0.9301 1.01 0.4183 0.4507 0.86 0.8342 0.5578 1.16 0.6635j 0.6289 0.96 0.85-1.08
rs2289191 1.8x10* 0.5135 0.2483 1.19 0.2495 0.8375 1.03 0.9829 0.5281 0.84 0.5019 0.2445 0.59 0.7259 0.7448 1.02 0.85-1.22
rs268598 1.8x10* 0.8682 0.7953 1.05 0.3995 0.5640 0.92 0.7729 0.2377 0.67 0.3160 0.1373 1.73 0.8752 0.8225 0.94 0.77-1.15
Table 5.7 continued
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Figure 5.3: LD plot and results o f SNPs (P-Fisher values) in GRIK1 that were genotyped in the NeuroDys pooling study. The SNP rs461119 was genotyping the NeuroDys 
Individual Genoytping Sample as a proxy for rs420121, as these SNPs are in perfect LD with each other ( r  = 1). Red bars denote P-values <0.05.
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5.3 Discussion
A second GWAS study of DD was carried out using the NeuroDys replication 
sample from the initial GWAS and the Illumina HumanlM-Duo array in the form of a 
pooling study. After QC filtering, 501,409 SNPs were successfully screened in a total of 
1279 cases and 1452 controls from the UK, central Europe and Finland. This sample 
had a power of 91% to detect a significant association at P < 5 x 10"4 with a variant that 
has a MAF of 0.4 and an OR of 1.3, although this power is reduced due to the loss of 
information that occurs when genotyping samples in pools. There was very little 
concordance between the results of this study and the initial GWAS, with just 4 SNPs 
from the top hits of the pooling study also being significant in the GWAS (rsl350317, 
rsl569012, rs268598 and rsl581413) and these were not deemed significant enough to 
be selected for replication in that study. In addition, none of the top hits were in genes 
that have shown association with DD previously.
38 SNPs in the top hits were successfully genotyped in the NeuroDys individual 
genotyping sample, consisting of 988 of the cases and 1121 of the controls that had 
been pooled. This sample had a power of 77% to detect a significant association at P < 5 
x 10*4 with a variant that has a MAF of 0.4 and an OR of 1.3, and 99% power to detect 
an association at P < 0.05 with a variant of the same MAF and effect size. Two SNPs in 
the initial pooling study achieved genome-wide levels of significance (rsl 1686995 and 
rs 12743401), as did one in the UK pool alone (rs6865447) but these could not be 
included in the panel for individual genotyping so unfortunately these results remain 
unconfirmed. None of the four SNPs that had also been significant at the P < 0.05 level 
in the initial GWAS were significant when they were individually genotyped in this 
study with the lowest P-value being 0.213 for rs l350317. Therefore these SNPs are 
likely to have been false positives in both the initial GWAS and the pooling study. Out 
of the 38 SNPs that were selected, 14 remained significant when individually genotyped 
in those samples that had been pooled.
When additional samples were included in the individual genotyping, the SNPs were 
genotyped in a total of 1518 cases and 2261 controls. This sample had a power of 98% 
to detect a significant association at P < 5 x 10"4 with a variant that has a MAF of 0.4 
and an OR of 1.3, and 100% power to detect an association at P < 0.05 with a variant
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that had the same MAF and effect size. Despite the increase in power, the significance 
of most of the SNPs decreased when including these additional samples. Most of the 
additional samples were from France and Hungary and so the decrease in significance is 
may have been due to the lack of association of these SNPs with DD in these samples; 
just one SNP showed a significant association in the French sample alone and none 
were significant in the Hungarian sample. This difference between samples may have 
been due to population differences in LD or allele frequencies, or could have been the 
result of different ascertainment criteria that was used in each population. However, 
some SNPs also showed a reduction in significance within the UK and central European 
samples with the addition of more samples which were recruited using the same 
ascertainment criteria as those in the pools, suggesting that it is more likely that these 
SNPs are not truly associated with DD.
Six SNPs that passed QC filters showed an increase in significance in the whole 
NeuroDys individual genotyping sample compared to the subset that had been pooled. 
The most significant of these was rs461119 which is within the first intron of (GRIK1). 
This gene encodes a glutamate receptor and as these receptors are the most predominant 
excitatory neurotransmitters in the mammalian brain, with a role in both short- and 
long-term synaptic plasticity (Headley & Grillner 1990), making it a good functional 
candidate for DD. The next most significant SNP was rsl2344734 which is in the 
transmembrane channel-like 1 gene (TMC1) on chromosome 9. The specific function of 
this gene is unknown but mutations in this gene have been associated with progressive 
postlingual hearing loss and profound prelingual deafness, particularly with deafness 
autosomal dominant type 36 (DFNA36) (Kurima et al. 2002; Meyer et al. 2005; Santos 
et al. 2005; Kitajiri et al. 2007b; Tlili et al. 2008; Kitajiri et al. 2007a; Kalay et al. 2005; 
Vreugde et al. 2002; Hilgert et al. 2008). DFNA36 is a form of sensorineural hearing 
loss which results from damage to the neural receptors of the inner ear, the nerve 
pathways to the brain, or the area of the brain that receives sound information. TMC1 is 
specifically expressed in the inner and outer hair cells of the cochlea and in 
neurosensory epithelia of the vestibular end organs (Kurima et al. 2002), and mouse 
models with a missense mutation in Tmcl have shown degeneration of these hair cells 
(Vreugde et al. 2002) suggesting that mutations in this gene cause deafness through 
damage to the cochlea hair cells. The role of this gene within hearing and its association
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with DD in this study suggest that it is possible that TMC1 may influence susceptibility 
to DD by affecting an auditory component of the disorder.
Perhaps the most functionally interesting of the other 5 SNPs that showed an 
increase in significance was rs4655653 within the gene WDR78. The exact function of 
this gene is unknown, but the family of WD-repeat domain containing proteins play key 
roles in the formation of protein-protein complexes and are critical for a wide range of 
biological functions including transduction, transcription regulation, cytoskeletal 
assembly and apoptosis (Li & Roberts 2001; Smith 2008). Interestingly, these proteins 
have also been associated with a number of human diseases including lissencephaly 
which is a rare brain formation disorder caused by abnormal neuronal migration 
(Dobyns & Truwit 1995). The lissencephaly gene 1 (LIS1) was the first WD-repeat gene 
to be identified as responsible for a human disease and is thought to be involved in a 
signal transduction pathway that is crucial for cerebral development (Reiner et al.
1993). Lissencephaly has also been found to be caused by a mutation in DCX-  the 
double cortin gene that shares a common domain with DCDC2. If the WD-repeat 
domain of WDR78 is found to have a similar function to that of LIS V s  domain and is 
also involved in neuronal migration then it could be a promising candidate gene for DD.
The individual genotyping follow up study was far from ideal because the SNPs 
were not individually genotyped in the Finnish subset of the sample due to insufficient 
funding. Of the SNPs that were followed up, 14 (37% of SNPs genotyped) were 
significant in the NeuroDys individual genotyping sample at the P < 0.05 significance 
level suggesting that many of these SNPs were false positives in the initial pooling 
study. These false positives are likely to have been caused by inaccuracies in the 
estimation of the allele frequencies due to pool-formation or pool-measurement errors. 
The pool-formation error rate may have been inflated as result of combining samples 
that had been prepared in different centres. The design of this study may have been 
improved by forming separate pools for each centre involved, however this would have 
involved genotyping 8 case pools and 8 control pools in replicate, more than doubling 
the cost of the experiment. These issues highlight the need to confirm significant 
findings from pooling studies through individual genotyping due to the inflated false- 
positive rate that comes with such studies, even when controlling for this inflation as 
much as is feasibly possible.
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Another limitation of this study was that a relatively small number of SNPs were 
followed up with individual genotyping and more variants with a significant association 
with DD may have been identified if a large proportion of SNPs further down the list of 
the top hits from the pooling stage had also been genotyped in the individual sample. 
However, it was not financially feasible to individually genotype all of the significant 
SNPs.
Future work for this study should involve the collection of more samples in order to 
increase the power to detect causal variants for DD. This could include increasing the 
control sample through the use of more population controls such as those in the Avon 
Longitudinal Study of Parents and Children (ALSPAC) cohort. These children have 
been tested for a variety of cognitive measures including reading ability, so a screened 
subset could be utilised in future DD studies. Those SNPs that were shown to be more 
significantly associated when including additional samples at the individual genotyping 
stage need to be replicated in a large independent sample before investigating further. 
Any interesting genes could then be fine mapped to identify functional variants. The 
function of the WD-repeat domains within WDR78 could be of particular interest if they 
are found to have similar functions to those within the lissencephaly gene, LIS1.
In conclusion, there was very little concordance between this pooling study and the 
initial GWAS. This study has identified a small number of SNPs that could be worthy 
of follow up, but they did not achieve genome-wide significance and would need to be 
replicated in a large independent sample before investigating further. This study was 
also unable to confirm many of the most significant hits through individual genotyping 
suggesting a larger error rate in the pools than suggested by the pool validation. Pooling 
studies remain to be an efficient approach to conducting a GWAS but this study 
suggests that when combining samples from different centres, high error rates may 
offset the savings made in terms of time and cost.
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Chapter 6: Cardiff Genome-wide Pooling 
Study
6.1 Introduction
Both the initial NeuroDys GWAS (Chapter 4) and the NeuroDys pooling study 
(Chapter 5) were carried out in collaboration with a number of groups across Europe. 
Whilst this increased the power of the study by increasing the size of the sample, it also 
meant that cases were not recruited using the same criteria. This may have resulted in 
the analysis of cases from different subsamples of the DD spectrum. For example, the 
German cases were recruited based on a test of spelling, but the UK cases were 
recruited using reading measures. The use of different ascertainment criteria could 
partly explain why SNPs that have shown an association in the UK sample have failed 
to show an association in samples from Germany in previous studies. For example, 
SNPs that were significantly associated with KIAA0319 (in the DYX2 linkage region) in 
samples from the UK (Francks et al. 2004; Cope et al. 2005a; Harold et al. 2006) were 
not significantly associated in this German sample (Schumacher et al. 2006a).
As well as genotyping different samples from the collaborative groups, the initial 
NeuroDys GWAS (Chapter 4) utilised genotypic data from population controls. Again 
this increased the power of the study due to a larger sample of controls and without an 
increase in cost, but these samples had not been screened for DD and so individuals 
with symptoms of DD may have been present in this control group which would reduce 
the power of this study to detect an association with the disease. In addition, the 
population control samples were genotyped separately from the cases, in different labs 
and using different arrays which may have resulted in systematic genotyping error 
differences existing between the DD cases and the population controls, inflating the 
false-positive rate even further (Clayton et al. 2005). Whilst these issues were controlled 
for as much as possible by selecting stringent QC filters, it is acknowledged that there 
may have still been a higher false-positive rate than if matched, screened controls had 
been used which had been prepared and genotyped under the same conditions as the 
cases.
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Although the UK cases from Oxford and Cardiff were ascertained using similar 
tests, Cardiff cases were recruited based on different criteria than those used in the 
NeuroDys replication and pooled samples. In the NeuroDys studies, these samples were 
considered to be cases if their reading performance was less than 1.25 standard 
deviations from the expected age-based norms. However, the Cardiff cases were 
selected if they had a reading age that was at least 2.5 years behind that expected based 
on their chronological age. It is thought that reading ability and disability occur along a 
continuum, with dyslexic individuals forming the lower tail end of the normal 
distribution (Shaywitz et al. 1992). Selecting individuals with severe phenotypes may 
increase the ability of a study to find a significant association with DD. A number of 
studies have found an increased level of significant association when testing a subset of 
their cases with more severe forms of DD (e.g. Deffenbacher et al. 2004; Francks et al. 
2004; Schumacher et al. 2006). Even though this results in smaller sample sizes, it is 
hoped that this is offset by an increase in the effect size due to the severity of the cases. 
The DYX2 locus in particular appears to be associated with the low tail of the 
distribution of reading ability. For example, Deffenbacher and colleagues (2004) only 
found linkage to 6p21.3 when they selected a severe subset of their sample and 
Schumacher and colleagues (2006a) found an increased relative-risk for their associated 
SNPs in DCDC2 when increasing the severity of their sample. As the Oxford 
ascertainment criteria did not select for as severe cases as the Cardiff criteria, this may 
have affected the ability to detect an association with DD in the NeuroDys UK case 
sample.
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6.1.2 Aims
To address these issues, an additional GWAS was undertaken using the Cardiff 
case-control sample. The aim of this study was to identify novel susceptibility variants 
that were associated in the uniform sample of severe DD cases and matched, screened 
controls. To reduce costs, this GWAS was also carried out as a pooling study using the 
Illumina HumanlM-Duo array in the first stage, with the most significant SNPs being 
selected for individual genotyping in the second stage. As well as attempting to identify 
novel variants, these results were compared with the results from the NeuroDys studies 
(Chapters 4 and 5) in an attempt to ascertain if any variants showed a significant 
association with DD across all studies.
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6.2 Methods
6.2.1 Cardiff Pooling Study
6.2.1.1 Sample
Because the NeuroDys UK control pool from the NeuroDys pooling sample 
consisted of only Cardiff controls (Chapter 5), this pool was also used as the control 
pool in the Cardiff pooling sample; as such, only a pool of Cardiff cases needed to be 
constructed. Samples from the Cardiff cases were quantified twice using PicoGreen. 
Samples that had a concentration > 5ng/ul and a call rate > 98% in the NeuroDys 
GWAS replication panel of SNPs were included. Samples also had to meet the 
ascertainment criteria as outlined in Chapter 2 (IQ > 85 and a reading age > 2.5 years 
below their chronological age). This resulted in a sample consisting of 302 cases. This 
sample overlaps both the initial Neurodys GWAS and NeuroDys replication samples to 
some degree, as shown in Table 6.1.
Samples in Cardiff Pool Present in Other Sample Sets
Cardiff
Pool
NeuroDys GWAS 
Sample
NeuroDys Replication 
Sample
NeuroDys UK 
Pool
Cases 302 132 170 157
Controls 219 0 219 219
Table 6.1: Sample used in the Cardiff Pools and overlap with other sample sets used in the NeuroDys 
studies
6.2.1.2 Pooling
Pools containing only Cardiff cases were constructed as outlined in Chapter 2. After 
construction, the case pool was quantified using PicoGreen and had a concentration of 
10 ng/pl so it was concentrated using Microcon tubes (see Chapter 2 for method) and 
subsequently diluted to a concentration of 50 ng/pl. As with the NeuroDys UK pools, to 
test the accuracy of the pool construction, primers for the SNPs rsl 1648084 and 
rsl 892577 from the NeuroDys GWAS replication panel of SNPs were designed using 
primer 3 software (http://frodo.wi.mit.edu/primer3/) and the extension primers were 
designed using FP PRIMER 1.0.1b (http://m034.pc.uwcm.ac.uk/FP_Primer.html) (see 
Table D.l in Appendix for primer sequences). These were then used to genotype the 
Cardiff case and control pools using the SNaPshot method in order to estimate the allele 
frequencies for these SNPs (see Chapter 2 for method). The estimated differences in
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allele frequencies between the case and control pools for these SNPs were then 
compared to the actual differences in allele frequencies when the pooled samples were 
genotyped individually.
6.2.1.3 Genotyping of Pools
Genotyping was performed using the Illumina lM-Duo chip in Cardiff according to 
the manufacturer’s protocol (see Chapter 2 for brief description). Each case pool and 
each control pool were run in replicates of 8. Chips were scanned using the Illumina 
iScan system and the raw intensities were normalised using BeadStudio v3.2 software. 
The normalised intensities were then extracted for statistical analysis.
To exclude poorly performing replicates, replicate arrays were excluded if their 
estimated allele frequencies produced a Pearson correlation of r < 0.995 with at least 
one other replicate array for that pool as these appeared to be outliers (see Table D.2 in 
Appendix for Pearson correlations between all arrays).
As with the NeuroDys pooling study, an approximation of allele A frequencies for 
each replicate was calculated with the help of Valentina Moskvina using the normalised 
intensities and the following equation:
Frequency of allele A = Xnorm / (Xnorm + Ynorm).
These frequencies were then averaged over the number of replicates in each pool.
SNPs were excluded from the analysis if they had a MAF < 0.05 in either cases or 
controls. In order to exclude those SNPs whose allele frequencies appeared to be poorly 
predicted by the pooling analysis, the MAFs of SNPs in the control pools were also 
compared with their frequencies in the CEPH population of the HapMap project. The 
correction coefficient, k, was calculated using the same method as was used in the 
NeuroDys pooling study (see section 5.2.1.6 for more information). SNPs with the 
worst 10% of k  values (5% in each direction) were excluded in order to remove those 
SNPs with extreme values of k without excluding a large proportion of true positive 
results. The coefficient of variation for each SNP across replicates was calculated by 
dividing the standard deviation of the allele frequencies by the mean allele frequency. 
Those SNPs that had a coefficient of variation > 0.5 across the replicate arrays were 
excluded in order to remove the outlying SNPs that showed the most variance across the
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arrays, indicating poorly performing assays (see Figure D.l in Appendix for histogram 
of coefficient of variation).
As with the NeuroDys pooling study, association analyses were carried out with the 
help of Valentina Moskvina using the Combined Z-test (see Chapter 5, section 5.2.1.7 
for more information).
6.2.2 Individual Genotyping of Cardiff Pools
6.2.2.1 Sample
Individual genotyping was carried out in those samples that were used to construct 
the pools, as well as additional cases and controls that fulfilled the ascertainment 
criteria, as shown in Table 6.2. Genotyping data from 3751 population controls from the 
1958 Birth Cohort were also used to compare against the cases, 1437 of which had 
made up the UK control sample in the initial NeuroDys GWAS sample (Chapter 4).
Samples in Cardiff Individual Genotyping Sample 
Present in Other Sample Sets
Cardiff Individual 
Genotyping Sample
NeuroDys 
GWAS Sample
NeuroDys
Replication
Sample
NeuroDys UK 
Pool
Cases 357 147 208 187
Controls 269 0 268 219
Table 6.2: Sample used to individually genotype the Cardiff pooling study follow-up panel and its 
overlap with other sample sets used in the NeuroDys studies.
6.2.2.2 Individual Genotyping
SNPs were chosen for follow up with individual genotyping based on their 
significance in the Cardiff pooling study. The top 100 non-redundant SNPs were 
entered into the Sequenom Mass ARRAY Assay Design 3.1 software in order to design 
2 multiplex panels of 35 SNPs (see Table D.3 in Appendix for primer sequences).
The panels of SNPs were genotyped in the case control sample using the Sequenom 
MassARRAY iPlex GOLD system as described in Chapter 2. Genotype calling was 
carried out using the Typer 3.4 software. The UK population controls had previously 
been genotyped on the Illumina HumanHap550 chip.
All SNP assays were optimised as described in the Chapter 2. Sequenom cluster 
plots for all SNPs were inspected manually, and SNP assays that did not produce
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distinct clusters were excluded. Genotyping assays were only considered suitable for 
analysis if genotypes for CEU individuals were the same as those in the HapMap when 
available during optimisation. SNPs were tested for Hardy-Weinberg equilibrium in 
cases and controls and their MAFs were calculated using PLINK vl .05 (Purcell et al. 
2007). To exclude poorly performing samples, those with a call rate < 70% were 
excluded.
SNPs were tested for an association with DD using logistic regression carried out in 
PLINK vl.05 (Purcell et al. 2007) using both the additive and genotypic models. This 
analysis was performed with the Cardiff pooling sample and with the additional Cardiff 
samples that were individually genotyped but were not in the pools (Cardiff individual 
genotyping sample). Data from the 1958 British Birth Cohort typed on the Illumina 
HumanHap550 array (n = 3748) were also included at a later stage to increase the size 
of the control sample (Cardiff sample with population controls).
6.2.2.3 Comparison With Previous GWAS
In order to ascertain the concordance across studies for those SNPs that were 
individually genotyped, their association results in this study were compared with those 
in the NeuroDys pooling study (Chapter 5), both when genotyped in the NeuroDys UK 
pool alone and in all NeuroDys pools. The results were also compared with those in the 
initial NeuroDys GWAS sample described in Chapter 4 (in both the UK subset and the 
whole sample). As the initial NeuroDys GWAS was carried out using the smaller 
Illumina HumanHap300 array, not all of the SNPs that were individually genotyped in 
this pooling study had been genotyped in the initial GWAS as well. For those SNPs, 
imputation was carried out on the NeuroDys dataset using PLINK vl.05 (Purcell et al. 
2007), as described in Chapter 2. Association analysis was then carried out in the same 
way as in the GWAS (see Chapter 4) using imputed genotypes for SNPs that had an 
information score greater than 0.8 as recommended in the PLINK documentation.
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6.3 Results
6.3.1 Cardiff Pooling Study
The aim for this section of the thesis was to identify variants that were significantly 
associated with DD in the Cardiff case-control sample alone, so a GWAS was 
conducted using pooled DNA. As explained in section 6.2.1.1 of this chapter, the 
control pool is the same as the UK pool of the NeuroDys study. However, the case pool 
consists of only Cardiff cases, plus additional cases that were not included in the 
NeuroDys pooling sample (Chapter 5) but had been genotyped in the initial GWAS 
(Chapter 4). Table 6.3 shows the results of validating these pooled samples using 
SNaPshot. For the SNP rsl 1648084, the pools had an error rate of 0.30% and for 
rs l892577 there was an error rate of 0.78%. This gave an overall average error rate of 
0.54%.
SNP
Difference in allele 
frequencies from individual 
genotyping (%)
Difference in allele 
frequencies estimated from 
pools (%) % Error rate
rsl 1648084 0.57 0.87 0.30
rsl 892677 4.71 3.93 0.78
Table 6.3: Comparison of difference in allele frequencies when the Cardiff case control samples were 
genotyped individually and in pools.
Genome-wide pooled genotyping of the Cardiff cases and controls was also carried 
out on the Illumina lM-Duo chip. Predicted allele frequencies for each SNP were 
averaged over the replicate case and replicate control assays. One of the chips for the 
case replicates had sections that could not be imaged by the iScan system (either due to 
hybridisation or staining issues) so it was not included in subsequent analyses. Another 
case replicate and a control failed QC with Pearson’s correlations r = 0.995 and 0.992 
respectively. The remaining 4 case replicates and 5 control replicates all passed QC 
with Pearson’s correlations r>  0.997 (see Table D.2 in Appendix for all correlations).
Following stringent QC filters, 753,768 SNPs were analysed. Figure 6.1 shows the 
P-values for these SNPs, calculated using the Combined Z-test. Three of these SNPs 
achieved a genome-wide level of significance, rsl 1198878 on chromosome 10 (P = 1.14 
x 10'9), rs6865447 on chromosome 5 (P = 1.51 x 10'9) and rs4687806 on chromosome 3 
(P = 4.37 x 10“8). A further 181 SNPs had P-values <1 x 10"4 (see Table D.4 in 
Appendix for a list of the 200 most significant SNPs).
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Figure 6.1: Manhattan plot of combined P-values (-loglO) from the Cardiff Pooling Study. The red line indicates genome-wide significance with a P-value of 5 x 10'8; the 
blue line indicates a P-value of 5 x 10'5
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6.3.2 Individual Genotyping of Follow-Up Panels
As with the NeuroDys pooling study, SNPs were selected for individual genotyping 
to validate interesting results (see Table 6.4). In selecting these SNPs, redundant SNPs 
(i.e. those in LD at an r2 > 0.8 with a more significant SNP) were removed from those 
184 SNPs that had a P-value < 1 x 10-4. The top 100 remaining SNPs were then selected 
for assay design, and assays were successfully designed for 70 of these SNPs.
The follow-up panels of SNPs were tested for an association with DD through 
individual genotyping in the Cardiff pooling sample. They were also genotyped in an 
additional 55 Cardiff cases and 50 controls (‘Cardiff individual genotyping sample’). 
Finally, for the SNPs in these panels that were also present on the Illumina 
HumanHap550 array, the Cardiff individual genotyping sample data was merged with 
data from the 1958 Birth Cohort to increase the size of the control sample.
When genotyping these panels in the Cardiff pooling sample, 292 cases and 215 
controls passed QC (call rate > 70%). When including the additional samples, 331 cases 
and 262 controls passed QC (call rate > 70%).
As shown in Table D.5 in the Appendix, 12 out of 70 SNPs failed optimisation. Of 
the remaining 58 markers, one SNP (rsl0978074) had a call rate of 66% in both the 
pooled samples and in all samples so was excluded from association analyses. The 
remaining 57 SNPs had call rates greater than 72% in both the Cardiff pooling sample 
and in the Cardiff individual genotyping sample. Seven SNPs had MAFs < 0.05 in both 
the Cardiff pooling sample and in the Cardiff individual genotyping sample but were 
retained in the analysis. Four of the SNPs were out of Hardy-Weinberg equilibrium in 
the controls. These were not excluded from the association analyses but any association 
found with these SNPs should be treated with caution.
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SNP Rank Chr Position (bp) Nearest RefSeq Gene Position Relative to Gene MAF cases MAF controls P-Comb OR
rs4687806 3 3 52119222 POC1A Intronic 0.23 0.11 4.4 x 10* 2.53
re11088038 4 21 27924144 NCRNA00113 Interqenic 0.14 0.05 2.1 x 10'' 3.23
rsl 1083783 5 19 51050518 SYMPK Intronic 0.07 0.19 2.5x10" 0.35
rsl 0978074 6 9 9894481 PTPRD Intronic 0.15 0.05 4.5x10" 3.13
rsl 7536837 8 9 72366156 TRPM3 Intronic 0.29 0.16 7.1 x 10" 2.16
rs6846073 9 4 38634119 FAM114A1 Interqenic 0.23 0.11 7.5x10" 2.35
rs2007343 10 20 59592324 CDH4 Intronic 0.40 0.25 9.8x10" 3.23
rs9890811 11 17 52767460 MSI2 Intronic 0.19 0.08 1.1 x 10* 2.56
rs6045824 12 20 1909977 PDYN Intronic 0.19 0.09 1.1 x10* 2.50
rs327216 15 8 26547380 DPYSL2 Intronic 0.20 0.09 1.3 x 10”* 2.37
rs488007 16 2 230393214 TRIP12 Intronic 0.20 0.09 1.3 x 10*° 2.44
rs1423363 17 5 58175888 RAB3C Intronic 0.11 0.23 1.6x10* 0.43
rs7404238 19 16 47320826 N4BP1 Intergenic 0.29 0.17 1.9 x 10* 2.06
rsl 0486656 20 7 34767285 NPSR1 Intronic 0.22 0.11 1.9x10* 2.3
rsl 352726 21 5 107065959 EFNA5 Intergenic 0.14 0.05 2.0x10’* 2.78
rsl 0745796 25 12 96330306 RMST Intergenic 0.15 0.06 2.6 x10"* 2.70
rs3758268 28 9 33394401 SUGT1P1 Intronic 0.18 0.08 3.3 x 10"* 2.39
rs7330054 29 13 109784633 COL4A2 Intronic 0.22 0.11 3.4x10-* 2.23
rs7320998 31 13 34345783 NBEA Intergenic 0.08 0.18 4.1 x 10* 0.39
rsl 0504912 32 8 92991692 RUNX1T1 Intergenic 0.05 0.15 4.3 x 10* 0.33
rsl 1617247 33 13 41003320 KIAA0564 Intergenic 0.20 0.10 5.0x10* 2.27
rsl 0493241 36 1 58556559 DAB1 Intergenic 0.23 0.12 5.8x10-* 2.10
rs7999 37 3 187853044 FETUB Exonic 0.14 0.06 5.8x10"* 2.63
rsl 2281150 39 11 84631655 DLG2 Intronic 0.08 0.18 6.1 x 10* 0.40
rsl 7440080 40 12 17276384 LM03 Intergenic 0.13 0.05 6.4 x 10-* 2.95
rs6695238 41 1 43411023 WDR65 Exonic 0.14 0.06 6.4x10-* 2.63
rs4431050 43 3 36855688 TRANK1 Intronic 0.20 0.10 8.8 x 10-* 2.19
rs2779708 44 9 129019546 RALGPS1 Intronic 0.35 0.23 8.9x10"* 1.84
rs1043180 46 8 11682230 NEIL2 3' UTR 0.22 0.11 1.0 x 10* 2.13
Table 6.4: SNPs in follow-up panel for individual genotyping. Chr -  chromosome; UTR -  untranslated region; MAF -  minor allele frequency; OR -  odds ratio; P-Comb -  P- 
value from combined Z-test.
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SNP Rank Chr Position (bp) Nearest RefSeq Gene Position Relative to Gene MAF cases MAF controls P-Comb OR
rs10036698 48 5 5842072 KIAA0947 Intergenic 0.19 0.09 1.0 x10"6 2.33
rs6581224 49 12 57670904 LRIG3 intergenic 0.18 0.09 1.1 x 10"° 2.25
rs10492922 52 16 27519162 KIAA0556 Intronic 0.19 0.09 1.2 x 10"6 2.22
rs1885170 53 9 17554267 SH3GL2 Intergenic 0.13 0.05 1.3 x 10"° 2.78
rs11800516 55 1 188170120 FAM5C Intergenic 0.19 0.09 1.3 x 10"° 2.22
rs2017069 56 2 223630015 KCNE4 Downstream 0.06 0.14 1.3 x 10"° 0.37
rs1600677 58 15 98535787 ADAMTS17 Intronic 0.05 0.14 1.5 x 10"° 0.37
rs11119153 59 1 207142181 LOC642587 Intergenic 0.06 0.15 1 .5 x 1 0 ° 0.38
rs10519003 60 15 57498029 FAM81A Intergenic 0.23 0.37 1.6x10"° 0.53
rs2838088 61 21 41965270 NCRNA00111 Intergenic 0.29 0.18 1.6x10"° 1.9
rs13250254 62 8 78160148 PEX2 Intergenic 0.45 0.31 1.6 x 10"° 1.78
rs12402777 63 1 188122473 FAM5C Intergenic 0.19 0.09 1.7x10"° 2.22
rs3906517 64 5 107169152 FBXL17 Intergenic 0.14 0.05 1.7x10"° 1.85
rs17533238 65 2 201209676 AOX1 Intronic 0.32 0.20 1.8x10"° 2.45
rs13375505 66 1 69191724 DEPDC1 Intergenic 0.15 0.06 1 .9 x 1 0 ° 2.21
rs1872183 69 5 180178532 MGAT1 Upstream 0.18 0.09 2 .0 x 1 0 ^ 1.9
rs3785327 71 16 56235199 GPR56 Intergenic 0.32 0.20 2 .2 x 1 0 ° 1.84
rs12679969 73 8 102156725 ZNF706 Intergenic 0.31 0.20 2.2x10"° 1.85
rs12218153 75 10 109013136 SORCS1 Intergenic 0.31 0.19 2 .2 x 1 0 ° 1.85
rs4787965 76 16 27458838 GTF3C1 Intronic 0.09 0.18 2.4x10"° 0.44
rs13059624 77 3 100016640 DCBLD2 Intronic 0.15 0.07 2 .4 x 1 0 ° 2.37
rs10490093 78 2 58779250 FANCL Intergenic 0.37 0.25 2.4x10"° 1.82
rs10497719 79 2 192085839 M Y01B Intergenic 0.24 0.14 2 .4 x 1 0 ° 1.98
rs10844773 82 12 7401511 CD163L1 Intronic 0.10 0.20 2.5x10"° 0.46
rs2745615 85 6 1582259 GMDS Intronic 0.22 0.12 2.6x10"° 2.01
rs11898211 86 2 223658537 KCNE4 Intergenic 0.21 0.11 2 .7 x 1 0 ° 2.08
rs17269545 87 15 57269689 M Y01E Intronic 0.06 0.15 2 .7 x 1 0 ° 0.40
rs10267147 89 7 155359690 SHH Intergenic 0.25 0.14 2.9x10"° 2.00
Table 6.4 continued
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SNP Rank Chr Position (bp) Nearest RefSeq Gene Location relative to gene MAF cases MAF controls P-Comb OR
rs2748516 91 14 23800302 TGM1 Intronic 0.18 0.09 3.1 x 10° 2.22
rs1125198 93 7 130580090 MKLN1 intergenic 0.21 0.11 3.3x10*° 2.08
rs1571581 95 9 102698290 LPPR1 intergenic 0.34 0.22 3.4 x 10*° 1.80
rs17180009 96 16 84978318 LOC732275 intergenic 0.11 0.21 3.4x10*° 0.47
rs804163 97 5 115706855 COMMD10 Intergenic 0.25 0.15 3.4x10*° 1.92
rs968592 98 11 1619112 MOB2 Intronic 0.32 0.2 3.4x10*° 1.83
rs8045270 99 16 85243688 FOXL1 Intergenic 0.17 0.08 3.4x10*° 2.21
rs1529074 104 3 34481950 PDCD6IP Intergenic 0.16 0.08 4.0x10*° 2.24
rs2050406 106 20 16563735 KIF16B Intergenic 0.17 0.08 4.1 x 10*° 2.21
rs10989439 110 9 103021853 LPPR1 Intronic 0.15 0.07 4.3x10*° 2.33
rs17804825 114 20 18183516 ZNF133 Intergenic 0.11 0.21 4.5 X10*6 0.47
rs6989022 115 8 121787847 SNTB1 Intronic 0.18 0.09 4.6x10*° 2.12
rs3741781 117 12 107702132 SSH1 3' UTR 0.19 0.09 4.6 xIO*5 2.19
Table 6.4 continued
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The results from the individual genotyping are shown in Table 6.5, in order of then- 
rank in the Cardiff pooling study. Although these SNPs were not as significantly 
associated as they had been in the pooling study, when genotyped individually in just 
the Cardiff pooled sample, 54 SNPs gave significant P-values (<0.05) and when 
genotyped in the whole Cardiff individual genotyping sample, 50 SNPs gave significant 
P-values. None of these SNPs were significant at a genome-wide level.
The top hit was rs4687806 (P = 1.0 x 10’5). Out of those SNPs selected for 
individual genotyping, this was also the most significant SNP in the pooling study (P- 
comb = 4.4 x 10'8). It remained the most significant SNP when analysing the additional 
Cardiff cases and controls as well (P = 2.0 x 10'5). This SNP was also significantly 
associated in the UK NeuroDys pool (P-comb = 0.0025) and in the entire NeuroDys 
pooling sample (P-Fisher = 0.0072). However, it didn’t show a high enough level of 
significance and was not selected for individual genotyping in that study. This SNP was 
not significantly associated with DD in the NeuroDys UK GWAS sample (P-add = 
0.618) or in the complete NeuroDys GWAS sample (P-add = 0.601) (Chapter 4). This 
SNP is an intronic SNP in the gene POC1 centriolar protein homolog A (POC1A) on 
chromosome 3. This gene is a homolog of the POC1 gene which is thought to be 
involved in centriole duplication and length control (Keller et al. 2009). Centrioles are 
organelles that are involved in the organisation of the mitotic spindle and in the 
completion of cytokinesis (Salisbury et al. 2002). By homology, POC1A may have a 
similar involvement in centrioles, but it is unclear how this may be linked with a DD 
phenotype and this gene does not show a high level of expression in the brain.
When the additional samples were combined with the pooled samples, the level of 
significance was reduced for a number of SNPs. However, 9 SNPs showed an increased 
level of significant association in all samples. The largest difference in P-values was for 
the SNP rs2050406 (P = 0.0015 and OR = 2.03 when genotyped in the pooled samples, 
P = 4.6 x 10-4 and OR = 1.99 when genotyped in all samples). This SNP also showed a 
high level of significance in the NeuroDys UK pool (P = 1 x 10-4) but was not as 
significantly associated in the complete NeuroDys pooling sample (P-Fisher = 0.0038) 
so was not selected for individual genotyping in the NeuroDys study (Chapter 5). This 
SNP is in an intergenic region on chromosome 20, with the nearest gene being kinesin 
family member 16B (KIF16B) which is over 360kb away. However, it is possible that 
this SNP affects the expression of this gene as the P-value of this SNP with expression
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levels of KIF16B is 0.0332 in lymphoblastoid cell lines in the Genevar database, but is 
not significantly associated in fibroblasts or T-cells (Dimas et al. 2009).
The most significant SNP to show an increase in significance with the additional 
samples was rsl 125198 (P = 1.8 x 10"4 and OR = 2.35 when genotyped in the Cardiff 
pooled samples, P = 1.3 x 10-4 and OR = 2.19 when genotyped in the Cardiff individual 
genotyping sample). This SNP did not show a high level of significance in the 
NeuroDys UK pool (P = 0.0012) or in the complete NeuroDys pooling sample (P-Fisher 
= 0.0031) (Chapter 5). This is an intronic SNP is in the gene muskelin 1, intracellular 
mediator containing kelch motifs (MKLN1) as shown in Figure 6.2. This gene encodes 
an intracellular protein that acts as a mediator of cell spreading and cytoskeletal 
responses to the extracellular matrix (ECM) component thrombospondin I (TSP-1) 
(Adams et al. 1998).
The next most significant SNP to show an increase in significance with the 
additional samples was rs804163 (P = 7.9 x 10"4 and OR = 1.92 when genotyped in the 
Cardiff pooling sample, P = 6.2 x 10"4 and OR = 1.83 when genotyped in the Cardiff 
individual genotyping sample). This SNP did not show a high level of significance in 
the NeuroDys UK pool (P = 0.0355) or in all NeuroDys pools combined (P-Fisher = 
0.0366) (Chapter 5). This SNP is in an intergenic region of chromosome 5, ~50kb 
downstream of the nearest gene, COMM domain containing 10 (COMMD10). It is 
possible that this SNP may affect the expression of this gene but this SNP is not in 
either of the gene expression databases looked at so this was not tested (Dimas et al. 
2009; Dixon et al. 2007).
The remainder of the SNPs showing increased significance with the additional 
samples would not remain significant after correcting for 57 tests (P-values > 0.0010).
Of the SNPs that were selected for individual genotyping from the Cardiff pooling 
study, 2 were significant in the initial NeuroDys GWAS sample (Chapter 4), both in the 
UK subset and the whole sample (rsl 1898211, UK NeuroDys GWAS P-add = 0.0332, 
NeuroDys GWAS P-add = 0.016; rsl7804825, UK NeuroDys GWAS P-add = 0.0086, 
NeuroDys GWAS P-add = 0.027) and 1 was significant in the UK NeuroDys subset 
only (rs488007, UK P-add = 0.0159). These SNPs remained significant when genotyped 
individually in the Cardiff pooled samples (P = 3 x 10"4- 0.04) and also showed 
significance in the NeuroDys pooling sample in both the UK pool alone (P = 3.5 x 10"4 
-  0.025) and when all pools were combined (P-Fisher = 1.4 x 1 O'4 - 0.011) (Chapter 5).
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However, rsl 1898211 was no longer significantly associated when the additional 
Cardiff cases and controls were included in the Cardiff individual genotyping sample (P 
= 0.0654). Therefore, the only SNP that showed significant association in both the UK 
and combined samples across all studies is rs l7804825. This SNP is in an intergenic 
region, with the nearest gene being ZNF133 which is 33.6 Kb away. This SNP is not 
significantly associated with the expression levels of ZNF133 in fibroblasts, 
lymphoblastoid cell lines or in T-cells in the Genevar database so it does not appear to 
influence the expression of this gene (Dimas et al. 2009).
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Cardiff Pooling 
Study
individual 
Genotyping in 
Cardiff Pooling 
sample
Whole Cardiff 
Individual 
Genotyping 
Sample
Cardiff Sample 
With Population 
Controls
NeuroDys UK 
Port
All
NeuroDys
Ports
NeuroDys 
UK Subset of 
GWAS
NeuroDys
GWAS
Sample
SNP P-comb OR P-add OR P-add OR P-add OR P-comb OR P-Fisher P-add OR P-add OR
rs4687806 4.4 x 10"® 2.53 1.0x10* 3.15 2.0x10* 2.79 0.0012 1.51 0.0025 1.65 0.0072 0.6175 1.08 0.6007 1.07
rsl 1088038 2.1 x 10'7 3.23 0.0020 2.42 0.0145 1.82 0.5605 1.09 1.0x10* 2.57 1.4x10* 0.1890 0.81 0.1648 0.84
rsl7536837 7.1 x 10'7 0.35 0.0024 2.16 0.0019 2.01 4.2 x 10* 1.84 0.0024
rs6846073 7.5 x10'7 2.35 0.0015 2.01 0.0024 1.83 0.1337 1.20 0.0170 1.88 0.1902
rs2007343 9.8 x 10'7 1.93 1.7x10* 1.78 0.0019 1.51 0.0504 1.20 1.4x10* 1.61 0.0010 0.9588 1.01 0.4991 0.94
rs327216 1.3 x 10* 2.37 0.0085 2.06 0.0198 1.69 0.7732 1.04 3.9 x 10* 2.06 1.6 x104 0.9956 1.00 0.7563 1.05
rs488007 1.3 x 10* 2.44 3.0x10* 2.36 0.0030 1.82 0.0536 1.28 0.0143 1.74 0.0105 0.0159 1.37 0.0917 1.22
rsl 423363 1.6 x 10* 0.43 3.3 x 10* 0.52 7.1 x 10* 0.57 1.7 x 10* 0.55 0.0032
rs7404238 1.9 x 10"6 2.06 0.0329 1.68 0.0432 1.62 0.6620 0.94 0.0572 1.41 0.1094 0.6240 0.94 0.3002 0.91
rsl0486656 1.9 x 10"* 2.3 0.0023 2.03 0.0120 1.64 0.0667 1.25 4.1 x 10* 1.96 5.0 x 10* 0.9412 1.01 0.7148 1.03
rsl 352726 2.0 x 10* 2.78 0.0037 2.10 0.0021 2.12 0.4609 1.11 0.0014 0.51 0.0128 0.9503 1.01 0.4881 1.09
rsl0745796 2.6 x 10-® 2.70 0.0048 3.17 0.0059 2.66 4.3x10* 2.21 8.2 x 10*
rs3758268 3.3 x 10* 2.39 0.0058 2.02 0.0274 1.64 0.6925 1.06 0.0030 1.83 0.0073 0.9311 1.01 0.3992 0.90
rs7330054 3.4 x 10* 2.23 5.6 x 10* 2.43 5.7 x 10* 2.13 2.8 x 10* 1.71 0.0401 1.43 0.0997 0.2930 1.17 0.8549 1.04
rsl 1617247 5.0 x 10* 2.27 0.0015 2.23 0.0040 1.91 0.9611 1.01 0.0084 1.54 0.0441 0.9864 1.00 0.9753 1.01
rsl0493241 5.8 x 10'® 2.10 0.0408 1.51 0.2379 1.21 0.6287 1.06 0.0380 1.43 0.0611 0.7169 1.05 0.7970 0.96
rs7999 5.8 x 10-® 2.63 0.0064 2.36 0.0328 1.77 0.0157 1.76 0.0287
rsl 2281150 6.1 x 10* 0.40 7.2 x 10* 0.32 1.3x10* 0.37 0.0434 0.65 3.0 x 10* 0.50 0.0034 0.5872 1.10 0.4356 1.09
re17440080 6.4X10* 2.95 0.0034 2.08 0.0041 1.86 0.0029 2.27 0.0043
rs6695238 6.4 x 10* 2.63 0.0186 2.49 0.0072 2.64 2.7 x 10* 2.46 6.7 x 10*
rs4431050 8.8 x 10* 2.19 0.0035 1.99 0.0217 1.57 0.0875 1.24 0.0198 1.53 3.2x10* 0.2802 1.15 0.6156 1.06
rs2779708 8.9x10* 1.84 6.4 x 10* 1.66 0.0064 1.43 0.2437 1.11 4.4 x 10* 1.59 0.0033 0.3272 0.91 0.8178 0.98
rs1043180 1.0x10* 2.13 0.0062 1.81 0.0025 1.80 0.0202 1.31 0.0025 1.58 0.0014 0.1689 1.18 0.2353 1.10
rsl0036598 1.0x10* 2.33 0.0677 1.68 0.1985 1.37 0.7030 0.94 0.0062 1.71 0.0393 0.7904 1.04 0.8702 1.03
rs6581224 1.1 x 10* 2.25 0.0036 1.82 0.0010 1.85 0.0930 1.22 0.0111 1.60 0.0282 0.2610 1.15 0.2207 1.11
re1885170 1.3x10* 2.78 0.0052 2.80 0.0121 2.29 3.7x10* 2.35 5.3 x 10*
rsl 1800516 1.3x10* 2.22 0.0012 2.45 0.0101 1.92 0.3725 1.20 0.1740
e, and in the CardiffTable 6.5: Results of the individual genotyping of the follow up panel for the Cardiff pooling samples, for the whole Cardiff individual genotyping samp 
sample with population controls (if on the Illumina HumanHap550 array). The results of these SNPs in the NeuroDys GWAS sample (if genotyped) and die NeuroDys 
pooling sample are also shown. OR -  odds ratio; P-comb -  P value from combined Z-test; P-Add -  P-value from additive test. Significant P-values (<0.05) are in bold. 
GWAS results in italics are based on imputed SNPs.
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SNP P-comb OR P-add OR P-add OR P-add OR P-comb OR P-Fisher P-add OR P-add OR
rs2017069 1.3x10-* 0.37 0.0089 0.48 0.0201 0.54 0.0743 0.69 0.0092 0.60 7.7 x 10* 0.7980 0.95 0.9544 0.97
rsl 1119153 1.5 x 10"6 0.38 0.0027 0.50 0.0061 0.57 0.0036 0.62 9.4 x10*7 0.35 9.6 x 10* 0.2423 0.84 0.3528 0.88
rsl 0519003 1.6 x 10* 0.53 5.7 x 10* 0.59 0.0014 0.63 0.0066 0.76 0.0022 0.58 7.4 x 10* 0.4797 0.93 0.1600 0.89
rs2838088 1.6x10* 1.9 1.8x10* 1.90 0.0043 1.56 0.0224 1.42 0.0550
rsl 3250254 1.6x10-* 1.78 4.9 x 10* 1.76 1.0x10* 1.64 0.0088 1.41 0.0235 0.7196 0.97 0.8662 1.01
rsl 2402777 1.7x10-® 2.22 6.7 x 10* 2.88 7.4x10* 2.31 0.1222 1.37 0.3057
rsl 7533238 1.8 x 10"® 1.85 0.0043 1.68 0.0055 1.64 0.1422 1.17 0.0075 1.52 0.0145 0.4449 0.91 0.5687 0.95
rsl 3375505 1.9x10-* 2.45 0.0088 1.89 0.1076 1.40 0.1920 1.19 0.0136 1.69 0.0677 0.3853 0.88 0.4528 0.91
rs1872183 2.0 x 10-® 2.21 5.1 x 10* 2.29 0.0010 2.02 0.1166 1.23 2.4x10* 1.86 6.6 x 10* 0.4437 1.11 0.5638 1.07
rs12218153 2.2 x 10-® 1.85 0.0026 1.78 0.0221 1.48 0.0085 1.34 0.0026 1.55 0.0013 0.6034 1.06 0.1568 1.15
rs4787965 2.4x10-* 0.44 0.0140 0.50 0.0291 0.55 0.0639 0.68 0.0012 0.55 0.0264 0.3308 0.83 0.6489 0.94
rsl0490093 2.4x10-* 1.82 0.0050 1.73 0.0099 1.56 8.1 x 10* 1.73 0.0021
rsl 0497719 2.4 x 10-* 1.98 0.0113 1.77 0.0130 1.60 0.0358 1.28 9.7 x 10* 1.66 0.0065 0.6124 1.06 0.5996 0.96
rsl0844773 2.5x10-* 0.46 2.6x10* 0.42 0.0026 0.51 7.8 x 10* 0.51 4.2 x 10* 0.43 1.9x10* 0.1391 1.19 0.2459 1.12
rs2745615 2.6 x 10* 2.01 0.0164 1.79 0.1956 1.34 0.3896 1.13 0.0545 1.39 0.0198 0.1927 1.20 0.1616 1.18
rsl 1898211 2.7x10* 2.08 0.0398 2.06 0.0654 1.81 0.3829 0.84 0.0251 1.51 0.0100 0.0332 1.34 0.0160 1.31
rsl 7269545 2.7x10* 0.40 0.0538 0.55 0.0930 0.62 0.2820 0.84 0.0384
rsl 0267147 2.9 x 10* 2.00 1.7x10* 2.03 3.9 x 10* 1.93 0.0122 1.55 0.0615
rs2748516 3.1 x 10* 2.22 0.0306 1.84 0.0466 1.67 4.6x10* 1.97 3.6 x 10*
rsl 125198 3.3 x 10* 2.08 1.8x10* 2.35 1.3x10* 2.19 2.2 x 10* 1.56 0.0012 1.86 0.0031 0.1293 1.22 0.0612 1.21
rsl 571581 3.4 x 10* 1.8 0.0015 1.74 0.0061 1.52 0.0090 1.30 0.0121 1.42 0.0389 0.5240 1.07 0.4093 1.07
rs804163 3.4x10* 1.92 7.9 x 10* 1.92 6.2 x 10* 1.83 0.0355 1.37 0.0366 0.6275 0.93 0.7378 0.96
rs968592 3.4 x 10* 1.83 0.0011 1.80 0.0022 1.71 0.0109 1.30 0.0246 1.38 0.1248 0.3481 1.12 0.9066 1.01
rs8045270 3.4x10* 2.21 0.0016 2.87 0.0078 2.20 0.0052 1.73 0.0039
rsl 529074 4.0 x 10* 2.24 0.1210 1.67 0.1257 1.58 4.2x10* 1.95 0.0044
rs2050406 4.1 x 10* 2.21 0.0015 2.03 4.6 x 10* 1.99 0.0084 1.36 1.0x10* 2.09 0.0038 0.2489 1.16 0.0583 1.20
rsl 0989439 4.3x10* 2.33 0.0060 3.34 0.0129 2.54 0.0063 1.69 0.0162
rsl7804825 4.5x10* 0.47 0.0010 0.47 0.0020 0.51 0.0123 0.67 3.5x10* 0.55 1.4x10* 0.0086 0.67 0.0270 0.79
rs6989022 4.6x10* 2.12 0.0043 1.97 0.0013 2.05 0.1731 1.20 0.0102 1.65 0.0226 0.0937 1.25 0.2158 1.15
rs3741781 4.6 x 10* 2.19 0.0036 2.52 0.0085 2.06 0.0014 1.83 0.0080
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Figure 6.2: LD plot and results of SNPs in MKLN1 that were genotyped in the Cardiff pooling study. Red bars indicate P-values < 5 x 10'5.
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Of the SNPs that were selected for individual genotyping in the Cardiff pooling 
study, 37 are on the Illumina HumanHap550 array so have been previously genotyped 
in the 1958 British Birth Cohort. In order to ascertain if any of the SNPs would increase 
in significance when including more controls, the data from the 262 controls that were 
individually genotyped were merged with data from 3748 population controls from the 
1958 British Birth Cohort to form a combined sample of 4010 controls (‘Cardiff sample 
with population controls’). Association analyses were then performed comparing these 
controls with all of the cases that were individually genotyped as part of the Cardiff 
pooling study (n = 331).
As shown in Table D.6 in the Appendix, all 37 SNPs passed QC with call rates > 
0.96 and MAFs > 0.05. Three SNPs were out of Hardy Weinberg equilibrium in the 
control sample. These were not excluded from the association analyses but any 
association found with these SNPs should be treated with caution. All samples passed 
QC with genotyping rates > 80%.
The results of these 37 SNPs in the Cardiff sample with population controls are 
shown in Table 6.5. Their P-values in the Cardiff pooling sample and in the Cardiff 
individual genotyping sample are also shown, along with their results in the NeuroDys 
pooling sample (Chapter 5) and the NeuroDys GWAS sample (Chapter 4).
When the Cardiff samples are combined with the population controls, 14 SNPs 
showed significant association with DD (P < 0.05) with 3 of these SNPs giving P-values 
< 5 x 104 (rs7330054, P = 2.8 x 10'5; rsl0844773, P = 7.8 x 10‘5; rsl 125198, P = 2.2 x 
10-4).
The two most significant SNPs were the only ones to show an increased level of 
significance in this larger sample using the population controls than when they were 
analysed in the Cardiff individual genotyping sample alone. When tested for association 
using the Cardiff individual genotyping sample, rs7330054 gave a P-value of 5.7 x 1 O'4 
(OR = 2.13) and a P-value of 2.8 x 10'5 (OR =1.71) when including the population 
controls. This SNP lies within intron 3 of the gene collagen type IV alpha 2 (COL4A2), 
as shown in Figure 6.3. No other SNPs in this gene had a P-value < 1 x 10-4 in the 
Cardiff pooling study, but the SNP rs7323190 -1Kb away, had a P-value of 0.0052. 
These SNPs are in LD with each other (D’= 1) but they are not highly correlated (r2 = 
0.19).
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The next most significant SNP was rs l0844773 which gave a P-value of 0.0026 
when tested for association using the Cardiff individual genotyping sample and a P- 
value of 7.8 x 10'5 when including the population controls. This SNP lies within 
intronl8 of the gene CD 163 molecule-like 1 (CD163L1) as shown in Figure 6.4. Again, 
no other SNPs in this gene had a P-value < 1 x 10-4 in the Cardiff pooling study, with 
the next most significant SNP being rsl 1053657 (P = 0.008) which is ~40Kb upstream 
of rsl 0844773. These SNPS are not in high LD with each other, with D ’ = 0.238 (r2 = 
0.01).
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6.3 Discussion
A genome-wide pooling study was conducted using Cardiff cases and controls in 
order to identify variants that are associated with DD in this more homogeneous sample. 
As with the NeuroDys pooling study, the Illumina Human lM-Duo array was employed. 
After QC filtering, 753,768 SNPs were tested for an association in the Cardiff pools 
which consisted of 302 cases and 219 controls.
184 SNPs had P-values < 1 x 10*4, and three of these achieved genome wide levels 
of significance (P < 5 x 10‘8). 57 of the top 120 SNPs were successfully genotyped 
individually in 292 cases and 215 controls that were in the pools, and in an additional 39 
cases and 47 controls. Two of the genome wide significant SNPs (rsl 1198878 and 
rs6865447) were not individually genotyped as assays for these SNPs (or any proxies 
with r2 > 0.8) could not be designed into the panels. Of the 57 SNPs, 54 remained 
significant (P < 0.05) when they were genotyped individually in the Cardiff pooling 
sample. The genome-wide significant SNP that was individually genotyped was the 
most significant hit (rs4687806, P = 1 x 10'5).
When including the additional Cardiff cases and controls, 50 of the SNPs remained 
significant, and 9 SNPs showed a higher level of significance. The most significant SNP 
to show an increase in significance when including the additional samples was 
rsl 125198 which had a P-value of 1.8 x 10"4 when genotyped individually in the Cardiff 
pooling sample and 1.3 x 10-4 with the additional Cardiff samples. With the addition of 
the population controls, this SNP still showed a high level of significance (P = 2.2 x 10' 
4) but had a smaller effect size (with Cardiff controls OR = 2.19, with population 
controls OR = 1.56). This is an intronic SNP within the gene MKLN1 which encodes an 
intracellular protein that acts as a mediator of cell spreading and cytoskeletal responses 
to the ECM component TSP-1 (Adams et al. 1998). TSPs are secreted by immature 
astrocytes during embryonic development and promote CNS synaptogenesis (Christian 
et al. 2008) and MKLN1 transcripts have been identified in many adult tissues including 
the brain (Adams et al. 1998). Tagnaouti and colleagues (2007) have shown that 
transcripts of MKLN1 are expressed throughout the CNS, particularly in the 
hippocampus and cerebellum. They also showed that muskelin localises to the nucleus 
of neurons as well as to axonal and dendritic projections, including synaptic sites, 
giving it a possible role within synaptogenesis (Tagnaouti et al. 2007). Therefore this
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gene appears to have a role within synaptogenesis in the hippocampus and cerebellum 
and so could have an interesting role within the context of DD.
Data from the 1958 Birth Cohort for the 37 SNPs in the follow up panel that are also 
present on the Illumina HumanHap550 array were combined with the Cardiff case- 
control data in order to increase the control sample size. After adding the population 
controls to the Cardiff sample, many SNPs were no longer significant, with 14 
remaining significant. A possible explanation for the reduction in significance of these 
SNPs is that the initial findings were false positives due to sampling variation. Another 
possibility is that the use of population controls that had not been screened for DD may 
have reduced the effect sizes of these variants and therefore the ability to detect a 
significant association. This could be tested in future studies by comparing the effects of 
including controls from the 1958 Birth Cohort against using population controls from 
the ALSPAC cohort. As discussed in Chapter 5, the children in this cohort have been 
tested for a variety of cognitive measures and could therefore be screened for symptoms 
of DD.
Of those that remained significant, two SNPs showed an increased level of 
significance in this larger sample. The most significant of these was rs7330054 which 
had a P-value of 5.7 x 10"4 when genotyped in just the Cardiff case control sample and a 
P-value of 2.8 x 10'5 with the addition of the population controls. This is an intronic 
SNP within the gene COL4A2 on chromosome 13. The next most significant SNP in 
this gene was rs7323190, which lies ~lKb upstream of rs7330054 and had a P-value of 
0.0052. These SNPs are in high LD with each other. The SNP rs7330054 had been 
genotyped in all the previous studies, but only showed a low level of significance in the 
UK NeuroDys pool (P = 0.0441), despite the large overlap in samples between the UK 
NeuroDys pool and the Cardiff pooling sample. This may either suggest that the UK 
pool was not able to estimate the allele frequencies of this SNP as accurately, resulting 
in a false negative, or this SNP does not show association in the Oxford sample.
COL4A2 encodes one of the six units of type IV collagen. The C-terminal portion of 
this protein is an inhibitor of angiogenesis and tumour growth; it inhibits proliferation 
and migration of endothelial cells and induces apoptosis (Kamphaus et al. 2000). This 
gene has ubiquitous expression, but shows its highest level of expression in the 
placenta. However, it has recently been linked with a range of cerebral small-vessel 
diseases in humans so may also have a role to play in the brain by affecting the blood
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vessels (Volonghi et al. 2010). Small-vessel disease is more common in older people 
and it is thought that it may contribute to cognitive decline by affecting information 
processing speed and executive function (Prins et al. 2005). It is possible that this gene 
may influence an individual’s susceptibility to DD by affecting the blood vessels in 
their brain, impairing their cognition and therefore their ability to read effectively.
The other SNP which showed a higher level of significance when including the 
population controls was rs l0844773 which had a P-value of 0.0026 in the Cardiff 
individual genotyping sample and a P-value of 7.8 x 10‘5 in the Cardiff sample with 
population controls. This is an intronic SNP within the gene CD163L1 on chromosome 
12. The SNP rsl 0844773 was also genotyped in all previous studies, and while it wasn’t 
significantly associated in the initial NeuroDys GWAS study, it showed a high level of 
significance in the UK pool (P = 4.2 x 10'5) and in all NeuroDys pools combined (P- 
Fisher = 1.9 x 10-4) but it wasn’t selected for follow up with individual genotyping in 
that study because it was not significantly associated in either the Central European pool 
or the Finnish pool alone. The gene CD163L1 encodes a member of the scavenger 
receptor cysteine-rich (SRCR) superfamily (Gronlund et al. 2000). Members of this 
family are secreted or membrane-anchored proteins, mainly found in cells associated 
with the immune system (Van Gorp et al. 2010). This may be an interesting function 
within the context of DD as immune disorders have previously been linked with DD 
due to a hypothetical common aetiology via prenatal effects of testosterone (Behan & 
Geschwind 1985), although the evidence for this has been inconclusive and the two 
types of disorders do not consistently cluster in families (Gilger et al. 1998). In addition, 
the DYX2 region overlaps the human histocompatbility antigen (HLA) region, raising 
the possibility that the association observed between DD and immune disorders in some 
studies may be genetically linked (Cardon et al. 1994; Grigorenko et al. 1997). This 
region is highly polymorphic however and contains many genes that influence immune 
function.
This sample had a power of < 3.3% to detect a significant association (P< 1 x lO"4) 
with a variant that has a MAF of 0.4 and an OR of 1.3, and a power of 54% to detect a 
significant association at the P < 0.05 level with a variant with the same MAF and effect 
size. However, this power is reduced due to the loss of information that occurs when 
genotyping samples in pools. This shows that this pooling study was greatly 
underpowered to detect variants at this level of significance in comparison with the
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NeuroDys pooling study due to the very small sample size employed. However, after 
individual genotyping, the Cardiff pooling study identified more significant associations 
than the NeuroDys pooling study. This may be due to the ability of this study to identify 
association with variants of large effect sizes due to the use of a homogeneous sample 
that was collected using consistent ascertainment criteria. After individual genotyping in 
the Cardiff pooling sample, the effect sizes of the follow-up SNPs ranged from 1.6 6  to 
3.34, which are remarkably higher than the effect sizes of the follow up SNPs in the 
NeuroDys pooling study (OR = 1.01 -  1.58).
Whilst the level of significance of the SNPs after individual genotyping was lower 
than it had been in the Cardiff pooling study, the proportion of SNPs that remained 
significant after individual genotyping in the Cardiff pooling sample (95% of SNPs 
genotyped) was higher than in the NeuroDys pooling study (37% of SNPs genotyped), 
which suggests that the Cardiff pooling study was able to estimate allele frequencies 
more accurately. This indicates that there was a higher error rate in the NeuroDys study, 
and as discussed in Chapter 5, this may have been a result of combining samples from 
different countries. In addition, the NeuroDys pools were genotyped in Bonn, whereas 
the Cardiff pools in this study were genotyped in Cardiff. It may be that there was a 
higher pool-measurement error rate in the pooled samples genotyped in Bonn, resulting 
in inaccuracies in the estimation of the allele frequencies. These inaccuracies may have 
offset the savings made in terms time and money. This suggests that in order for pooling 
studies to be a valuable method of screening large samples at a lower cost, they ideally 
need to be conducted using samples that have been ascertained, prepared and genotyped 
in the same centres. However, this is not often possible in large collaborative GWAS 
studies involving several research groups.
In general, there was little concordance across all the GWAS studies conducted in 
this project. 47 of the 50 SNPs that were significant after individual genotyping in this 
study were also significant in the UK pool of the NeuroDys study and 42 of these were 
also significant when combining all the NeuroDys pools. It is not surprising that many 
of these SNPs were also significant in the UK pool as the case pools in each study had a 
large overlap of samples and the control pools were identical. None of these SNPs were 
selected for individual genotyping in that study, mainly because they were not 
significant in more than one pool. This suggests that these SNPs do not show a high 
level of association with DD in other population samples, possibly due to the difference
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in ascertainment criteria used. In the initial GWAS study, only one of these SNPs 
showed significant association in both the UK and combined samples (rsl7804825, P = 
0.0086 in UK sample, P = 0.0270 in all samples). This SNP is in an intergenic region, 
33.6 Kb upstream of the nearest gene, ZNF133.
In conclusion, this pooling study has highlighted three variants of potential interest 
within the genes MKLN1, COL4A2 and CD163L1 which may be worthy of further 
investigation in larger, independent samples. If they show replication in other samples, 
then these genes could be fine-mapped in order to identify any underlying causal 
variants. It should be noted that a relatively small proportion of SNPs were followed up 
and more significantly associated SNPs may have been confirmed using individual 
genotyping. This study has provided further evidence that pooling studies represent a 
cost effective approach to identifying variants that are significantly associated with a 
complex trait.
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Chapter 7: Copy Number Variant Analysis 
Using GWAS Data
7.1 Introduction
7.1.1 Structural Variation in the Human Genome
Single nucleotide polymorphisms were once thought to be the main source of 
genetic and phenotypic variation, but the advent of genome scanning technologies has 
enabled the identification of an unexpectedly large amount of structural variation in the 
human genome (Feuk et al. 2006; Stankiewicz & Lupski 2010). Structural variants are 
defined as ‘a change of genomic DNA greater than 1 kb in size that distinguishes two 
genomes in one species’ (Stankiewicz & Lupski 2010) and can be microscopic (i.e. 
those large enough to view with a microscope) or submicroscopic (Feuk et al. 2006). 
The microscopic variants were observed decades before the availability of sequencing 
technology and include aneuplodies, rearrangements, heteromorphisms and fragile sites. 
The development of new technologies (e.g. genome-scanning arrays and next- 
generation sequencing) has allowed the researcher to investigate the genome at a much 
higher resolution and this has led to the identification of smaller, submicroscopic 
variants including copy number variants (CNVs), segmental duplications, inversions 
and translocations (Feuk et al. 2006).
CNVs are segments of DNA ranging from 1 kb to several Mbs in size that are 
variable in copy number compared to a reference genome of the same species (Feuk et 
al. 2006; Stankiewicz & Lupski 2010). CNVs can be insertions, translocations, 
deletions, duplications and triplications. They can be simple in structure or may involve 
complex gains or losses of homologous sites at multiple sites in the genome (Redon et 
al. 2006). They can be inherited or sporadic and large de novo CNVs are thought to be 
the most pathogenic (Stankiewicz & Lupski 2010).
7.1.2 Mechanisms of Copy Number Change
A change in copy number requires a change in chromosome structure, joining two 
formerly separated DNA sequences (Hastings et al. 2009). Segmental duplications are
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defined as sequences in the reference genome assembly sharing >90% sequence 
similarity over >1 kb with another genomic location (Bailey et al. 2002) and CNVs are 
often reported to occur in regions that are flanked by segmental duplications (Freeman 
et al. 2006; Redon et al. 2006). When segmental duplications have DNA sequence 
identity greater than -97% and are located less than ~10Mb away from each other, they 
can lead to misalignment of chromosomes or chromatids and can mediate non-allelic 
homologous recombination (NAHR) - one of the three major mechanisms proposed for 
genomic rearrangements (Stankiewicz & Lupski 2002; Gu et al. 2008). As shown in 
Figure 7.1, non-allelic segmental duplications can sometimes be misaligned during 
meiosis or mitosis and this misalignment and the subsequent crossover between them 
can result in genomic rearrangements in progeny cells (Gu et al. 2008). When this 
occurs between segmental duplications that are on the same chromosome and in direct 
orientation with each other, this can result in duplications and/or deletions, as shown in 
Figure 7.1 A. When it occurs between segmental duplications on the same chromosome 
in reverse orientation it can result in inversions (shown in Figure 7.IB) and when it 
occurs between segmental duplications on different chromosomes it can result in 
translocations (shown in Figure 7.1C).
234
A:
A k. B C k Dmm r\
3 E E 3  I B
Deletion
B C■ ■ P
Duplication
b c
B:
D
,r:~ . i
B C
L t = ]
A ■  LI D
n  r~r~
Inversion
C :
D ele tio n  D uplication
Figure 7.1: Diagrams illustrating how NAHR via segmental duplications (indicated by the red arrows) 
can result in A: deletions (via mechanism 1) and/or duplications (via mechanism 2), B: inversions and C: 
translocations. Adapted from Gu et al. (2008).
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However, not all CNVs are flanked by segmental duplications. Some CNVs may be 
formed by a range of mechanisms of DNA repair that use very limited or no homology, 
such as non-homologous end joining (NHEJ). NHEJ is another major mechanism in the 
formation of CNVs (Gu et al. 2008) and involves the rejoining of the ends of double­
stranded breaks. When these are rejoined inaccurately, small deletions or ‘information 
scars’ are formed (Gu et al. 2008; Hastings et al. 2009).
The third major mechanism for the formation of CNVs is fork stalling and template 
switching (FoSTeS) (Gu et al. 2008). This is the process in which a replication fork 
stalls at one position during DNA replication and the lagging strand disengages from the 
original template, transfers and then anneals to another replication fork nearby due to 
microhomology at the 3’ end. This lagging strand ‘primes’ and then DNA synthesis is 
restarted (Lee et al. 2007; Gu et al. 2008; Hastings et al. 2009). The priming results in a 
‘join point’ with a transition from one segment of the genome to another. Switching to 
another fork located downstream (forward invasion) would result in a deletion whilst 
switching to a fork located upstream (backward invasion) would result in duplication 
(Gu et al. 2008).
7.1.3 Possible Effects of CNVs on Phenotypes
CNVs can cause phenotypic variation or disease in several ways, as shown in Figure 
7.2. One of the most commonly recognised mechanisms involves altering the copy 
number of a gene (or genes) sensitive to a dosage effect (Lupski et al. 1992). CNVs can 
affect gene dosage directly when they encompass a dosage-sensitive gene (Figure 
7.2A). As shown in the lower panel of Figure 7.2A, dosage-insensitive genes can also 
be affected by CNVs if a deletion of the gene unmasks a recessive mutation on the 
homologous chromosome. CNVs can also have a direct effect on gene-dosage when 
they only partly overlap a gene, shown in Figure 7.2B. CNVs overlapping a gene can 
also lead to the formation of new transcripts through gene fusions or exon shuffling. 
CNVs may also alter gene expression indirectly through position effects (Kleinjan & 
van Heyningen 2005), as shown in Figure 7.2C. This can be caused by deletion or 
duplication of an important regulatory element (upper panel) or through the unmasking 
of a functional polymorphism within an effector (lower panel).
CNVs can be benign, can have subtle influences on phenotypes (such as modifying 
an individual’s response to a particular drug), can cause disease or susceptibility to a 
disease in the current generation, or can predispose to disease in the next generation
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(Inoue & Lupski 2002). Although some CNVs might appear to be benign and are 
prevalent in certain populations, they may contribute to a complex disease phenotype 
when present in combination with other genetic (e.g. SNPs and other CNVs) and 
environmental factors (Feuk et al. 2006).
Some evidence has also suggested that CNVs may contribute to phenotypic 
variation that has a role in determining fitness. A gene ontology (GO) analysis of genes 
that were known to be affected by CNVs that had been identified in the literature to date 
by Feuk et al (2006) showed an enrichment of genes that are involved in immune 
responses and responses to biotic stimuli. These enrichments indicated that structural 
variation may have a role in the adaptability and fitness of an organism in response to 
external pressures (Feuk et al. 2006).
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7.1.4 Frequency of CNVs in the Human Genome
Previous studies of SNPs have revealed that any two randomly selected human 
genomes differed by 0.1%, but the study of CNVs in recent years has increased this 
estimate to 1% and most of this variation is due to CNVs (Beckmann et al. 2007; Redon 
et al. 2006). Whilst a SNP only affects a single base pair, their abundance in the genome 
makes them the most frequent source of variation (Beckmann et al. 2007). CNVs on the 
other hand are far less numerous but they can affect between 1 kb to several Mb of 
sequence and so add up to a significant fraction of the genome (Redon et al. 2006). 
Large-scale CNVs have been shown to be distributed heterogeneously throughout the 
genome and the proportion of any given chromosome susceptible to CNV varies from 
6 % to 9% (Redon et al. 2006). Recent studies have identified 11,700 CNVs overlapping 
1000 genes (Redon et al. 2006; Conrad et al. 2010), however this is likely to be an 
underestimation of the actual amount of copy number variation present in the genome as 
current methods are unable to accurately detect CNVs between 1-50 kb in size (Redon 
et al. 2006).
CNVs are also thought to be more prone to mutation than SNPs. Mutation rates for 
genomic rearrangements range between 1 O'4 and 10"5, at least 1000 to 10,000 fold more 
frequent than point mutations (Stankiewicz & Lupski 2010).
Altogether, their frequency, high mutation rates and ability to affect phenotypic 
variation make CNVs important sources of genomic variation to consider when 
identifying susceptibility variants for genetic diseases (Beckmann et al. 2007).
7.1.5 Identifying CNVs
As mentioned earlier, the development of new technologies has allowed us to 
investigate the genome at a much higher resolution, either in a genome-wide or a 
targeted manner. The main approaches for identifying structural variants have been 
array-based analyses (Feuk et al. 2006). Array-based comparative genome hybridisation 
(aCGH) approaches provide the most robust methods for carrying out genome-wide 
scans to identify CNVs (Pinkel et al. 1998). These approaches use labelled fragments 
from a genome of interest, which are competitively hybridised with a second 
differentially labelled reference genome to arrays that are spotted with cloned DNA 
fragments (e.g.bacterial artificial chromosome (BAC) clones). Differences in the
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fluorescent intensities identify regions of relative loss and gain in the test sample (Feuk 
et al. 2006; Carter 2007).
Another array-based approach to identifying CNVs is to use commercial genome- 
wide SNP-arrays. The combined intensity signals from both alleles at a particular SNP 
are measured and expressed as a log2 R ratio (LRR) between the recorded intensity and 
the expected intensity. The expected intensity is derived from the average intensity of 
the genotype clusters (Wain et al. 2009). Additionally, some studies use the ratio of 
fluorescence signals between allelic probes, termed the B allele frequency (BAF), since 
these ratios would be expected to be 0, 0.5 and 1.0 in the absence of CNVs. A large 
number of calling algorithms have been developed to turn these intensity signals into 
CNV calls and many of these, such as QuantiSNP (Colella et al. 2007) and PennCNV 
(Wang et al. 2007), use a hidden Markov model (HMM). This model segments the 
contiguous data into several predefined and biologically meaningful discrete states (see 
section 7.2.2 for more information on the PennCNV algorithm). However, the probes on 
these SNP arrays are not uniformly distributed across the genome and are particularly 
sparse in regions of segmental duplication, which creates problems for the design of 
robust genotyping SNP assays in these regions (Carter 2007). For example, a deletion 
might cause contiguous SNPs to show a loss of heterozygosity because hemizygous 
genotypes will be judged to be homozygous. This can cause deviation from the Hardy- 
Weinberg equilibrium or they may appear to violate Mendelian inheritance and so many 
SNPs in such regions were not included in early genome-wide genotyping arrays (Wain 
et al. 2009). As a result, the resolutions of these arrays vary across the genome and they 
particularly lack probe coverage in and around duplicated sequences (Cooper et al. 
2008).
Assays for screening targeted regions of the genome are mainly PCR-based, the 
most commonly used of which has been real-time quantitative PCR (qPCR). This 
method enables the comparison of the relative quantification of a gene of interest with a 
reference gene known to be a single copy. Alternative PCR-based methods exist which 
allow simultaneous screening of multiple regions, such as quantitative multiplex of 
short fluorescent fragments (QMPSF), multiplex amplifiable probe hybridisation 
(MAPH) and multiplex ligation-dependent probe amplification (MLPA) (Feuk et al.
2006).
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Sequencing-based approaches can map CNVs far more accurately than the above 
methods, providing resolution of CNV boundaries at the single nucleotide level and 
enabling the detection of inversions or translocations as well as deletions and 
duplications (Fanciulli et al. 2010). The DNA sequence of an individual of interest can 
be compared against a reference genome to identify structural variants and Khaja et al 
(2006) used this method to identify 13,066 previously undescribed structural variations 
in the human genome. With the development of next-generation sequencing in recent 
years, it has become possible to generate new assemblies of complete sequences from 
single individuals, enabling more robust and reliable genome comparisons and CNV 
identification (Fanciulli et al. 2010).
7.1.7 CNVs in Complex Neuropsychiatric Diseases
Large duplications and deletions have been associated with a number of specific 
genetic disorders for many years and this had led to the establishment of genetic 
diagnostic tests for certain microdeletion and microduplication syndromes such as 
DiGeorge syndrome and Charcot-Marie-Tooth disease (Freeman et al. 2006).
However, recent studies have also found CNVs that are associated with more 
complex diseases such as autism spectrum disorders (ASDs), schizophrenia and ADHD. 
ASDs comprise a heterogeneous group of neurodevelopmental abnormalities 
characterised by impairment of social interactions, problems in communication and a 
restricted range of behaviours and interests. The genetic cause of ASDs is only 
recognised in ~10% - 20% of cases (Stankiewicz & Lupski 2010). A number of CNV 
studies have shown the importance of CNVs in the aetiology of ASDs, particularly with 
de novo CNVs (Autism Genome Project Consortium 2007; Sebat et al. 2007; Marshall 
et al. 2008; Christian et al. 2008; Morrow et al. 2008; Weiss et al. 2008; Kumar et al. 
2008; Glessner et al. 2009; Pinto et al. 2010). The most recent of these was conducted 
by Pinto and colleagues (2010) who compared the rates of rare (<1%) CNVs in 996 
individuals with ASD against 1287 matched controls using the Illumina HumanlM 
array. They found a significant burden of CNVs in the ASD cases and identified the rate 
of de novo CNVs to be 5.3%. These CNVs have implicated many novel genes for ASD 
(Pinto et al. 2010).
Schizophrenia is a severe psychiatric disorder characterised by hallucinations,
delusions, cognitive deficits and apathy. Epidemiologic studies on twins indicate that
schizophrenia has a complex genetic background with heritability estimated at 73% -
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90% (Stankiewicz & Lupski 2010). The two largest CNV studies in schizophrenia were 
carried out by the International Schizophrenia Consortium (ISC 2008) and Stefansson et 
al. (2008). The ISC carried out their CNV analysis by screening 3391 patients with 
schizophrenia and 3181 controls from six European populations using the Affymetrix 
Human SNP 5.0 and 6.0 arrays and found an increased burden of CNVs in their cases 
(ISC 2008). Stefansson et al. (2008) identified 6 6  de novo CNVs in an Icelandic 
population using the Illumina HumanHap300 array and then examined their frequencies 
in a total of 4718 schizophrenia cases and 41,199 controls from nine European countries 
and China using a combination of the Illumina HumanHap300 and HumanHap550 
arrays and the Affymetrix Human SNP 6.0 array. They found deletions associated with 
schizophrenia in the regions 1 q21.1, 15ql 1.2 and 15ql3.3. Interestingly, the ISC study 
(2008) also found association of deletions with schizophrenia in the 1 q2 1.1 and 15ql3.3 
loci.
Two recent studies have also identified CNVs in individuals with ADHD. Elia and 
colleagues (2010) screened 335 individuals with ADHD using the Illumina 
HumanHap550 array and found 222 CNVs (158 deletions and 64 duplications) that had 
not been identified in the sample of 2026 healthy controls. They found that their ADHD 
CNV gene set was significantly enriched for genes that had been reported as candidates 
in studies of autism, schizophrenia and Tourette syndrome as well as for genes known 
to be important for psychological and neurological functions, including learning and 
central nervous system development. Lesch and colleagues (2010) screened 99 
individuals with ADHD using aCGH, using a pool of 100 unscreened blood donors as 
reference DNA. They found 17 CNVs (4 deletions and 13 duplications) in cases that 
were not present in a total of 2726 screened controls. These ADHD CNVs could be of 
particular interest within the context of DD as a high rate of ADHD is observed in 
children with DD (Gilger et al. 1992; Shaywitz et al. 1995; Willcutt & Pennington 
2 0 0 0 ) and twin and family studies have suggested that there are shared genetic links 
between these disorders (Willcutt et al. 2000; Willcutt et al. 2007) (as discussed in 
Chapter 1). Therefore, any regions of the genome in which CNVs are found in both 
disorders could provide some information about the genetic overlap of these disorders.
From large CNV studies such as these, it has been noticed that some regions of the 
genome appear to be ‘hotspots’ for CNVs associated with a range of diseases. Two 
studies have identified a number of CNV hotspots across the genome. Mefford and
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Eichler (2009) defined hotspots as ‘regions predicted to be susceptible to recurrent 
rearrangement based on the flanking genomic architecture’. The criteria they used to 
identify these hotspots was a unique sequence (50kb-10Mb) flanked by large (>10kb), 
highly homologous (>95%) segmental duplications that provide the substrate for 
NAHR. They identified a total of 12 regions across the genome in which CNVs had 
been identified for a range of diseases, including schizophrenia, MR and autism (see 
Table E.3 in Appendix). Itsara and colleagues (2009) combined their CNV data from 
~2500 healthy individuals with published CNVs from more than 12,000 individuals 
from other control and neurological disease collections (including schizophrenia, MR 
and autism) and identified 27 candidate neurological disease loci across the genome 
using the same definition of hotspots adopted by Mefford and Eichler (2009) (see Table 
E.3 in Appendix). As expected, many of the hotspot loci in these two studies share some 
degree of overlap.
7.1.8 Aims
CNVs could provide an additional source of genetic variation that has not yet been 
investigated within DD. The aim for this section of the thesis was to carry out CNV 
analysis using the Cardiff DD cases and the 1958 Birth Cohort that were genotyped in 
the first stage of the NeuroDys GWAS (see Chapter 4). The overall burden of CNVs in 
cases and controls were compared, and regions of the genome that harboured 
significantly more CNVs in the cases than the controls were identified. The findings 
were also compared with previous CNV studies to identify if any CNVs in the DD cases 
lay in the CNV disease ‘hotspot’ regions or overlapped associated CNVs in other 
diseases such as ADHD.
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7.2 Methods
7.2.1 Sample
The sample used in this study consisted of the Cardiff subset of 178 cases that were 
genotyped on the Illumina HumanHap300 array and 1135 samples from the 1958 Birth 
Cohort (1958 BC) that were used in the initial NeuroDys GWAS sample, as discussed 
in Chapter 4.
As previously described in Chapter 2, the Cardiff case criteria is an IQ > 85 and a 
reading age that is > 2.5 years below their chronological age. DNA for these case 
samples were extracted from either blood or saliva samples using phenol/chloroform 
methodology as previously described (see Chapter 2). DNA quantification and dilution 
was also as described (Chapter 2), with a final sample dilution of 50ng/pl. As part of the 
NeuroDys GWAS, 102 of these cases were genotyped on the Illumina HumanHap300 
array according to manufacturer’s instructions at the University of Bonn while the rest 
of the cases (n = 76) were genotyped using the same array at Oxford University. The 
1958 Birth Cohort had previously been genotyped on the Illumina HumanHap550 array. 
These samples all had SNP call rates > 97% in the GWAS. For this CNV study, a more 
relaxed call rate filter was used than had been previously implemented in the GWAS 
because SNPs within regions of CNVs are likely to have lower call rates. Using such a 
stringent call rate filter could therefore result in some true CNVs being missed.
7.2.2 Calling CNVs
In order to allow for intensity differences occurring between SNPs due to factors 
other than the presence of CNVs, it is important to carry out CNV analysis using 
normalised intensity signals. Intensity signals for these samples were normalised using 
Illumina BeadStudio v3.2. Because the performance of external controls can vary from 
sample to sample, Illumina have developed a self-normalisation algorithm that uses 
information contained within the array itself (www.illumina.com). This algorithm is 
designed to adjust for channel-dependant background and global intensity differences. 
These normalised intensities were then used to calculate the LRR and BAF of each 
marker in each sample using the BeadStudio software. The LRR is a measure of the 
total fluorescent intensity from both sets of alleles at each SNP and the BAF is a
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measure of the relative ratio of the fluorescent signals between two alleles at each SNP 
figures. Examples of the plots of these measures are shown in Figure 7.3.
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Figure 7.3: Examples o f  BAF (top plots) and LRR plots (bottom plots) for a deleted region (left side) and 
a duplication region (right side)
The LRRs and BAFs were then used to generate CNV calls using the PennCNV 
software (2009 Aug 27 version), applying the GC-model wave adjustment (Wang et al.
2007). As the cases and controls were genotyped using different arrays, the CNV calling 
was carried out for each sample group separately. The PennCNV software detects 
CNVs using a HMM based approach and uses a six-state definition to model CNV 
states, as shown in Table 7.1. This algorithm attempts to exploit all the available 
information for each SNP by incorporating the LRR and BAF together with the distance 
between neighbouring SNPs and the population frequency of the B allele into the 
HMM. Incorporating the distance between neighbouring SNPs enables the probability 
of having a copy number state change between them to be determined. The population 
B allele frequency for each SNP had been calculated using a large set of individuals 
with mixed ethnic backgrounds and of normal phenotypes and enables the 
determination of the likelihood of the copy number genotypes for each copy number 
state. PennCNV also allows the user to adjust the data for ‘genomic waves’. These 
waves refer to variations in hybridisation intensity which show high correlation with 
DNA quantity and GC content (Diskin et al. 2008). The GC adjustment procedure
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implemented in PennCNV is a regression model which corrects and adjusts for genomic 
waves (Diskin et al. 2008).
By assuming that the vast majority of offspring CNVs are inherited from parents, 
Wang et al. (2007) used family-based CNV calls as a reference to indirectly estimate 
that the false-positive rate of the PennCNV algorithm is 1.0% and it has a sensitivity of 
82.2% in the absence of family data.
State Copy Number Description
1 0 Deletion of two copies
2 1 Deletion of one copy
3 2 Normal state
4 2 Copy-neutral with LOH
5 3 Single copy duplication
6 4 Double copy duplication
Table 7.1: Six-state definition o f  CNVs used by PennCNV (adapted from W ang et al. 2007). LOH -  Loss 
o f heterozygosity.
7.2.3 Sample QC Filtering
Intensity data from poor quality DNA samples are likely to produce more false 
positive CNV calls. A high LRR standard deviation (SD) can indicate large variability 
between the signal intensities from the SNPs and so can be used to filter out poorly 
performing samples. Removing those samples that have high LRR SDs and high CNV 
call rates improves the quality of the data and reduces the number of false positives. In 
order to identify outlying samples, histograms of the raw CNVs called by PennCNV 
were produced showing the LRR SDs in each sample (shown in Figure 7.4) and the 
number of CNVs identified in each sample (shown in Figure 7.5, zoomed in to those 
samples with fewer than 200 CNVs). Based on these histograms, samples with LRR 
SDs >0.3 and those that harboured more than 30 CNVs were removed.
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Figure 7.4: Histogram o f  the Log R Ratio standard deviations o f all samples before QC filtering
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Figure 7.5: Histogram o f the number o f CNVs in all samples before QC filtering. The scale has been 
adjusted to show only those samples that had fewer than 200 CNVs in order to identify the cut off more 
clearly.
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7.2.4 CNV QC Filtering
In order to reduce the number of false positive scores, CNVs were filtered based on 
their size, the number of SNPs used to call the CNVs and their SNP density. To be 
confident in a CNV call, it needs to be based upon as much signal intensity information 
as possible; large CNVs that are based on high numbers of SNPs and have a high 
density of SNPs are more likely to be true calls. In order to obtain a high-quality 
dataset, CNVs were excluded if they were smaller than lOOkb, if they were based on 
information from less than 10 SNPs and if their length/SNP ratio was greater than 30kb 
per SNP.
7.2.5 Merging CNVs
It has been previously noticed that the HMM algorithm can artificially split CNVs 
into smaller segments (ISC 2008). Therefore, any CNVs that appeared to be artificially 
split by the PennCNV algorithm were joined. The rationale used involved joining two 
CNVs if the length of the sequence between them was less than 50% of the length of the 
larger CNV, as shown in Figure 7.6. A programme has been created by Dobril Ivanov 
which enables the user to perform this merging step computationally and can be found 
here: http://x001 .psycm.uwcm.ac.uk/.
„ 400kb  ^ lOOkb
100kb
< 50% of larger CNV
*  600k b -----------------------►
Figure 7.6: Diagram illustrating the rationale used to jo in  CNVs. In this example, two CNVs o f the same 
type are identified next to each other in the same individual, one is 400kb and the other is 100kb and lies 
lOOkb away. As the distance between these two CNVs is less than 50% o f the length o f  the larger CNV 
(i.e. less than 200kb), these CNVs are joined to form one 600kb CNV.
7.2.6 Filtering CNVs on Frequency
For this study, analysis was restricted to rare CNVs that occurred in less than 1% of 
the total sample. Common CNV regions are not likely to be adequately covered by the 
SNP arrays as markers that lie within common CNV regions are likely to show 
departure from Mendelian inheritance or Hardy Weinberg equilibrium, causing them to
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be excluded from the SNPs arrays (Beckmann et al. 2007). As such, common CNVs are 
not thought to be reliably called and past CNV studies have focused on rare (i.e. <1% 
frequency) CNVs. In addition, it is likely that many of the common CNVs are tagged by 
the SNPs on this array and so any association of common CNVs with DD should have 
been picked up in the initial GWAS (Conrad et al. 2010; WTCCC 2010). It has been 
estimated that even on first generation SNP arrays, 40-50% of common copy number 
variants (MAF >5%) were tagged (r2 >0.8) and this proportion has increased with the 
newest arrays (~ 65% for the Illumina 1M array) (McCarroll et al. 2008). Rare CNVs 
are also considered to be more likely to be pathogenic (WTCCC 2010).
7.2.7 Statistical Analysis
The CNV association analyses were carried out using PLINK vl.06 (Purcell et al.
2007). P-values given are 2-tailed, based on comparing the rates of CNVs in cases and 
controls with the use of 10,000 permutations. The genomic coordinates used in this 
study are based on the March 2006 human genome sequence assembly (UCSC hg l8 , 
National Centre for Biotechnology Information build 36).
7.2.7.1 Burden Analysis
Burden analysis involves performing a global association test of CNV burden in 
cases and controls to identify if either sample group has a statistically higher rate of 
CNVs. As larger CNVs have shown a higher rate in cases in previous studies (e.g ISC
2008), burden analysis was performed on CNVs of all sizes, as well as those greater 
than 500kb and greater than 1Mb.
7.2.7.2 Regional Analysis
In order to identify specific loci that showed a significant excess of CNVs in cases 
compared with controls, overlapping CNVs were grouped using PLINK. These groups 
were then tested for a significant excess of CNVs in the cases compared with the 
controls.
To investigate whether or not any of the genes that were overlapped by CNVs 
within the significant regions identified had shown association in any of the previous 
studies, association results for SNPs within these genes (plus 1 Okb upstream and 
downstream) were extracted from the previous NeuroDys GWAS, NeuroDys pooling 
study and the Cardiff pooling study.
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7.2.8 Proof of Principle Test Using HapMap Samples
The controls in this dataset were genotyped on the Illumina HumanHap550 array 
whereas the cases were genotyped using the HumanHap300 array. As these arrays differ 
in the number of SNPs, this could affect the number of CNVs that are identified in each 
sample. As the controls were genotyped on the larger chip, this is likely to result in the 
data being biased to having more CNVs in the controls than in the cases. In order to test 
if this difference in genotyping platform is likely to cause a significant difference in the 
rate of CNVs identified, 120 samples from the HapMap CEU population which had 
been genotyped on both array were compared.
BeadStudio projects for these samples when genotyped on each platform were 
downloaded from the Illumina ftp website (http://www.illumina.com/forms/flp.ilmn). 
The LRRs and BAFs were extracted and were run through PennCNV. As with the case 
control samples, data from each array type were called separately from each other. The 
same QC filters were applied to the HapMap samples as were applied to the case control 
dataset, but samples were only included in further analysis if they passed QC in both the 
300 array dataset and the 550 array dataset. CNVs at a frequency greater than 1% were 
excluded, as before.
7.2.9 Comparison with Other CNV Studies
7.2.9.1 ADHD CNV Studies
The ADHD CNV regions identified in the studies by Elia et al (2010) and Lesch et 
al (2010) were investigated in this DD dataset and CNVs were reported if they 
overlapped these regions at all in either the cases or controls (see Table E.2 in Appendix 
for a list of these regions). Association analysis was then performed comparing the rates 
of these CNVs in the DD cases with the 1958 Birth Cohort controls.
7.2.9.2 Disease Hotspots
Any CNVs that overlapped the regions identified as CNV ‘hotspots’ by Mefford and 
Eichler (2009) and Itsara and colleagues (2009) (see table E.3 in Appendix for a list of 
these regions) in this DD dataset were reported and association analyses were 
performed comparing their rates in the DD cases vs. the 1958 Birth Cohort controls.
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7.3 Results
7.3.1 QC Filtering
After CNV calling using PennCNV, a total of 29,745 CNVs were identified in 159 
cases and 1135 controls. After applying QC filters to the samples, 120 cases (of which 
74 had been genotyped in Bonn and 46 had been genotyped in Oxford) and 1030 control 
samples remained, with 16,063 CNVs. Figure 7.7 shows the LRR SDs for those samples 
passing QC, separated by sample group. This plot shows very similar mean values 
between the population controls (mean LRR SD = 0.21) and those cases that were 
genotyped in Bonn (mean LRR SD = 0.20), but those samples genotyped in Oxford 
tended to have higher SDs (mean LRR SD = 0.30). This could indicate some form of 
inter-centre experimental variability existing between the intensity scores from those 
samples that were genotyped in Bonn and those that were genotyped in Oxford.
After QC filtering and merging, 1148 CNVs remained, 163 of which were in cases. 
The intensity plots of the 9 CNVs that were larger than 2 Mb were manually inspected. 
The largest of these was a 33 Mb duplication in one of the controls that covered the 
majority of chromosome 21, which could indicate a that this individual had Down’s 
syndrome, and so this sample was removed from the analysis, leaving 1147 CNVs and 
1030 controls. The number of CNVs that passed QC in each sample is shown in Figure 
7.8. On average, more CNVs were identified in those samples which were genotyped in 
Oxford (average CNV count = 3.24) than those genotyped in Bonn (average CNV count 
= 1.84) and those within the 1958 Birth Cohort (average CNV count = 2.06). This could 
be a reflection of the higher LRR SDs that were observed in those samples genotyped in 
Oxford.
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Figure 7.7: Box plots o f  the Log R Ratio standard deviations o f  samples that passed QC within each 
sample group.
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Figure 7.8: Box plot showing the number o f  CNVs identified in samples that passed QC within each 
sample group.
CNVs that were present in more than 1% of the whole sample were excluded, 
leaving 1147 CNVs, of which 163 were in cases (see Table E.l in Appendix for a list of 
all CNVs passing QC). The average length of these CNVs was 293 kb in cases and 277 
kb in controls.
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7.3.2 Proof of Principle Test Using HapMap Samples
To test the effect of comparing CNV rates in samples that were genotyped using 
different arrays (i.e. the Illumina HumanHap300k and HumanHap550k arrays), CNVs 
were identified in samples that are within the HapMap CEU population and had been 
genotyped on each platform. The same QC filters used in this data set were applied, 
including a frequency filter of 1%. 117 of the sample in the 300k array dataset passed 
QC, as did 110 of the samples in the 550k dataset, leaving 110 samples that passed QC 
in both datasets. This left a total of 61 CNVs identified when these samples were 
genotyped on the 300k array and 72 CNVs identified when these same samples were 
genotyped on the 550k array. Table 7.2 shows the results of the burden analyses on 
these CNVs, comparing the number and size of the CNVs identified when using 
intensities from each platform. Although more CNVs were identified when genotyping 
these samples on the 550k array, there was no significant difference in the number of 
CNVs called for any of the size ranges or CNV types (i.e. deletions or duplications). As 
would be expected due to the larger number of SNPs, CNVs identified were on average 
larger when these samples were run on the 550k array, but again, this difference was not 
significant. An overlap check was run on these CNVs in which CNVs were classed as 
the same if they overlapped each other by 75%. Using this criterion, 58 of the CNVs 
identified using the 300k array were also found using the 550k array. This suggests that 
when using the above QC filters, nearly all of the CNVs (95% in this case) identified 
using the 300k array can also be identified using the 550k array. This shows that the 
difference in the number of SNPs on these arrays should not significantly affect the 
number of CNVs that are identified in each of the sample groups and that any 
significant difference is more likely to be due to affection status rather than the 
genotyping platform.
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Deletions Duplications Deletions and Duplications
Number Rate RateP
Av. Size 
(kb)
Size
P Number Rate
Rate
P
Av. Size 
(kb)
Size
P Number Rate
Rate
P
Av. Size 
(kb)
Size
P
> 100kb
300k chip 
550k chip
22
28
0.20
0.25
0.545
199.2
213
0.741
36
41
0.33
0.37
1
346.3
425.9
0.514
58
69
0.5273
0.6273
0.418
291
319.9
0.760
> 500kb
300k chip 
550k chip
0
1
0
0.01
1
0
579.8
1
7
7
0.06
0.06
1
965.8
1345
0.401
7
8
0.06364
0.07273
1
965.8
1249
0.514
> 1Mb
300k chip 
550k chip
0
0
0
0
1
0
0
1
3
4
0.03
0.04
1
1480
1857
0.572
3
4
0.02727
0.03636
1
1480
1857
0.571
Table 7.2: Results of burden analysis between CNVs in the HapMap CEPH samples when genotyped on the 300k and 550k arrays. Av -  average; Rate P -  P-value when the 
rates of CNVs are compared between the two arrays; Size P -  P-value when the average sizes of the CNVs are compared between the two arrays.
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7.3.3 Burden Analyses
7.3.3.1 All Cases Compared With 1958 Birth Cohort
When comparing the rates of CNVs in DD cases with those in the 1958 Birth 
Cohort controls, there was a significant excess of all CNVs in the cases (P = 3 x 10"4, 
case/control ratio = 1.42), as shown in Table 7.3. This excess appeared to be largely 
driven by deletions, which were present in cases at double the rate found in the controls 
(P = 1 x 10"4, case/control ratio = 2.00). When looking at duplications alone, these were 
present at a higher rate in the controls but the difference was not significant (P = 0.207, 
case/control ratio = 0.81). When focusing the burden analysis on larger CNVs, this 
excess of deletions in cases was no longer significant (P = 0.286, case/control ratio = 
1.83). However, the case/control ratio is still similar to the ratio for smaller CNVs 
which suggests that the lack of significance may be due to the small number of large 
CNVs identified. There was no significant difference in the sizes of CNVs found in 
cases compared with controls (P = 0.646), including when looking at deletions (P = 
0.594) and duplications (P = 0.325) separately.
7.3.3.2 Cases Genotyped in Bonn Compared with Those Genotyped in Oxford
As the two Cardiff case subsets were genotyped on the arrays in different centres, 
burden analysis was carried out between the subsets to investigate whether or not the 
excess of CNVs in cases could be attributable to experimental variation between 
centres rather than a true excess of CNVs in DD cases. The results are shown in Table 
7.4. When comparing the rate of CNVs found in Cardiff cases genotyped in Oxford 
with those identified in Cardiff cases genotyped in Bonn, there was a greater than 2- 
fold excess of CNVs in those cases genotyped in Oxford (P = 1 x 10-4, Oxford/Bonn 
ratio = 2.25). Again this overall excess appeared to be down to deletions in particular (P 
= 1 x 10'4, Oxford/Bonn ratio = 2.73) and there was no significant difference in the rate 
of duplications (P = 0.332, Oxford/Bonn ratio = 1.44). Each of the case sample groups 
were then compared separately with the controls, and a significant excess of deletions 
was found in the Oxford-typed cases (P = 1 x 10‘4, Oxford cases/controls ratio = 3.28), 
but no significant excess was observed when comparing the rate of deletions identified 
in the Bonn-typed cases with those identified in the controls (P = 0.324, Bonn 
cases/controls ratio = 1.20). The only significant result when comparing the Bonn-
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typed cases with the controls was for the average sizes of the duplications, which 
showed a trend towards being larger in the Bonn-typed cases (P = 0.047).
Therefore technical issues appear to be driving the significant excess of CNVs 
in the complete group of cases compared with the controls.
Deletions Duplications Deletions and Duplications
Number Rate Rate P Av. Size (kb)
Size
P Number Rate Rate P
Av. Size 
(kb)
Size
P Number Rate RateP
Av. Size 
(kb)
Size
P
>100kb
Cases
Controls
118
507
0.983
0.492
1 xIO-4
238.1
215.9
0.594
45
477
0.375
0.463
0.207
380.9
332.2
0.325
163
984
1.358
0.955
3 x 10"4
293
277
0.646
> 500kb
Cases
Controls
4
19
0.033
0.018
0.286
1253
1285
0.968
10
86
0.083
0.084
1.000
1033
876.2
0.314
14
105
0.117
0.102
0.675
1096
949
0.477
> 1Mb
Cases
Controls
1
7
0.008
0.007
1.000
2622
2393
0.949
4
20
0.033
0.019
0.503
1555
1413
0.726
5
27
0.042
0.026
0.385
1769
1660
0.846
Table 7.3: Results of burden analysis between CNVs in cases and controls. Significant P-values are in bold. Av -  average; Rate P -  P-value when the rates of CNVs are 
compared between cases and controls; Size P -  P-value when the average sizes of the CNVs are compared between cases and controls.
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Deletions Duplications Deletions and Duplications
Sample Groups Number Rate RateP Av. Size (kb)
Size
P Number Rate Rate P
Av. Size 
(kb)
Size
P Number Rate Rate P
Av. Size 
(kb)
Size
P
Oxford Cases 74 1.61 228.7 21 0.46 291.9 95 2.07 263
1 X10-4 0.752 0.332 0.167 1 X10"4 0.299
Bonn Cases 44 0.59 249.3 24 0.32 455.1 68 0.92 320
Oxford Cases 74 1.61 228.7 21 0.46 291.9 95 2.07 263
1 x 10"4 0.853 1.000 0.593 1 x10^ 0.803
1958 BC Controls 507 0.49 215.9 477 0.46 332.2 984 0.96 277
Bonn Cases 44 0.59 249.3 24 0.32 455.1 68 0.92 320
0.324 0.498 0.089 0.047 0.783 0.317
1958 BC Controls 507 0.49 215.9 477 0.46 332.2 984 0.96 277
Table 7.4: Results of burden analysis of CNVs between cases typed in Bonn and Oxford, cases typed in Oxford vs. 1958 Birth Cohort controls and between cases typed in 
Bonn vs. 1958 Birth Cohort Controls. Significant P-values are in bold. Av -  average; Rate P -  P-value when the rates of CNVs are compared between cases and controls; Size 
P -  P-value when the average sizes of the CNVs are compared between cases and controls.
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7.3.3.3 Effect of Sample Origin on CNV Burden
To test if the type of sample that the DNA was extracted from (i.e. blood or saliva, 
referred to hereafter as the ‘sample origin’) affected the number of CNVs identified, 
burden analysis was carried out on the small subset of samples for which their origin 
had been recorded (n = 61, 36 from blood and 25 from saliva). The results are shown in 
Table 7.5. When comparing the rates of CNVs between each sample origin, although 
more CNVs were identified in those samples that were extracted from saliva, this 
difference was not significant (P = 0.167, saliva/blood ratio = 1.78), nor was there any 
significant difference when looking at duplications (P = 0.808, saliva/blood ratio = 
0.79). However, there was a trend towards a significant excess of deletions in those 
samples extracted from saliva, which had a deletion rate which was over double that 
found in those extracted from blood (P = 0.058, saliva/blood ratio = 2.41). This 
suggests that DNA extracted from saliva samples may have a higher rate of deletions 
than those extracted from blood due to technical artefacts. There was no significant 
difference between the average sizes of the CNVs identified in these samples (P = 
0.238).
As all of the samples known to be extracted from blood were genotyped in Bonn 
and those samples genotyped in Oxford showed a significant excess of CNVs, sample 
origin burden analysis was also carried out using just those cases that were genotyped 
in Bonn in order to allow for any experimental variation that may have existed between 
the centres. There was no overall significant excess of CNVs in samples from either 
origin (P = 0.786, saliva/blood ratio =1.14). There was a higher rate of deletions in 
those samples extracted from saliva (saliva/blood ratio = 1.60) and a higher rate of 
duplications in those samples extracted from blood (saliva/blood ratio = 0.39), but these 
differences were not significant (P = 0.401 and 0.219, respectively). There was also no 
significant difference between the average sizes of the CNVs in each sample origin 
group (P = 0.534).
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Deletions Duplications Deletions and Duplications
Sample Type Number Rate RateP
Av. Size 
(kb)
Size
P Number Rate
Rate
P
Av. Size 
(kb)
Size
P Number Rate RateP
Av. Size 
(kb)
Size
P
Oxford and Bonn
Saliva (n = 36) 38 1.06 0.058 219.2 0.688 8 0.22 0.808 230.2 0.181 46 1.28 0.167 229.1 0.238
Blood (n = 25) 11 0.44 204.5 7 0.28 549.1 18 0.72 306.9
Bonn Only
Saliva (n = 27) 19 0.70 0.401 469 0.302 3 0.11 0.219 280.8 0.464 22 0.82 0.786 257.7 0.534
Blood (n = 25) 11 0.44 218.1 7 0.28 549.1 18 0.72 306.9
Table 7.5: Comparison of CNVs in DNA samples extracted from saliva and blood for both all the cases and just those genotyped in Bonn. Av -  average; Rate P -  P-value 
when the rates of CNVs are compared between cases and controls; Size P -  P-value when the average sizes of the CNVs are compared between cases and controls.
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7.3.4 Regional Analysis
No CNVs were found to be overlapping the putative DD susceptibility genes, 
KIAA0319, DCDC2, and DYX1C1. Regional analysis was carried out to identify any 
regions across the autosomal chromosomes that showed a significant excess of CNVs 
in cases. The results are shown in Table 7.6. 18 regions showed a significant excess of 
CNVs in the cases, the most significant of these was on chromosome 15q23 shown in 
Figure 7.9, with 5 deletions identified in the cases (rate = 0.042) and 2 deletions 
identified in the controls (rate = 0.002).
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Figure 7.9: UCSC track showing the deletions identified within the 15q23 locus with the deletions in the 
cases depicted as the lighter red bars and those in the controls as the darker red bars. RefSeq genes within 
this region are also shown.
All of the cases that had CNVs within this locus had been genotyped in Oxford. As 
this sample group showed higher LRR SDs and significantly higher CNV rates than 
those that were genotyped in Bonn, the regional analysis was repeated comparing only 
those cases that had been genotyped in Bonn with the 1958 Birth Cohort to investigate 
whether or not any of these significant loci would remain significant. The results are 
shown in Table 7.7.
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| Significant Region
Type
Cases (n = 120) Controls (n = 1030)
Cases
/Controls P
Genes Intersected by 
CNVsLocus Start bp End bp Length (bp) Number Rate Number Rate
15q23 69941054 70112649 171595 Del 5 0.042 2 0.002 21.46 0.0002 MY09A
16p13.3* 651906 686885 34979 Del 3 0.025 0 0 0.0016
RAB11FIP3, C16orf11, SOLH, 
NHLRC4, PIGQ, RAB40C, 
WFIKKN1, C16orf13, FAM195A, 
WDR90, RHOT2, STUB1, 
WDR24, JMJD8, FBXL16, 
RHBDL1, METRN, HAGHL, 
NARFL, FAM173A, MSLN, 
MSLNL, MIR662, RPUSD1, 
CHTF18
6q14.3 86602842 86718986 116144 Del 3 0.025 2 0.002 12.88 0.0095
NT5E, SNX14, SYNCRIP, 
SNORD50A, SNORD50B, 
SNHG5
7q36.1 151667867 151701091 33224 Del 2 0.017 0 0 0.0099 MLL3, FABP5L3, LOC100128822
15q22.31 63587909 63776413 188504 Del 2 0.017 0 0 0.0102 DPP8, PTPLAD1, C15orf44, SLC24A1, DENND4A
14q21.1-
q21.3* 42981353 43306266 324913 Dup 3 0.025
2 0.002 12.88 0.0104 -
4q35.1 186489132 186618822 129690 Del 2 0.017 0 0 0.0108 SNX25, LRP2BP, UFSP2, ANKRD37, C4orf47, CCDC110
19p13.3* 1317545 1364574 47029 Del 2 0.017 0 0 0.0111
CDC34, GZMM, BSG, HCN2, 
POLRMT, FGF22, RNF126, 
FSTL3, PRSSL1, C19orf21
16p13.3* 1325651 1442858 117207 Del 2 0.017 0 0 0.0112
CACNA1H, TPSG1, TPSB2, 
TPSAB1, TPSD1, UBE2I, 
BAIAP3, C16orf42, GNPTG, 
UNKL, CCDC154, C16orf91, 
CLCN7
19p13.3 556985 602852 45867 Del 2 0.017 0 0 0.0115
MUM1, NDUFS7, GAMT,
DAZAP1, RPS15, APC2, 
C19orf25, PCSK4, REEP6, 
ADAMTSL5, PLK5P
Table 7.6 Regions of the genome showing a significant excess of CNVs in the whole DD case sample compared with the controls and the genes that are intersected by these 
CNVs. * Indicates those regions that remain significant when comparing CNVs in cases genotyped in Bonn only with the controls (see Table 7.7). Functionally interesting 
genes are in bold.
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Sifjnificant Reg on
Type
Cases (n = 120) Controls (n = 1030)
Cases
/Controls P
Genes Intersected by 
CNVsLocus Start bp End bp Length (bp) Number Rate Number Rate
18q22.3 70700538 70779005 78467 Del 2 0.017 0 0 0.0117 ZNF407
2p16.3 48351619 48481460 129841 Del 2 0.017 0 0 0.0119 FOXN2, KLRAQ1
12q24.31 121565488 121682631 117143 Del 2 0.017 0 0 0.0119 ZCCHC8, RSRC2, KNTC1
17q25.1* 69345596 70164827 819231 Dup 2 0.017 0 0 0.0127
RPL38, MGC16275, TTYH2, 
DNAI2, KIF19, BTBD17, 
GPR142, GPRC5C, CD300A, 
CD300LB, CD300C, C17orf77, 
CD300LD, CD300E
6q26 162644237 162769931 125694 Dup 3 0.025 3 0.003 8.58 0.019 PARK2
11 p11.2 46350333 46480589 130256 Del 2 0.017 1 0.001 17.17 0.0291
CREB3L1, DGKZ, MDK, 
CHRM4, AMBRA1, HARBI1, 
KIAA0652
9p21.1* 28288064 28332179 44115 Del 2 0.017 1 0.001 17.17 0.0297 LING02
1 p21.1* 102439976 102571645 131669 Del 2 0.017 1 0.001 17.17 0.0305 -
Table 7.6 continued.
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Significant Region
Type
Cases (n =74) Controls (n = 1030)
Cases/Controls PLocus Start bp End bp Length Number Rate Number Rate
15q23 69941054 70112649 171595 Del 0 0 2 0.002 1.0
16p13.3 651906 686885 34979 Del 2 0.027 0 0 0.004
6q14.3 86602842 86718986 116144 Del 0 0 2 0.002 1.0
7q36.1 151667867 151701091 33224 Del 1 0.014 0 0 0.069
15q22.31 63587909 63776413 188504 Del 0 0 0 0.000 1.0
14q21.1-q21.3 42981353 43306266 324913 Dup 2 0.027 2 0.002 13.92 0.025
4q35.1 186489132 186618822 129690 Del 0 0 0 0 1.0
19p13.3 556985 602852 45867 Del 1 0.014 0 0 0.067
16p13.3 1325651 1442858 117207 Del 2 0.027 0 0 0.004
18q22.3 70700538 70779005 78467 Del 1 0.014 o 0 0.066
19p13.3 1317545 1364574 47029 Del 2 0.027 0 0 0.004
2p16.3 48351619 48481460 129841 Del 0 0 0 0 1.0
12q24.31 121565488 121682631 117143 Del 1 0.014 0 0 0.070
17q25.1 69345596 70164827 819231 Dup 2 0.027 0 0 0.004
6q26 162644237 162769931 125694 Dup 1 0.014 3 0.003 4.64 0.252
11p11.2 46350333 46480589 130256 Del 0 0 1 0.001 1.0
9p21.1 28288064 28332179 44115 Del 2 0.027 1 0.001 27.84 0.012
1p21.1 102439976 102571645 131669 Del 2 0.027 1 0.001 27.84 0.014
Table 7.7: Comparison of CNVs in cases genotyped in Bonn only compared with controls for those regions that showed a significant excess of CNVs in all cases when 
compared with controls (see Table 7.6). Regions of the genome a significant excess of CNVs in the whole DD case sample compared with the controls. Seven regions remain 
significant as indicated by the P-values < 0.05 that are in bold.
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Seven of the loci remained significant when only including CNVs from those 
samples genotyped in Bonn, and these did not include the most significant region from 
the original analysis. Of the seven loci that remained significant, the four most 
significant loci consisted o f 2 regions on 16pl3.3, one on 19pl3.3 and the fourth on 
17q25.1, all of which had P-values of 0.004. Within both of the 16pl3.3 and the 
19pl3.3 loci, 2 deletions were identified in the cases and none were found in the 
controls (as shown in Figures 7.10 and 7.11) and within the 17q25.1 locus 2 
duplications were identified with no CNVs in the controls (Figure 7.12). The two 
significant loci within 16pl3.3 are nearly 630kb away from each other and three 
deletions that flank these regions were identified in the controls.
Table 7.8 shows the genes that are overlapped by CNVs in the first 16pl3.3 CNV 
locus, together with their coverage within the NeuroDys GWAS (Chapter 4), NeuroDys 
pooling study (Chapter 5) and within the Cardiff pooling study (Chapter 6) as well as 
the SNPs that showed the most significant association within each gene (plus lOkb of 
sequence in either direction) in each study. Three genes within this locus had 
significant results in the initial NeuroDys GWAS, and 2 of these also showed 
significance in the Cardiff pooling study. The SNP rs2038227 within intron 5 of the 
gene RAB11 family interacting protein 3 (class II) (RAB11FIP3) showed significant 
association in the initial GWAS (P = 0.029) and another SNP just 1.5kb upstream of 
this gene (rs3760048) gene showed significant association in the Cardiff pooling study 
(0.008). Both of these SNPs are within a deletion that was identified in an individual 
diagnosed with DD. A SNP within both the chromosome 16 open reading frame 11 
(C16orfll) and small optic lobes homolog (SOLH) genes was significantly associated 
with DD in the initial NeuroDys GWAS (rs7763, P = 0.012). Another SNP within 
SOLH was also significantly associated in the Cardiff pooling study (rs9934705, P = 
0.030) and both of these SNPs were overlapped by a single deletion identified in an 
individual with DD. None of the significant SNPs in this region are in high LD with 
each other (r2 < 0.8). Within this region, SOLH could be of particular interest as it is 
thought to be involved in protein-protein interactions during visual development and 
shows high expression in the brain (Kamei et al. 1998). Other genes within this region 
which could be of functional interest but were not significantly associated in any of the 
GWAS or pooling studies include the gene STIP1 homology and U-box containing 
protein 1 (STUB1). This gene was overlapped by two deletions which were identified in
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DD cases (see Figure 7.10) and it encodes the U-box family ubiquitin protein ligase 
CHIP (carboxy terminus of Hsc70-Interacting Protein) which has been shown to 
interact with the DD susceptibility gene DYX1C1 (Hatakeyama et al. 2004). CHIP 
participates in the degradation of estrogen receptors alpha (ERa) and beta (ERP) which 
are important in brain development and cognition functions and this led Massinen and 
colleagues (2009) to propose that DYX1C1 may affect brain development through the 
regulation of ERa and ERp. Another functionally interesting gene within this locus is 
Meteroin (METRN) which is thought to be involved in both glial cell differentiation and 
axonal network formation during neurogenesis (Nishino et al. 2004) and so may have a 
role within neuronal migration. This gene was overlapped by one deletion identified in 
an individual with DD (Figure 7.10).
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Figure 7.10: UCSC track showing the deletions identified within the two significant loci on 16pl3.3 with the deletions in the cases depicted as the lighter red bars and those 
in the controls as the dark red bars. RefSeq genes within this region are also shown.
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NeuroDys GWAS NeuroDys Pooling Study Cardiff Pooling Study
Locus Gene Coverage Most Significant SNP P-min Coverage
Most Significant 
SNP
Fisher
P Coverage
Most Significant 
SNP
P-
comb
RAB11FIP3 0.94 rs2038227 0.029 0.67 rs4984887 0.778 0.88 rs3760048 0.008
C16orf11 0.33 rs7763 0.012 0.66 rs3213574 0.168 0.67 rs3213574 0.080
SOLH 0.54 rs7763 0.012 0.54 rs4984887 0.078 0.41 rs9934705 0.030
NHLRC4 0.25 rs7190878 0.169 0.75 rs7189540 0.833 0.67 rs3213574 0.080
PIGQ 1.00 rs4984890 0.314 1.00 rs710925 0.361 0.91 rs7190878 0.700
RAB40C 0.96 rs4144003 0.322 0.96 rs4984678 0.211 0.96 rs1045277 0.820
WFIKKN1 0.86 rs4984677 0.396 0.87 rs4984678 0.211 0.83 rs2269556 0.510
FAM195A 0.00 N/A N/A 0.20 rs11642546 0.712 0.80 rs2269561 0.710
WDR90 0.71 rs3752493 0.170 0.94 rs3752493 0.465 0.90 rs12930932 0.830
RHOT2 0.71 rs3752493 0.170 0.83 rs3752493 0.465 0.89 rs3752496 0.810
STUB1 0.90 rs4984913 0.101 0.70 rs4984913 0.518 0.78 rs1139897 0.900
16p13.3a WDR24 0.90 rs4984913 0.101 0.80 rs4984913
0.518 0.80 rs3830141 0.750
JMJD8 0.85 rs4984913 0.101 0.57 rs4984913 0.518 0.75 rs1128550 0.910
FBXL16 0.64 rs4984913 0.101 1.00 rs4984913 0.518 1.00 rs11640115 0.750
RHBDL1 0.61 rs3752493 0.170 0.76 rs3752493 0.465 0.84 rs1045763 0.348
METRN 0.00 N/A N/A 0.29 rs11540048 0.782 1.00 rs12599342 0.940
HAGHL 0.70 rs12448432 0.250 0.30 rs2071951 0.663 1.00 rs4589552 0.090
NARFL 0.79 rs3752556 0.061 0.43 rs2071951 0.663 1.00 rs2071950 0.080
FAM173A 0.62 rs12448432 0.250 0.12 rs11540048 0.782 1.00 rs3809663 0.360
MSLN 0.64 rs3764246 0.053 0.55 rs9927150 0.804 0.82 rs13336445 0.600
MSLNL 1.00 rs3764246 0.053 0.68 rs3817833 0.195 0.65 rs3764247 0.760
MIR662 0.44 rs3764246 0.053 0.44 rs9927150 0.804 0.60 rs2235505 0.340
RPUSD1 0.56 rs1052629 0.607 0.59 rs1052629 0.263 0.82 rs3765334 0.380
CHTF18 0.53 rs1052629 0.607 0.55 rs1052629 0.263 0.58 rs3765334 0.380
Table 7.8: This table shows the genes in the first 16pl3.3 locus with their coverage (if any) in the NeuroDys GWAS and pooling study and in the Cardiff Pooling study, along 
with the most significant SNP within the gene (+/- lOkb) in each study and the P-value for this SNP. N.B. Coverage may differ between the pooling studies due to different 
QC filters. P-values <0.05 are in bold, as are functionally interesting genes.
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Table 7.9 shows the genes that are overlapped by CNVs in the second 16pl3.3 
CNV locus. SNPs near the gene calcium channel, voltage-dependent, T type, alpha 1H 
subunit (CACNA1H) (rsl 1865234, P = 0.007) and tryptase delta 1 (TPSD1) (rs3765436, 
P = 0.039) showed significant association in the initial Neurodys GWAS. CACNA1H is 
only partially overlapped by the case CNVs in this region, as shown in Figure 7.10 and 
rsl 1865234 lies 6.5kb upstream of this gene so is actually overlapped by a deletion 
identified in a control individual rather than in a DD case. The SNP rs3765436 lies 
2.8kb downstream of TPSD1 and is overlapped by a CNV identified in a DD case 
individual. Three other SNPs within this region showed significant association in the 
NeuroDys pooling study. The most significant of these was rsl 132356 (P = 0.005) 
which is an exonic SNP within BAI1-associated protein 3 (BAIAP3), and also lies 4.7 
kb downstream of chromosome 16 open reading frame 42 (C16orf42) and 7.3 kb 
upstream of N-acetylglucosamine-1-phosphate transferase, gamma subunit (GNPTG). 
The next most significant SNP within this region in the NeuroDys pooling study was 
rs2369696 (P = 0.008) which is an intronic SNP within the gene unkempt homolog 
(Drosophila)-like (UNKL) and the third was rs3751894 (P = 0.022) which is an intronic 
SNP within the gene coiled-coil domain containing 154 (CCDC154), and also lies 7.5 
kb upstream of chromosome 16 open reading frame 91 (C16orf91) and 8 kb 
downstream of chloride channel 7 (CLCN7). All three of these SNPs are overlapped by 
2 deletions in the cases and none of the SNPs within this significant CNV region are in 
high LD with each other. Two genes within this region could be of functional interest. 
CA CNA1H  encodes a T-type member of the alpha-1 subunit family which is a protein 
in the voltage-dependent calcium channel complex. These T-type channels may be 
involved in the modulation of firing patterns of neurons which is important for 
information processing as well as in cell growth processes (Perez-Reyes 2006) and 
studies have suggested that certain mutations in the CA CNA1H gene may lead to 
childhood absence epilepsy (Tan et al. 2006). BAIAP3 encodes a brain-specific 
angiogenesis inhibitor which is a member of the secretin receptor family and is 
predominantly expressed in the brain (Shiratsuchi et al. 1998). The expression profile 
of the protein encoded by this gene and its similarity to other proteins suggest that it 
may be involved in synaptic functions (Shiratsuchi et al. 1998).
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NeuroDys GWAS NeuroDys Pooling Study Cardiff Pooling Study
Locus Gene Coverage Most Significant SNP
P-
min Coverage
Most Significant 
SNP
Fisher
P Coverage
Most Significant 
SNP
P-
comb
CACNA1H 0.50 rsl 1865234 0.007 0.53 rs4984639 0.279 0.72 rs909910 0.470
TPSG1 0.43 rsl 054645 0.079 0.89 rs4984639 0.279 0.89 rs3897150 0.800
TPSB2 0.42 rsl 054645 0.079 0.50 rs9937881 0.130 0.80 rsl 1866966 0.150
TPSAB1 0.00 N/A N/A 0.50 rs9937881 0.130 1.00 rs35262813 0.900
TPSD1 0.57 rs3765436 0.039 0.79 rs9937881 0.130 0.79 rs9937881 0.080
UBE2I 0.75 rs4984803 0.221 0.81 rs7187167 0.112 0.89 rs7187167 0.940
16p13.3b BAIAP3 0.35 rs742460 0.190 0.61 rsl 132356 0.005 0.77 rs8063 0.930
C16orf42 0.22 rs742460 0.190 0.67 rsl 132356 0.005 0.89 rs2235632 0.400
GNPTG 0.25 rsl 061497 0.089 0.63 rsl 132356 0.005 0.71 rs2235632 0.400
UNKL 0.14 rsl 061497 0.089 0.68 rs2369696 0.008 0.72 rs8058617 0.920
CCDC154 0.43 rs7194275 0.114 0.17 rs3751894 0.022 0.68 rs4984834 0.200
C16orf91 0.25 rs7194275 0.114 0.12 rs3751894 0.022 0.83 rs4984834 0.200
CLCN7 0.50 rsl 040497 0.088 0.43 rs3751894 0.022 0.71 rs3751894 0.630
Table 7.9: This table shows the genes in the second 16pl3.3 locus with their coverage (if any) in the NeuroDys GWAS and pooling studies and in the Cardiff pooling study, 
along with the most significant SNP within the gene (+/- lOkb) in each study and the P-value for this SNP. N.B. Coverage may differ between the pooling studies due to 
different QC filters. P-values <0.05 are in bold, as are functionally interesting genes.
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Figure 7.11 shows the genes that are overlapped by CNVs in the significant 19pl3.3 
CNV locus and Table 7.10 shows the most significant SNPs in or near each of these 
genes in the previous studies. In this region, the only gene that harbours a significant 
SNP in any of the previous studies is polo-like kinase 5, pseudogene (PLK5P). The 
SNP rsl040499 lies in the 3’ UTR of this gene and showed marginal significant 
association in the initial NeuroDys GWAS (P = 0.048). However, this particular gene is 
only partially overlapped by the CNVs in this region, and this SNP is not in the same 
region of the gene that is overlapped by the deletions identified in the cases.
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Figure 7.11: UCSC track showing the deletions identified within the 19pl3.3 locus in two cases. RefSeq genes within this region are also shown.
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NeuroDys GWAS NeuroDys Pooling Study Cardiff Pooling Study
Locus Gene Coverage Most Significant SNP
P-
min Coverage
Most Significant 
SNP
Fisher
P Coverage
Most Significant 
SNP
P-
comb
MUM1 1.00 rs713042 0.097 1.00 rs8109377 0.269 1.00 rsl 2609120 0.460
NDUFS7 0.60 rs266805 0.210 0.86 rs2074895 0.695 0.88 rs6510605 0.200
GAMT 0.33 rs265271 0.953 0.80 rs265271 0.283 0.83 rsl 142530 0.180
DAZAP1 0.60 rs3786978 0.448 1.00 rs265271 0.283 1.00 rs3786974 0.760
RPS15 1.00 rs4807928 0.585 1.00 rs3760994 0.864 1.00 rs2292457 0.930
19p13.3 APC2 1.00 rs4807928 0.585 1.00 rs8100242 0.629 1.00 rsl 2977033 0.640
C19orf25 1.00 rs791464 0.120 1.00 rs3894776 0.653 1.00 rsl 1878689 0.410
PCSK4 1.00 rs791464 0.120 1.00 rsl 2459408 0.321 1.00 rsl 1878689 0.410
REEP6 1.00 rs791464 0.120 1.00 rsl 2459408 0.321 1.00 rs28658577 0.720
ADAMTSL5 1.00 rs2277748 0.133 1.00 rsl 2459408 0.321 1.00 rsl 2459408 0.470
PLK5P 0.12 rsl 040499 0.048 0.20 rs6510612 0.360 1.00 rs6510612 0.980
Table 7.10: This table shows 
with the most significant SNP 
QC filters. P-values <0.05 are
the genes in the 19pl3.3 locus with their coverage 
within the gene (+/- lOkb) in each study and the P 
in bold, as are functionally interesting genes.
(if any) in the NeuroDys GWAS and pooling studies and in the Cardiff pooling study, along 
■value for this SNP. N.B. Coverage may differ between the pooling studies due to different
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Figure 7.12 shows the genes that are overlapped by CNVs in the significant 17q25.1 
CNV locus and Table 7.11 shows the most significant SNPs in or near each of these 
genes in the previous studies. Two SNPs within these genes showed significant 
association in the initial NeuroDys GWAS. These are rsl 171196 which is 4.4kb 
downstream of CD300 molecule-like family member b (CD300LB) (P = 0.011) and 
rs783239 which is an intronic SNP within the chromosome 17 open reading frame 77 
(Cl 7orf77) and an exonic SNP within CD300 molecule-like family member d 
(CD300LD) (P = 0.009). Another SNP in this region (rs2706506) showed significant 
association in the NeuroDys pooling study (P = 0.011). This SNP lies 5.6 kb upstream 
of CD300a molecule (CD300A). These three SNPs are all overlapped by the two 
duplications that were identified within this region and they are not in high LD with 
each other (r2 < 0.14, D ’ < 0.68). As yet, none o f the genes in this region are known to 
be of functional interest within DD.
The significantly associated SNPs in these loci would not have survived correction 
for multiple testing in these previous studies and as such they were far down the list of 
significant hits and were not followed up in any of the previous studies. However, the 
finding of a significant excess of CNVs in DD cases in these regions could warrant 
further investigation of the affected genes.
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Figure 7.12: UCSC track showing the duplications identified within the 17q25.1 locus in two cases. RefSeq genes within this region are also shown.
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NeuroDys GWAS NeuroDys Pooling Study Cardiff Pooling Stud'i
L ocu s G ene Coverage Most Significant SNP P-min Coverage
Most Significant 
SNP
Fisher
P Coverage
Most Significant 
SNP P-comb
RPL38 0.44 rs4789632 0.193 0.41 rs7207252 0.342 1.00 rs2054834 0.880
MGC16275 0.37 rs7206926 0.270 0.25 rs7207252 0.342 0.87 rs7207252 0.160
TTYH2 0.49 rs7206926 0.270 0.82 rs747742 0.353 0.84 rs2382838 0.860
DNAI2 0.55 rs3803792 0.064 0.66 rs7219585 0.266 0.73 rsl 1650353 0.580
KIF19 0.67 rs2382646 0.087 0.76 rs747321 0.075 0.78 rs938287 0.640
BTBD17 0.92 rs2382646 0.087 0.92 rs2382646 0.157 0.80 rs3869467 0.650
17q25.1 GPR142 0.67 rs2382646 0.087 0.76 rs747321 0.075 0.78 rs938287 0.640
GPRC5C 0.39 rs2891033 0.082 0.77 rs2251065 0.065 0.69 rs7215253 0.670
CD300A 0.51 rs8070953 0.422 0.70 rs2706506 0.011 0.71 rs2706506 0.340
CD300LB 0.90 rsl 171196 0.011 0.86 rsl 0512596 0.674 1.00 rsl 107704 0.350
CD300C 0.75 rsl 976492 0.198 0.88 rs809740 0.350 0.87 rs965229 0.850
C17orf77 0.83 rs783239 0.009 0.97 rs524216 0.511 0.95 rsl 522875 0.210
CD300LD 0.65 rs783239 0.009 0.86 rsl 1650378 0.293 0.89 rsl 699597 0.440
CD300E 0.74 rs581157 0.095 0.35 rs16978145 0.407 0.86 rs6501728 0.480
Table 7.11: This table shows the genes in the 17q25.1 locus with their coverage (if any) in the NeuroDys GWAS and pooling studies and in the Cardiff pooling study, along 
with the most significant SNP within the gene (+/- lOkb) in each study and the P-value for this SNP. N.B. Coverage may differ between the pooling studies due to different 
QC filters. P-values <0.05 are in bold, as are functionally interesting genes.
276
7.3.5 Comparison with Other CNV Studies
Whilst the burden analysis appeared to suggest that there may be some inter-centre 
experimental variation that resulted in a significant excess of deletions being identified 
in those cases that had been genotyped in Oxford in comparison with those genotyped 
in Bonn, this needs to be confirmed with further validation. Therefore, in order to retain 
as much power as possible and to reduce the possibility of false-negative results, all 
cases were used in the comparisons with other CNV studies. It is important to note 
however that due to the nature of the data, interesting results will need to be interpreted 
with caution until they can be reliably validated.
73.5.1 ADHD CNV studies
The CNVs found in this study were compared with two CNV studies of ADHD. 
These studies identified a number of regions in which CNVs were found in ADHD 
cases but not in healthy controls (Elia et al. 2010; Lesch et al. 2010). The results of any 
CNVs identified in DD cases that overlapped these ADHD CNV regions are shown in 
Table 7.12. This table also shows if any CNVs in these regions were identified within 
the 1958 Birth Cohort and gives the P-value from the association test between the rates 
of CNVs in DD cases with those in controls for each of these regions.
CNVs were identified in DD cases for 12 of the ADHD CNV regions. Interestingly, 
CNVs were also found in the 1958 Birth Cohort controls in six of these regions. Figure 
7.13 shows the ADHD CNV region on chromosome 17 identified by Lesch et al.
(2010) which had significantly more duplications in the DD cases than were identified 
in the 1958 Birth Cohort controls (P = 0.012), as was found during the regional analysis 
in section 7.3.3 of this chapter. This was one of the 5 regions that remained significant 
when excluding the cases that had been genotyped in Oxford.
Elia et al (2010) performed Gene Ontology (GO) analysis on the genes that were 
overlapped by CNVs, and interestingly, ‘learning’ was among the six most highly 
enriched GO Biological Process categories. Two of the ADHD CNV genes that were 
associated with learning were protein tyrosine phosphatase, receptor type, D (.PTPRD) 
and Parkinson disease (autosomal recessive, juvenile) 2, parkin (PARK2), both of 
which were also overlapped by CNVs in DD. Figure 7.14 depicts those CNVs that 
overlap PTPRD with one deletion identified in an individual with DD (rate = 0.008),
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and 3 deletions identified in the controls (rate = 0.0029). This gives a CNV case/control 
ratio of 2.76 and a P-value of 0.36, suggesting that whilst there was an excess of CNVs 
in DD cases within this gene, this excess was not significant. The deletion identified in 
the DD case overlaps one of the ADHD deletions entirely, disrupting the first two 
introns and the second exon of this gene. The three other ADHD deletions are 
overlapped by deletions that were identified in the controls.
As shown in Figure 7.15, one deletion and 3 duplications identified in DD cases 
(rate of deletions = 0.008, rate of duplications = 0.025, total rate = 0.033) and 7 
deletions and 3 duplications identified in the controls (rate of deletions = 0.0068, rate of 
duplications = 0.0029, total rate = 0.0097) overlap PARK 2. This gives a CNV 
case/control ratio of 3.40 and a P-value of 0.048 for this gene, suggesting that there is a 
significantly higher rate of CNVs in the DD cases than in the controls within this gene. 
This region was highlighted as one of the significant regions in section 7.3.3 of this 
chapter, giving a P-value of 0.019 when looking at duplications alone. When looking at 
deletions alone the P-value is 1, suggesting that the excess of CNVs in this gene is due 
to the presence of the duplications. The duplications identified in the DD cases all 
overlap the ADHD duplication region defined by Elia et al (2010) entirely, whereas the 
deletion identified in one DD case is downstream from the ADHD deletion region. Two 
of the DD duplications appear to disrupt the first two introns and second exon of 
PARK2 while the third is larger and also disrupts the third intron and the third exon. 
Interestingly, CNVs within PARK2 have also been reported in schizophrenia by Xu et 
al (2008).
Another ADHD CNV region of potential interest is 3p26.3, shown in Figure 7.16. 
Although there is not a significant excess of CNVs in DD cases in this region, the genes 
close homolog of LI (CHL1) and contactin 6 (CNTN6) are of functional interest. CHL1 
encodes for an extracellular matrix and cell adhesion protein that is thought to play a 
role in nervous system development and in synaptic plasticity by regulating cell 
migration in nerve regeneration and cortical development and is expressed at high 
levels in the adult and fetal brain (Holm et al. 1996; Hillenbrand et al. 1999). CNTN6 
(previously known as NB-3) encodes a contactin which mediate cell surface interactions 
during development and is involved in oligodendrocyte generation through the 
activation of NOTCH1 (Takeda et al. 2003). It shows high expression in the fetal 
cerebellum and this expression increases until adulthood (Lee et al. 2000).
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The region 9q24.3 is also of potential interest as this is considered to be a ‘hotspot’ 
region for CNVs. This region is discussed in the next section.
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^m y-
Study
Region Type
in
Study
DD Cases 1958 Birth Cohort controls
Case
/Control P Genes Overlapped by CNVsChr Start bp End bp Deis Dups Rate Dels Dups Rate
Elia et al. 
2010 
(n = 335 
trios)
3 38411 1118424 dup 1 0 0.008 0 1 0.001 8.58 0.202 CHL1, CNTN6
3 176011208 176181941 del 0 1 0.008 0 0 0 0.106 NAALADL2
3 176307146 176434458 del 0 1 0.008 0 0 0 0.106 NAALADL2
4 190175635 190482064 dup 0 1 0.008 1 1 0.002 4.29 0.288 -
6 162672945 162801747 del/dup 0 3 0.025 4 3 0.007 3.68 0.077 PARK2
9 36587 415228 del 0 2 0.017 0 5 0.005 3.43 0.159 FOXD4, CBWD1, LOC642313, C9orf66, DOCKS
9 9084805 10423023 del 1 0 0.008 3 0 0.003 0.360 PTPRD
9 11685785 11847464 del 2 0 0.017 3 0 0.003 5.72 0.085 -
9 12032535 12665264 del 1 0 0.008 7 0 0.007 1.23 0.646 -
13 62104068 62161921 del 1 0 0.008 0 0 0 0.103 -
17 31889664 33323543 del 0 1 0.008 0 0 0 0.101
PIGW, ZNHIT3, MY019, GGNBP2, 
MRM1, DHRS11, LHX1, AATF, 
MIR2909, ACACA, C17orf78, 
TADA2A, DUSP14, SYNRG, 
DDX52, HNF1B, LOC284100
Lesch et 
al. 2010 
(n = 99)
17 69250000 70180000 dup 0 2 0.017 0 0 0 0.012
RPL38; MGC16275, TTYH2, 
DNAJ2, KIF19, BTBD17, GPR142, 
GPRC5C, CD300A, CD300LB, 
CD300C, C17orf77, CD300LD, 
CD300E, RAB37
Table 7.12: Presence of CNVs in DD cases and 1958BC controls within the CNVs regions identified in ADHD cases in studies by Elia et al. (2010) and Lesch et a l  (2010). 
Only those regions in which CNVs were found within DD cases are shown. P-values < 0.05 are in bold. Chr -  chromosome; del -  deletion; dup -  duplication. Genes of 
functional interest are highlighted in bold.
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Figure 7.13: UCSC track showing the duplications identified within the 17q25.1 locus in two DD cases (shown in blue) which overlap a duplication region identified in 
ADHD cases by Lesch et al (2010) (shown in green). RefSeq genes within this region are also shown.
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shown in dark blue). The deletions identified in ADHD cases by Elia et al (2010) are also shown (in dark green).
281
chr6 <q26) I L T -I1 I I I
Sc*1*
chr6s
Chromosom* BandI
MPP3K4
MPP3K4
NCPNrt8824l
Segmenta \ Duns
PHRK2H4* 
r*w<a H4«
I w>|---------
1620896801 1625000001 1630000001DO lot ions, OO cases <PLJNK_CNV_track)
Deletions, 19566C controls (PL1NK CNV truck)
Duplicat ions,DO cases <PLINK £NV_tr*ck)
Duplications, 1958BC controls (PLINK CNV trac
Oolot ions, ftDHO cases <PLINK CNV t r ack)
Duplications, fiDHO cases (PLINK CNV track)_^ 
cnrooosoa* Banos Localized by FISH Mapping Clones
kefSea c o n e s   1 f- ~f~+~
PPCPC ( h
Oupiications of >1000 Bases of Non-KopoatNaskoo Sequence
PMCPCf-— H PHCPCI h ■%
Figure 7.15: UCSC track showing the CNVs overlapping PARK2 in DD cases (deletions shown in red and duplications shown in blue) and the 1958BC controls (deletions 
shown in dark red, duplications shown in dark blue). The CNV regions identified in ADHD cases by Elia et al (2010) are also shown (deleted region shown in dark green, 
duplicated region shown in light green).
Chr3 ( p » . 3 )
Seal*
c n r 3 :
see k&h 
s e e e e e l
D e l e t i o n s ,
l e e e e e e l  
o o  c a s e s  (PLINK cn v  t r a c k )
D e l e t i o n s ,  I958B C  c o n t r o l s  (PLINK cnv  t r a c k )  
Duo 1 i c a t i o n s , 0 0  c a s e s  ( P L I i*  cn v  t r a c k )  
D u p l i c a t i o n s ,  19SBBC c o n t r o l s  (PLINK CNV t r a c k )
D e l e t i o n s ,  NDHO c a s e s  <PLir*( CNV t r a c k )  
D u p l i c a t i o n s ,  PiDHO c a s e s  (PLINK CNV t r a c k )
C h ro m o so m e Band I
C hrom osom e B a n d s  L o c a l i z e d FISH M apping C lo n e s
CHLl
R e f S e q  G e n e s
! 5 e e e e e l
CNTN6l
S e g m e n ta l  D u p s an D u p l i c a t i o n s  o f  > t e e e  B a s e s  o f  N o n -R e p e a tn a s k e d  S e q u e n c e« «  I
Figure 7.16 UCSC track showing the deletion identified within the 3p26.3 locus in a DD case (shown in red) and a duplication identified in a control (shown in dark blue) 
which overlap a duplication region identified in ADHD cases by Elia et al (2010) (shown in green). RefSeq genes within this region are also shown.
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7.3.5.2 Disease Hotspots for CNVs
Of the 26 regions identified as being human genome hotspots for CNVs in the 
recent reviews by Itsara et al. (2009) and Mefford and Eichler (2009), 5 were 
overlapped by CNVs identified in this dataset, the results of which are shown in Table 
7.13. Four of these regions have a higher rate of CNVs in DD compared with the 
controls, but none of them showed a significant excess. Despite the lack of significance, 
three of these regions are still of interest as CNVs have been identified within these 
regions in a number of neurological diseases such as autism (Autism Genome Project 
Consortium 2007; Weiss et al. 2008; Sebat et al. 2007; Christian et al. 2008; Marshall 
et al. 2008), mental retardation (de Vries et al. 2005) and schizophrenia (ISC 2008).
The locus 9q24.3 was overlapped by 2 duplications in the DD cases and 5 
duplications in the controls, giving a case/control ratio of 3.43 and a P-value of 0.158. 
Interestingly, this region was also identified as an ADHD region by Elia and colleagues 
(2010), as shown in Figure 7.17. CNVs in this region have also been identified in cases 
with autism (Autism Genome Project Consortium 2007) and schizophrenia (ISC 2008). 
In autism cases, 4 duplications were found in the cases, all of which overlap the 
duplications identified in the DD cases and the 1958 Birth Cohort controls. In cases 
with schizophrenia, 3 deletions and 18 duplications were found in the cases and 2 
deletions and 23 duplications were identified in the controls. Figure 7.17 shows that the 
region where all these CNVs are overlapping contains the dedicator of cytokinesis 8 
(DOCK8) gene. This gene encodes a member of the DOCK180 family of guanine 
nucleotide exchange factors which interacts with Cdc42 and is thought to affect the 
organisation of filamentous actin (Ruusala & Aspenstrom 2004), giving it a possible 
role within neuronal migration.
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DD Cases 1958 BC controls
Locus Start bp End bp Type Diseases
Type in 
this 
study
All
CNVs Dup Del Rate
All
CNVs Dup Del Rate
Cases
/Controls P
9p24.3 140575 1599250 del/dup Aut8, Schiz” dup 2 2 0 0.017 5 5 0 0.005 3.43 0.158
15q11.1- 
q13.3 18376200 30756771 dup
Aut8'”1, Schiz”, 
MR8, Cons” del/dup 0 0 0 0 11 10 1 0.011 0 0.399
16p12.2-
16p12.1 21441805 22688093 dup Schiz”, Cons” del/dup 1 1 0 0.008 3 2 1 0.003 2.86 0.358
17q12 31800000 33300000 del RenalAbnormalities'1 dup 1 1 0 0.008 0 0 0 0 0.097
22q11.21- 
q11.23 17200000 22000000
del
/dup
Autae, MR9, 
Schiz”', 
Prematurity 
&/or Dev 
Delay**, 
Consb
del/dup 2 2 0 0.017 12 8 4 0.012 1.43 0.65
Table 7.13: Table showing the number of CNVs in DD cases and the population controls within regions that have been highlighted as human disease hotspots in reviews by 
Itsara et al. (2009) and Mefford and Eichler (2009). Only those ‘hotspot’ regions which were overlapped by CNVs identified in this study are shown. Aut -  Autism; Schiz -  
Schizophrenia; MR -  Mental Retardation; Cons -  controls in ISC 2008 study; Dev delay -  Developmental delay. References: “Autism Genome Project Consortium (2007)b 
International Schizophrenia Consortium (2008),0 Weiss et al. (2008), dSebat et al. (2007),e Christian et al. (2008),f Marshall et al. (2008), gde Vries et al. (2005),h Mefford et 
al. (2007),1 Xu et al. (2008),j Ben-Shachar et al. (2008),k Ou et al. (2008).
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Figure 7.17: UCSC track showing the duplications in DD cases (light blue) and 1958 Birth Cohort 
controls (dark blue) which are within the 9p24.3 hotspot region. Also shown are the ADHD deletion 
region (shown in green), deletions and duplications found in schizophrenia cases (purple and orange), 
deletions and duplications found in the ISC controls (pale pink and brown) and the duplications found in 
autism cases (dark pink). RefSeq genes within this region are also shown.
Another ‘hotspot’ region in which a higher rate of CNVs was identified in the DD 
cases compared with the controls is the locus 16pl2.2-16pl2.1, shown in Figure 7.18. 
This locus was overlapped by one duplication identified in a DD case, and two 
duplications and one deletion identified in the 1958 BC controls, giving a case/control 
ratio of 2.86 and a P-value of 0.358. CNVs in this region have also been identified in 
cases with autism (Autism Genome Project Consortium 2007) and schizophrenia (ISC 
2008), as well as in controls in the ISC study (2008). The duplications identified in the 
DD case and the 1958 BC controls lie in between two regions of segmental 
duplications, as do 4 deletions and 8 duplications identified in schizophrenia cases, and 
8 deletions and 6 duplications identified in the ISC controls. Within this region are the
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genes METTL9, IGSF6 and OTOA. Methyltransferase-like 9 (.METTL9, also known as 
PAP 1) is a member of the immunoglobulin superfamily and is thought to be involved in 
embryonic development, possibly through a role in cell proliferation (Shu et al. 2006). 
Immunoglobulin superfamily, member 6 (IGSF6) also encodes for a member of the 
immunoglobulin superfamily, the expression of which is limited to the immune tissues 
such as the spleen and lymph node (Bates et al. 1998). This gene is in the intron of 
METTL9 on the reverse strand and is thought to be the same gene as METTL9 by Shu et 
al (2006). Otoancorin (OTOA) encodes an adhesion protein that is specifically 
expressed in the inner ear and is thought to be involved in the attachment of the inner 
ear acellular cells to the apical surface of the underlying nonsensory cells (Zwaenepoel 
et al. 2002). Mutations in this gene have been associated with a form of autosomal 
recessive deafness (Zwaenepoel et al. 2002).
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Figure 7.18: UCSC track showing the duplication in a DD case (light blue), and the deletion (dark red) 
and two duplications (dark blue) in 3 the 1958 BC controls which are within the 16pl2.2-pl2.1 hotspot 
region. Deletions and duplications found in schizophrenia cases (purple and orange) and deletions and 
duplications found in the ISC controls (pale pink and brown) are also shown as are the RefSeq genes in 
this region.
Figure 7.19 shows the hotspot locus 22ql 1.21-ql 1.23 which was overlapped by two 
duplications in the DD cases and eight duplications and four deletions in the controls, 
giving a case/control ratio of 1.43 and a P-value of 0.65. CNVs in this region have also 
been identified in a number of cases with autism (Autism Genome Project Consortium 
2007; Sebat et al. 2007; Christian et al. 2008), schizophrenia (ISC 2008; Xu et al. 2008) 
mental retardation (de Vries et al. 2005), developmental delay (Ben-Shachar et al. 2008; 
Ou et al. 2008) and in the controls in the ISC study (2008). In this region,
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hemizyogosity occurs once in every 4,000 live births and these deletions produce a 
range of phenotypes including velo-cardio-facial syndrome (VCFS) and DiGeorge 
syndrome and has also been reported to increase risk for schizophrenia (Williams et al. 
2006). Only duplications were identified in the DD cases in this region, the larger of 
which overlaps a region in which duplications have also been found in cases with 
autism (Autism Genome Project Consortium 2007; Christian et al. 2008) and 
developmental delay (Ou et al. 2008). Interestingly, the most consistent features 
amongst the autism subjects with these duplications were intellectual disability, 
neuropsychological problems and speech disorder (Christian et al. 2008). Ou and 
colleagues (2008) identified 5 duplications in this region and found that the individuals 
harbouring these duplications all had some degree of general developmental delay or 
speech delay in combination with variable dysmorphic features and one of these 
patients also had ADHD.
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Figure 7.19: UCSC track showing the duplications (light blue) in two DD cases, and the deletions (dark 
red) and duplications (dark blue) in 12 controls which are within the 22ql 1.21-ql 1.22 hotspot region. 
RefSeq genes within this region are also shown. Also shown are the deletions and duplications found in 
schizophrenia cases (purple and orange), deletions and duplications found in the ISC controls (pale pink 
and brown), deletions and duplications found in autism cases (pink and dark pink), deletions and 
duplications found in cases with mental retardations (grey and dark green), and deletions and duplications 
found in individuals with developmental delay (green and pale blue).
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7.4 Discussion
To my knowledge, this is the first genome-wide study of CNVs in DD. After QC 
filtering, 1147 rare CNVs were identified in a sample consisting of 120 DD cases and 
1030 in the 1958 Birth Cohort controls.
7.4.1 Proof of Principle Test Using HapMap Samples
Although the cases and controls were genotyped on different sized arrays, the proof 
of principle test using HapMap samples showed that while more CNVs are identified on 
the 550k array, this was not a significant increase and 95% of the CNVs identified using 
the 300k array were also found when samples were genotyped on the 550k array. Whilst 
the rates of CNVs at all sizes were marginally higher when using the 550k array, the 
rates of CNVs >500kb were very similar between the two platforms, as has been found 
in previous studies (Itsara et al. 2009). This implies the number of shorter CNVs in the 
cases may have been underestimated as these were genotyped on the smaller array 
(McCarroll et al. 2008). This test was only carried out on 110 HapMap samples and 
would need to be conducted on a larger scale to be sure that the type of array used does 
not have a significant effect on CNV burden when using these QC filters. However, as 
the controls were genotyped on the larger array, this would have skewed the burden in 
favour of more CNVs being identified in controls than in cases, and so any significant 
excess burden in cases is unlikely to be due to the different sizes of the arrays and can 
be relied upon.
7.4.2 Burden Analyses
The burden analysis between all DD cases and the 1958 Birth Cohort controls 
showed a significant excess of CNVs >100kb in the cases (P = 3 x 10-4, case/control 
ratio = 1.42) and this excess appeared to be largely driven by deletions. There was no 
excess of CNVs >500kb in the cases. This result suggests that DD cases harbour 
significantly more small (i.e. <500kb) CNVs than are found in controls. When looking 
at all CNVs >100kb, there were more deletions than duplications in both cases and 
controls, but when focussing on CNVs >500kb the rates of deletions and duplications 
were very similar. This has also been observed in previous studies (Itsara et al. 2009) 
and it has been suggested that the relative enrichment of deletions at smaller sizes may 
reflect higher de novo rates of occurrence of deletions, whereas their lower rates at
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larger sizes is consistent with large deletions being more detrimental than duplications 
(Turner et al. 2008).
However, the cases had been genotyped in two different centres in Bonn (n = 74) 
and Oxford (n = 46) and the excess of deletions in cases seemed to be coming from 
those cases that had been genotyped in Oxford. Bonn cases alone did not show a 
significant excess of CNVs when compared with the controls, whereas the Oxford cases 
still showed a significant excess of deletions, even though it was the smaller case 
sample (P = 1 x lO-4, Oxford cases/controls ratio = 3.28). This suggests that there is 
some inter-centre variability between the cases genotyped in these two centres. This 
excess of deletions in cases genotyped in Oxford may well be real, but it is perhaps 
more likely that these CNVs represent false positives. A high rate of CNVs can indicate 
poor quality samples, but these samples were all extracted and prepared in the same 
centre (Cardiff). Therefore it is likely to be a genotyping quality issue and the higher 
LRR SDs (indicating a higher level of variation in the intensities between SNPs) that 
were observed with the cases genotyped in Oxford correlates with this. Interestingly, the 
rate of duplications between the two case samples was not significantly different, which 
suggests that genotyping quality issues can result in more deletions being identified but 
doesn’t have such a large effect on duplications. As these CNVs in cases genotyped in 
Oxford passed the QC filters, they cannot be confidently excluded until validation has 
been attempted using another method, such as aCGH or qPCR, but they are worth 
bearing in mind when carrying out the regional analyses.
In addition, the case DNAs originated from either blood or saliva samples. DNA 
extracted from saliva samples is often at a lower concentration and of poorer quality 
than blood-derived DNA which may result in the identification of more CNVs. Whilst 
there was no significant difference in the rate of CNVs identified when DNA was 
extracted from either sample type, information on the origin of the samples was only 
available for a small subset of die sample. A larger number of samples would need to be 
tested to be confident that there was no significant difference when extracting DNA 
from saliva compared to blood samples. The 1958 Birth Cohort would have been 
extracted from cell lines, but DNA from cell-lines and blood-derived DNA have yielded 
similar results in previous studies suggesting that cell line artefacts are not a major 
contributor to estimates of CNV burden (Itsara et al. 2009).
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It is possible that even if these cases had all originated from the same sample type 
and had been genotyped in the same centre, batch effects may still have existed which 
could affect intensity signals from sample to sample (McCarroll 2008). To address such 
issues, algorithms need to be designed so that sample-specific and batch-specific 
influences on signal intensities can be controlled for as much as possible.
7.43 Regional Analyses
No CNVs were identified in DD susceptibility genes. However, 18 regions across 
the genome were identified which harboured significantly more CNVs in the DD cases 
than the controls. The number of CNVs across the human genome is not yet known, and 
therefore a correction for multiple testing based on this number is not possible to define 
(Wain etal. 2009).
The most significant of the regions was 15q23 which had 5 deletions in the cases.
All of these cases with CNVs in this region had been genotyped in Oxford. In order to 
prioritise regions of interest and to reduce the possibility that these significant regions 
are false positives, regional analysis was also conducted on just those cases that had 
been genotyped in Bonn to see if any would remain significant. Of the original 18 
regions, 7 had significantly more CNVs in the DD cases genotyped in Bonn than were 
identified in the controls. The four most significant of these were 2 regions on 16pl3.3, 
one on 17q25 and one on 19pl3.3. These regions all harboured a number of genes, each 
of which were investigated to see if they had shown significance in a previous 
NeuroDys study. Within the first region on 16pl3.3, 2 deletions were identified in the 
cases and none were found in the controls. The two CNVs in this region overlap 25 
genes. Of these, perhaps the most interesting is the gene STIP1 homology and U-box 
containing protein 1 (STUB1). STUB1 lies on the section of this region which is 
overlapped by both of the deletions identified in the cases and did not show significant 
association with DD in the previous GWAS. What makes this gene particularly 
interesting is that it encodes the protein CHIP which has been shown to interact with the 
DD susceptibility gene, DYX1C1 (Hatakeyama et al. 2004). CHIP promotes the 
degradation of a variety of proteins, including the estrogen receptors ERa and ERf3. The 
CHIP-mediated degradation of ERa has been shown to be ligand-dependent and is 
blocked when estrogen is added, whilst degradation of ERp is estrogen-dependent (Fan 
et al. 2005; Tateishi et al. 2004; Tateishi et al. 2006). Estrogen receptors are important 
in brain development (Wang et al. 2001; Wang et al. 2003; McCarthy 2008) and are
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also thought to be involved in cognitive processes and memory (Liu et al. 2008; Luine 
et al. 1998; Fugger et al. 2000; Rissman et al. 2002). ER|3 in particular has a role in 
neuronal migration and neuronal survival in the developing cortex and Erp knock-out 
mice show very similar phenotypes as the post-mortem brains of DD individuals (Wang 
et al. 2001; Wang et al. 2003; Massinen et al. 2009). Interestingly, Massinen et al.
(2009) showed that over-expression of DYX1C1 reduces the protein levels of ERa and 
ERp, which doesn’t quite fit in with the findings that knockdown via in utero RNAi of 
D yxlcl prevents correct neuronal migration and causes malformations similar to those 
seen in post-mortem studies of individuals with DD (Threlkeld et al. 2007; Wang et al. 
2006; Rosen et al. 2007). If STUB1 had a reduced copy number (as in these DD cases), 
one might expect the expression of this gene to be reduced, resulting in a reduction of 
CHIP and therefore a reduction in the degradation of the estrogen receptors, which 
doesn’t fit in with the model that a reduction of ERP affects neuronal migration and may 
result in a DD phenotype. However, as explained in section 7.1.3 o f this chapter, CNVs 
can influence phenotypes in a variety of ways and the effects of deleting STUB1 would 
need to be investigated in functional studies in order to fully understand how CNVs in 
this region may result in a DD phenotype.
There were two other genes in this region which are also of potential functional 
interest. SOLH, which is thought to be involved in protein-protein interactions during 
visual development (Kamei et al. 1998) and two different SNPs in this gene had shown 
significant association with DD in the previous DD GWAS studies; one in the initial 
NeuroDys GWAS (rs7763, P = 0.012) and the other in the Cardiff pooling study 
(rs9934705, P = 0.030), however neither of these SNPs would have passed multiple 
testing in these studies. The other functionally interesting gene in this region is METRN 
which is thought to be involved in both glial cell differentiation and axonal network 
formation during neurogenesis (Nishino et al. 2004), giving it a potential role within 
neuronal migration. However, these genes were only overlapped by one of the deletions 
in this region as opposed to STUB1 which was overlapped by both.
The other significantly associated region of 16pl3.3 lies ~640kb away from the 
previous one and also harbours two deletions in cases with DD and no CNVs in the 
controls. These CNVs overlap 13 genes, of which two are particularly interesting. 
BAIAP3 (or BAP3) lies in the region which is overlapped by both of the case deletions 
and this gene encodes a brain-specific angiogenesis inhibitor which shows predominant
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expression in the brain (Shiratsuchi et al. 1998). Shiratsuchi et al. (1998) found that the 
expression profile of this inhibitor protein and its sequence similarity to Muncl3 and 
synaptotagmin suggests that it may be involved in neuronal processes such as regulating 
the release of neurotransmitters. Synaptotagmin promotes the formation of filopodia in 
fibroblasts (Feany & Buckley 1993) which are involved in motility and recognition in 
growth cones and so, by similarity, BAIAP3 may also have a role in neuronal migration.
The other interesting gene in this region is CA CNA1H which encodes a T-type 
member of the alpha-1 subunit family which is a protein in the voltage-dependant 
calcium channel complex and these types of channels may be involved in modulating 
the firing patterns of neurons (Perez-Reyes 2006).
Another significant region was 19pl3.3 which harboured two deletions in the cases 
with none identified in the controls. These CNVs overlap 11 genes, none of which are 
of known functional interest within DD. Perhaps the most interesting gene in this region 
is PLK5P which showed nominal significance in the initial NeuroDys GWAS 
(rsl 040499, P = 0.048). However, this gene is on the very edge of the region and is only 
partially overlapped by one of the deletions. In addition, PLK5P is thought to be a 
psuedogene and so there is very little information regarding its function.
The fourth most significant region was 17q25.1 in which two duplications were 
identified in the cases and none were found in the controls. These duplications overlap 
exactly the same region which contains 14 genes. SNPs in or near three of these genes 
showed significant association with in the initial NeuroDys GWAS (rsl 1711196 4.4kb 
downstream of CD300LB, P = 0.11 and rs783239 in CD300LD and CD300E, P = 0.009) 
and a SNP in another gene showed significant association in the NeuroDys pooling 
study (rs2706506 5.6kb upstream of CD300A, P = 0.011). These genes are all members 
of the CD300 molecule family which are leucocyte surface molecules that regulate 
dendritic cell and monocyte function and so are thought to trigger or inhibit immune 
responses (Clark et al. 2009). As mentioned previously, this may be interesting as the 
DYX2 locus lies over the human histocompatability antigen (HLA) region which 
contains many genes that influence immune function. As such, immune disorders have 
previously been linked with DD, although the evidence for this has been inconclusive 
(Gilgeretal. 1998).
All of these CNVs need to be validated using other methods before they can be 
relied upon. In addition, the CNVs identified in these regions are very rare and
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identified in only a couple of cases and so may only confer a susceptibility to DD in a 
small proportion of individuals. CNV studies on larger samples will need to be 
conducted to see if the results in these regions can be replicated. Based on this evidence 
alone, the STUB1 gene appears to be the most interesting gene from the regional 
analysis and this gene had not been significantly associated with DD in previous 
studies.
7.4.4 Overlap with ADHD CNVs
12 regions across the genome were identified in which DD CNVs overlapped CNVs 
that had been found in cases with ADHD by Elia et al. (2010) and Lesch et al. (2010). 
CNVs in 6 of these regions were also found in the 1958 Birth Cohort but no CNVs in 
these regions were identified in the screened controls in each of these ADHD studies.
As the 1958 Birth Cohort had not been screened, it is possible that some of the 
individuals may have symptoms of DD or ADHD and so the pathogenicity of the CNVs 
in these regions for these disorders cannot be ruled out. Further investigation of these 
regions may provide information behind the mechanisms underlying the comorbidity of 
ADHD and DD.
Interestingly, the region 17q25.1 discussed above which showed a significant excess 
of duplications in the DD cases was also found to contain a CNV in a case with ADHD 
(Lesch et al. 2010). As genes in this region are associated with the immune system, this 
region may provide a link between ADHD and DD via disorders of the immune system.
Another interesting result is that the genes PTPRD and PARK2, which were 
overlapped by ADHD CNVs, were also overlapped by CNVs in DD cases and these 
genes are thought to be involved in learning. Deletions were found to overlap PTPRD in 
4 ADHD cases by Elia et al. (2010) and in one DD case and 3 controls in this study. The 
protein encoded by PTPRD is a member of the protein tyrosine phosphatise (PTP) 
family and has been shown to have high expression in the hippocampus of mice 
(Mizuno et al. 1993). It is thought to be involved in spatial learning and axonal guidance 
of motor neurons (Uetani et al. 2000; Uetani et al. 2006), making it good candidate gene 
for DD as well as ADHD.
PARK2 was overlapped by a duplication and a deletion in two ADHD cases in the
study by Elia et al (2010). The same region of PARK2 was also overlapped by 3
duplications identified in DD cases and 7 deletions and 3 duplications identified in the
controls. The precise function of PARK2 is still unknown but mutations in this gene are
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known to cause a familial form of Parkinson’s disease (Kitada et al. 1998). It encodes 
Parkin which is an E3 ubiquitin ligase and loss of this ubiquitin ligase activity appears 
to be the mechanism underlying autosomal-recessive juvenile Parkinsonism (von Coelln 
et al. 2004). Interestingly, Parkin has been shown to be positively regulated by CHIP 
(Imai et al. 2002), the protein that is encoded by STUB1 which was overlapped by a 
significant excess of deletions in the DD cases. This suggests that these genes may lie 
on a pathway which may be involved in DD. CHIP was shown to enhance Parkin- 
mediated ubiquitination (and subsequent degradation) o f the Pael receptor (Pael-R), the 
accumulation of which in the endoplasmic reticulum of dopaminergic neurons can lead 
to neurodegeneration (Imai et al. 2002). CNVs overlapping this gene have also been 
found in cases with schizophrenia (Xu et al. 2008), suggesting that this gene is a hotspot 
for CNVs and may be involved in the pathogenicity of a variety of neurological 
disorders.
7.4.5 CNVs in Hotspot Regions
The hotspot regions that have been identified across the genome may indicate that 
there is a lack of specificity for phenotypes caused by CNVs in the same region. The 
wide range of phenotypes associated with rearrangements in a number of loci points to a 
common disease mechanism for a wide range of neurocognitive deficits. It is possible 
that while these deletions and duplications are primarily responsible for disease, the 
actual specificity of disease is determined by other genetic, epigenetic and 
environmental modifiers (Mefford & Eichler 2009).
Of the hotspot regions highlighted by Itsara et al (2009) and Mefford and Eichler 
(2009), 5 were overlapped by CNVs in this study. Perhaps the most interesting of these 
regions is 9q24.3 which was overlapped by 2 duplications identified in the DD cases 
and 5 duplications in the controls. CNVs in this region have also been identified in 
cases with schizophrenia (ISC 2008) and autism (Autism Genome Project Consortium 
2007) as well as in an individual with ADHD (Elia et al. 2010). The CNVs identified in 
these disorders all overlap the DOCK8 gene. This gene has been shown to interact with 
Cdc42 and is thought to affect the organisation of filamentous actin (Ruusala & 
Aspenstrom 2004). Cdc42 has a well recognised role in neuronal migration (Kozma et 
al. 1995; Nobes & Hall 1995; Luo 2000), as discussed in Chapter 3, but it was not 
shown to be significantly associated with DD in the candidate gene study of this thesis. 
This suggests that as well as in DD, impaired/altered neuronal migration may also be
involved in the pathogenicity of ADHD, autism and schizophrenia. The majority of 
CNVs found to be overlapping DOCK8 are duplications, suggesting that having extra 
copies of this gene may somehow be involved in neurological diseases. This needs to be 
investigated further through functional studies.
The region 22ql 1.21-ql 1.22 seems to be particularly prone to CNVs, with deletions 
and duplications identified in individuals with DD in this study, schizophrenia (ISC 
2008; Xu et al. 2008), autism (Autism Genome Project Consortium 2007; Christian et 
al. 2008), mental retardation (de Vries et al. 2005) and developmental delay (Ben- 
Shachar et al. 2008; Ou et al. 2008). This is likely to be due to the segmental 
duplications flanking this region altering copy number via NAHR. This study identified 
a duplication in a DD case and in one of the controls. Autistic individuals with 
duplications in this region were observed to have intellectual disability, 
neuropsychological problems and speech disorder (Christian et al. 2008). This is 
particularly interesting as speech disorders are thought to share some comorbidity with 
DD, with half of the individuals with SLI also having DD (Flax et al. 2003), as 
discussed in Chapter 1. In addition, Ou et al (2008) found that individuals in this region 
all had some degree of general developmental delay or speech delay and one individual 
also had ADHD. This suggests that this region may be important during intellectual and 
speech development, but the effects of rearrangements in this region may be modified 
though other genetic or environmental factors to cause a range of diseases with varying 
severity.
Combing the hotspot regions identified by Itsara and colleagues (2009) and Mefford 
and Eichler (2009) resulted in large regions of the genome being tested which may have 
been over-inclusive. As such, these regions may have contained CNVs within DD by 
chance so it is difficult to be sure that these CNVs are contributing to disease in a 
similar way to other CNVs that have been identified in these regions. However, the DD 
CNVs still overlap some interesting regions, and if validated, could be worthy of 
follow-up.
7.4.6 Summary and Future Work
This CNV study has highlighted a number of novel candidate regions for DD that
had not shown association in the previous GWAS studies. Carrying out CNV analysis
using GWAS data enables the investigation of genetic variants that may not have been
identified in the GWAS at no extra experimental cost. However, larger studies need to
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be conducted to replicate the presence of CNVs in these regions in individuals with DD 
and functional studies need to be carried out to understand how copy number changes in 
these genes may be involved in increasing an individual’s susceptibility to DD. It is 
important to note that the CNVs identified in this study need to be validated using an 
alternative method such as aCGH or qPCR before they can be relied upon. If these 
CNVs are indeed real, then the genes STUB1 and PARK2 and the interaction between 
them and DYX1C1 would be of particular interest.
This study also highlights the issues that can arise when carrying out CNV analysis 
using GWAS data. Whilst SNP genotype calls may not be as adversely affected by 
carrying out genotyping in different centres (provided the appropriate QC is carried 
out), the intensity scores are far more sensitive to experimental variation which may 
increase the rate of false positive results. Future GWAS should ideally be carried out 
with cases and controls being genotyped on the same arrays at the same centres in order 
to reduce the variability in the intensity signals. The case sample size used in this study 
is very small and underpowered to detect the rare CNVs. Future CNV studies of DD 
need to be carried out using much larger samples and with age-matched screened 
controls in order to confidently identify CNVs that may be involved in DD.
The array used to genotype the cases was one of the early SNP arrays that did not 
contain any probes for CNVs. New hybrid arrays include non-polymorphic probes to 
detect common CNVs and probes for many more SNPs, such as those purposely 
excluded from early arrays (McCarroll et al. 2008) and so future CNV studies should be 
conducted using these arrays. However, in general, the resolution of these platforms still 
needs to be improved and there is a need for technologies that can confidently resolve 
genes down to less than lkb in size, as these are much more abundant in the human 
genome while still having the capacity to disrupt genes (Kirov 2010). The development 
of next-generation sequencing has enabled resolution of whole genomes down to the 
single nucleotide level, and as the cost of these techniques decrease, they may well 
become the method of choice when conducting CNV analysis.
In conclusion, whilst this is a small study on the role of CNVs in DD, it has 
highlighted a number of novel regions that may have not been considered interesting 
based on the initial GWAS results. CNVs appear to affect a wide range of phenotypes 
and are worthy of further investigation in larger, more homogeneous samples for future 
studies of DD.
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Chapter 8: Final Discussion
The main aim of the research presented in this thesis was to identify susceptibility 
variants for DD using several approaches. DD is one of the most common 
neurobehavioral disorders and has a highly heritable component (see Chapter 1). 
Linkage and association studies have been conducted to identify genes that underlie the 
genetic predisposition to DD. So far, nine putative susceptibility loci for DD have been 
identified and designated DYX1-DYX9 by the Human Gene Nomenclature Committee 
(www.genenames.org).
A candidate gene study was conducted selecting genes within the DYX  susceptibility 
loci that had plausible roles in neuronal migration or showed homology with genes 
which have shown previous association with DD. The first GWAS of DD was 
conducted by the NeuroDys collaboration and data from this study was analysed to 
identify new susceptibility variants for DD. An additional GWAS was also carried out 
as part of the NeuroDys collaboration in the form of a pooling study, testing a larger 
number of SNPs across the genome for an association with DD. Pooled DNA was also 
used to conduct a GWAS using just the Cardiff case control sample in an effort to 
identify susceptibility variants that are significantly associated with DD in this 
homogenous case-control sample Finally, CNV analysis was also conducted using data 
from the first NeuroDys GWAS to investigate this source of variation for an association 
with DD.
8.1 Research Findings
Initial work focused on identifying new susceptibility variants for DD by testing
variants within a small number of candidate genes for an association with DD in the
Cardiff case-control sample. The genes CDC42 and PRTG were selected based on their
location within DD susceptibility loci (DYX8 and DYX1, respectively) and because of
their putative roles within neuronal migration. The genes KIAA0319L and DCDC2b
were also selected for this candidate gene study due to their position within the DYX8
susceptibility locus and their homology with two replicated susceptibility genes for DD,
KIAA0319 and DCDC2, respectively. Finally, RIOK3 was also tested for an association
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with DD because a survey of gene expression showed that two SNPs within the putative 
DD susceptibility gene KIAA0319 were associated with expression levels of RIOK3 
(Myers et al. 2007). These genes were tested for association using tag SNPs identified 
from HapMap with the exception of DCDC2b in which high resolution DNA melting 
analysis was used to identify novel SNPs. None of the variants tested within these genes 
showed a significant association with DD in the Cardiff case-control sample after 
correction for multiple testing. However, no study of this size can confidently exclude a 
gene from involvement in disease susceptibility. Furthermore, the lack of significant 
association of the putative neuronal migration genes CDC42 and PRTG with DD in this 
study does not discount this pathway from having a role within DD.
The next stage of research focussed on a GWAS of DD which was conducted as part 
of the NeuroDys collaboration. This was carried out using the Illumina HumanHap300 
array and a discovery sample of 585 cases and 2326 population controls from the UK 
and Germany. Twenty-seven of the most significant SNPs identified were selected from 
this GWAS and followed up in an independent replication sample of 1244 cases and 
1955 screened controls from the UK, Germany, Switzerland, the Netherlands, Austria 
and Finland. Eight of these SNPs had P-values < 0.05 in the replication sample with 
none achieving genome-wide significance. Many SNPs showed a different direction of 
effect in the replication sample compared to the discovery sample, suggesting a high 
false positive rate in the SNPs selected for follow-up from the intial GWAS. When 
combining genotyping data from both sample sets, the most interesting result came from 
the SNX29 gene in which two SNPs showed an increased significance in the combined 
sample (rs6498274: P-gen = 2.46 x 10"4, P-add = 2.65 x 10’5, OR = 1.19; rs905950: P- 
gen = 5.19 x 10-4, P-add = 4.52 x 10'5, OR = 1.18) compared to their results in the initial 
discovery sample alone (rs6498274: P-gen = 1.32 x 10"4, P-add = 4.47 x 10'5, OR =
1.31; rs905950: P-gen = 5.19 x KT4, P-add = 2.04 x 10‘5, OR = 1.30). This gene is a 
member of the sorting nexin family and this family of proteins contain PX domains 
which are thought to be involved in cell polarity (Worby & Dixon 2002; Teasdale et al. 
2001), which may suggest a possible link with neuronal migration. Of the previously 
replicated susceptibility genes for DD, only DCDC2 showed significant association in 
the GWAS. Eleven SNPs within DCDC2 were significantly associated with DD in the 
GWAS and three of these were in LD with each other and the SNP rs807701 which has 
shown association with DD in previous studies (Schumacher et al. 2006a). A large
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number of SNPs within the DYX  susceptibility loci were significant at the 0.05 level. 
However, after running set-based analysis to correct for the number of independent 
SNPs in each region, one SNP within the DYX5 locus remained significant (rs6796074, 
best corrected P-add = 0.008). This SNP lies in an intergenic region towards the edge of 
the DYX5 susceptibility locus, 129kb from the polymorphism D3S3665 which has 
shown evidence of linkage with DD previously (Nopola-Hemmi et al. 2001).
As the significant SNPs in the initial GWAS did not show strong evidence of 
association with DD in the replication study, the NeuroDys collaboration conducted a 
larger GWAS using the replication sample from the first GWAS and the Illumina 1M- 
Duo array. This was carried out in the form of a pooling study in order to reduce the 
time and cost of this second GWAS. There was little concordance between the two 
GWAS, with only 4 SNPs of the most significant SNPs of the pooling study also being 
significant in the initial GWAS at P < 0.05. 38 of the most significant SNPs were 
selected for individual genotyping in the 988 cases and 1121 controls that had been 
pooled. After individual genotyping, 14 SNPs were significant at the 0.05 level. This 
indicates that there were some inaccuracies in the estimations of the allele frequencies 
from the pooled samples, possibly due to pool-formation or pool-measurement errors. 
When including an additional 568 cases and 1140 controls, 6 SNPs showed an increased 
level of significance. The most significant of these was rs461119 (P-add = 3.0 x 10-4,
OR = 1.23) which is within the GRIK1 gene on chromosome 21. This gene encodes a 
glutamate receptor, and as these are the predeominant excitatory neurotransmitters in 
the mammalian brain (Headley & Grillner 1990), this gene could be a good functional 
candidate for DD. The next most significant SNP was rs l2344734 (P-add = 0.0021, OR 
= 1.2) which is within the TMC1 gene on chromosome 9. Mutations in this gene have 
previously been associated with progressive post-lingual hearing loss and profound pre- 
lingual deafness (Kurima et al. 2002; Vreugde et al. 2002) and so this gene could have a 
possible role in an auditory component of DD. Although not as significant, another 
interesting SNP was rs4655653 (P-add = 0.0149, OR = 1.15) which is within the gene 
WDR78. This gene belongs to the WD-repeat family of proteins. LIS1 (a gene involved 
in the neuronal migration disorder lissencephaly) also contains WD-repeat domains and 
is thought to be in a crucial pathway for cerebral development (Reiner et al. 1993). If 
the WD-repeat domains of WDR78 share a similar function to those of LISJ then 
WDR78 could be a good candidate for DD.
An additional GWAS was conducted using the Illumina lM-Duo array on just the 
Cardiff cases and controls in order to identify susceptibility variants that show 
association in this more homogeneous sample of severe DD cases and screened 
controls. This was also carried out in the form of a pooling study in order to reduce the 
time and cost. 57 of the most significant SNPs were genotyped in 292 cases and 215 
controls which had been included in the pools. Whilst the significance of these SNPs 
was generally lower when individually genotyped, 54 remained significant at the 0.05 
level, which is a higher rate than in the NeuroDys pooling study. This suggests that 
estimations of allele frequencies were more accurate for these pools, possibly due to the 
use of a homogeneous sample which had been collected, extracted and prepared in the 
same centre. When including an additional 39 cases and 47 controls, the most 
significant SNP was rsl 125198 (P-value = 1.3 x 10-4, OR = 2.19) which is within a 
potentially functionally interesting gene, MLKN1. This gene shows highest expression 
in the cerebellum and hippocampus and may have a role within synaptogenesis 
(Tagnaouti et al. 2007). When including data for 3748 population controls from the 
1958 Birth Cohort, two SNPs showed a higher level of significance. The most 
significant SNP was rs7330054 (P = 2.8 x 10‘5, OR =1.71) which is within COL4A2. 
This gene has been linked with a number of cerebral small vessel diseases in humans 
which are thought to affect information processing speed and executive function 
(Volonghi et al. 2010; Prins et al. 2005). Therefore, this gene may have a role within 
DD susceptibility by affecting an individual’s ability to link graphemes with phonemes 
and so impairing their ability to read efficiently. The other significant SNP was 
rsl0844773 (P = 7.8 x 10‘5, OR = 0.51). This SNP is within CD163L1 which encodes a 
member of SRCR superfamily which are mainly found in cells of the immune system 
(Gronlund et al. 2000; Van Gorp et al. 2010). This could be interesting within the 
context of DD as DD has previously been linked with immune disorders (Gilger et al. 
1998). In general, there was little concordance across all the GWAS. Although many of 
the most significant SNPs within the Cardiff pool also showed a high level of 
significance in the UK pool, they were not significant in the Central European or 
Finnish pools.
Finally, a CNV analysis was conducted using data from the Cardiff cases in the 
initial GWAS and the 1958 Birth Cohort as controls, identifying 1147 rare CNVs. There 
was a significant excess of deletions in the cases compared with the controls (P = 1 x
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10-4, case/control ratio = 2.00). However, this excess appeared to be driven by technical 
differences in those cases that had been genotyped in Oxford, suggesting that the CNVs 
in this dataset need to be treated with caution. This highlights the need for homogenous 
samples that have been prepared and genotyped in the same centre when conducting 
CNV studies. When removing those samples that were genotyped in Oxford, there was 
no longer a global significant excess of CNVs in the cases, but a number of regions 
showed a higher rate o f CNVs in the remaining cases compared with the controls. 
Perhaps the most interesting of these is the region on 16pl3.3 (P = 0.004, 2 deletions in 
cases, none in controls). The two deletions identified in cases in this region both overlap 
the gene STUB1 which encodes the protein CHIP. CHIP has been shown to interact with 
the putative DD susceptibility gene DYX1C1 (Hatakeyama et al. 2004) and promotes the 
degradation of estrogen receptors which are thought to be involved in cognitive 
processes and memory (Liu et al. 2008; Luine et al. 1998; Fugger et al. 2000; Rissman 
et al. 2002). In particular, the estrogen receptor ERp has a role within neuronal 
migration and the brains of ERfi knock-out mice show similar phenotypes to those 
identified in post-mortem studies of brains of individuals with DD (Wang et al. 2001; 
Wang et al. 2003; Massinen et al. 2009). This suggests that STUB1 may affect an 
individual’s susceptibility to DD via the action of estrogen receptors. Another 
interesting region identified in this CNV study was 6q26. There was a significant excess 
of CNVs overlapping the PARK2 gene within this region (P = 0.048, case/control ratio 
= 3.4), particularly for duplications (P = 0.019, case/control ratio = 8.62). Duplications 
and deletions in this region have also been identified in individuals with ADHD (Elia et 
al. 2010), suggesting that this region could provide information about the shared genetic 
aetiology between these disorders. Mutations in PARK2 cause a familial form of 
Parkinson’s disease (Kitada et al. 1998). Interestingly, PARK2 has also been shown to 
be positively regulated by CHIP (Imai et al. 2002), the protein encoded by STUB1. This 
raises the possibility that both of these genes lie on a pathway which could affect an 
individual’s susceptibility to DD. CNVs in this region have also been identified in 
schizophrenia (Xu et al. 2008), suggesting that this region is a hotspot for CNVs. CNVs 
in individuals with DD were found to overlap other regions of the genome which appear 
to be hotspots for CNVs in a number of neurocognitive diseases, suggesting that CNVs 
may be involved in a wide range of diseases. However, the CNVs identified in this
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study need to be interpreted with caution and validated with alternative methods before 
these results can be relied upon.
8.2 Thesis Limitations
The main limitation of the studies conducted in this thesis has been power. Power 
calculations show that in order to have at least 80% power to detect a significant 
association with a variant that has a MAF of 0.4 and an OR of 1.3 at the 0.05 level, 
more than 450 cases and 450 controls are required. At the genome-wide level of 
significance, this increases to over 2300 cases and 2300 controls. The study designs 
used in this thesis would have only detected common variants of large to moderate 
effect sizes and so it is likely that some variants associated with DD were missed due to 
their small effect size. The recruitment of a larger sample set of cases and screened 
controls which have been ascertained using the same, stringent criteria could greatly 
increase the power to detect true associations with DD.
In addition, the methods used in these studies would only be able to detect 
association with common polymorphisms in the genome. As discussed in Chapter 1, the 
genetic aetiology of DD appears to be complex and it could be caused by a combination 
of common polymorphisms of various effect sizes as well as rare polymorphisms, gene- 
gene interactions, gene-environment interactions and other unsuspected genomic 
mechanisms which were not explored in this thesis.
Conducting a candidate gene study allows for genes to be prioritised based on 
previous evidence of association or linkage as well as in terms of their suspected 
functional relevance within a disorder or trait. The nature of candidate gene studies 
makes them considerably cheaper than GWAS and enables specific genes of interest to 
be densely mapped and tested for association. However, the precise biology of DD is 
unknown. Whilst replicated susceptibility genes for DD so far have highlighted a 
possible role for neuronal migration within DD, this is a complex process involving a 
large network of pathways. Therefore, it is possible to find evidence connecting a large 
number of genes to DD via neuronal migration. Selecting those that were within 
replicated linkage regions of DD may have improved the selection of these candidate 
genes, but these regions are quite broad, containing a large number of genes of possible 
functional interest.
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Carrying out the first GWAS of DD enabled the systematic testing of the whole 
genome for an association with reading disability. Because no prior assumptions are 
made about the biology of this complex disorder or the location of the variants, this 
represents an unbiased approach to identifying new susceptibility loci for diseases 
(Hirschhom & Daly 2005). In order to increase the sample size, this study was 
conducted by the NeuroDys consortium, involving samples from 6 European countries. 
Whilst this increased the power of this study, using heterogeneous sample sets may 
have introduced other limitations such as population stratification. Population 
stratification may cause differences in allele frequencies between cases and controls, 
whether the alleles are causally related to the disease or not. These samples were 
collected by different centres, using slightly different ascertainment criteria and were 
genotyped in different centres, all of which may have contributed to the false positive 
rate. The use of population controls can increase the power of a study without a 
significant increase in genotyping costs. However, the population controls were 
genotyped on different arrays to the cases and in different centres, which may have also 
contributed to the false positive rate. Furthermore, these population controls had not 
been screened and so it is possible that some of the controls had symptoms of DD, 
which would reduce the power of this study to identify susceptibility variants. 
Population stratification was controlled for as much as possible through the use of the 
MDS component and centre as covariates when performing logistic regression analysis, 
but the false positive rate may have still been inflated in comparison to a study that used 
a more homogeneous sample of cases and controls, which may explain the lack of 
replication in the replication sample. The Illumina HumanHap300 array used in this 
GWAS is one of the earlier SNP arrays and provides 76% coverage of common genetic 
variation in the human genome (Magi et al. 2007). It is therefore possible that some of 
the variants that confer susceptibility for DD were missed. Furthermore, the distribution 
of markers across the genome is not even, which means that some loci have good 
coverage, while others have very poor. For example, one of the well replicated 
susceptibility genes for DD, KIAA0319, only had coverage of 48% in this GWAS.
The second GWAS conducted by the NeuroDys consortium used the Illumina 
HumanlM-Duo array which has an improved coverage of 95%, however a large 
proportion of the SNPs on this array were excluded during QC filtering. Conducting this 
second GWAS in the form of a pooling study provided significant savings in terms of
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both time and money. However, it also resulted in a loss of detailed information that 
could have been obtained through individual genotyping. For example, the design of 
this study prevented the analysis of componential phenotypes of DD and does not allow 
the formation of haplotypes. There was also likely to have been a loss in power as a 
result of specific errors that can arise in pooling studies, such as pool-formation and 
pool-measurement errors. This pooling study combined samples which had been 
extracted and prepared in different centres and this may have resulted in inflation of the 
pool-formation error rate. These errors affect the ability of a study to estimate allele 
frequency differences accurately and so can increase the rate of false positives, which 
may have been why only a small proportion of the top SNPs remained significant after 
individual genotyping. Due to insufficient funding, individual genotyping was not 
carried out with those samples which had been included in the Finnish pool, which may 
have also affected the number of SNPs that were significant after individual genotyping. 
In contrast, the Cardiff case-control pooling study used a uniform sample of cases and 
controls and had a much higher proportion of SNPs remaining significant after 
individual genotyping, indicating a greater level of accuracy when estimating the allele 
frequencies. This suggests that in order for pooling studies to be a valuable method of 
screening large samples at a lower cost, they ideally need to be conducted using samples 
that have been collected and prepared in the same centres. However, this is not always 
possible and meant that the Cardiff pooling study had a much smaller sample, and 
therefore a reduced power to detect variants of small effect sizes. This is illustrated by 
the observation that the SNPs which remained significant after individual genotyping all 
had relatively large effect sizes (OR between 1.43 and 2.79). In both of these pooling 
studies, only a relatively small number of significant SNPs could be followed up with 
individual genotyping due to financial constraints and more significant associations may 
have been confirmed with individual genotyping if larger panels of SNPs had been 
selected.
The use of intensity data from GWAS using SNP arrays enables CNVs within the 
genome to be tested for an association with a particular disease or trait, without an 
increase in experimental costs on top of the initial GWAS. However, the use of SNP 
arrays for CNV analysis has a number of limitations. As mentioned earlier, the SNP 
probes on an array are not uniformly distributed across the genome, particularly with 
the earlier arrays. They are especially sparse in regions of segmental duplications which
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create problems when designing robust SNP assays in these regions. This means that 
common CNVs cannot be reliably detected using such methods. These arrays are also 
not able to reliably identify smaller CNVs, which is why stringent QC filters in terms of 
size and probe density needed to be used. However, this may have resulted in the 
exclusion of some causal CNVs. Further limitations come from the design of the initial 
GWAS, in which the population controls were genotyped on a larger array to the cases, 
which may have introduced bias in the rates of CNVs identified between the cases and 
controls. However, this difference did not appear to have a significant impact in this 
study. A more significant limitation was that the cases had been genotyped in two 
different centres, and technical differences in those genotyped in Oxford appeared to be 
driving a significant excess of deletions in the cases. Whilst SNP genotype calls may 
not be adversely affected by carrying out genotyping in different centres, the intensity 
scores are far more sensitive to experimental variation which may increase the rate of 
false positive results. As such, it is important that these CNVs are validated using other 
methods before the results of this study can be relied upon. However, even if all the 
cases and controls had been conducted in the same centre, it is likely that these samples 
would have still been extracted at different times, and analysed in different experimental 
plates or batches, all of which would influence the intensity signals from sample to 
sample (McCarroll 2008). It is therefore important to carefully dissect the sample- and 
batch-specific influences on signal intensities and develop algorithmic approaches 
which can control for these factors. This is beyond the scope of this current project 
however.
8.3 Further Work
There is still a lot more research to be done in order to gain a better understanding of 
the genetic component of DD. This study has highlighted a number of interesting 
variants, but these all need to be replicated in large independent samples before they can 
confidently be considered to have a role within susceptibility to DD. However, the 
power of these analyses is inadequate and further susceptibility variants for DD could 
be identified upon further interrogation of the genome.
Future meta-analysis of GWAS of DD may provide greater power to detect 
susceptibility variants for this disorder. This will require collaboration with more groups
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that have used appropriate ascertainment criteria. Additional control data from GWAS 
of other population cohorts could also be included to increase power further. Even if 
these studies are conducted on different arrays to the one used in this dataset, imputation 
could be used in order to impute the genotypes of un-typed markers before combining 
the data.
In terms of the GWAS data already collected, further work may involve sub­
phenotype analysis, haplotype analysis and gene ontology analysis. Although 
heritability estimates of DD have suggested that there may be a shared genetic aetiology 
between many components of reading, Castles and colleagues (1999) have suggested 
that there may also be some partial genetic independence between the cognitive 
processes involved in reading, such as phonological skills and orthographic skills. 
Analysis of these sub-phenotypes of DD may highlight variants which are strongly 
associated with particular components of DD. This would require detailed phenotypic 
information for all the cases and controls and it may be difficult to standardise the 
component tests used across all groups of the NeuroDys collaboration, particularly 
when comparing those conducted in different languages.
Haplotype analysis of the GWAS data may identify significant associations that 
were not seen with single SNPs. Such an association may suggest that the haplotype 
itself is directly associated with DD or that the haplotype indirectly tags the true 
associated variant more effectively than any individually genotyped SNPs (McCarthy et 
al. 2008). Over recent years novel methods of haplotype analysis have been implicated 
or are under development, which are fast enough and hence practical to use even for 
marker densities of 500,000 SNPs/genome (Nolte et al. 2007).
Gene ontology (GO) is a method used to describe gene products in terms of their 
associated biological processes, cellular components and molecular functions in a 
species-independent manner (Harris et al. 2004). A number of methods have been 
developed to identify GO categories that are amongst association signals in a GWAS 
and so prioritise genes/pathways for further investigation. These methods are based on 
the assumption that susceptibility alleles for a given disorder are likely to be distributed 
among genes whose functions are, to some extent, related (Holmans et al. 2009). Under 
this model one would expect to see an overall excess of SNPs with moderate P-values 
for association on a list of SNPs representing a set of genes from relevant related 
biological pathways (Holmans et al. 2009). In Cardiff, Prof. Pete Holmans has designed
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the ALIGATOR program, which converts a list of significant SNPs into a list of 
significant genes, applying corrections for gene size and non-independent categories 
and is not influenced by LD (Holmans et al. 2009). These genes are then examined for 
any enrichment of individual GO categories.
In terms of CNV analysis, future work could involve attempting to validate the 
interesting CNVs identified in this study using an alternative method such as qPCR. 
Alternatively, an additional whole genome scan of CNVs could be conducted using 
aCGH methods. These approaches provide the most robust method for scanning the 
whole genome (Pinkel et al. 1998) and custom arrays (e.g. Agilent custom arrays) could 
be produced in order to densely cover particular regions of interest. In addition, a CNV 
study could be conducted on probands and their parents in the form of trios to determine 
if any de novo or inherited CNVs are associated with DD.
The recent development of ‘next-generation’ sequencing technologies are set to 
have a large impact on the field of genetics. What sets next-generation sequencing apart 
from conventional capillary-based sequencing is the ability to process millions of 
sequence reads in parallel rather than 96 at a time (Mardis 2008). Being a relatively new 
technology, next generation sequencing is still expensive. However, sequencing 
platforms are now available which enable researchers to prioritise genome-wide exon 
(or ‘exome’) sequencing in order to sequence coding regions at a workable financial 
cost. With the appropriate algorithms, analysing the genome on a single nucleotide level 
will enable the identification of rare variants which cannot be tested using commercial 
SNP arrays. It will also enable accurate detection of large deletions and duplications, as 
well as inversions and translocations (Fanciulli et al. 2010).
The development of next-generation sequencing has been of particular importance 
to the 1000 Genomes Project (Via et al. 2010). This project is an international 
collaboration and involves sequencing 2000 individuals from at least 20 different 
populations representing Africa, Europe, East Asia, and the Americas. The main goal of 
this project is to describe most of the genetic variation that occurs at a population 
frequency of > 1% (Via et al. 2010). The first stage of this analysis has already been 
conducted and of the 9 million novel SNPs that have been identified so far, 
approximately 8 million are seen in only one HapMap population (Via et al. 2010). It is 
hoped that the results of this project will allow researchers to identify genetic variation 
at a greater degree of resolution and also improve current imputation methods. It will
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enable the development of new population-specific genotyping arrays, maximising 
genome coverage while minimising the ascertainment bias that affects currently 
available arrays, especially for non-European populations (Via et al. 2010). It will also 
provide a valuable resource as a reference genome when attempting to identify novel 
rare variants or conducting CNV analysis.
8.5 Conclusions
This study has sought to identify susceptibility variants for DD using a number of 
techniques including a candidate gene study, collaborative GWAS, pooling studies and 
CNV analysis. Despite the lack of genome-wide significant findings, these approaches 
have been successful in identifying a number of interesting regions but these regions 
need to be confirmed in large independent samples. Future studies of DD may benefit 
from a combination of approaches, with systematic analysis of the genome using SNP 
arrays or next-generation sequencing in large, well-powered samples to highlight 
regions of interest, followed by CNV analysis and targeted candidate gene studies.
By improving our understanding of the genetics underlying this complex 
neurobehavioral disorder, we can hope to gain a better understanding of the biological 
processes involved in reading in general and how and where particular deficits may 
occur. It may also enable young children to be screened for their potential risk of 
developing DD and allow tailored tuition to be provided in order to reduce this risk.
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